800 W. Airport Freeway
Suite 110
Irving, Texas 75062
Phone: (972) 871-7578
Fax: (972) 871-7579

RCTS, INC. *"Your Assurance for Quality in Clinical Testing"*

RCTS STUDY NUMBER: 1837

A CLINICAL STUDY OF TOPICAL ZEATIN (0.10%, 0.025%) FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Sponsor:	Senetek PLC 620 Airpark Road Napa, CA 94558		
Sponsor's Representative:	Frank Massino Phone: 707-226-3900 ext. 109 E-Mail: Frank@senetek.net		
Document Type:	Clinical Study Report		
Study Materials:	Zeatin (0.10%; Group A) Zeatin (0.025%; Group B)		
Type of Study:	Efficacy (12 Weeks)		
Medical Investigator:	Ponciano D. Cruz, Jr., MD Board Certified Dermatologist		
Sub Investigator:	Barry T. Reece, MS, MBA Vice President/Managing Partner, RCTS, Inc.		
Testing Facility:	RCTS, Inc. 800 W. Airport Freeway, #110 Irving, TX 75062		
First Subject Enrolled:	04-April-2005	**Last Subject Completed:**	12-July-2005
Document Status:	Final	**Date:**	06-September-2005

SIGNATURE

I, the undersigned, certify that this document accurately describes the conduct and results of this investigation.

Medical Investigator:

Ponciano D. Cruz, MD
Medical Investigator
Board Certified Dermatologist

signature

9-6-05
date

Sub-Investigator:

Barry T. Reece, MS, MBA
Sub-Investigator
Vice President/Managing Partner
RCTS, Inc.

signature

9-6-05
date

STATEMENT OF QUALITY ASSURANCE

This study was conducted in accordance with the intent and purpose of Good Clinical Practice regulations described in CFR 21, Part 50 (Protection of Human Subjects - Informed Consent), Part 56 (Institutional Review Boards) and the International Conference on Harmonization – Good Clinical Practice Guidelines, May 9, 1997, Federal Register.

For Purposes of this clinical study:

☒ Informed Consent was obtained.

☐ Informed Consent was not obtained.

☐ An IRB review was not required.

☒ An IRB was convened and approval to conduct the proposed clinical research was granted.

This study report has been reviewed to ensure that it correctly describes the methods of testing and that the reported results accurately reflect the data obtained during the clinical study (RCTS Panel No. 1837; RCTS Test Article Code Nos.: 1837.7906, 1837.7907 and 1837.7908).

In addition, the Quality Assurance Department conducted in-study inspections on a random sampling of subjects during the study. Written status reports of inspections and findings were submitted to Management.

Date of Inspection	Type of Inspection	Date Reported to Management
4/04/05	Critical Phase Inspection: Study organization and management, screening procedures, informed consent, screener, dermatologic medication and skin care/cosmetic product history information.	4/05/05
4/11/05	Critical Phase Inspection: Day 1 procedures including study organization and management, Expert and Self Evaluations, photography, baseline TEWL and NOVA DPM measurements and distribution of product and diary.	4/11/05

4/26/05	Critical Phase Inspection: Week 2 activities	4/26/05
5/13/05	Critical Phase Inspection: Week 4 activities	5/17/05
6/10/05	Critical Phase Inspection: Week 8 activities	6/13/05
7/5/05	Critical Phase Inspection: Week 12 activities	7/5/05
7/18/05	Review of Data Tables	8/1/05
08/29/05	Review of Draft Final Report	8/30/05
08/30/05	Review of Final Report	08/31/05
09/02/05	Final Review of Final Report	09/06/05

On the basis of the audits conducted, this report is considered to be a true and accurate reflection of the source data.

9.6.05

Laura O'Farrell, BS
Quality Assurance

Date

STUDY SYNOPSIS

Study Title:	A 12-Week Efficacy Evaluation of Topical Zeatin (0.10%, 0.025%) for Improving the Appearance of Photodamaged Skin
Sponsor:	Sentek PLC 620 Airpark Road Napa, CA 94558
Sponsor's Representative:	Frank Massino, Chief Executive Officer
Contract Research Organization (CRO):	RCTS, Inc. 800 W. Airport Freeway, Suite 110 Irving, TX 75062
RCTS Study #:	1837
Study Site:	Single centre: RCTS, Inc. 800 W. Airport Freeway, Suite 110 Irving, TX 75062
Dates of Study:	04-April-2005 to 12-July-2005
Type of Study:	Efficacy (12 week)
Study Objectives:	The primary objective of this study was to compare the efficacy and tolerance of topical Zeatin (0.10% and 0.025%) when applied twice daily for 12 consecutive weeks for improving the clinical signs of age-related changes in photodamaged facial skin. Additionally, to determine the effects of the test articles on skin tolerance (irritation) and acne (inflammatory and non-inflammatory acne lesions).
Study Design:	This was a 12 week, double-blinded study designed to determine the efficacy and tolerance of two concentrations (0.10% and 0.025%) of Zeatin. Approximately fifty female subjects between 30 to 65 years of age with mild to moderate signs of photodamaged facial skin were enrolled into this study. Twenty-five subjects were assigned to a group/cell which evaluated Zeatin at a concentration of 0.10% and 25 subjects were assigned to a group/cell which evaluated Zeatin at a concentration of 0.025%. Subjects were instructed to apply the test products to their face twice daily, in the early morning and in the evening (approximately 1 hour before bedtime), for 12 consecutive weeks. Subjects were instructed to follow the morning application with the Sponsor provided sunscreen (SPF 30). At baseline and at 2, 4, 8 and 12 weeks the subjects' faces were evaluated by the Sub-Investigator for the following: • Skin aging, including observations on wrinkles (coarse and fine), roughness, mottled hyperpigmentation and overall severity of skin aging; • Presence of Irritation (i.e., tolerance); • Presence of Acne (i.e., acne lesion counts) and the Overall Severity of Acne; and

- Global assessment of improvement of skin aging (2, 4, 8, and 12 week visits only).

Additionally, the following instrumental measurements were taken on the cheeks of each subject at baseline and weeks 2, 4, 8 and 12:

- Transepidermal water loss (TEWL);
- Skin moisture measurements (NOVA DPM); and
- Standard clinical photographs.

Finally, each subject was asked to evaluate themselves at the 2, 4, 8 and 12 week visits to determine the improvement over baseline in the following parameters:

- Texture
- Blotchiness (brown spots)
- Skin Color
- Fine Wrinkles
- Overall Improvement

Study Population: Healthy female subjects, aged 30 to 65 years, fulfilling all of the inclusion, and none of the exclusion, criteria were eligible for participation in the study. The target was to complete 25 evaluable subjects for each cell. Actual enrollment was 73 subjects, of which 57 (Cell 1 = 30; Cell 2 = 27) completed the study.

Investigational Products: All test articles were provided by Senetek PLC.

Dosage and Frequency: Subjects were instructed to use the test article twice daily for 12 weeks according to the following instructions:

- Wash your face with a mild cleanser and dry completely prior to application of the product to your face;
- Apply a liberal amount of the product to your face in the early morning and about one hour before bedtime;
- In the morning, after the product has absorbed into the skin, apply the sunscreen that was provided to you to your face;
- Other than the product being provided to you, do not introduce any new products into your skin care regimen;
- Do not apply any topical medications to your face;
- Do not take any steroid or retinoid medications; and
- Do not apply the test article or makeup to your face the morning of a scheduled visit.

Evaluation of Efficacy: Efficacy was determined by the following methods after two, four, eight and twelve weeks of product use:

- Expert Evaluation [Cutaneous Signs of Skin Aging (Fine Wrinkles, Coarse Wrinkles, Roughness and Mottled Hyperpigmentation), Overall Severity of Skin Aging, Global Assessment of Improvement of Skin

Aging, Skin Irritation, Overall Severity of Acne, Count of Individual Acne Lesions (Inflammatory, Non-Inflammatory and Total Acne Lesions)];

- Subject's Self Evaluation (Skin Texture, Skin Color, Blotchiness – Brown Spots, Fine Wrinkles and Overall Improvement);
- Effect of the treatments on Transepidermal Water Loss (TEWL);
- Effect of the treatments on Skin Capacitance (NOVA DPM, an indirect measure of skin moisturization); and
- Digital Photographs (left and right facial profiles, full facial photo, and close-up photos of the right and left peri-orbital area).

Adverse Events: All local and systemic adverse events observed by or reported to the investigators were evaluated. The intensity, duration and causal relationship to the investigational test articles were rated for all adverse events.

Adverse Event Results: During this study, 34 adverse events were recorded. One (1) of the adverse events was considered serious. The breakdown for adverse events is as follows:

Type of Adverse Event	Frequency of Adverse Events
Blemishes (breakout)	11
Headache	1
Peeling/Sloughing	1
Swelling	1
Watery eye	1
Clogged pores	1
Hand Surgery (considered a serious adverse event unrelated to test article use)	1
Tightness	6
Redness	3
Redness with bumps	1
Dryness	2
Rash/bumps	1
Eyes Burning	2
Bronchitis	1
Bump	1

The relationship of the event to the test article can be found in Appendix 2, Data Listing 10.

Conclusions: Under the conditions of this study:

Skin Aging

- **Fine Wrinkles**

  Sub-Investigator's Assessment of Skin Aging for Fine Wrinkles

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the appearance of Fine Wrinkles for both Groups A and B after 4, 8 and 12 weeks of test article use. No significant difference in the appearance of Fine Wrinkles was observed at Week 2, regardless of the test group.
  - When comparing the Fine Wrinkle data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

  Subject's Self Assessment for Fine Wrinkles

  - Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in the appearance of Fine Wrinkles at all time points.
  - When comparing the changes observed in both groups, there was no significant difference in the data generated between Groups A and B at any time point.

- **Coarse Wrinkles**

  Sub-Investigator's Assessment of Skin Aging for Coarse Wrinkles

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the appearance of Coarse Wrinkles for subjects assigned to Group B values after 12 weeks of test article use. No other significant differences were observed at any time point.
  - Subjects in Group A did not show a significant change, relative to baseline, in Coarse Wrinkle values; however, it was highly suggestive that reduction in Coarse Wrinkle values was observed at Week 12.
  - When comparing the Coarse Wrinkle data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

- **Roughness**

  Sub-Investigator's Assessment of Skin Aging for Roughness

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the skin's Roughness for both Groups A and B at all time points.
  - When comparing the Roughness data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point. However, the data were highly suggestive that subjects in Group A had a greater improvement in Roughness values, relative to Group B, at the Week 12 time point.

Subject's Self Assessment of Skin Texture

- Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in their skin's texture at all time points.
- When comparing the Skin Texture data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

- **Overall Severity of Skin Aging**

  Sub-Investigator's Assessment of Skin Aging for Overall Severity of Skin Aging

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the Overall Severity of Skin Aging values for both Groups A and B at all time points.
  - When comparing the Overall Severity of Skin Aging data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

- **Global Assessment of Improvement**

  Sub-Investigator's Global Assessment of Improvement of Skin Aging

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the Global Assessment of Improvement in Skin Aging values for both Groups A and B at all time points.
  - When comparing the Global Assessment of Improvement in Skin Aging data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

  Subject's Self Assessment of Overall Improvement

  - Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in their skin at all time points.
  - When comparing the Overall Improvement data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

Skin Color

Sub-Investigator's Assessment of Skin Aging for Mottled Hyperpigmentation

- The Sub-Investigator detected a significant improvement in Mottled Hyperpigmentation for subjects in Group A at Weeks 4, 8 and 12.
- The Sub-Investigator detected a significant improvement in Mottled Hyperpigmentation for subjects in Group B at all time points.
- It was highly suggestive that Group B performed better than Group A at Week 4.

- When comparing the Mottled Hyperpigmentation data generated by Group A to that generated by Group B, It was highly suggestive that Group B performed better than Group A at Week 4.

Subject's Self Assessment of Blotchiness – Brown Spots

- Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in the Blotchiness-Brown Spots of their skin at Weeks 8 and 12.
- When comparing the Blotchiness-Brown Spots data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

Subject's Self Assessment of Skin Color

- Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in their Skin's Color at all time points.
- When comparing the Skin Color data generated by Group A to that generated by Group B, It was highly suggestive that Group B performed better than Group A at Weeks 4 and 8.

Skin Barrier Properties (TEWL) Moisturization (NOVA DPM)

TEWL Measurements

- Subjects in Group A produced significantly elevated TEWL values, relative to baseline, at Weeks 2 and 12.
- There was no significant difference in TEWL values, relative to baseline, detected for subjects in Group B at any time point.
- It was highly suggestive that subjects in Group B had lower TEWL values than subjects in Group A at the Week 8 time point.

NOVA DPM Measurements

- Subjects in Group A had significantly increased NOVA DPM values (an indirect measure of skin moisturization), relative to baseline, at Week 8.
- Group B had significantly increased NOVA DPM values at Weeks 8 and 12.
- There was no significant difference between Groups A and B at any time point.

Safety

Sub-Investigator's Assessment of Skin Irritation

- The Sub-investigator detected a significant improvement, relative to baseline, in skin irritation for subjects in Group A at Weeks 4, 8 and 12.
- The Sub-investigator detected a significant improvement, relative to baseline, in skin irritation for subjects in Group B at all time points.

- There was no significant difference between Groups A and B at any time point.

Sub-Investigator's Assessment of Overall Severity of Acne

- Group A had significantly improved (reduced) values, relative to baseline, for Overall Severity of Acne at Week 8.
- No significant difference, relative to baseline, in the Overall Severity of Acne was observed at any time point for subjects in Group B.
- There was no significant difference between Groups A and B at any time point.

Count of Individual Acne Lesions

- Inflammatory Acne Lesions
  - There were no significant changes in the inflammatory acne lesion counts, relative to baseline, for either group regardless of the time point.
  - There was no significant difference between Groups A and B at any time point.
- Non-Inflammatory Acne Lesions
  - Group A had significantly decreased Non-Inflammatory Acne Lesion counts at Weeks 2, 8 and 12, relative to baseline.
  - Subjects in Group B did not show a significant change, relative to baseline, in the presence of Non-Inflammatory Acne Lesions at any time point.
  - Group A performed significantly better than Group B at decreasing the number of Non-Inflammatory Acne Lesions at Week 8.
- Total Inflammatory & Non-Inflammatory Acne Lesions
  - Group A had significantly lower Total Acne Lesion counts at Weeks 8 and 12, relative to baseline.
  - Subjects in Group B did not show a significant change, relative to baseline, in the Total Inflammatory and Non-Inflammatory Acne Lesion counts at any time point.
  - Group A performed significantly better than Group B at decreasing the number of Total Acne Lesion counts at Week 8.

Therefore, in general, the test articles (0.10% and 0.025% Zeatin) performed at parity and helped to improve:

- The appearance of Fine Wrinkles (Weeks 4, 8 and 12)
- Coarse Wrinkles (Group B at Week 12)
- Roughness (at all time points)
- Overall Severity of Skin Aging (at all time points)
- Mottled Hyperpigmentation (Group A at Weeks 4, 8 and 12; Group B at all time points)
- Blotchiness-Brown Spots (Weeks 8 and 12)
- Overall Skin Color (at all time points)

Additionally, the test articles were well tolerated with both the Sub-Investigator and Subjects not detecting any significant increase in irritation. In fact, the Sub-Investigator detected a significant improvement in the appearance of irritation, relative to baseline, after 4, 8 and 12 weeks of test article use (subjects in Group B actually showed a reduction in irritation at Week 2 as well).

Regarding the effect of the test articles on acne counts, while the test articles performed, in general, at parity (no significant difference between subjects who used the Zeatin at 0.10% and those that used Zeatin at 0.025%), subjects using Zeatin at 0.10% seemed to show a greater reduction, relative to baseline, in the presence of non-inflammatory and total acne lesions.

Finally, neither test article was effective at reducing TEWL. In fact, subjects in Group A (Zeatin at 0.10%) showed elevated TEWL values at Weeks 2 and 12. However, regarding NOVA DPM measurements, subjects in Group B (Zeatin at 0.025%) showed elevated NOVA DPM values at Weeks 8 and 12. Subjects in Group A showed elevated NOVA DPM values at Week 8 only.

STUDY PERSONNEL

Key Senetek PLC Personnel:

Chief Executive Officer	Frank Massino

Key RCTS, Inc., Personnel:

Medical Investigator	Ponciano D. Cruz, Jr., MD Board Certified Dermatologist
Sub-Investigator	Barry T. Reece, MS, MBA Vice President/Managing Partner RCTS, Inc.
Clinical Research Coordinator	Dorsi Simmons, BS
Quality Assurance	Laura O'Farrell, BS

TABLE OF CONTENTS

LIST OF TEXT TABLES

LIST OF POST-TEXT TABLES

(Section 9)

LIST OF APPENDICES

(Section 10)

GLOSSARY OF ABBREVIATIONS AND TERMS

AE	Adverse event
ANOVA	Analysis of Variance
AU	Arbitrary Units
CFR	Code of Federal Regulations
DPM	Dermal Phase Meter
GCP	Good Clinical Practice
ICH	International Conference on Harmonization
IRB	Institutional Review Board
TEWL	Transepidermal Water Loss
QA	Quality Assurance
RCTS	RCTS, Inc.
SAE	Serious adverse event
SOP	Standard Operating Procedure
SPF	Sun Protection Factor
VAS	Visual Analog Scale

1 ETHICS AND GOOD CLINICAL PRACTICE

1.1 INSTITUTIONAL REVIEW BOARD

Prior to initiation of the study, the clinical study protocol (dated 03/17/05) and informed consent form were reviewed and approved on 03/28/2005 by an Institutional Review Board (IRB) operating in accordance with Title 21 of the Code of Federal Regulations (CFR), Part 56. Protocol amendment 1 was reviewed and approved on 07/15/2005. The clinical study site (RCTS, Inc.) and Principal Investigator were also approved by the IRB on 03/28/2005. The IRB that provided approval for all aspects of this study was the IntegReview Institutional Review Board. Further details on the IRB, including the IRB approval letter can be found in Appendix 1.2.

1.2 ETHICAL CONDUCT OF THE STUDY

This study was carried out in compliance with the protocol and in accordance with RCTS, Inc.'s standard operating procedures (SOPs). These are designed to ensure adherence to Good Clinical Practices (GCPs), as described in:

1. International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice 1996. Directive 91/507/EEC, The Rules Governing Medicinal Products in the European Community.
2. US 21 CFR dealing with clinical studies (including parts 50 and 56 concerning informed consent and IRB regulations).
3. Declaration of Helsinki, concerning medical research in humans (Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects, Helsinki 1964, amended Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996, Edinburgh, 2000).

The investigator agreed, when signing the protocol, to adhere to the instructions and procedures described in it, and thereby to adhere to the spirit of GCPs to which it conforms. A signed statement of Quality Assurance is included on Page 4.

1.3 SUBJECT INFORMATION AND CONSENT

The investigator (or his designee) explained the nature of the study, its purpose and associated procedures, the expected duration and the potential benefits and risks of participation to each subject prior to her entry into the study (i.e., before procedures associated with selection for the study are performed). Each subject was provided a duplicate of the informed consent form, had ample opportunity to ask questions and was informed about the right to withdraw from the study at any time without any disadvantage and without having to provide reasons for this decision. No subject entered the study before her informed consent was obtained. A copy of the informed consent form presented for review and signature to all study subjects is provided in Appendix 1.3 of this report.

2 STUDY OBJECTIVES

Primary study objectives were as follows:

1) Observations by the sub-investigator to determine the improvement, relative to baseline, of wrinkles (coarse and fine), roughness, mottled hyperpigmentation, global assessment of overall severity and degree of improvement in skin aging as it relates to the face;
2) Subject self-assessment to determine the improvement of wrinkles, texture, blotchiness, color and perform a global assessment to document the overall improvement in their facial skin;
3) Effect of the treatment(s) on Transepidermal Water Loss (TEWL); and
4) Effect of the treatment(s) on Skin Capacitance (an indirect measure of skin moisturization).

Secondary study objectives were:

5) Observation by the sub-investigator for skin irritation and acne lesion counts; and
6) Subject self-assessment of skin tolerance.

3 INVESTIGATIONAL PLAN

3.1 OVERALL STUDY DESIGN

This was a 12 week, double-blinded study designed to determine the efficacy and tolerance of two concentrations (0.10% and 0.025%) of Zeatin. Subjects were instructed to use the Zeatin (0.10%, 0.025%) cream twice a day for 12 weeks according to the instructions supplied to them. Evaluations occurred at baseline (prior to test article application) and after two, four, eight and twelve weeks of product use. At each visit the following measurements were performed:

- Sub-Investigator's Assessment of Cutaneous Signs of Skin Aging (Fine Wrinkles, Coarse Wrinkles, Roughness and Mottled Hyperpigmentation), Overall Severity of Skin Aging, Global Assessment of Improvement (2, 4, 8 and 12 week visits only), Skin Irritation, Overall Severity of Acne and a Count of Individual Acne Lesions (Inflammatory, Non-Inflammatory and Total Lesions);
- Subject's Self Assessment of Skin Texture, Skin Color, Blotchiness – Brown Spots, Fine Wrinkles and Overall Improvement at the 2, 4, 8, and 12 week visits;
- Digital Photographs (left and right facial profiles, full facial photo, and close-up photos of the right and left peri-orbital area); and
- Instrumental Measurements (Transepidermal Water Loss and NOVA DPM).

3.2 DISCUSSION OF DESIGN

This was a 12 week, double-blinded study designed to determine the efficacy and tolerance of two concentrations (0.10% and 0.025%) of Zeatin. Fifty female subjects between the ages of 30 to 65 with mild to moderate signs of photodamaged facial skin were enrolled into this study. Twenty-five subjects were assigned to Group A which evaluated Zeatin at a concentration of 0.10% and 25 subjects were assigned to Group B which evaluated Zeatin at a concentration of 0.025%. Subjects applied the test products to their face twice daily, in the morning and in the evening (approximately 1 hour before bedtime), for 12 consecutive weeks. Subjects were instructed to follow the morning application with the Sponsor provided sunscreen (SPF 30). At baseline and after 2, 4, 8 and 12 weeks of test article application, the subjects' faces were evaluated by the sub-investigator for clinical signs of skin aging, including observations for wrinkles (coarse and fine), roughness, mottled hyperpigmentation, overall severity of skin aging, irritation, overall severity of acne and a count of individual acne lesions (inflammatory, non-inflammatory lesions). Additionally at 2, 4, 8 and 12 weeks, the sub-investigator provided a global assessment of the overall improvement, relative to baseline, in skin aging. Furthermore, at each post-baseline visit, the subjects underwent a self assessment evaluation to determine the improvement in texture, blotchiness – brown spots, wrinkles and overall improvement. Finally, transepidermal water loss (TEWL) measurements, skin moisture measurements (NOVA DPM) and standard clinical photographs were taken at baseline and at weeks 2, 4, 8 and 12.

3.3 STUDY PROCEDURES

3.3.1 Screening

Prior to study initiation, each subject was screened to ensure they met all of the inclusion, and none of the exclusion, criteria outlined in sections 3.4.1 and 3.4.2. Potential subjects were interviewed and examined by the Sub-Investigator or his designee to establish their eligibility for inclusion in the study. Subjects were given a full description of the nature and purpose of the study. If a subject was willing to participate, they had to provide written informed consent before proceeding with the study.

Screening procedures included the following activities for prospective participants:

1. Investigator, or designee, explaining the investigational study and eligibility requirements;
2. Subject signing an informed consent and photographic release form prior to any study-related procedures;
3. Recording of demographic information;
4. Subjects filling out a brief dermatologic, medication and skin care/cosmetic product history;
5. Administering a urine pregnancy test for those females of childbearing potential; and
6. Assigning a specific subject number to subjects admitted to the study.

3.3.2 Baseline Measurements

Upon arrival at the testing facility, qualified subjects were directed into an exam room where they were allowed to equilibrate for at least 15 minutes under controlled environmental conditions ($70^oF \pm 3^oF$; 45% $\pm$ 10% relative humidity). During equilibration the subjects were interviewed regarding any changes to their medical history. Additionally, subjects were asked to provide a detailed account of all concomitant medications taken, and skin care products used on their face, since their screening visit. Subjects were also evaluated to ensure that no cuts, abrasions or other dermal deviations were present which might have prevented further participation on the clinical study. Following equilibration, each subject underwent a series of clinical measurements designed to assess the skin's overall condition (see 3.3.2.1 to 3.3.2.3).

3.3.2.1 Photography

Digital photographs of both the left and right facial profiles (taken at an angle of 45 degrees) and a full face photo were taken of each subject using a Fuji S2 Pro digital camera attached to a Canfield Scientific VISIA CR Booth (Canfield Scientific, Fairfield, NJ). Photographs were taken under standard lighting, polarized lighting (crossed and parallel) and ultra violet lighting. Digital photographs were downloaded onto disks and were printed out and placed in a photo album.

Close-up digital photographs of both the left and right peri-orbital areas were taken using a digital camera (Fuji S2 Pro). The digital camera was fitted with a dual flash system and the subjects were placed in a facial positioning device (Canfield Scientific, New Jersey, USA). All photographs were stored on optical media until the end of the study. Digital photographs were downloaded onto disks and were printed out and placed in photo albums.

3.3.2.2 Sub-Investigator's Assessment of the Subjects' Faces

At the Baseline (Day 1) visit the Sub-Investigator evaluated each subject's face for the presence of:

- Fine Wrinkles
- Coarse Wrinkles
- Roughness
- Mottled Hyperpigmentation

The Sub-Investigator used the following five-point scale to describe the above parameters:

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

The Sub-Investigator evaluated the Overall Severity of Skin Aging using the 10 point scale below. The scale was an integrated assessment of all the signs of photoaging (wrinkles, roughness and mottled hyperpigmentation) previously evaluated.

NONE	MILD			MODERATE			SEVERE		
0	1	2	3	4	5	6	7	8	9

Subjects with a baseline severity score greater than 6 were excluded from the study.

The Sub-Investigator proceeded to determine the baseline level of irritation present on the subjects' faces using the following four-point scale:

0: None
1: Mild
2: Moderate
3: Severe

In addition, individual acne lesions were counted on the subject's face and recorded on the subject's case report forms (CRF). The lesion counts were taken from the facial area: forehead, left and right cheeks, and chin above the jaw line (excluding the nose). The counts were added together to form three groups of lesion counts: inflammatory, non-inflammatory and total lesion counts. Open and closed comedones made up the non-inflammatory counts; papules and pustules made up the inflammatory counts and all of the lesions collectively composed the total lesion counts. The following are definitions of each lesion type counted:

- Open comedone – A mass of sebaceous material that is impacted behind an open follicular orifice (blackhead).
- Closed comedone – A mass of sebaceous material that is impacted behind a closed follicular orifice (whitehead).
- Papule – A small, palpable, solid elevation less than 1 cm in diameter.
- Pustule – A small, circumscribed elevation of the skin which contains yellow/yellowish-white exudates.

In addition to individual acne lesion counts, the overall severity of acne was determined using the same scale as described above for determining irritation.

3.3.2.3 Instrumental Measurements

Following equilibration, Transepidermal Water Loss (TEWL) and Skin Capacitance Measurements (NOVA DPM) were taken at the center of both subjects' cheeks and recorded onto the subjects' CRF. TEWL measurements were taken in duplicate using a TEWA meter (Courage & Khazaka, Köln, Germany) and moisture measurements were taken in triplicate using the NOVA DPM 9003® (NOVA Technologies, Gloucester, MA, USA).

3.3.2.4 Subjects' Test Article Use Instructions

Following baseline measurements, each subject was placed into one of two groups and provided with the test article and a sensitive skin sun block lotion. Subjects receiving the test article with 0.10% Zeatin were placed into Group A; subjects receiving the test article with 0.025% were placed into Group B. Subjects were instructed to use the test article and sunscreen in the following manner:

1. Wash your face with a mild cleanser and dry completely prior to application of the product to your face;
2. Apply a liberal amount of the product to your face in the early morning and about one hour before bedtime;
3. In the morning, after the product has absorbed into the skin, apply the sunscreen, which was provided to you, to your face. Avoid prolonged sun exposure;
4. Other than the product being provided to you, do not introduce any new products into your skin care regimen;
5. Do not apply any topical medications to your face;
6. Do not take any steroid or retinoid medications; and
7. Do not apply the test article or makeup to your face the morning of a scheduled visit.

Finally, all subjects were provided with a daily diary to record the dates and times of test article application and any observations or comments they felt pertinent to the study.

As an indication of compliance, weights of the test articles were determined at baseline and at all subsequent visits.

3.3.3 Week 2, Week 4, Week 8 and Week 12 Visits

Subjects arriving after two, four, eight and twelve weeks of product use were directed into an environmentally controlled room ($70^oF \pm 3^oF$, 40% ± 15% RH) where they were allowed to equilibrate for approximately 15 minutes. Following equilibration, the same measurements taken at baseline were repeated in the same manner with the following additions:

- Sub-Investigator's Assessment of Skin Aging: Global Assessment of Improvement; and
- Subject's Self Assessment (Skin Texture, Skin Color, Blotchiness – Brown Spots, Fine Wrinkles and Overall Improvement).

The Sub-Investigator used the following six-point scale to describe the global improvement of the subject's skin relative to baseline:

1 = Excellent Improvement
2 = Marked Improvement
3 = Moderate Improvement
4 = Slight Improvement
5 = No Improvement
6 = Worse

The Subjects used the following five-point scale to assess the change in Skin Texture, Skin Color, Blotchiness – Brown Spots, Fine Wrinkles and Overall Improvement:

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Subjects were also provided with a new daily diary at weeks 2, 4 and 8 to record the date and times of test article application and any observations or comments they felt pertinent to the study.

3.3.4 Visit Schedule

The visit schedule and assessments are summarized in Text Table 3-1.

Text Table 3-1 Visit Schedule and Assessments

STUDY WEEK	0	2	4	8	12
Informed Consent	X				
Eligibility Criteria	X				
Dermatologic/Skin Care/Cosmetic Hx	X				
Laboratory Studies: Urine Pregnancy	X				X[1]
Admission to Study	X				
Test Products/Diary Dispensed	X		X	X	
Test Products/Diary Collected			X	X	X
Twice Daily Application of Study Materials	X	X	X	X	X
Sub-Investigator Skin Evaluations (including acne lesion counts)	X	X	X	X	X
Subject Tolerance	X	X	X	X	X
Review of Concomitant Skin Care Products/Medications	X	X	X	X	X
TEWL/Moisture Measurements	X	X	X	X	X
Photography	X	X	X	X	X
End of Study Information/Exit Form[1]					X

[1]Exit form and urine pregnancy test completed upon study completion or early discontinuation

3.4 SELECTION OF SUBJECTS

A sufficient number of subjects were enrolled to complete approximately 50 subjects (25 subjects per cell). An individual subject was allowed to participate in the study one time only.

3.4.1 Inclusion Criteria

Subjects included in the study:

1. Were female, ambulatory, 30 to 65 years of age and in reasonably good health;

2. Were postmenopausal, surgically sterile or were using a medically acceptable form of birth control with a negative urine pregnancy test;

3. Had mild to moderate changes associated with skin aging (1-6 overall severity score);

4. Were willing to refrain from using lotions, moisturizers, other skin care products (except those provided by the testing facility) or any medications on their facial area during the treatment period. Subjects were permitted to use their color cosmetics (e.g., foundation, blush) as long as the color cosmetics did not contain anti-aging ingredients;

5. Were willing to have clinical photographs taken to document their improvement;

6. Agreed to refrain from applying any products (including the test product) to their face the day of their visits. Subjects must have also agreed not to bathe or shower within two hours of their study visit (i.e., bathing or showering must have occurred no less than 2 hours before their study visits);

7. Agreed not to wear any facial makeup to any of their visits (lip and eye color were acceptable);

8. Indicated willingness to participate in the study by signing an informed consent document and a photo release document; and

9. Were Fitzpatrick Skin Types I – III.

3.4.2 Exclusion Criteria

Subjects excluded from the study:

1. Were pregnant or lactating;

2. Had a global severity score greater than 6 (see page 25);

3. Had a history or evidence of any chronic or reoccurring skin disease or disorder (e.g., psoriasis, eczema, atopic dermatitis, mild to moderate acne, etc.) affecting the face;

4. Had a known allergy to any component of the study formulation or a proclivity to cutaneous hyper-reactivity;

5. Required the use of a tanning bed or participated in activities that involved excessive prolonged exposure to the sun;

6. Had used systemic retinoids within 6 months prior to study entry (e.g., acitretin, isotretinoin);

7. Had used topical retinoids within 2 months prior to study entry (e.g. tretinoin, adapalene);

8. Had received treatment with systemic corticosteroids within 6 months or topical corticosteroids to the face within 1 month prior to study entry;

9. Had used topical products containing 5% or more α-hydroxy acids and/or β-hydroxy acids (e.g., Avon Anew, Olay BHA products, and any dermatologist products, such as the Murad line) within 1 month prior to study entry;

10. Had used peptide products (e.g., Olay Regenerist, Strivectin) within 1 month prior to study entry;

11. Had undergone phenol or trichloroacetic acid (TCA) deep peels within 1 year or medium to light peels within 3 months;

12. Had undergone facial cosmetic procedures such as dermabrasion, non-ablative laser rejuvenation or laser resurfacing within 1 year prior to study entry;

13. Had botulinum toxin injections or facial fillers (e.g., lipids, collagen, Restylane) within 6 months prior to study entry;

14. Had procedures of rhytidectomy (face-lifts), blepharoplasty, or had facial implants (silicone or Gore-Tex);

15. Were unwilling to use the SPF 30 sunscreen during the study;

16. Had participated in any facial clinical trial involving an investigational drug or cosmetic product or procedure within the past 28 days; and

17. Had moderate to severe acne or other chronic recurring skin disorder.

3.4.3 Interruption or Discontinuation of Treatment

In accordance with legal requirements and ICH-GCP guidelines (see Section 1.2), every subject or her legal representative had the right to refuse further participation in the study at any time and without providing reasons (see also Section 1.3). A subject's participation was terminated immediately upon her request. The investigator made every attempt to obtain the reason and record this on the subject's data sheet.

The termination of an individual's participation was to be considered in the case of a serious adverse event (SAE). If the subject, during the course of the study, developed conditions which would have prevented her entry into the study according to the safety-related medical exclusion criteria, she was to be withdrawn immediately.

The subject may have been withdrawn from the study at any time at the discretion of the investigator for medical reasons and/or due to non-adherence to the treatment scheme and other duties stipulated in the study protocol. The reasons were to be fully documented on the subject's data sheet.

3.4.4 Withdrawals

The following medical and other reasons justified a premature termination (by subject or investigator) of the subject from the study:

- withdrawal of informed consent,
- serious adverse events,
- allergic reactions to the study materials,
- subject's request,
- the subject missed visits that exceeded what was outlined in the protocol,
- subject was lost to follow-up,
- investigator's judgment, and/or
- adverse event.

If a subject withdrew from the study, all efforts were made to complete a final evaluation, if possible. Subjects discontinued due to an adverse event (AE) were, in most cases, followed until the AE was resolved, a reasonable explanation was provided for the event, or the subject was referred to her primary medical doctor (PMD). The specific AE in question was recorded on the appropriate form.

3.5 TREATMENTS

3.5.1 Investigational Product

Text Table 3-2 Investigational Product Information

Identity	Client's Test Article Codes	RCTS Test Article Codes	Manufacturer	Date Received (and quantity received)	Physical Description
Group A Zeatin	Group A	1837.7906	Senetek PLC 620 Airpark Road Napa, CA 94558	4/8/2005 (100 tubes)	White Cream
Group B Zeatin	Group B	1837.7907	Senetek PLC 620 Airpark Road Napa, CA 94558	4/8/2005 (100 tubes)	White Cream
Sensitive Skin Sunblock	Sensitive Skin Sunblock	1837.7908	Senetek PLC 620 Airpark Road Napa, CA 94558	4/8/2005 (125 bottles) 6/2/05 (60 bottles)	White Cream

The investigational products were supplied to the study site by Senetek PLC and stored at room temperature, 68°-77°F (20°-25°C). The product labels were printed in English and complied with RCTS Laboratory standards.

3.5.2 Handling of Study Products

The investigational products were supplied to the investigator by Senetek PLC. Study products were kept in an appropriate, secure area and stored according to the Sponsor's instructions. The study site confirmed receipt of the investigational products and used the investigational products only within the framework of this clinical study and in accordance with the study protocol.

All study products were used only for this protocol and not for any other purpose.

3.5.3 Assignment of Treatment Placement

Each subject who signed an informed consent and successfully completed the screening procedures was enrolled in the study. Upon enrollment, each subject was assigned a unique subject number.

3.5.4 Duration of Treatment

Each subject was instructed to apply Zeatin (0.10% or 0.025%) cream to their face twice daily, in the morning and evening, for twelve consecutive weeks. In the morning, after the Zeatin cream dried, the Sensitive Skin Sun block (SPF 30) was applied to the subject's entire face. In the evening the subject was instructed to wait an hour after application of the test article before retiring to bed.

3.5.5 Treatment Compliance

Subjects documented use of the test articles by recording the time and date of application on their daily diaries. Additionally, at each scheduled visit (except the Week 2 visit) the test articles were weighed at the testing facility.

3.6 BACKGROUND INFORMATION

Demographic data consisted of the age, gender and race of each subject. A summary of the demographics data is found in Post-Text Table I.

3.7 EFFICACY VARIABLES

Efficacy assessments were performed using instrumental measurements (TEWL and NOVA DPM) and visual evaluations of the subjects' faces as outlined in 3.3.2.2. Data collected at post-baseline visits were compared to baseline visits to determine the significance of the measured changes.

3.8 SAFETY VARIABLES

Safety assessments were performed using visual evaluations (Sub-Investigator's Evaluation of Skin Irritation, Overall Severity of Acne and Record of Individual Acne Lesions) and through anecdotal information (e.g., stinging, burning, itching) which was captured in the subjects' diaries.

3.8.1 Adverse Events

Information about all local and systemic adverse events (AEs), whether volunteered by the subject, discovered by investigator questioning, or detected through other means was collected and recorded on Adverse Event forms and followed as appropriate.

An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a test article, which did not necessarily have a causal relationship with the study treatment. An AE could, therefore, refer to any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of an investigational product, whether or not considered related to the investigational product.

Medical conditions/diseases present before starting study treatment were only considered AEs if they worsened after starting study treatment (i.e., after any procedures specified in the protocol had been initiated).

Each adverse event was also described by:

1. its duration (start and end dates),
2. the severity grade (mild, moderate, severe),
3. its relationship to the study drug (definitely unrelated, unlikely, possible, probable, definitely related),
4. the action(s) taken, and
5. as relevant, the outcome.

3.8.2 Serious Adverse Events (SAEs)

Information about all SAEs was collected and recorded on the SAE Report form. To ensure patient safety, each SAE was reported to the Sponsor within 24 hours of learning of its occurrence. A serious adverse event was defined as any undesirable sign, symptom, or medical condition which:

1. was fatal or life-threatening,
2. required or prolonged hospitalization,
3. resulted in persistent or significant disability/incapacity,
4. constituted a congenital anomaly or a birth defect, or
5. was medically significant, may have jeopardized the subject, and may have required medical or surgical intervention to prevent one of the outcomes listed above.

Events **not** considered to be serious adverse events were:

- hospitalization for the treatment, which was elective or pre-planned, for a pre-existing condition that did not worsen, and
- treatment on an emergency, outpatient basis for an event **not** fulfilling any of the definitions of serious given above and **not** resulting in hospital admission.

Details pertaining to the relationship of an AE to study drug, severity of an AE, AE monitoring, documentation and SAE reporting are provided for in the clinical study protocol (Appendix 2, Data Listing 10 of this report).

3.8.3 Pregnancy Testing

A urine pregnancy test was required at study entry and exit for those female subjects who were not surgically sterile or post-menopausal.

4 PROTOCOL AMENDMENTS

- One (1) amendment was made to the original Protocol.
    - Protocol Amendment 1 clarified that female subjects must be ambulatory, 30-65 years of age, in reasonably good health and Fitzpatrick Skin Types I-III. Additionally, it added to the exclusionary criteria that a panelist who had participated in a facial study in the past 28 days would not qualify for participation in this study.

5 DATA MANAGEMENT

5.1 DOCUMENTATION

The testing facility maintained detailed records on all study subjects. Data for this study was recorded on Case Report Forms (CRFs) provided by the Sponsor. All data were recorded completely, promptly, and legibly on the CRFs. Corrections were made in a manner that did not obscure or eliminate the original error, by striking through the original data with one line, and all corrections on the CRF were initialed and dated. The testing facility maintains a copy of all completed CRFs in its study files.

Originals and/or Certified copies of all data sheets, source documents, correspondence and study reports, etc. will be kept on hard-copy file by RCTS, Inc. for a minimum of two years from completion of the study. After two years, the investigator will obtain approval prior to any destruction. Storage is maintained at either the RCTS, Inc. facility at 800 W. Airport Freeway, Suite 110, Irving, TX 75062 in a secured room accessible only to RCTS employees, or at an offsite location that provides a secure environment with burglar/fire alarm systems, camera detection, and controlled temperature and humidity. Originals or copies of the source documents, correspondence, study reports, etc. will be available for the Sponsor's review on the premises of RCTS, Inc. or at a secure location off-site.

5.2 DATA COLLECTION

Individual subject files were maintained. These files included the name or initials of the subject, any AEs encountered, and other notes, as appropriate. The data sheets were kept in order and current, so that they reflected the latest observations on the subjects enrolled in the study.

The original signed informed consent form was attached to each subject’s file. When the study treatment was completed, the informed consent form was kept in the appropriate file folder; otherwise a note indicating where the records could be located was made. All records were kept in conformance to applicable national laws and regulations.

5.3 QUALITY ASSURANCE

This study was conducted in accordance with the intent and purpose of Good Clinical Practice Regulations (21 CFR 50, 21 CFR 56 and 21 CFR 54). The study data and this Final Report was reviewed and signed by a representative of the Quality Assurance staff of RCTS, Inc. The investigator allowed representatives of the Sponsor’s monitoring team (and, if necessary, city, state or federal regulating agencies) to inspect all study records, Case Report Forms at regular

intervals throughout the study. These inspections are for the purpose of verifying the adherence to the protocol, the completeness and exactness of the data being entered in the report form, and compliance with regulations.

As a part of the quality assurance procedure, the Quality Assurance (QA) group performed in-study audits and assured that all data in the tables reflected what was on the source documents. Finally, the QA group audited this final report to ensure the accuracy in reporting of results.

6 STATISTICAL METHODS

6.1 SAMPLE SIZE ESTIMATION

The sample size of 50 subjects was agreed to by the Sponsor and the testing facility for determining the efficacy and subjects' tolerance of a facial skin care product.

6.2 POPULATION

All subjects who completed a visit beyond the baseline visit were evaluable for efficacy.

6.3 STATISTICAL AND ANALYTICAL PLAN

Only those subjects who satisfied the criteria for an evaluable subject were included in the statistical analysis of cosmetic efficacy. An evaluable subject was one who met all entry criteria, did not use any systemic or other unapproved topical skin care product or medication during the study, completed at least one post-baseline visit and evaluation, and complied with the treatment regimen.

The primary objective of this study was to determine the efficacy of topical Zeatin (0.10%, 0.025%) for improving the appearance of photodamaged skin when topically applied twice daily for up to 12 weeks. The primary efficacy endpoint was the change from baseline in the individual clinical signs of skin aging (wrinkles (coarse and fine), roughness and mottled hyperpigmentation). For the primary analysis of efficacy, the skin aging parameters at each follow-up visit (weeks 2, 4, 8 and 12) versus baseline scores were assessed using a Wilcoxon signed rank test. The Investigator's and subjects' global evaluations of efficacy were analyzed using a Wilcoxon signed rank test for all follow-up evaluations (weeks 2, 4, 8 and 12). The change from baseline in TEWL and skin moisture content were determined for each respective skin treatment site and analyzed using a paired difference t-test. Finally, Groups A and B were compared to each other using a one factor analysis of variance (ANOVA).

Data were analyzed with the confidence interval placed at 95% ($p \leq 0.05$) and performed using the SAS® system.

6.3.1 Analysis of Subject Demographics

Descriptive statistics were used to summarize demographic characteristics (age, gender and race). A summary of the demographics data is found in Post-Text Table I (page 80).

6.4 CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED ANALYSIS

No changes in the conduct of the study or the planned analyses occurred.

7 RESULTS

7.1 SUBJECTS EVALUATED

Subjects' individual data tables are provided in Appendix 2 of this report. Diary comments, test article weights, and AEs can also be found in Appendix 2.

7.1.1 Subject Disposition

Seventy-three (73) subjects were enrolled in the study, of which 39 were enrolled in Group A and 34 were enrolled in Group B.

- Six (6) test subjects [Subject Nos.: 20, 22, 28, 34, 38 and 56] were dropped before their baseline visit due to reasons unrelated to the conduct of the study and, therefore, never received test article.
- Five (5) test subjects [Subject Nos.: 1, 9, 15, 33 and 63] were dropped after receiving test article; however, the reasons for discontinuation were unrelated to the conduct of the study.
- One (1) test subject [Subject No.: 61] was dropped due to violation of an exclusionary criteria (had been on a previous facial study within the last 28 days).
- Three (3) test subjects [Subject Nos.: 6, 54 and 73] were dropped due to non-serious adverse events (see Data Listing 10, Appendix 2, Page 221).
- One (1) test subject [Subject No.: 26] was discontinued due to a serious adverse event. Subject No.: 26, was admitted to the hospital for hand surgery (see Data Listing 10, Appendix 2, Page 221).

7.1.2 Protocol Deviations

Deviations to the protocol can be found in Appendix 2, Data Listing 11 (Page 223).

7.1.3 Baseline Demographic and Background Characteristics

All subjects enrolled met all of the inclusion, and none of the exclusion, requirements for study entry. Of the 73 subjects that were enrolled, 100% were female. Additionally, 39 subjects were assigned to Group A (0.10% Zeatin) and 34 subjects were assigned to Group B (0.025% Zeatin). The mean age of subjects enrolled into Group A was 49.9 years with a standard deviation of 7.0 years. The mean age of subjects enrolled into Group B was 50.2 years with a standard deviation of 8.1 years. Additionally, the ethnic composition of Group A was 87% Caucasian and 13% Hispanic. The ethnic composition of Group B was 85% Caucasian, 9% Hispanic, 3% Asian/pacific Islander and 3% Native American.

Of the 57 subjects that completed the study, 30 subjects were assigned to Group A and 27 subjects to Group B. The mean age of subjects that completed Group A was 51.1 years with a standard deviation of 6.6 years. The mean age of subjects that completed Group B was 50.0 years with a standard deviation of 8.7 years. Additionally, the ethnic composition of Group A was 90% Caucasian and 10% Hispanic. The ethnic composition of Group B was 85% Caucasian, 11% Hispanic and 4% Native American.

A summary of demographic information is provided in Post-Text Table I (Page 80).

7.2 TEST ARTICLES

7.2.1 Study Test Articles

All enrolled subjects, up to the point of discontinuation, received the scheduled applications of the test articles, as specified by the protocol.

7.3 ASSESSMENT OF EFFICACY

7.3.1 SUB-INVESTIGATOR'S ASSESSMENT OF SKIN AGING: FINE WRINKLES, COARSE WRINKLES, ROUGHNESS, MOTTLED HYPERPIGMENTATION, OVERALL SEVERITY OF SKIN AGING AND GLOBAL ASSESSMENT OF IMPROVEMENT

A summary of each assessment for each test article is located in Text Tables 7-1, 7-3, 7-5, 7-7, 7-9 and 7-11. Text Tables 7-2, 7-4, 7-6, 7-8, 7-10 and 7-12 provide a comparison of the baseline values to post-treatment values. A graphic representation of the data can be found in Text Figures 7-1 through 7-5.

Text Table 7-1 Sub-Investigator's Assessment of Fine Wrinkles

		Visits				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	2.61	2.45	2.17	1.90	1.73
	SD	0.62	0.62	0.79	0.88	0.91
	Median	3.00	2.00	2.00	2.00	1.00
	N	31	31	30	30	30
Group B	Mean	2.55	2.45	2.21	1.96	1.93
	SD	0.87	0.91	0.99	0.92	0.96
	Median	3.00	3.00	2.00	2.00	2.00
	N	29	29	28	28	27

Scale:

0 = None; 1 = Minimal; 2 = Mild; 3 = Moderate; 4 = Severe

Text Table 7-2 Intra-Subject Change in Fine Wrinkles

		Intra-Subject Change**			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	-0.16	-0.47	-0.73	-0.90
	SD	0.37	0.51	0.58	0.61
	Median	0.00	0.00	-1.00	-1.00
	N	31	30	30	30
	P-Value*	0.063***	**<0.001**	**<0.001**	**<0.001**
Group B	Mean	-0.10	-0.32	-0.57	-0.67
	SD	0.31	0.55	0.63	0.68
	Median	0.00	0.00	-0.50	-1.00
	N	29	28	28	27
	P-Value*	0.250	**0.008**	**<0.001**	**<0.001**
	P-Value^: Group A vs. Group B	0.518	0.207	0.266	0.150

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$
** Intra-subject change = Difference in values at two different time points (post-treatment minus baseline).
***Although not less than or equal to 0.05, the data are highly suggestive of a difference.
^P-Value derived from One-Factor Analysis of Variance Test.

Text Figure 7-1 Sub-Investigator's Assessment of Fine Wrinkles (Median Scores)



The data in Text Table 7-2 show the results of subtracting baseline values for Fine Wrinkles (as determined by the Sub-Investigator) from post-treatment values for Fine Wrinkles. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test.

The results indicate that when the changes in post-baseline values for Fine Wrinkles were compared to baseline values:

- There was a significant improvement (reduction), relative to baseline, in Fine Wrinkles at Weeks 4, 8 and 12 for Groups A and B.
- There was no significant difference, relative to baseline, in values for Fine Wrinkles at Week 2 for Groups A and B; however, it is highly suggestive ($P_{\text{Week 2 vs. Baseline}} = 0.063$) that an improvement in Fine Wrinkles was observed for Group A at Week 2.

When comparing the two groups together, there was no evidence that the Fine Wrinkle values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

Text Table 7-3 Sub-Investigator's Assessment of Coarse Wrinkles

		Visit				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	1.97	1.97	1.97	1.83	1.77
	SD	1.17	1.08	1.13	1.15	1.22
	Median	2.00	2.00	2.00	2.00	2.00
	N	31	31	30	30	30
Group B	Mean	1.83	1.76	1.71	1.68	1.70
	SD	1.42	1.43	1.51	1.54	1.49
	Median	1.00	1.00	1.00	1.00	1.00
	N	29	29	28	28	27

Scale:

0 = None; 1 = Minimal; 2 = Mild; 3 = Moderate; 4 = Severe

Text Table 7-4 Intra-Subject Change in Coarse Wrinkles Intra-Subject Change

		Intra-Subject Change**			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	0.00	-0.03	-0.17	-0.23
	SD	0.26	0.18	0.53	0.57
	Median	0.00	0.00	0.00	0.00
	N	31	30	30	30
	P-Value*	1.000	1.000	0.188	0.063***
Group B	Mean	-0.07	-0.14	-0.18	-0.22
	SD	0.26	0.36	0.39	0.42
	Median	0.00	0.00	0.00	0.00
	N	29	28	28	27
	P-Value*	0.500	0.125	0.063***	**0.031**
	P-Value^: Group A vs. Group B	0.309	0.142	0.752	0.950

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$
** Intra-subject change = Difference in values at two different time points (post-treatment minus baseline).
***Although not less than or equal to 0.05, the data are highly suggestive of a difference.
^P-value derived from One-Factor Analysis of Variance Test.

Text Figure 7-2 Expert Assessment of Coarse Wrinkles (Median Scores)



The data in Text Table 7-4 show the results of subtracting baseline values for Coarse Wrinkles (as determined by the Sub-Investigator) from post-treatment values for Coarse Wrinkles. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test.

The results indicate that when the changes in post-baseline values for Coarse Wrinkles were compared to baseline values:

- There was a significant improvement, relative to baseline, in Coarse Wrinkles at Week 12 for Group B. No other significant differences were observed at any other time points for Group B; however, it is highly suggestive ($P_{\text{Week 8 vs. Baseline}} = 0.063$) that an improvement in Coarse Wrinkles was observed at Week 8.
- There were no significant differences at any time points, relative to baseline, in Coarse Wrinkle values for Group A; however, it is highly suggestive ($P_{\text{Week 12 vs. Baseline}} = 0.063$) that an improvement in Coarse Wrinkles was observed at Week 12.

When comparing the two groups together, there was no evidence that the Coarse Wrinkle values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

Text Table 7-5 Sub-Investigator's Assessment of Roughness

		Visit				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	2.68	1.77	1.27	0.77	0.37
	SD	0.48	0.96	0.83	0.77	0.49
	Median	3.00	2.00	1.00	1.00	0.00
	N	31	31	30	30	30
Group B	Mean	2.41	1.59	1.07	0.82	0.44
	SD	0.68	0.91	0.72	0.77	0.64
	Median	3.00	2.00	1.00	1.00	0.00
	N	29	29	28	28	27

Scale:
0 = None; 1 = Minimal; 2 = Mild; 3 = Moderate; 4 = Severe

Text Table 7-6 Intra-Subject Change in Roughness

		Intra-Subject Change**			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	-0.90	-1.40	-1.90	-2.30
	SD	0.83	0.62	0.76	0.60
	Median	-1.00	-1.00	-2.00	-2.00
	N	31	30	30	30
	P-Value*	**<0.001**	**<0.001**	**<0.001**	**<0.001**
Group B	Mean	-0.83	-1.39	-1.64	-2.00
	SD	0.93	0.63	0.87	0.62
	Median	-1.00	-1.00	-2.00	-2.00
	N	29	28	28	27
	P-Value*	**<0.001**	**<0.001**	**<0.001**	**<0.001**
	P-Value^: Group A vs. Group B	0.683	0.958	0.266	0.070***

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$
** Intra-subject change = Difference in values at two different time point (post-treatment minus baseline).
***Although not less than or equal to 0.05, the data are highly suggestive of a difference.
^P-value derived from One-Factor Analysis of Variance Test.

Text Figure 7-3 Sub-Investigator's Assessment of Roughness (Median Scores)



The data in Text Table 7-6 show the results of subtracting baseline values for Roughness (as determined by the Sub-Investigator) from post-treatment values for Roughness. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test.

The results indicate that when the changes in post-baseline values for Roughness were compared to baseline values:

- There was a significant improvement, relative to baseline, in Roughness at all time points for Groups A and B.

When comparing the two groups together, there was no evidence of a significant difference at any time point. However, it is highly suggestive ($P_{\text{Week 12 vs. Baseline}} = 0.070$) that Group A performed better than Group B at Week 12.

Text Table 7-7 Sub-Investigator's Assessment of Mottled Hyperpigmentation

		Visit				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	1.97	1.84	1.57	1.63	1.47
	SD	0.87	0.93	0.90	0.85	0.90
	Median	2.00	2.00	1.50	2.00	1.00
	N	31	31	30	30	30
Group B	Mean	1.86	1.62	1.25	1.29	1.26
	SD	0.92	1.01	0.70	0.81	0.71
	Median	2.00	1.00	1.00	1.00	1.00
	N	29	29	28	28	27

Scale:
0 = None; 1 = Minimal; 2 = Mild; 3 = Moderate; 4 = Severe

Text Table 7-8 Intra-Subject Change in Mottled Hyperpigmentation

		Intra-Subject Change**			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	-0.13	-0.37	-0.30	-0.47
	SD	0.34	0.56	0.53	0.57
	Median	0.00	0.00	0.00	0.00
	N	31	30	30	30
	P-Value*	0.125	**0.002**	**0.012**	**<0.001**
Group B	Mean	-0.24	-0.57	-0.54	-0.59
	SD	0.51	0.50	0.64	0.80
	Median	0.00	-1.00	0.00	0.00
	N	29	28	28	27
	P-Value*	**0.039**	**<0.001**	**<0.001**	**0.001**
	P-Value^: Group A vs. Group B	0.281	0.099***	0.196	0.591

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at p≤0.05
** Intra-subject change = Difference in values at two different time point (post-treatment minus baseline).
***Although not less than or equal to 0.05, the data are highly suggestive of a difference.
^P-value derived from One-Factor Analysis of Variance Test.

Text Figure 7-4 Sub-Investigator's Assessment of Mottled Hyperpigmentation (Median Scores)



The data in Text Table 7-8 show the results of subtracting baseline values for Mottled Hyperpigmentation (as determined by the Sub-Investigator) from post-treatment values for

Mottled Hyperpigmentation. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test.

The results indicate that when the changes in post-baseline values for Mottled Hyperpigmentation were compared to baseline values:

- There was a significant improvement, relative to baseline, in Mottled Hyperpigmentation at all time points for Group B.
- There was a significant improvement, relative to baseline, in Mottled Hyperpigmentation at Weeks 4, 8 and 12 for Group A; however, no significant difference was observed at Week 2.

When comparing the two groups together, there was no evidence of a significant difference at any time point; however it is highly suggestive ($P_{\text{Week 4 vs. Baseline}} = 0.099$) that Group B performed better than Group A at Week 4.

Text Table 7-9 Sub-Investigator's Assessment of Overall Severity of Skin Aging

		Visits				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	3.97	3.55	3.07	2.90	2.70
	SD	1.17	1.26	1.31	1.42	1.47
	Median	4.00	3.00	3.00	2.50	2.00
	N	31	31	30	30	30
Group B	Mean	4.03	3.45	3.00	2.86	2.81
	SD	1.43	1.70	1.49	1.58	1.57
	Median	4.00	4.00	2.50	3.00	3.00
	N	29	29	28	28	27

Scale:

0 = None; 1-3 = Mild; 4-6 = Moderate; 7-9 = Severe

Text Table 7-10 Intra-Subject Change in Overall Severity of Skin Aging

		Intra-Subject Change**			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	-0.42	-0.90	-1.07	-1.27
	SD	0.50	0.61	0.78	0.78
	Median	0.00	-1.00	-1.00	-1.00
	N	31	30	30	30
	P-Value*	**<0.001**	**<0.001**	**<0.001**	**<0.001**
Group B	Mean	-0.59	-1.00	-1.14	-1.30
	SD	0.57	0.54	0.80	0.72
	Median	-1.00	-1.00	-1.00	-1.00
	N	29	28	28	27
	P-Value*	**<0.001**	**<0.001**	**<0.001**	**<0.001**
	P-Value^: Group A vs. Group B	0.267	0.504	0.987	0.720

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$
** Intra-subject change = Difference in values at two different time points (Post-Treatment minus Baseline).
^P-value derived from One-Factor Analysis of Variance Test.

Text Figure 7-5 Sub-Investigator's Assessment of Overall Severity of Skin Aging (Median Scores)



The data in Text Table 7-10 show the results of subtracting baseline values for Overall Severity of Skin Aging (as determined by the Sub-Investigator) from post-treatment values for Overall Severity of Skin Aging. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test.

The results indicate that when the changes in post-baseline values for Overall Severity of Skin Aging were compared to baseline values:

- There was a significant improvement, relative to baseline, in Overall Severity of Skin Aging at all time points for both Groups A and B.

When comparing the two groups together, there was no evidence that the Overall Severity of Skin Aging values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

Text Table 7-11 Sub-Investigator's Assessment of the Improvement of Skin Aging

		Visit			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	4.74	4.23	4.23	4.23
	SD	0.44	0.43	0.43	0.43
	Median	5.00	4.00	4.00	4.00
	N	31	30	30	30
Group B	Mean	4.66	4.39	4.32	4.26
	SD	0.48	0.50	0.48	0.45
	Median	5.00	4.00	4.00	4.00
	N	29	28	28	27

Scale:
1 = Excellent Improvement; 2 = Marked Improvement; 3 = Moderate Improvement; 4 = Slight Improvement; 5 = No Improvement; 6 = Worse

Text Table 7-12 Intra-Subject Change in the Improvement of Skin Aging

		Intra-Subject Change**			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	0.26	0.77	0.77	0.77
	SD	0.44	0.43	0.43	0.43
	Median	0.00	1.00	1.00	1.00
	N	31	30	30	30.0
	P-Value*	**0.008**	**0.000**	**0.000**	**0.000**
Group B	Mean	0.34	0.61	0.68	0.74
	SD	0.48	0.50	0.48	0.45
	Median	0.00	1.00	1.00	1.00
	N	29	28	28	27
	P-Value*	**0.002**	**0.000**	**0.000**	**0.000**
	P-Value^: Group A vs. Group B	0.472	0.196	0.462	0.824

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$

** The Intra-Subject Change scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from Baseline, or a negative value, indicative of a worsening from Baseline

^P-value derived from One-Factor Analysis of Variance Test.

The data in Text Table 7-12 show the results of subtracting baseline values for Improvement of Skin Aging (as determined by the Sub-Investigator) from post-treatment values for Improvement of Skin Aging. The p-values obtained as a result of the change (post-treatment minus baseline) were obtained using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test. Additionally, the scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from baseline, or a negative value, indicative of a worsening from baseline.

The results indicate that when the changes in post-baseline values for Improvement of Skin Aging were compared to baseline values:

- There was a significant improvement, relative to baseline, in Improvement of Skin Aging at all time points for both Groups A and B.

When comparing the two groups together, there was no evidence that the Improvement in Skin Aging values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

7.3.2 SUBJECT'S SELF ASSESSMENT: SKIN TEXTURE, SKIN COLOR, BLOTCHINESS – BROWN SPOTS, FINE WRINKLES AND OVERALL IMPROVEMENT

Subject self assessment summaries for each test article are located in Text Tables 7-13, 7-15, 7-17, 7-19 and 7-21. Text Tables 7-14, 7-16, 7-18, 7-20 and 7-22 provide a comparison of the change at Weeks 2, 4, 8 and 12 to baseline.

Text Table 7-13 Subject Self Assessment of Skin Texture

		Visit			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	2.48	2.27	1.97	1.83
	SD	0.72	0.58	0.41	0.59
	Median	2.00	2.00	2.00	2.00
	N	31	30	30	30
Group B	Mean	2.24	2.25	1.79	1.78
	SD	0.64	0.65	0.50	0.64
	Median	2.00	2.00	2.00	2.00
	N	29	28	28	27

Scale:
1 = Much Improved; 2 = Somewhat Improved; 3 = No Change;
4 = Somewhat Worse; 5 = Much Worse

Text Table 7-14 Self Assessment of Skin Texture: Comparison of Post-Treatment to Baseline

		Intra-Subject Change**			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	0.52	0.73	1.03	1.17
	SD	0.72	0.58	0.41	0.59
	Median	1.00	1.00	1.00	1.00
	N	31	30	30	30
	P-Value*	**0.001**	**0.000**	**0.000**	**0.000**
Group B	Mean	0.76	0.75	1.21	1.22
	SD	0.64	0.65	0.50	0.64
	Median	1.00	1.00	1.00	1.00
	N	29	28	28	27
	P-Value*	**0.000**	**0.000**	**0.000**	**0.000**
	P-Value^: Group A vs. Group B	0.208	0.941	0.132	0.704

*P-Values generated from the Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$

^P-Value derived from a One-Factor Analysis of Variance Test.

**Note: The Intra-Subject Scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from Baseline, or a negative value, indicative of a worsening from Baseline

***Although not less than or equal to 0.05, the data are highly suggestive of a difference.

The data in Text Table 7-14 show the results of subtracting baseline values for Skin Texture (as determined by the Subject) from post-treatment values for Skin Texture. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test. Additionally, the scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from baseline, or a negative value, indicative of a worsening from baseline.

The results indicate that when the changes in post-baseline values for Skin Texture were compared to baseline values:

- There was a significant improvement, relative to baseline, in Skin Texture at all time points for both Groups A and B.

When comparing the two groups together, there was no evidence that the Skin Texture values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

Text Table 7-15 Subject Self Assessment of the Evaluation of Skin Color

		Visit			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	2.74	2.67	2.37	2.27
	SD	0.58	0.55	0.76	0.69
	Median	3.00	3.00	2.00	2.00
	N	31	30	30	30
Group B	Mean	2.72	2.39	2.07	2.19
	SD	0.53	0.57	0.54	0.74
	Median	3.00	2.00	2.00	2.00
	N	29	28	28	27

Scale:
1 = Much Improved; 2 = Somewhat Improved; 3 = No Change;
4 = Somewhat Worse; 5 = Much Worse

Text Table 7-16 Self Assessment of Skin Color: Comparison of Post-Treatment to Baseline

		Intra-Subject Change**			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	0.26	0.33	0.63	0.73
	SD	0.58	0.55	0.76	0.69
	Median	0.00	0.00	1.00	1.00
	N	31	30	30	30
	P-Value*	**0.035**	**0.006**	**0.000**	**0.000**
Group B	Mean	0.28	0.61	0.93	0.81
	SD	0.53	0.57	0.54	0.74
	Median	0.00	1.00	1.00	1.00
	N	29	28	28	27
	P-Value*	**0.021**	**0.000**	**0.000**	**0.000**
	P-Value^: Group A vs. Group B	0.753	0.084***	0.077***	0.693

*P-Values generated from the Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$
^P-Value derived from a One-Factor Analysis of Variance Test
**Note: The Intra-Subject Scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from Baseline, or a negative value, indicative of a worsening from Baseline
***Although not less than or equal to 0.05, the data are highly suggestive of a difference.

The data in Text Table 7-16 show the results of subtracting baseline values for Skin Color (as determined by the Subject) from post-treatment values for Skin Color. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor Analysis of Variance test. Additionally, the scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from baseline, or a negative value, indicative of a worsening from baseline.

The results indicate that when the changes in post-baseline values for Skin Color were compared to baseline values:

- There was a significant improvement, relative to baseline, in Skin Color at all time points for both Groups A and B.

When comparing the two groups together, there was no evidence of a significant difference at any time point relative to baseline; however it is highly suggestive ($P_{\text{Week 4 vs. Baseline}} = 0.084$ and $P_{\text{Week 8 vs. Baseline}} = 0.077$) that Group B performed better than Group A at Weeks 4 and 8.

Text Table 7-17 Subject Self Assessment Evaluation of Blotchiness – Brown Spots

		Visits			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	3.00	2.90	2.50	2.57
	SD	0.37	0.48	0.68	0.63
	Median	3.00	3.00	3.00	3.00
	N	31	30	30	30
Group B	Mean	2.86	2.79	2.32	2.26
	SD	0.44	0.50	0.77	0.76
	Median	3.00	3.00	2.50	2.00
	N	29	28	28	27

Scale:
1 = Much Improved; 2 = Somewhat Improved; 3 = No Change;
4 = Somewhat Worse; 5 = Much Worse

Text Table 7-18 Self Assessment Evaluation of Blotchiness – Brown Spots: Comparison of Post-Treatment to Baseline

		Intra-Subject Change**			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	0.00	0.10	0.50	0.43
	SD	0.37	0.48	0.68	0.63
	Median	0.00	0.00	0.00	0.00
	N	31	30	30	30
	P-Value*	1.000	0.453	**0.001**	**0.002**
Group B	Mean	0.14	0.21	0.68	0.74
	SD	0.44	0.50	0.77	0.76
	Median	0.00	0.00	0.50	1.00
	N	29	28	28	27
	P-Value*	0.219	0.070***	**0.000**	**0.000**
	P-Value^: Group A vs. Group B	0.188	0.380	0.477	0.158

*P-Values generated from the Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$

^P-Value derived from a One-Factor Analysis of Variance Test

**Note: The Intra-Subject Scores recorded at Week 2 were adjusted to reflect either a positive value, indicative of an improvement from Baseline, or a negative value, indicative of a worsening from Baseline

***Although not less than or equal to 0.05, the data are highly suggestive of a difference.

The data in Text Table 7-18 show the results of subtracting baseline values for Blotchiness (as determined by the Subject) from post-treatment values for Blotchiness. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test. Additionally, the scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from baseline, or a negative value, indicative of a worsening from baseline.

The results indicate that when the changes in post-baseline values for Blotchiness were compared to baseline values:

- There was a significant improvement, relative to baseline, in Blotchiness at Weeks 8 and 12 for Group A. No other significant difference was observed at any other time point.
- There was a significant improvement, relative to baseline, in Blotchiness at Weeks 8 and 12 for Group B. No other significant difference was observed at any other time point; however, it is highly suggestive ($P_{\text{Week 4 vs. Baseline}} = 0.070$) that the appearance of Blotchiness-Brown Spots was improved at Week 4.

When comparing the two groups together, there was no evidence that the Skin Blotchiness values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

Text Table 7-19 Self Assessment of Fine Wrinkles

		Self Assessment of Fine Wrinkles			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	2.61	2.30	2.07	2.10
	SD	0.72	0.53	0.45	0.61
	Median	3.00	2.00	2.00	2.00
	N	31	30	30	30
Group B	Mean	2.41	2.29	2.07	1.93
	SD	0.50	0.60	0.47	0.78
	Median	2.00	2.00	2.00	2.00
	N	29	28	28	27

Scale:
1 = Much Improved; 2 = Somewhat Improved; 3 = No Change;
4 = Somewhat Worse; 5 = Much Worse

Text Table 7-20 Self Assessment of Fine Wrinkles: Comparison of Post-Treatment to Baseline

		Intra-Subject Change**			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	0.39	0.70	0.93	0.90
	SD	0.72	0.53	0.45	0.61
	Median	0.00	1.00	1.00	1.00
	N	31	30	30	30
	P-Value*	**0.011**	**0.000**	**0.000**	**0.000**
Group B	Mean	0.59	0.71	0.93	1.07
	SD	0.50	0.6	0.47	0.78
	Median	1.00	1.00	1.00	1.00
	N	29	28	28	27
	P-Value*	**0.000**	**0.000**	**0.000**	**0.000**
	P-Value^: Group A vs. Group B	0.248	0.782	0.965	0.253

*P-Values generated from the Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$

^P-Value derived from a One-Factor Analysis of Variance Test

**Note: The Intra-Subject Scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from Baseline, or a negative value, indicative of a worsening from Baseline

***Although not less than or equal to 0.05, the data are highly suggestive of a difference.

The data in Text Table 7-20 show the results of subtracting baseline values for Fine Wrinkles (as determined by the Subject) from post-treatment values for Fine Wrinkles. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived

from a One-Factor Analysis of Variance test. The values recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from baseline, or a negative value, indicative of a worsening from baseline.

The results indicate that when the changes in post-baseline values for Fine Wrinkles were compared to baseline values:

- There was a significant improvement, relative to baseline, in Fine Wrinkles at all time points for both Groups A and B.

When comparing the two groups together, there was no evidence that the Fine Wrinkle values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

Text Table 7-21 Subject Self Assessment of Overall Improvement

		Visit			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	2.58	2.23	2.00	1.87
	SD	0.72	0.43	0.45	0.51
	Median	3.00	2.00	2.00	2.00
	N	31	30	30	30
Group B	Mean	2.34	2.18	2.00	1.89
	SD	0.48	0.55	0.47	0.58
	Median	2.00	2.00	2.00	2.00
	N	29	28	28	27

Scale:
1 = Much Improved; 2 = Somewhat Improved; 3 = No Change;
4 = Somewhat Worse; 5 = Much Worse

Text Table 7-22 Self Assessment of Overall Improvement: Comparison of Post Treatment to Baseline

		Intra-Subject Change**			
	Descriptive Statistics	Week 2	Week 4	Week 8	Week 12
Group A	Mean	0.42	0.77	1.00	1.13
	SD	0.72	0.43	0.45	0.51
	Median	0.00	1.00	1.00	1.00
	N	31	30	30	30
	P-Value*	**0.007**	**0.000**	**0.000**	**0.000**
Group B	Mean	0.66	0.82	1.00	1.11
	SD	0.48	0.55	0.47	0.58
	Median	1.00	1.00	1.00	1.00
	N	29	28	28	27
	P-Value*	**0.000**	**0.000**	**0.000**	**0.000**
	P-Value^: Group A vs. Group B	0.168	0.511	1.000	0.906

*P-Values generated from the Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$

^P-Value derived from a One-Factor Analysis of Variance Test

**Note: The Intra-Subject Scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from Baseline, or a negative value, indicative of a worsening from Baseline.

***Although not less than or equal to 0.05, the data are highly suggestive of a difference.

The data in Text Table 7-22 show the results of subtracting baseline values for Overall Improvement (as determined by the Subject) from post-treatment values for Overall Improvement. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor Analysis of Variance test. Additionally, the scores recorded at Weeks 2, 4, 8 and 12 were adjusted to reflect either a positive value, indicative of an improvement from baseline, or a negative value, indicative of a worsening from baseline.

The results indicate that when the changes in post-baseline values for Overall Improvement were compared to baseline values:

- There was a significant improvement, relative to baseline, in Overall Improvement at all time points for both Groups A and B.

When comparing the two groups together, there was no evidence that the Overall Improvement values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

7.3.3 Transepidermal Water Loss (TEWL) Measurements

A summary of the TEWL measurements for each test article is located in Text Table 7-23. Text Table 7-24 provides a comparison of the baseline values to post-treatment values. A graphic representation of the data can be found in Text Figure 7-6.

Text Table 7-23 TEWL Measurements

				TEWL Measurements ($g/m^2/hr$)				
RCTS Test Article Codes	Client Test Article Codes	Site Measured	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
1837.7906	Group A	Average of Right Cheek and Left Cheek	Mean	10.71	12.71	11.61	11.30	11.84
			SD	4.82	5.13	4.08	3.90	4.19
			Median	8.68	11.20	10.49	10.51	10.65
			N	31	31	30	30	30
			% Change		19%	8%	6%	11%
1837.7907	Group B	Average of Right Cheek and Left Cheek	Mean	11.30	12.78	11.50	10.55	12.23
			SD	4.14	5.37	3.29	3.08	3.72
			Median	11.10	12.00	11.85	10.90	12.00
			N	29	29	28	28	27
			% Change		13%	2%	-7%	8%

Text Table 7-24 Intra-Subject Change in TEWL Measurements

				Intra-Subject Change in TEWL Measurements (g/m²/hr)**			
RCTS Test Article Code	Client Test Article Code	Site Measured	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
1837.7906	Group A	Average of Right Cheek and Left Cheek	Mean	2.00	0.79	0.49	1.03
			SD	3.82	2.48	3.37	2.74
			Median	1.85	0.31	0.54	1.11
			N	31	30	30	30
			P-Value*	**0.007**	0.090***	0.431	**0.049**
1837.7907	Group B	Average of Right Cheek and Left Cheek	Mean	1.48	-0.06	-1.01	0.70
			SD	3.98	2.78	2.65	3.03
			Median	0.38	0.48	-0.78	1.05
			N	29	28	28	27
			P-Value*	0.056***	0.908	0.053***	0.240
			P-Value^: Group A vs. Group B	0.605	0.221	0.066***	0.672

*P-values generated from a paired-difference t-test. Bolded values are significant at $p \leq 0.05$

** Intra-subject change = Difference in TEWL values at two different time points (Post-Baseline minus Baseline)

***Although not less than or equal to 0.05, the data are highly suggestive of a difference.

^P-Value derived from a One Factor Analysis of Variance Test

Text Figure 7-6 TEWL Measurements



The data in Text Table 7-24 show the results of subtracting baseline TEWL values from TEWL post-treatment values. The value obtained as a result of the change was compared to zero using a paired-difference t-test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor Analysis of Variance test. Values were considered significant ($P \leq 0.05$) if the change was significantly greater than zero (no change).

The results indicate that:

- When the post-treatment TEWL values were compared to baseline, there were significant increases in TEWL values at Weeks 2 and 12 for Group A. No other significant differences were observed at any other time point; however it is highly suggestive ($P_{\text{Week 4 vs. Baseline}} = 0.090$) that the Week 4 TEWL values were elevated over baseline. [An increase in TEWL values can indicate a disruption in the barrier properties of the skin].
- No significant differences were observed at any time point for Group B; however it is highly suggestive ($P_{\text{Week 2 vs. Baseline}} = 0.056$ and $P_{\text{Week 8 vs. Baseline}} = 0.053$) that at Week 2 TEWL values were elevated and at Week 8 the values were depressed over baseline. Group B's Week 2 TEWL values increased indicating the product induced skin barrier damage; however, Week 8 TEWL values decreased indicating the product improved the skin's barrier properties.
- When comparing the two groups together, there was no evidence of a significant difference at any time point; however, it is highly suggestive ($P_{\text{Week 8 vs. Baseline}} = 0.066$) that Group B performed better (i.e., had lower TEWL values) than Group A at Week 8.

7.3.4 SKIN MOISTURE MEASUREMENTS

A summary of the DPM measurements for each test article is located in Text Table 7-25. Text Table 7-26 provides a comparison of the baseline values to post-treatment values. A graphic representation of the data can be found in Text Figure 7-7.

Text Table 7-25 DPM Measurements

				DPM Measurements (au)				
RCTS Test Article Code	Client Test Article Code	Site Measured	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
1837.7906	Group A	Average of Right Cheek and Left Cheek	Mean	121.88	121.40	122.07	137.53	121.98
			SD	23.36	26.28	27.33	39.31	21.52
			Median	117.00	111.33	111.33	133.50	118.17
			N	31	31	30	30	30
			% Change		-0.40%	0.15%	12.84%	0%
1837.7907	Group B	Average of Right Cheek and Left Cheek	Mean	111.31	114.03	113.14	120.80	119.38
			SD	21.52	24.83	12.63	22.89	18.62
			Median	102.67	106.33	110.50	119.17	112.00
			N	29	29	28	28	27
			% Change		2.45%	1.65%	8.52%	7%

Text Table 7-26 Intra-Subject Change in DPM Measurements

				Intra-Subject Change in DPM Measurements (au)**			
RCTS Test Article Code	Client Test Article Code	Site Measured	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
1837.7906	Group A	Average of Right Cheek and Left Cheek	Mean	-0.48	-0.20	15.27	-0.29
			SD	28.43	26.40	34.97	25.80
			Median	0.00	-4.67	9.33	3.17
			N	31	30	30	30
			P-Value*	0.925	0.967	**0.024**	0.952
1837.7907	Group B	Average of Right Cheek and Left Cheek	Mean	2.72	3.95	11.61	9.78
			SD	17.80	16.82	24.26	24.31
			Median	4.00	4.84	13.67	9.33
			N	29	28	28	27
			P-Value*	0.417	0.225	**0.018**	**0.047**
			P-Value^: Group A vs. Group B	0.605	0.482	0.647	0.136

*P-values generated from a paired-difference t-test. Bolded values are significant at $p \leq 0.05$

** Intra-subject change = Difference in NOVA DPM values at two different time points (Post-Baseline minus Baseline)

^P-Value derived from a One Factor Analysis of Variance Test

Text Figure 7-7 Mean DPM Values



The data in Text Table 7-26 reveal the following:

- When the post-treatment NOVA DPM values for Group A were compared to baseline values, a significant increase* at Week 8 was measured. No other significant differences were observed at any other time point.
- When the post-treatment NOVA DPM values for Group B were compared to baseline values, there were significant increases at Weeks 8 and 12. No other significant differences were observed at any other time point.
- When comparing the two groups together, there was no evidence that the NOVA DPM values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

*An increase in NOVA DPM values indicates, indirectly, an increase in the skin's moisture properties.

7.4 SAFETY RESULTS

7.4.1 SUB-INVESTIGATOR'S ASSESSMENT OF SKIN IRRITATION, OVERALL SEVERITY OF ACNE AND RECORD OF INDIVIDUAL ACNE LESIONS

A summary of skin irritation, overall severity of acne and a count of the individual acne lesion for each test article is located in Text Tables 7-27, 7-29, 7-31, 7-33 and 7-35. Text Tables 7-28, 7-30, 7-32, 7-34 and 7-36 provide a comparison of the baseline values to post-treatment values. A graphic representation of the data (mean & median values) can be found in Text Figures 7-8 through 7-12.

Text Table 7-27 Sub-Investigator's Assessment of Skin Irritation

		Visit				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	1.10	0.94	0.67	0.33	0.43
	SD	0.40	0.63	0.66	0.48	0.50
	Median	1.00	1.00	1.00	0.00	0.00
	N	31	31	30	30	30
Group B	Mean	0.97	0.69	0.43	0.32	0.15
	SD	0.42	0.54	0.57	0.55	0.36
	Median	1.00	1.00	0.00	0.00	0.00
	N	29	29	28	28	27

Scale:

0 = None; 1 = Mild; 2 = Moderate; 3 = Severe

Text Table 7-28 Intra-Subject Change in Skin Irritation Data

		Intra-Subject Change**			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	-0.16	-0.43	-0.77	-0.67
	SD	0.52	0.63	0.57	0.55
	Median	0.00	-0.50	-1.00	-1.00
	N	31	30	30	30
	P-Value*	0.180	**0.002**	**<0.001**	**<0.001**
Group B	Mean	-0.28	-0.54	-0.64	-0.78
	SD	0.53	0.51	0.49	0.42
	Median	0.00	-1.00	-1.00	-1.00
	N	29	28	28	27
	P-Value*	**0.021**	**<0.001**	**<0.001**	**<0.001**
	P-Value^: Group A vs. Group B	0.408	0.624	0.441	0.347

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at p≤0.05
** Intra-Subject Change = Difference in values at two different time points (Post-Baseline Minus Baseline)
^P-value derived from One-Factor Analysis of Variance Test.

Text Figure 7-8 Sub-Investigator's Assessment of Skin Irritation (Median Scores)



The data in Text Table 7-28 show the results of subtracting baseline values for Skin Irritation (as determined by the Sub-Investigator) from post-treatment values for Skin Irritation. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a

Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test. Values were considered significant ($P \leq 0.05$) if the change was significantly greater than zero (no change).

The results indicate that when the changes in post-baseline values for Skin Irritation were compared to baseline values:

- There was a significant improvement, relative to baseline, in Skin Irritation at all time points relative to baseline for Group B.
- There was a significant improvement, relative to baseline, in Skin Irritation at Weeks 4, 8 and 12 for Group A; however, no significant changes were observed at Week 2.

When comparing the two groups together, there was no evidence that the Skin Irritation values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

Text Table 7-29 Sub-Investigator's Assessment of Overall Severity of Acne

		Visit				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	0.81	0.84	0.90	0.50	0.70
	SD	0.48	0.37	0.40	0.51	0.53
	Median	1.00	1.00	1.00	0.50	1.00
	N	31	31	30	30	30
Group B	Mean	0.66	0.66	0.57	0.57	0.56
	SD	0.48	0.48	0.57	0.50	0.51
	Median	1.00	1.00	1.00	1.00	1.00
	N	29	29	28	28	27

Scale:

0 = None; 1 = Mild; 2 = Moderate; 3 = Severe

Text Table 7-30 Intra-Subject Change in Overall Severity of Acne Data

		Intra-Subject Change**			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	0.03	0.10	-0.30	-0.10
	SD	0.48	0.48	0.53	0.55
	Median	0.00	0.00	0.00	0.00
	N	31	30	30	30
	P-Value*	1.000	0.453	**0.012**	0.508
Group B	Mean	0.00	-0.07	-0.07	-0.07
	SD	0.65	0.54	0.54	0.68
	Median	0.00	0.00	0.00	0.00
	N	29	28	28	27
	P-Value*	1.000	0.727	0.727	0.774
	P-Value^: Group A vs. Group B	0.838	0.208	0.116	0.912

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$

** Intra-Subject Change = Difference in values at two different time points (Post-Baseline Minus Baseline)

^P-value derived from One-Factor Analysis of Variance Test.

Text Figure 7-9 Sub-Investigator's Assessment of Overall Severity of Acne (Median Scores)



The data in Text Table 7-30 show the results of subtracting baseline values for Overall Severity of Acne (as determined by the Sub-Investigator) from post-treatment values for Overall Severity of Acne. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test.

The results indicate that when the changes in post-baseline values for Overall Severity of Acne were compared to baseline values:

- There was a significant improvement, relative to baseline, in Overall Severity of Acne at Week 8 for Group A. No significant differences were observed at Weeks 2, 4 and 12.
- No significant changes, relative to baseline, were observed in Overall Severity of Acne at any time points for Group B.

When comparing the two groups together, there was no evidence that the Overall Severity of Acne values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

Text Table 7-31 Sub-Investigator's Assessment of Inflammatory Acne Lesions

		Visit				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	1.65	1.94	2.47	1.47	1.83
	SD	2.58	2.14	2.48	2.32	2.68
	Median	1.00	1.00	2.00	0.00	0.50
	N	31	31	30	30	30
Group B	Mean	1.21	1.66	1.57	1.36	1.26
	SD	1.61	2.50	2.54	3.63	2.89
	Median	0.00	1.00	0.00	0.00	0.00
	N	29	29	28	28	27

Text Table 7-32 Intra-Subject Change in Inflammatory Acne Lesion Data

		Intra-Subject Change**			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	0.29	0.77	-0.23	0.13
	SD	3.05	3.28	3.08	3.06
	Median	0.00	0.00	0.00	0.00
	N	31	30	30	30
	P-Value*	0.407	0.165	0.891	0.941
Group B	Mean	0.45	0.46	0.25	0.15
	SD	2.44	2.57	3.27	2.74
	Median	0.00	0.00	0.00	0.00
	N	29	28	28	27
	P-Value*	0.459	0.490	0.800	0.921
	P-Value^: Group A vs. Group B	0.682	0.411	0.856	0.948

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$

** Intra-Subject Change = Difference in values at two different time points (Post-Baseline Minus Baseline)

^P-value derived from One-Factor Analysis of Variance Test.

Text Figure 7-10 Sub-Investigator's Assessment of Inflammatory Acne Lesions (Median Scores)



The data in Text Table 7-32 show the results of subtracting baseline values for Inflammatory Acne Lesions (as determined by the Sub-Investigator) from post-treatment values for Inflammatory Acne Lesions. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor Analysis of Variance test.

The results indicate that when the changes in post-baseline values for Inflammatory Acne Lesions were compared to baseline values:

- There was no evidence of any significant changes in Inflammatory Acne Lesions at any time point, relative to baseline, for either Group A or Group B.

When comparing the two groups together, there was no evidence that the Inflammatory Acne Lesion values generated in Group A were significantly different from those generated in Group B, regardless of the time point.

Text Table 7-33 Sub-Investigator's Assessment of Non-Inflammatory Acne Lesions

		Visit				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	8.19	4.23	6.20	2.63	4.67
	SD	11.84	6.34	9.00	5.18	7.14
	Median	4.00	2.00	2.00	0.00	2.00
	N	31	31	30	30	30
Group B	Mean	3.00	1.55	2.68	2.07	1.52
	SD	4.68	2.08	6.59	3.67	1.99
	Median	2.00	0.00	0.00	0.00	0.00
	N	29	29	28	28	27

Text Table 7-34 Intra-Subject Change in Non-Inflammatory Acne Lesion Data

		Intra-Subject Change*			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	-3.97	-1.83	-5.40	-3.37
	SD	10.38	8.21	9.11	8.40
	Median	-1.00	0.00	-2.00	-2.00
	N	31	30	30	30
	P-Value*	**0.048**	0.396	**<0.001**	**0.020**
Group B	Mean	-1.45	-0.29	-0.89	-1.48
	SD	4.48	7.53	3.49	5.18
	Median	-1.00	0.00	0.00	0.00
	N	29	28	28	27
	P-Value*	0.127	0.181	0.177	0.264
	P-Value^: Group A vs. Group B	0.585	0.725	**0.018**	0.190

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at p≤0.05

** Intra-Subject Change = Difference in values at two different time points (Post-Baseline Minus Baseline)

^P-value derived from One-Factor Analysis of Variance Test.

Text Figure 7-11 Sub-Investigator's Assessment of Non-Inflammatory Acne Lesions (Median Scores)



The data in Text Table 7-34 show the results of subtracting baseline values for Non-Inflammatory Acne Lesions (as determined by the Sub-Investigator) from post-treatment values for Non-Inflammatory Acne Lesions. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test.

The results indicate that when the changes in post-baseline values for Non-Inflammatory Acne Lesions were compared to baseline values:

- There was a significant decrease, relative to baseline, in Non-Inflammatory Acne Lesions at Weeks 2, 8 and 12 for Group A. No evidence of a significant difference was observed at Week 4.
- No evidence of a significant change, relative to baseline, was observed at any time point for Group B.

When comparing the two groups together, Group A performed significantly better (i.e., had a greater impact on reducing the appearance of non-inflammatory acne lesions) than Group B at the Week 8 visit. No other significant differences between the groups were observed, regardless of the time point.

Text Table 7-35 Sub-Investigator's Assessment of Total Acne Lesions (Inflammatory & Non-Inflammatory Lesions)

		Visit				
	Descriptive Statistics	Baseline	Week 2	Week 4	Week 8	Week 12
Group A	Mean	9.84	6.16	8.67	4.10	6.50
	SD	13.07	6.68	10.67	6.69	8.83
	Median	7.00	4.00	4.50	1.00	3.00
	N	31	31	30	30	30
Group B	Mean	4.21	3.21	4.25	3.43	2.59
	SD	5.81	3.23	8.24	5.49	3.39
	Median	3.00	3.00	1.00	1.50	2.00
	N	29	29	28	28	27

Text Table 7-36 Intra-Subject Change in Total Acne Lesions (Inflammatory & Non-Inflammatory Lesions)

		Intra-Subject Change**			
	Descriptive Statistics	Week 2 vs. Baseline	Week 4 vs. Baseline	Week 8 vs. Baseline	Week 12 vs. Baseline
Group A	Mean	-3.68	-1.07	-5.63	-3.23
	SD	11.17	10.65	10.10	9.70
	Median	-1.00	0.00	-2.00	-1.50
	N	31	30	30	30
	P-Value*	0.116	0.814	**0.001**	**0.044**
Group B	Mean	-1.00	0.18	-0.64	-1.52
	SD	4.99	8.90	4.34	5.83
	Median	0.00	0.00	0.00	0.00
	N	29	28	28	27
	P-Value*	0.466	0.446	0.401	0.237
	P-Value^: Group A vs. Group B	0.503	0.715	**0.032**	0.360

*P-values generated from a Wilcoxon Signed-Rank Test. Bolded values are significant at $p \leq 0.05$

** Intra-Subject Change = Difference in values at two different time points (Post-Baseline Minus Baseline)

^P-value derived from One-Factor Analysis of Variance Test.

Text Figure 7-12 Sub-Investigator's Assessment of Total Acne Lesions (Median Scores)



The data in Text Table 7-36 show the results of subtracting baseline values for Total Acne Lesions (as determined by the Sub-Investigator) from post-treatment values for Total Acne

Lesions. The p-values obtained as a result of the change (post-treatment minus baseline) were generated using a Wilcoxon Signed-Rank test. The p-values obtained when comparing Group A to Group B were derived from a One-Factor ANOVA test.

The results indicate that when the changes in post-baseline values for Total Acne Lesions were compared to baseline values:

- There was a significant decrease, relative to baseline, in Total Acne Lesions at Weeks 8 and 12 for Group A. No evidence of a significant change was observed at Weeks 2 and 4.
- No evidence of a significant change, relative to baseline, was observed at any time point for Group B.

When comparing the two groups together, Group A performed significantly better (i.e., had a greater impact on reducing the appearance of the total number of acne lesions) than Group B at the Week 8 visit. No other significant differences between the groups were observed, regardless of the time point.

7.4.2 Overall Experience of Adverse Events

All treatment-emergent adverse events are listed in Data Listing 10 (Appendix 2).

During this study, 34 adverse events were recorded. One (1) of the adverse events was considered serious. The breakdown for adverse events is as follows:

Type of Adverse Event	Frequency of Adverse Events
Blemishes (breakout)	11
Headache	1
Peeling/Sloughing	1
Swelling	1
Watery eye	1
Clogged pores	1
Hand Surgery (considered a serious adverse event unrelated to test article use)	1
Tightness	6
Redness	3
Redness with bumps	1
Dryness	2
Rash/bumps	1
Eyes Burning	2
Bronchitis	1
Bump	1

The relationship of the event to the test article can be found in Appendix 2, Data Listing 10.

8 DISCUSSION AND OVERALL CONCLUSIONS

Conclusions:

This was a 12 week, double blinded, single centre study designed to determine the efficacy and tolerance of two concentrations of Zeatin (0.10% and 0.025%). Under the conditions of this study:

Skin Aging

- **Fine Wrinkles**

  Sub-Investigator's Assessment of Skin Aging for Fine Wrinkles

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the appearance of Fine Wrinkles for both Groups A and B after 4, 8 and 12 weeks of test article use. No significant difference in the appearance of Fine Wrinkles was observed at Week 2, regardless of the test group.
  - When comparing the Fine Wrinkle data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

  Subject's Self Assessment for Fine Wrinkles

  - Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in the appearance of Fine Wrinkles at all time points.
  - When comparing the changes observed in both groups, there was no significant difference in the data generated between Groups A and B at any time point.

- **Coarse Wrinkles**

  Sub-Investigator's Assessment of Skin Aging for Coarse Wrinkles

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the appearance of Coarse Wrinkles for subjects assigned to Group B values after 12 weeks of test article use. No other significant differences were observed at any time point.
  - Subjects in Group A did not show a significant change, relative to baseline, in Coarse Wrinkle values; however, it was highly suggestive that reduction in Coarse Wrinkle values was observed at Week 12.
  - When comparing the Coarse Wrinkle data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

- **Roughness**

  Sub-Investigator's Assessment of Skin Aging for Roughness

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the skin's Roughness values for both Groups A and B at all time points.
  - When comparing the Roughness data generated by Group A to that generated by Group B, no significant difference

between the groups was observed at any time point. However, the data were highly suggestive that subjects in Group A had a greater improvement in Roughness values, relative to Group B, at the Week 12 time point.

Subject's Self Assessment of Skin Texture

- Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in their skin's texture at all time points.
- When comparing the Skin Texture data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

- **Overall Severity of Skin Aging**

  Sub-Investigator's Assessment of Skin Aging for Overall Severity of Skin Aging

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the Overall Severity of Skin Aging values for both Groups A and B at all time points.
  - When comparing the Overall Severity of Skin Aging data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

- **Global Assessment of Improvement**

  Sub-Investigator's Global Assessment of Improvement of Skin Aging

  - The Sub-Investigator noticed a significant improvement, relative to baseline, in the Global Assessment of Improvement in Skin Aging values for both Groups A and B at all time points.
  - When comparing the Global Assessment of Improvement in Skin Aging data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

  Subject's Self Assessment of Overall Improvement

  - Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in their skin at all time points.
  - When comparing the Overall Improvement data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

Skin Color

Sub-Investigator's Assessment of Skin Aging for Mottled Hyperpigmentation

- The Sub-Investigator detected a significant improvement in Mottled Hyperpigmentation for subjects in Group A at Weeks 4, 8 and 12.

- The Sub-Investigator detected a significant improvement in Mottled Hyperpigmentation for subjects in Group B at all time points.
- It was highly suggestive that Group B performed better than Group A at Week 4.
- When comparing the Mottled Hyperpigmentation data generated by Group A to that generated by Group B, It was highly suggestive that Group B performed better than Group A at Week 4.

Subject's Self Assessment of Blotchiness – Brown Spots

- Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in the Blotchiness-Brown Spots of their skin at Weeks 8 and 12.
- When comparing the Blotchiness-Brown Spots data generated by Group A to that generated by Group B, no significant difference between the groups was observed at any time point.

Subject's Self Assessment of Skin Color

- Subjects in both Groups A and B noticed a significant improvement, relative to baseline, in their Skin's Color at all time points.
- When comparing the Skin Color data generated by Group A to that generated by Group B, It was highly suggestive that Group B performed better than Group A at Weeks 4 and 8.

Skin Barrier Properties (TEWL) Moisturization (NOVA DPM)

TEWL Measurements

- Subjects in Group A produced significantly elevated TEWL values, relative to baseline, at Weeks 2 and 12.
- There was no significant difference in TEWL values, relative to baseline, detected for subjects in Group B at any time point.
- It was highly suggestive that subjects in Group B had lower TEWL values than subjects in Group A at the Week 8 time point.

NOVA DPM Measurements

- Subjects in Group A had significantly increased NOVA DPM values (an indirect measure of skin moisturization), relative to baseline, at Week 8.
- Group B had significantly increased NOVA DPM values at Weeks 8 and 12.
- There was no significant difference between Groups A and B at any time point.

Safety

Sub-Investigator's Assessment of Skin Irritation

- The Sub-investigator detected a significant improvement, relative to baseline, in skin irritation for subjects in Group A at Weeks 4, 8 and 12.
- The Sub-investigator detected a significant improvement, relative to baseline, in skin irritation for subjects in Group B at all time points.
- There was no significant difference between Groups A and B at any time point.

Sub-Investigator's Assessment of Overall Severity of Acne

- Group A had significantly improved (reduced) values, relative to baseline, for Overall Severity of Acne at Week 8.
- No significant difference, relative to baseline, in the Overall Severity of Acne was observed at any time point for subjects in Group B.
- There was no significant difference between Groups A and B at any time point.

Count of Individual Acne Lesions

- Inflammatory Acne Lesions
  - There were no significant changes in the inflammatory acne lesion counts, relative to baseline, for either group regardless of the time point.
  - There was no significant difference between Groups A and B at any time point.
- Non-Inflammatory Acne Lesions
  - Group A had significantly decreased Non-Inflammatory Acne Lesion counts at Weeks 2, 8 and 12, relative to baseline.
  - Subjects in Group B did not show a significant change, relative to baseline, in the presence of Non-Inflammatory Acne Lesions at any time point.
  - Group A performed significantly better than Group B at decreasing the number of Non-Inflammatory Acne Lesions at Week 8.
- Total Inflammatory & Non-Inflammatory Acne Lesions
  - Group A had significantly lower Total Acne Lesion counts at Weeks 8 and 12, relative to baseline.
  - Subjects in Group B did not show a significant change, relative to baseline, in the Total Inflammatory and Non-Inflammatory Acne Lesion counts at any time point.

- Group A performed significantly better than Group B at decreasing the number of Total Acne Lesion counts at Week 8.

Therefore, in general, the test articles (0.10% and 0.025% Zeatin) performed at parity and helped to improve:

- The appearance of Fine Wrinkles (Weeks 4, 8 and 12)
- Coarse Wrinkles (Group B at Week 12)
- Roughness (at all time points)
- Overall Severity of Skin Aging (at all time points)
- Mottled Hyperpigmentation (Group A at Weeks 4, 8 and 12; Group B at all time points)
- Blotchiness-Brown Spots (Weeks 8 and 12)
- Overall Skin Color (at all time points)

Additionally, the test articles were well tolerated with both the Sub-Investigator and Subjects not detecting any significant increase in irritation. In fact, the Sub-Investigator detected a significant improvement in the appearance of irritation, relative to baseline, after 4, 8 and 12 weeks of test article use (subjects in Group B actually showed a reduction in irritation at Week 2 as well).

Regarding the effect of the test articles on acne counts, while the test articles performed, in general, at parity (no significant difference between subjects who used the Zeatin at 0.10% and those that used Zeatin at 0.025%), subjects using Zeatin at 0.10% seemed to show a greater reduction, relative to baseline, in the presence of non-inflammatory and total acne lesions.

Finally, neither test article was effective at reducing TEWL. In fact, subjects in Group A (Zeatin at 0.10%) showed elevated TEWL values at Weeks 2 and 12. However, regarding NOVA DPM measurements, subjects in Group B (Zeatin at 0.025%) showed elevated NOVA DPM values at Weeks 8 and 12. Subjects in Group A showed elevated NOVA DPM values at Week 8 only.

9 POST-TEXT TABLES

Follow:

Table I

Demographics of Subjects

		Group A		Group B	
		Enrolled	Completed	Enrolled	Completed
Age of Test Subjects	Mean	49.8	51.1	50.2	50.0
	SD	7.0	6.6	8.1	8.7
	Median	50.0	51.5	52.0	52.0
	Range	31-64	38-64	32-64	32-64
	N	37	30	36	27
Gender of Test Subjects	Female	100%	100%	100%	100%
Ethnicity of Test Subjects	Caucasian	34 (87%)	27 (90%)	29 (85%)	24 (85%)
	Hispanic	5 (13%)	3 (10%)	3 (9%)	3 (11%)
	Native American	0 (0%)	0 (0%)	1 (3%)	1 (4%)
	Asian/Pacific Islander	0 (0%)	0 (0%)	1 (3%)	0 (0%)
Number of Completed Subjects	57				
Number of Discontinued Subjects	16				

10 APPENDICES

Follow

APPENDIX 1 STUDY INFORMATION

1.1 Protocol and Protocol Amendment

CLINICAL PROTOCOL

Title:	A Clinical Study of Topical Zeatin (0.1%, 0.025%) for Improving the Appearance of Photodamaged Skin
Date:	March 17, 2005
RCTS Panel Number:	1837
Sponsor:	Senetek PLC 620 Airpark Road Napa, CA 94558
Sponsor's Representative:	Frank Massino Phone: 707-226-3900 ext. 109 E Mail: Frank@senetek.net
Test Articles:	Zeatin (0.1%) Zeatin (0.025%)
Medical Investigator:	_____ Ponciano Cruz, Jr., MD Date Board Certified Dermatologist
Address:	RCTS, Inc. 800 W. Airport Freeway, Suite 110 Irving, Texas 75062
Phone: Fax:	972-871-7578 214-441-2583

Approvals:

Linh Kobylar, BA Quality Assurance RCTS, Inc.	Date
Barry T. Reece, MS, MBA Sub Investigator Vice President/Managing Partner RCTS, Inc.	Date
Frank Massino CEO Senetek PLC	Date

TABLE OF CONTENTS

SUMMARY

Treatment Articles:	Zeatin (0.10%) Zeatin (0.025%)
Control Articles:	Not Applicable
Route of Administration:	Topical application to the face
Objective:	To compare the efficacy and tolerance of topical zeatin (0.1% and 0.025%) applied twice daily for 12 weeks for improving the clinical signs of age-related changes in photodamaged facial skin.
Study Population:	Enroll approximately 50 subjects (25 subjects in Cell I and 25 Subjects in Cell II)

Structure: [X] Parallel Group — Duration of Treatment: Approx. 12 Weeks

[ ] Crossover

[ ] Other (intra-individual) — Duration of Study: Approximately 14 Weeks

Multicenter:	☐ Yes ☒ No	Number of Centers: 1 US site Common Training: ☒ Yes ☐ No
Masking:	☐ None ☐ Evaluator-Masked ☐ Patient-Masked ☒ Double-Masked ☐ Triple-Masked	
Method of Patient Assignment: Randomization:	☒ Yes	☐ No
Concurrent Control:	☒ None ☐ No Treatment ☐ Placebo ☐ Active ☐ Other	 Specify: Specify:

Estimated Total Sample Size: 25 subjects completed per cell

Efficacy Variables:
Primary:

1. Observations by the sub-investigator to determine the improvement of wrinkles (coarse and fine), roughness, mottled hyperpigmentation, global assessment of overall severity and degree of improvement relative to baseline;
2. Subject self-assessment to determine the improvement of wrinkles, texture, blotchiness, color and perform a global assessment to document the overall improvement in their facial skin;
3. Effect of the treatment(s) on Transepidermal Water Loss (TEWL); and
4. Effect of the treatment(s) on Skin Capacitance (an indirect measure of skin moisturization)

Secondary:

5. Observation by the sub-investigator for skin irritation and acne lesion counts; and
6. Subject self-assessment of skin tolerance.

Adverse Events:		Volunteered
		Elicited
	X	Both

Evaluability

Only subjects who meet all of the inclusion and none of the exclusion criteria will be evaluable.

Analyses

The primary statistical objectives of this study are to describe the efficacy of Zeatin (0.1% or 0.025%) with regard to the reduction in the signs of photoaging when used by a population of normal, healthy female subjects for 12 weeks. The test article(s) will be deemed effective if the post treatment data associated with the primary efficacy variables show a significant improvement relative to baseline values.

1. INTRODUCTION

Kinetin is a cytokinin that regulates various aspects of plant growth and differentiation. The antiaging actions of kinetin on human skin were first demonstrated by Rattan and Clark (*Biochem. Biophys. Res. Commun.* 201:665-672, 1994) in cultured human fibroblasts, where the presence of kinetin delayed the onset and decreased the extent of many morphological and biochemical characteristics associated with serial passaging of cells. The effectiveness of kinetin in maintaining normal cell function in aging cells provides the basis for its use for preserving the vitality of aging skin.

Previous studies with a total of 96 subjects were conducted at the University of California, Irvine by Dr. Gerald Weinstein and Dr. Jerry McCullough (*Cosmetic Dermatology* 15: 29-32, 2003) to assess the tolerance and effectiveness of topical kinetin products ranging in concentration from 0.005% to 0.10% (Kinerase7) for the treatment of mild to moderately photodamaged facial skin. Treatments after 12 and 24 weeks produced significant improvement in the appearance of skin texture, mottled hyperpigmentation and fine wrinkles compared to baseline as assessed by both the physician and the subject. Treatments also produced an improvement in skin barrier function as assessed by a decrease in transepidermal water loss. Overall, the treatments were well tolerated by the subjects.

Zeatin, is cytokinin plant growth factor, 6-[4-hydroxy-3-methyl-but-2-enylamino] adenine, that like kinetin, also has growth modulatory, anti-oxidative and ant-senescence effects in human skin cells (Rattan and Sodagam, 2004). Zeatin is a plant cytokinin that has been identified to be present in the tRNA of a wide variety of organisms. There is a large body of information regarding the biosynthesis, activity and degradation of zeatin in bacteria, fungi and higher plants. The recent studies of Rattan and Sodagam have demonstrated several beneficial and youth-preserving effects of *trans*-zeatin on human cells (skin fibroblasts) undergoing aging *in vitro.* Although kinetin and zeatin are very much alike in their anti-aging effects on human skin cells, on a short-term basis, human skin fibroblasts can tolerate higher concentrations of zeatin. Kinetin is a DNA-based modified adenine, whereas, zeatin is a tRNA-based modified adenine.

2. OBJECTIVE

The primary objective of this study is to determine the cosmetic efficacy and subjects' tolerance of topical zeatin (0.10% and 0.025%) applied twice daily for 12 weeks for improving the clinical signs and symptoms of photodamaged facial skin.

3. TEST ARTICLES

3.1. Study Test Articles

Enough test articles will be supplied to evaluate approximately 25 subjects per cell. Depending on cell assignment, the subjects will receive one of the following test articles:

3.1.1. Zeatin (0.1%)
Lot Number TBD
Provided by Senetek PLC (Napa, CA)
Test article will be stored at room temperature (59-86^{o}F, 15-30^{o}C)

3.1.2. Zeatin (0.025%)
Lot Number TBD
Provided by Senetek PLC (Napa, CA)
Test article will be stored at room temperature (59-86^{o}F, 15-30^{o}C)

A certificate of analysis, or equivalent, for the Zeatin will be provided to the testing facility by the Sponsor. A copy of the certificate of analysis, or equivalent, will be provided in the final report.

Test articles will be coded by the Sponsor in a manner consistent with the study design.

3.2. Test Article Usage

Each subject will be randomly assigned to one of two cells and provided with the test article associated with their cell. Subjects will be instructed to use the test article twice daily for 12 weeks according to the following instructions:

1. Wash your face with a mild cleanser and dry completely prior to application of the product to your face;
2. Apply a liberal amount of the product to your face in the early morning and about one hour before bedtime;
3. In the morning, after the product has absorbed into the skin, apply the sunscreen that was provided to you to your face; and
4. Other than the product being provided to you, do not introduce any new products into your skin care regimen.

For test article accountability see 15.2

4. SUBJECTS:

4.1. Subject Population

Subjects will be normal, healthy female volunteers between the ages of 30 and 65.

4.2. Inclusion Criteria

Subjects must satisfy all of the following criteria:

1. Subjects must be ambulatory, 30 to 65 years of age and in reasonably good health;

2. Female subjects must be postmenopausal, surgically sterile or using a medically acceptable form of birth control with a negative urine pregnancy test;

3. Subjects must have mild to moderate changes associated with skin aging (1-6 overall severity score);

4. Subjects are willing to refrain from using lotions, moisturizers, or other skin care products (except those provided by the testing facility) or any medications on their facial area during the treatment period. Subjects are permitted to use their color cosmetics (e.g., foundation, blush) as long as the color cosmetics do not contain anti-aging ingredients;

5. Subjects are willing to have clinical photographs taken to document their improvement;

6. All subjects must agree to refrain from applying any products (including the test product) to their face the day of their visits. Additionally, subjects must not have bathed or showered within two hours of their study visit (i.e., bathing or showering must have occurred no less than 2 hours before their study visits);

7. Subjects must agree not to wear any facial makeup to any of their visits (lip and eye color are acceptable); and

8. Subjects have indicated willingness to participate in the study by signing an informed consent document and a photo release document.

4.3. Exclusion Criteria

Subjects with any of the following conditions are not eligible for participation:

1. Subject is pregnant or lactating;

2. Subject with a global severity score greater than 6 (see section 5.1.2.3);

3. Subject has history or evidence of any chronic or reoccurring skin disease or disorder (e.g., psoriasis, eczema, atopic dermatitis, mild to moderate acne, etc.) affecting the face;

4. Subject has a known allergy to any component of study formulation or a proclivity to cutaneous hyper-reactivity;

5. Subject requires the use of a tanning bed or participates in activities that involve excessive prolonged exposure to the sun;

6. Subject has used systemic retinoids within 6 months prior to study entry (e.g., acitretin, isotretinoin);

7. Subject has used topical retinoids within 2 months prior to study entry (e.g. tretinoin, adapalene);

8. Subject has received treatment with systemic corticosteroids within 6 months or topical corticosteroids to the face within 1 month prior to study entry;

9. Subject has used topical products containing 5% or more α-hydroxy acids and/or β-hydroxy acids (e.g., Avon Anew, Olay BHA products, and any dermatologist products, such as the Murad line) within 1 month prior to study entry;

10. Subject has used peptide products (e.g., Olay Regenerist, Strivectin) within 1 month prior to study entry;

11. Subject has undergone phenol or trichloroacetic acid (TCA) deep peels within 1 year or medium to light peels within 3 months;

12. Subject has undergone facial cosmetic procedures such as dermabrasion, non-ablative laser rejuvenation or laser resurfacing within 1 year prior to study entry;

13. Subject has had botulinum toxin injections or facial fillers (e.g., lipids, collagen, Restylane) within 6 months prior to study entry;

14. Subject has ever had procedures of rhytidectomy (face-lifts), blepharoplasty, or had facial implants (silicone or Gore-Tex);

15. Subject is unwilling to use the SPF 30 sunscreen during the study;

16. Subject has participated in any clinical trial involving an investigational drug or cosmetic product or procedure within the past 30 days; and

17. Subjects with moderate to severe acne or other chronic recurring skin disorder.

5. STUDY PROCEDURES

5.1. Study Design

This is a 12 week, double-blinded study designed to determine the efficacy of two concentrations (0.1% and 0.025%) of Zeatin. Fifty female volunteer subjects age 30 to 65 with mild to moderate signs of photodamaged facial skin will be enrolled into this study to evaluate the cosmetic efficacy and tolerance of topical zeatin (0.10% and 0.025%). Twenty-five subjects will be assigned to a cell which evaluates Zeatin at 0.10% and 25 subjects will be assigned to a cell which evaluates Zeatin at 0.025%. Subjects will apply the test products to the entire facial skin twice daily, in the early morning and in the evening (approximately 1 hour before bedtime) for 12 consecutive weeks. Subjects will be assessed for tolerance profile at weeks 2, 4, 8 and 12. At study entry (baseline), and at 2, 4, 8 and 12 weeks, the

treated facial skin will be evaluated for clinical signs of skin aging, including observations by the sub-Investigator on wrinkles (coarse and fine), roughness, mottled hyperpigmentation, as well as subject self-assessment of improvement over baseline (wrinkles, texture, blotchiness, color and overall improvement). In addition, transepidermal water loss (TEWL) and skin moisture measurements will be taken on the cheeks of all subjects. Finally, standard clinical photographs of the face will be taken at baseline and at weeks 2, 4, 8 and 12.

5.1.1. Pre-Qualification of Test Subjects

Prior to study initiation, each subject will be screened to ensure they meet all of the inclusion and none of the exclusion criteria outlined above. Potential subjects will be interviewed and examined by the Sub-Investigator or his designee to establish their eligibility for inclusion in the study. Subjects will be given a full description of the nature and purpose of the study. If a subject is willing to participate, they must provide written informed consent before proceeding with the study.

Screening procedures will include the following activities for prospective participants:

1. Investigator, or designee, explains the investigational study and eligibility requirements;
2. Subject signs informed consent prior to any study-related procedures;
3. Record demographic information;
4. Brief dermatologic, medication and skin care/cosmetic product history;
5. Urine pregnancy test for females of childbearing potential; and
6. Subjects admitted to study will be assigned a specific subject number.

5.1.2. Day 0 (Baseline)

Qualified subjects arriving at the testing facility will be directed into an exam room where they will be allowed to equilibrate for at least 15 minutes under controlled environmental conditions ($70^{o}F \pm 3^{o}F$; 45% ± 10% relative humidity). During equilibration the subjects will be interviewed regarding any changes to their medical history since their screening visit, asked to provide a detail account of all concomitant medications and skin care products and their face evaluated to ensure no cuts, abrasions or other dermal deviations are present which might prevent further participation on the clinical study. Following equilibration, each subject will undergo a series of clinical measurements designed to assess the skin's overall condition.

5.1.2.1 Transepidermal Water Loss (TEWL)

TEWL refers to the amount of water vapor loss through the stratum corneum. If the water loss through the stratum corneum is altered, a corresponding change (increase or decrease) in TEWL will be observed. An observed increase in TEWL values can be a result of either Evaporative Water Loss (e.g. sweating or evaporation) or skin barrier damage. An observed decrease in TEWL values can be a result of either improvement in barrier function or the presence of a barrier over the skin.

In this study, TEWL measurements will be taken using a TEWA meter (Courage & Khazaka, Köln, Germany). The TEWA meter is composed of a probe, containing two sensors (humidity and temperature), connected to a central processing unit. The probe will be placed in the center of both cheeks and measurements taken in duplicate. The corresponding data generated from the TEWL measurements will be entered onto the subject's case report form (CRF).

5.1.2.2 Skin Moisture Measurements

Although a direct measurement of the skin's moisture content is possible, it is not practical. However, an indirect measure of the skin's moisture content is possible by measuring changes in the skin's electrical properties. Impedance based capacitance measurements can be taken on the skin using the NOVA DPM 9003® (NOVA Technologies, Gloucester, MA, USA). The instrument performs measurements at varying frequencies of the applied alternating current. The instrument takes a number of measurements at pre-selected frequencies up to 1 MHz. The actual calculation of the capacitance value is proprietary; however, the value displayed is directly related to capacitance and is displayed on the instrument in arbitrary units. A higher value indicates a greater capacitance which is indirectly related to the level of moisture at the test site.

In this study NOVA DPM measurements will be taken in the center of both cheeks. The probe will rest gently on the skin and measurements taken in triplicate. The corresponding data generated from the NOVA DPM measurements will be entered onto the subject's case report form (CRF).

5.1.2.3 Expert Assessment of Subject's Facial Skin

At the baseline (Day 0) visit the Sub-Investigator will evaluate each subject's face for the presence of the following:

- Fine Wrinkles
- Coarse Wrinkles
- Roughness
- Mottled Hyperpigmentation

The Sub-Investigator will use the following five-point scale to describe the above parameters:

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

Finally, the Sub-Investigator will evaluate the overall severity of skin photodamage using the 10 point scale below. The scale is an integrated assessment of all the signs of photoaging (wrinkles, roughness and mottled hyperpigmentation) previously evaluated.

OVERALL SEVERITY SCORE

NONE	MILD			MODERATE			SEVERE		
0	1	2	3	4	5	6	7	8	9

Subjects with baseline severity scores greater than 6 will be excluded from the study.

5.1.2.4 Clinical Photography

Clinical photographs of each subject will be taken using a Fuji S2 digital camera attached to a Canfield Scientific VISIA CR Booth (Canfield Scientific, Fairfield, NJ). The subject will be positioned in the booth and photos taken of both the left and right profiles as well as a frontal photo. The profile photographs will be taken at an angle of 45^{o}. Photographs will be taken using standard lighting, polarized lightening (crossed and parallel) and UV lightening. Additionally, close-up photographs of the peri-orbital area will be taken on both the left and right sides of the subject's face. No formal assessments or analysis of the photographs will be made. All subjects must sign a photographic consent form to participate in the study.

5.1.2.5 Irritation and the Overall Severity of Acne

The baseline level of irritation will be assessed using the following four-point scale:

0: None.
1: Mild.
2: Moderate.
3: Severe.

In addition, individual acne lesions will be recorded. The lesion counts will be taken from the facial area [forehead, left and right cheeks, and chin above the jaw line (excluding the nose)]. The counts will be added together to form three groups of lesion counts: inflammatory, non-inflammatory and total lesion counts. Open and closed comedones will make up the non-inflammatory group; papules and pustules will make up the inflammatory group and all of the lesions will compose the total lesion count group. The following are definitions of each lesion type counted:

- Open comedone – A mass of sebaceous material that is impacted behind an open follicular orifice (blackhead)
- Closed comedone – A mass of sebaceous material that is impacted behind a closed follicular orifice (whitehead)
- Papule – A small, palpable, solid elevation less than 1 cm in diameter
- Pustule – A small, circumscribed elevation of the skin which contains yellow /yellowish-white exudates.

5.1.2.6 Distribution of Test Article and Instructions to Subjects

Following baseline clinical measurements, subject will be provided with the test article and instructed to use the test article according to the following instructions:

1. Wash your face with a mild cleanser and dry completely prior to application of the product to your face;
2. Apply a liberal amount of the product to your face in the early morning and about one hour before bedtime;
3. In the morning, after the product has absorbed into the skin, apply the sunscreen, which was provided to you, to your face. Avoid prolonged sun exposure;
4. Other than the product being provided to, do not introduce any new products into your skin care regimen;
5. Do not apply any topical medications to your face;
6. Do not take any steroid or retinoid medications; and
7. Do not apply the test article or makeup to your face the morning of a scheduled visit.

Finally, all subjects will be provided with a daily diary to record the dates and times of test article application and to record any observations or comments they feel pertinent to the study.

Following test article and diary distribution, each subject will be instructed to return to the testing facility at 2, 4, 8 and 12 weeks. Subjects will be instructed not to apply the test article the day of their visits.

5.1.3. Week 2

Subjects arriving at the testing facility on week 2 will be directed into an exam room where they will equilibrate for at least 15 minutes under controlled environmental conditions (70°F ± 3°F; 45% ± 10% relative humidity). During equilibration subjects will be queried for concomitant medication/skin care products/cosmetics and adverse events. Following equilibration, subjects will undergo the same measurements as described above (5.1.2.1 to 5.1.2.5). In addition to the measurements performed at baseline, the following additional measurements will be taken:

5.1.3.1 Global Assessment of Improvement

The sub-investigator will rate the overall improvement compared to baseline using a 6-point scale: (1) excellent improvement (100%); (2) marked improvement (~75%); (3) moderate improvement (~50%); (4) slight improvement (~25%); (5) no improvement (0%); (6) worse. Color photographs taken at baseline will be used to assist the sub-investigator in the global evaluation.

GLOBAL ASSESSMENT OF RESPONSE



5.1.3.2 Subject's Perception of Efficacy

At each follow-up evaluation the subject will be asked to complete a self-assessment questionnaire to assess the improvement from baseline for each of the following:

Skin texture
Skin color
Blotchiness (brown spots)

Fine wrinkles
Overall improvement

Subjects will use the following five-point scale to document the changes on their face:

(1) = much improved;
(2) = somewhat improved;
(3) = no change;
(4) = somewhat worse;
(5) = much worse.

In addition to measurements, the diary distributed at the baseline visit will be collected and a new diary distributed to each subject. No new test article will be distributed at the week 2 visit.

5.1.4. Weeks 4, 8 and 12

Subjects arriving at the testing facility on weeks 4, 8 and 12 will be directed into an exam room where they will equilibrate for at least 15 minutes under controlled environmental conditions ($70^{o}F \pm 3^{o}F$; 45% ± 10% relative humidity). During equilibration the subjects will be queried for concomitant medication/skin care products/cosmetics and adverse events. Following equilibration, subjects will undergo all measurements performed previously (see sections 5.1.2.1 to 5.1.2.5 and 5.1.3.1 to 5.1.3.2). Additionally, at Weeks 4 and 8 used test article will be exchanged for new and old diaries exchanged for new.

5.2. Duration of Study

Enrollment Phase: Approximately Two weeks to recruit 50 subjects

Total Duration of Subject Participation: Approximately 12 Weeks

Total Trial Duration: Approximately 15 weeks

5.3. Subject Population

Fifty evaluable female subjects with mild-to-moderate age-related changes in facial skin will participate in this clinical study. An evaluable subject is one who has passed the inclusion and exclusion criteria; given informed consent; received the assigned test formulation and applied the test article according to the treatment schedule, and has been adequately followed to establish valid endpoints of efficacy and tolerance. Replacement subjects may be enrolled with consent from the sponsor.

5.3.1. Subject Numbering

Each subject who satisfies the inclusion and exclusion criteria will be assigned a number for treatment in accordance with their chronological order of qualification for the study. Once a treatment number has been assigned to a subject it cannot be re-assigned to any other subject.

6. STATISTICAL METHODS

6.1. Sample Size Estimation

The sample size of 25 evaluable subjects per cell was requested by the Sponsor.

6.2. Population

All subjects who receive treatment and complete the study will be considered evaluable.

6.3. Statistical and Analytical Plan

Upon completion of the research study, the data will be analyzed by the Sponsor for tolerance and efficacy at each follow-up interval versus baseline. Only those subjects who satisfy the criteria for an evaluable subject will be included in the statistical analysis of cosmetic efficacy. An evaluable subject is one who meets all entry criteria, not used any systemic or other unapproved topical skin care product or medication during the study, completed at least one post-baseline visit and evaluation, and complied with the treatment regimen.

Skin irritation reactions during the study will be summarized using descriptive statistics and percentages whenever it is appropriate. The primary objective of this study is to determine the efficacy of topical zeatin (0.10%, 0.025%) for improving the appearance of skin aging when topically applied twice daily for up to 12 weeks. The primary efficacy endpoint is the change from baseline in the individual clinical signs of skin aging (wrinkles (coarse and fine), roughness and mottled hyperpigmentation). For the primary analysis for efficacy, the skin aging parameters at each follow-up visit (weeks 2, 4, 8 and 12) versus baseline scores will be assessed using a paired Student's *t*-test and a Wilcoxon signed rank test. The Investigator's and subject's global evaluation of efficacy will be summarized descriptively for all follow-up evaluations (weeks 2, 4, 8 and 12). The change from baseline in TEWL and skin moisture content will be determined for each respective skin treatment site and statistically analyzed.

7. STUDY COMPLETION STATUS

7.1. Normal Study Completion

Subjects who complete all visits of the study.

7.2. Discontinued Subjects

The investigator (and/or sponsor) may discontinue the subject at any time based on his/her discretion. Reasons for discontinuation and forms required for each example are as follows:

7.2.1. Adverse Events

Subjects may be discontinued because of adverse event(s) that, in the opinion of the investigator, present a significant risk to their safety or well-being.

7.2.2. Lost to Follow up

Subjects who fail to return for scheduled visits and who cannot be reached by phone (at least two documented phone calls must be completed), are considered Lost to Follow up. If the subject is reached by phone and explains the reason for not returning, then Lost to Follow up is NOT the reason for discontinuation.

7.2.3. Subject Decision Unrelated to Adverse Event

Subjects may be discontinued if they do not wish to continue due to scheduling conflicts or any other personal reason.

7.2.4. Noncompliance

Subjects that do not comply with the protocol requirements will be discontinued from the study. Examples of noncompliance include: uncooperative or unwilling to follow protocol.

7.2.5. Inclusion/Exclusion Violation

Those subjects entered into the study and later found to be in violation of the inclusion/exclusion criteria will be discontinued.

7.2.6. Other

This category is to be used for any other discontinuation reason that may occur during the study.

8. CONCOMITANT MEDICATIONS AND INTERFERING THERAPIES

Other than sunscreens or mild cleansers and use of color cosmetics, no topical skin care products or medications of any kind can be used on the face. Subjects will be instructed not to take any prescription medications (except those allowed by protocol), without prior consultation with the Investigator. If concomitant therapy must be added then the reason, the name of the drug, the daily dose, and date of initiation and/or discontinuation of therapy will be recorded on the Concomitant Medication Page of the Case Report Form.

9. DATA ANALYSIS

9.1. Evaluability

Only subjects who meet all of the inclusion and none of the exclusion criteria, who miss no more than 1 visit (as long as the visit missed is not the first or last visit) and use the test article according to the Sponsor's instructions with the frequency outlined in the protocol will be considered evaluable.

9.2. Analysis

The primary objective of this study is to determine the efficacy of topical Zeatin (0.10%, 0.025%) for improving the appearance of skin aging when topically applied twice daily for up to 12 weeks. The primary efficacy endpoint is the change from baseline in the individual clinical signs of skin aging (wrinkles (coarse and fine), roughness and mottled hyperpigmentation). For the primary analysis for efficacy, the skin aging parameters at each follow-up visit (weeks 2, 4, 8 and 12) versus baseline scores will be assessed using a paired Student's *t*-test and a Wilcoxon signed rank test. The Investigator's and subject's global evaluation of efficacy will be summarized descriptively for all follow-up evaluations (weeks 2, 4, 8 and 12). The change from baseline in TEWL and skin moisture content will be determined for each respective skin treatment site and statistically analyzed.

10. ADVERSE EVENTS

10.1. Introduction

All adverse events occurring during the course of a study will be documented on Adverse Event Forms. A separate Adverse Event Form will be filled out for each adverse event. All items on the form will be completed. For NONSERIOUS events, if information is missing at the initial visit and the subject will be returning for follow-up examination in a reasonably short period of time, the investigator may hold the Adverse Event Form until the scheduled follow-up examination. If the subject will not be returning in a reasonable period of time, the investigator will forward the form to the Sponsor and provide the missing information by letter or telephone call when the information is known. For SERIOUS adverse events, an Adverse Event Form will be returned to the Sponsor as soon as practical, even if it is incomplete, with new information submitted by telephone call as soon as it becomes known.

10.2. Nonserious Adverse Event

An adverse event is defined as any untoward medical occurrence in a patient, or clinical investigation subject, administered a test product whether or not it is caused by this treatment. An adverse event can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporarily associated with the use of a test product, whether or not considered related to the test product.

Events that occur prior to the administration of the investigational product are not considered adverse events.

Possible expected occurrences due to the application of the test articles may be tingling, stinging, burning, dryness and/or itching. These reactions will not be reported as adverse events.

A non-serious adverse event is defined as a change in a subject's medical health, which is neither life-threatening, does not require hospitalization, does not prolong a current hospitalization, and is not disabling.

10.3. Serious Adverse Event

Serious adverse events are defined as any finding which suggests a significant hazard, contraindication, side effect, or precaution. Additionally, any adverse event which results in a fatality, is life-threatening, is permanently disabling, requires inpatient hospitalization, prolongs a current hospitalization, or a congenital anomaly is also considered a serious adverse event.

A life-threatening adverse event means that the subject was, in the view of the investigator, at immediate risk of death from the reaction as it occurred. It does not include a reaction that, had it occurred in a more serious form, might have caused a death. Serious, alarming and/or unusual adverse events must be reported to the following individual within 24 hours of the investigator's knowledge of the event:

SENETEK CONTACT:
Frank Massino
Phone: 707-226-3900 ext. 109
E Mail: Frank@senetek.net

An Adverse Event Form will be completed for all serious adverse events and forwarded to the Sponsor within 24 hours. Additionally, a phone call will be made to confirm delivery of the report. When new significant information is obtained as well as when outcome of an event is known, the Sponsor will be informed by telephone call. Depending on the nature and seriousness of the adverse event, a copy of the medical record of the patient as well as results of laboratory tests performed may be requested. If the subject was hospitalized, a copy of the discharge summary may be forwarded to the Sponsor as soon as it is ready. In all instances, investigators will follow subjects until an outcome to the event is known.

11. INFORMED CONSENT AND INSTITUTIONAL REVIEW BOARD

All subjects in this study will be completely informed, according to informed consent guidelines, about the pertinent details and purpose of the study. A written Informed Consent form will be understood and signed by each subject prior to enrollment into the study. The investigator or his designee will supply the consent form, approved by an Institutional Review Board, and a copy of such provided to the Sponsor. The study site will keep the original signed copies of all consent forms in its files and will provide the subject with a duplicate copy.

This study must be reviewed and approved by an appropriate Institutional Review Board (also known as an Ethics Committee). A copy of the letter indicating IRB approval will be provided to the Sponsor prior to study initiation. Annual updates will be provided to the IRB by the investigator for studies longer than a year.

12. SUBJECT IDENTIFICATION AND CONFIDENTIALITY

Subjects will be identified on the study CRFs by their Subject Number and their initials. CRFs are confidential documents and will only be available to the Investigator, the sponsor's representative and the IRB.

13. CONFIDENTIALITY/PUBLICATION OF THE STUDY

The existence of this clinical study is confidential and should not be discussed with persons outside of the study. Additionally, the information in this document and in the study contains commercially sensitive information that is confidential and may not be disclosed unless Federal or State law or regulations require such disclosure. Subject to the foregoing, this information may be disclosed only to those persons involved in the study who have a need to know, but all such persons must be instructed not to further disseminate this information to others. These restrictions of disclosure will apply equally to all future information supplied which is indicated as confidential.

14. STUDY MONITORING

The study may be monitored at any time. The monitor from the Sponsor will maintain a close liaison with the testing facility to clarify any problem(s) that may arise in the study and to ensure that the study is conducted according to the protocol. The liaison ordinarily consists of personal visits and/or frequent communications via telephone, fax and/or email.

The investigator will allow a Sponsor monitor to inspect all Case Report Forms and corresponding portions of a study subject's records, if necessary, to verify that the study was performed according to this protocol and that test results and collected data were faithfully and accurately recorded.

15. STUDY MANAGEMENT

15.1. Data Collection

The testing facility will maintain detailed records on all study subjects. Data for this study will be recorded on Case Report Forms (CRFs) provided by the Sponsor. All data will be recorded completely, promptly, and legibly on the CRFs. Corrections will be made in a manner that does not obscure or eliminate the original error, by striking through the original data with one line, and all corrections on the CRF should be initialed and dated. The testing facility will maintain a copy of all completed CRFs in its study files.

15.2. Test Article Accountability

The principal investigator or his designee, upon receipt of the clinical supplies, will conduct an inventory and complete and sign the Receipt of Clinical Supplies form (Supplied by the Sponsor), mailing it to the Sponsor. A copy will be maintained for the investigator's records.

The clinical staff will keep a current record of the inventory and dispensing of all test articles. All test articles will be weighed prior to distribution and upon collection from the subjects. Additionally, the clinical staff will confirm on the subject's data sheet (or CRF) dispensation of the test article. These records will be made available to the Sponsor's monitor for the purpose of accounting for all clinical supplies. Any significant discrepancy and/or deficiency will be recorded, with an explanation. All supplies sent to the investigator will be accounted for and in no case will the test articles be used in any unauthorized situation. After all subjects have completed the study, the testing facility will return the remaining test articles to the Sponsor with a copy of the inventory and dispensation log.

15.3. Record Retention

All records relating to the conduct of this study will be held by the investigator for a period of no less than two (2) years in a secure area. Additionally, the Sponsor will be contacted prior to the destruction of any study related records. Should the Sponsor require archiving for longer than 2 years, prior agreement between RCTS and the Sponsor must be obtained.

15.4. Quality Assurance

This study will be conducted in accordance with the intent and purpose of Good Clinical Practice Regulations (21 CFR 50, 21 CFR 56 and 21 CFR 54). The study data and Final Report will be reviewed and signed by a representative of the Quality Assurance staff of RCTS, Inc. The investigator will allow representatives of the Sponsor's monitoring team (and, if necessary, city, state or federal regulating agencies) to inspect all study records, Case Report Forms at regular intervals throughout the study. These inspections are for the purpose of verifying the adherence to the protocol, the completeness and exactness of the data being entered in the report form, and compliance with regulations.

16. STUDY PLAN

STUDY WEEK	0	2	4	8	12
Informed Consent Eligibility Criteria	X X				
Dermatologic/Skin Care/Cosmetic Hx	X				
Laboratory Studies: Urine Pregnancy	X				X[1]
Admission to Study	X				
Test Products Dispensed	X		X	X	
Test Products Collected			X	X	X
Twice Daily Application of Study Materials	X	X	X	X	X
Skin Evaluations	X	X	X	X	X
Subject Tolerance	X	X	X	X	X
Acne Lesion Counts	X	X	X	X	X
Concomitant Skin Care Products/Medications	X	X	X	X	X
TEWL/Moisture Measurements	X	X	X	X	X
Photography	X	X	X	X	X
End of Study Information/Exit Form					X

[1] Exit form completed upon study completion or early discontinuation.

17. APPENDICES

Appendix A

ADVERSE EVENTS – DEFINITION OF CAUSALITY

Adverse Events – Definition of Causality

1	Definitely Unrelated	-	Should be reserved for those events, which occur prior to test article administration (i.e., washout or single-masked placebo) or those events which cannot be even remotely related to study participation (e.g., injuries sustained in an automobile accident).
2	Unlikely	-	Whether or not there was a temporal relationship between the test article and the suspected adverse event, it is more likely than not that the event could have been produced by the subject's clinical state or other modes of therapy administered to the subject.
3	Possible	-	The suspected adverse event may follow a reasonable temporal sequence from test article administration but could have been produced or mimicked by the subject's clinical state or by other modes of therapy concomitantly administered to the subject.
4	Probable	-	The suspected adverse event follows a reasonable temporal sequence from test article administration, abates upon discontinuation of the test articles, and cannot be reasonably explained by the known characteristics of the subject's clinical state.
5	Definitely Related	-	Should be reserved for those events which have no uncertainty in their relationship to test article administration (e.g., Positive Rechallenge).

Appendix B

OBLIGATIONS OF INVESTIGATORS

Summary of Clinical Investigator Obligations

1. Obtain approval from the Institutional Review Board (IRB) before enrolling any subjects; Submit verification of the approval to the Sponsor; Submit periodic progress reports to the IRB (at least annually); Obtain annual reapproval from the IRB; Submit a final report to the IRB and notification that the study is complete or was terminated early; Maintain records of all RB correspondence;

2. Obtain written informed consent from every subject (or legal representative) enrolled in the study and maintain records of consent as part of his/her study records;

3. Approve the protocol and conduct the study according to the protocol and applicable regulations; Inform the Sponsor of all deviations from the protocol and immediately inform the IRB of any protocol deviation made to protect the safety of the subject; Approve all protocol amendments; Obtain IRB approval of all amendments prior to their implementation;

4. Report all serious adverse events related to the test article (and for medical device studies, all adverse device effects) to the Sponsor and the IRB immediately; report all other adverse events to the Sponsor as specified in the protocol;

5. Maintain proper control and documentation of all test articles;

6. Keep careful and accurate records of all clinical study data which are generally more exact and complete than those kept in ordinary medical practice;

7. Make study records available for inspection by the sponsor and representatives of relevant regulatory agencies; keep study records until approval for destruction has been obtained from the Sponsor;

8. Make the necessary arrangements, including emergency treatment, to ensure proper conduct of the investigation and the personal safety and well being of the subjects;

9. Submit the following records and reports to the Sponsor, if required:

    a. Prior to the beginning of the Study

        (1) A signed Investigator Agreement;

        (2) A current CV and CVs for all sub-investigators listed in the Investigator Agreement;

        (3) Approval letter from the IRB;

        (4) IRB-approved consent form;

        (5) Signed and dated copy of the approved Protocol Title page.

b. While Study is in Progress

(1) Signed receipt of the test articles (clinical supplies);

(2) Completed original Case Report Forms (including Adverse Event forms) for each subject enrolled in the study;

(3) Immediate notification of serious adverse events and protocol deviations;

(4) IRB annual re-approval letter;

(5) Signed protocol amendments; IRB approval of amendments and amended consent forms, if applicable;

c. Once the Study is Completed

(1) Documentation of disposition of all test articles;

(2) A final study report or signature on the Clinical Study Report (CSR).

Appendix C

ELEMENTS OF INFORMED CONSENT

Elements of Informed Consent

In conducting a clinical investigation, the Principal Investigator (PI) should adhere to the ethical principles which have their origin in the Declaration of Helsinki. The following information must be provided to each subject in obtaining informed consent. Informed consent must be documented in writing, using a form approved by the Independent Ethics Committee/Independent Review Board (IEC/IRB) which does not waive or appear to waive the subject's legal rights. This form should be signed and dated by the subject (or the subject's legal representative) and by the PI (or his designee) prior to the conduct of any study procedures. The subject (or representative) should be given a copy of the signed written informed consent. This information should be revised (and re-reviewed by the IRB) if new information becomes available that is relevant to the subject.

1. State that the study involves research.

    a. Explain the purposes of the research.

    b. State the expected duration of the subject's participation.

    c. State the approximate number of subjects involved in the study

    d. Describe the procedures to be followed.

    e. Identify any experimental procedures.

2. Describe the subject's responsibilities.

    a. Describe any anticipated prorated payments to be made to the subject for participating. [NOTE: In clinical studies on medical devices conducted in Europe, subjects who cannot be expected to derive any direct therapeutic benefit shall receive payments or inducements only for expense, time, and inconvenience].

    b. Describe any anticipated expenses to the subject, if any.

3. Describe any reasonably foreseeable risks or discomforts to the subject.

4. Describe any benefits to the subject (or to others) which may reasonably be expected from the research.

5. Note available, appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject.

6. a. Note the extent to which confidentiality of records identifying the subject will be maintained.

    b. Note that confidentiality of records that identify the subject will be maintained and will not be made publicly available to the extent permitted by the applicable laws and/or regulations.

c. Note that relevant regulatory authorities (such as the Food and Drug Administration in the US), the sponsor's monitor(s), auditor(s), and the IEC/IRB may inspect the study records and will be granted access to the subject's original medical records for verification of the clinical trial procedures and/or data, without violating the confidentiality of the subject to the extent permitted by the applicable laws and regulations.

d. Note that by signing the written informed consent form, the subject (or the subject's legal representative) is authorizing access to these records.

7. For research involving more than minimal risk, explain what compensation or medical treatments are available should a research-related injury occur. Explain what they consist of, or where further information may be obtained.

8. a. Tell whom to contact for answers to pertinent questions about

(i) the research, and

(ii) the research subjects' rights.

b. Tell whom to contact in the event of a research-related injury to the subject.

9. State that:

a. participation is voluntary, and

b. refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled.

10. a. Note that the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.

b. Describe the consequences of his/her withdrawal from the study and any procedures for orderly termination of participation by the subject.

c. Describe the circumstances under which the subject's participation may be terminated without the subject's consent.

11. State that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject.

PAGE INTENTIONALLY LEFT BLANK

Protocol Amendment No.: 1 – RCTS Panel 1837

1. **Original Protocol**

Inclusion Criteria

1. Subjects must be ambulatory, 30 to 65 years of age and in reasonably good health;

1. **Amended Protocol** (amended language shown in italics)

Inclusion Criteria

1. *Female* subjects must be ambulatory, 30 to 65 years of age and in reasonably good health;
9. *Fitzpatrick Skin Types I – III;*

Reason for Amendment:
To add female subjects and Fitzpatrick Skin Types I-III to inclusion criteria.

2. **Original Protocol**

Exclusion Criteria

16. Subject has participated in any clinical trial involving an investigational drug or cosmetic product or procedure within the past 30 days; and

2. **Amended Protocol (amended language shown in italics)**

Exclusion Criteria

16. Subject has participated in any *facial* clinical trial involving an investigational drug or cosmetic product or procedure within the past 30 days; and

Reason for Amendment:
To clarify the exclusion criteria.

Approvals:

For RCTS:

Barry Reece, M.S., M.B.A.
Vice President/Managing Partner
RCTS, Inc.

4/4/2005
Date

For the Sponsor:

Frank Massino
CEO
Senetek PLC

7/15/05
Date

1.2 IRB Approval Letter

IntegReview, Inc.
3001 S. Lamar Blvd., Suite 210
Austin, Texas 78704

INTEG REVIEW
Ethical Review Board

Tel. 512.326.3001
Local Fax. 326.3446
http://www.integreview.com

IRB Registration Numbers: IRB00001035 and IRB0003657

March 28, 2005

Ponciano D. Cruz, Jr., M.D.
RCTS, Inc.
800 W. Airport Freeway, Ste. 110
Irving, TX 75062

Re: Senetek PLC, Protocol Number 2005.091, Reliance Clinical Testing Services (RCTS) Study Number 1837, "A Clinical Study of Topical Zeatin (0.1%, 0.025%) for Improving the Appearance of Photodamaged Skin"

Dear Dr. Cruz:

The above-referenced study meets the requirements for a research study that may be reviewed through expedited review procedures set forth in FDA regulations. Therefore, utilizing the expedited review procedures authorized in 21 CFR 56.110, initial approval was granted by **Charles F. Ryan, Ph.D.** for IntegReview on the initial review of the above-referenced study.

Approved:
- Principal Investigator
- Investigative site(s) as submitted with initial submission documents
- Protocol dated March 17, 2005
- Informed Consent, English language, dated March 28, 2005 (refer to IntegReview modifications as reflected on the following document containing revision marks)
- Recruiting materials:
  - One print media advertisement
  - One Recruitment Sheet

The reviewer also reviewed the safety letter, for the test product, as appropriate.

Equipment required at study site(s) to treat life-threatening reactions for this study:
☐ Injectable Epinephrine ☐ Injectable Benadryl
☐ Crash cart ☐ Ambu bag ☐ Oxygen ☐ Other (describe):
☐ No equipment required because subject will be dosed on an outpatient basis
☒ No equipment required due to the non-invasive nature of this study

IMPORTANT
- **The following changes may not be implemented until you have received approval from IntegReview except where necessary to eliminate apparent immediate hazards to the human subjects:**
  - **Protocol Amendments**
  - **Change in the Principal Investigator and/or Sub Principal Investigators (only if the Sub PI's will be performing study-related procedures that the PI is not qualified through expertise to perform)**
  - **Change in the address at the study site or the addition of a study site(s)**
- **Only Informed Consent documents <u>containing IntegReview's approval</u> stamp and recruiting materials <u>containing IntegReview's approval</u> stamp may be utilized.**

- **Only IntegReview staff may initiate modifications to Informed Consent documents. The Informed Consent document for your site will be maintained in our computer files, and IntegReview will make all revisions following IRB approval.**
- **Revision requests should be submitted on IntegReview's Request for Review/Approval Form, which can be obtained from our office or on our Website at www.integreview.com.**

IntegReview approval for this study expires **March 28, 2006**. In order to obtain extended IRB approval, IntegReview must receive your form for continuing review four weeks prior to the IRB expiration date. Appropriate forms will be forwarded to you approximately 2 months prior to the approval expiration date. Should the study end before you receive notification, submit a Study Closure Notification form, which can be obtained from our office or on our Website at www.integreview.com, to notify us of the study closure.

REPORTING REQUIREMENTS

To ensure compliance with the Code of Federal Regulations (CFR), Parts 56.108 (a) (3), 312.32 (c) (1) (i) 312.66 as well as International Conference on Harmonisation (ICH), E6: Good Clinical Practice: Consolidated Guideline, IntegReview requires notification of the following for review/approval:

- **Report within 10 working days**:
  - Unexpected adverse experience
  - Any unanticipated problems involving risks to human subjects or others
  - All changes in research activity, **including violations of the protocol (an act performed by the investigator and/or research staff of allowing or conducting activity inconsistent with the IRB approved protocol, such as allowing the enrollment of a subject who does not meet the inclusion/exclusion criteria, misdosing study subjects, incorrectly randomizing study drug, etc.)** approved or not approved by the sponsor
- **Submit prior to publication/distribution:**
  - Any modification(s) to the previously approved Informed Consent document
  - New and/or modifications to previously approved recruiting materials
- **Submit four weeks prior to IntegReview approval expiration date:**
  - Continuing review documents
- **Submit upon completion of the study** (that is when all data has been collected):
  - Notification of study closure – upon completion of the study (study remains active only for data analysis) report on IntegReview's Study Closure Notification Form located on our Website or you may contact our office to request form.

NOTE: Requests for review/approval of modifications to study documents previously approved by IntegReview should be submitted on IntegReview's Request for Review/Approval Form.

At its discretion, IntegReview reserves the right to visit the study site.

IntegReview is organized and operates in accordance with Good Clinical Practices and International Conference of Harmonisation for IRB's as identified in Title 21 of the Code of Federal Regulations, Parts 50 and 56 and ICH Guidelines for Good Clinical Practices, E6. In addition, Standard Operating Procedures have been created to ensure compliance with these regulations and guidelines.

If you have any questions regarding these procedures or if you wish to appeal the decision, you may address your comments to IntegReview. Your comments will be reviewed, discussed and you will receive a response after your request has been considered.

Failure to comply with the Code of Federal Regulations or the requirements or determinations of IntegReview can result in suspension or termination of IntegReview approval.

Sincerely,

Pricilla R. Gage, CIM
Compliance Coordinator

1.3 Sample Informed Consent Form and Photographic Release Form

APPROVED BY
INTEGREVIEW ETHICAL REVIEW BOARD
MARCH 28, 2005

INFORMED CONSENT
AGREEMENT TO BE IN A RESEARCH STUDY

NAME OF TESTING COMPANY:	RCTS, Inc.
CITY AND STATE:	Irving, Texas
NUMBER AND NAME OF STUDY:	2005.091/1837; "A Clinical Study of Topical Zeatin (0.1%, 0.025%) for Improving the Appearance of Photodamaged Skin"
NAME OF PERSON IN CHARGE OF THE RESEARCH STUDY (INVESTIGATOR):	Ponciano D. Cruz, Jr., M.D.
ADDRESS OF STUDY SITE:	RCTS, Inc. 800 W. Airport Freeway, Suite 110 Irving, TX 75062
TELEPHONE NUMBERS, DAYTIME: **AFTER HOURS:**	972-871-7578 972-572-3255 972-841-2916 (Cell number)

INTRODUCTION

You are being asked to volunteer for a research experiment. Before agreeing to participate in this study, it is important that you read this form. This form, called a consent form, describes the purpose, procedures, benefits, financial payment, risks and discomforts of the study. It also describes the alternative procedures that are available to you and your right to withdraw from the study at any time. No promises or guarantees can be made as to the results of the research study. Please ask as many questions as you need to so that you can decide whether you want to be in the study.

The investigator is being paid to conduct this study.

If you are not completely truthful with the investigator and study staff regarding your health history, you may harm yourself by participating in this study.

PURPOSE OF STUDY

This study is being done to see how safe and effective a facial cream will work to treat the appearance of photo-damaged skin.

If you qualify for the study, you will receive one of two different concentrations (0.1% or 0.025%) of the test product. You will be provided with the following instructions for use:

- Wash your face with a mild cleanser and dry completely prior to application of the test product to your face;
- Apply a liberal amount of the test product to your face in the early morning and about one hour before bedtime;
- In the morning, after the test product has absorbed into the skin, apply the sunscreen, which was provided to you, to your face. Avoid prolonged sun exposure;
- Other than the test product being provided to, do not introduce any new products into your skin care regimen;
- Do not apply any topical medications to your face;

APPROVED BY
INTEGREVIEW ETHICAL REVIEW BOARD
MARCH 28, 2005

- Do not take any steroid or retinoid medications; and
- Do not apply the test product or makeup to your face the morning of a scheduled visit.

This is a double-blind study, which means that neither you nor the investigator will know which test product you are receiving. However, the study staff can get this information quickly if you have a problem.

The test product you receive will be assigned by chance, like the flip of a coin.

HOW LONG THE STUDY WILL LAST AND THE NUMBER OF SUBJECTS EXPECTED TO PARTICIPATE

It is expected that the length of time you will participate in this study will be approximately twelve (12) weeks. Approximately fifty (50) female subjects, ages 30 to 65, are expected to participate in this study.

TO BE IN THIS STUDY

You cannot be in this study if you are currently in any clinical study involving an investigational drug or if you have been in a study for cosmetic products or procedures in the last 30 days.

WHAT WILL HAPPEN DURING THE STUDY

Screening:

Before the study starts, you will be asked to sign this consent form, give your medical history, and to inform site personnel if you are taking any over-the-counter or prescription medications or vitamins.

As part of the screening and study process you will be required to undergo all of the tests listed below:

- Urine pregnancy tests for female subjects at screening and at the end of the study.

Study Procedures:

Following the screening process, you will be directed into an environmentally controlled room where you will adjust to room temperature for approximately fifteen (15) minutes. During this time the following procedures will take place:

- During the fifteen (15) minute wait period, an expert grader will evaluate several aspects of your facial skin condition.
- Also during the wait period, a technician will take clinical photographs (front, left and right profiles) of your face.
- Following the fifteen (15) minute wait period, water loss measurements using a non-invasive (does not hurt) instrument called a TEWAMETER will be taken. The instrument's probe will rest gently on the center of your cheek and measurements will be taken two times on both sides of your face.
- Lastly, moisture measurements using an instrument called a NOVA DPM will also be taken non-invasively (does not hurt). The instrument's probe will rest gently on the center of your cheek and measurements will be taken three times on both sides of your face.

After all measurements and assessments are completed you will be given your test product and daily diary along with instructions for use.

It will be your responsibility to keep the test product out of the reach of children.

The same measurements and assessments completed at your baseline visit will be repeated at your 2, 4, 8 and 12 week visits. At each visit you and the expert grader will evaluate your skin to determine whether or not an

APPROVED BY
INTEGREVIEW ETHICAL REVIEW BOARD
MARCH 28, 2005

improvement in your skin condition is noticeable. Additionally, you will be asked if you have taken any new medications. You are required to bring your test product and diary to each return visit.

POSSIBLE SIDE EFFECTS AND RISKS OF THE STUDY TEST PRODUCT

It is possible you might experience the following side effects:

- Tingling
- Stinging
- Burning
- Dryness
- Itching

If you are not completely truthful with the investigator and study staff regarding any side effects, you may harm yourself by participating in this study.

DANGERS OF PREGNANCY AND BIRTH CONTROL

If you are female, it is very important that you do not become pregnant during this study. The only certain way to prevent pregnancy is to not have sex. If you are a woman and choose to have sex during this study, you must use a medically proven type of birth control throughout the study.

Acceptable methods of birth control for this study include:

- Birth control pills
- Depo-Provera®
- IUD (intrauterine device)
- Diaphragm with spermicide
- Condom with spermicide
- Postmenopausal
- Surgically sterile

Even if you use a medically proven birth control method, there is a chance you could still become pregnant.

You will not be allowed to be in the study if you are pregnant or breastfeeding. The test product or procedures may involve currently unforeseeable risks to breast-fed babies. A pregnancy test could be wrong and if you become pregnant during the study you will be receiving the test product while pregnant. The effects of the test product on an unborn baby are unknown. If you become pregnant during study, stop using the test product and call the investigator at once.

POSSIBLE BENEFITS OF THE STUDY

Since you do not require treatment with the test product, you will receive no medical benefit from this study, other than the benefit of free clinical tests.

ALTERNATIVES TO PARTICIPATING IN THIS STUDY

Since this study is for research only, the alternative would be not to participate.

RELEASE OF YOUR MEDICAL RECORDS AND PRIVACY (CONFIDENTIALITY)

Records of you being in this study will be kept confidential except as required by law. However, the investigator, the testing company and/or its representative will look at and copy information that is collected during the study. The following will be given a copy of this information:

- Testing company (RCTS, Inc.)
- Food and Drug Administration (FDA)
- Other government offices

APPROVED BY
INTEGREVIEW ETHICAL REVIEW BOARD
MARCH 28, 2005

The Institutional Review Board (IRB), IntegReview, may inspect and copy your records, which will identify you by name. Therefore, absolute confidentiality cannot be guaranteed. By signing this consent form, you authorize the investigator to release your study-related medical records to the testing company and/or its representative, the FDA and the IRB. If the study results are presented at meetings or printed in publications, your name will not be used.

PAYMENT FOR INJURY RELATED TO THE STUDY

There are no anticipated injuries associated with using this test product.

LEGAL RIGHTS

You will not lose any of your legal rights as a research subject by signing this consent form.

WHOM TO CONTACT

For answers to questions about this research or to report a research related injury, contact:

Barry Reece
Office: 972-871-7578
After hours: 972-572-3255

Questions about your rights as a study subject as provided in the Experimental Subjects' Bill of Rights found in this informed consent form may be addressed to:

Chairperson
IntegReview
3001 S. Lamar Blvd., Suite 210
Austin, Texas 78704
512-326-3001 between 8 a.m. and 5 p.m.
Central Time (call collect)
integreview@integreview.com

Although IntegReview has approved the information provided in this informed consent form and has granted approval for the investigator to conduct the study this does not mean IntegReview has approved your participation in the study. You must evaluate the information in this informed consent form for yourself and decide whether or not you wish to participate.

PAYMENT FOR BEING IN THE STUDY

If you leave the study before finishing all visits you will be paid $20.00 for each completed visit. Upon successful completion you will be paid $150.00. Payment will be available after your last scheduled study visit.

YOUR PARTICIPATION IN THE STUDY

Your participation in this study is entirely voluntary. You cannot be forced to be in this study. You may not want to be in this study or you may leave the study at any time without penalty or loss of benefits to which you are otherwise entitled and without affecting your future medical care. The investigator, the testing company, IntegReview, or the FDA may take you out of the study without your permission at any time for the following reasons:

- If you do not follow the instructions of the investigator
- If it is discovered that you do not meet the study requirements
- If the study is cancelled
- If it appears to be medically harmful to you

If you leave the study or if you are taken out of the study for any reason, you may be asked to return to the investigator's office for a final visit. This is to make sure that you are in good health.

THIS IS AN IMPORTANT DOCUMENT - KEEP FOR FUTURE REFERENCE

VERSION CONTROL

prg/3-28-05
g:\current ic's\senetek plc\2005.091\3-28-05.doc

APPROVED BY
INTEGREVIEW ETHICAL REVIEW BOARD
MARCH 28, 2005

ADDITIONAL COSTS

You may be responsible for medical expenses that are not covered by your medical or hospital insurance or by third party or governmental programs providing such coverage.

NEW FINDINGS

You will be told about any significant new findings developed during the course of the research about the test product. This information can help you decide if you wish to continue your participation in the study.

EXPERIMENTAL SUBJECT'S BILL OF RIGHTS

As a subject involved in an investigational research study, you have the following rights.

1. Be informed of the nature and purpose of the experiment.

2. Be given an explanation of the procedures to be followed in the medical experiment, and any drug or device to be used.

3. Be given a description of any attendant discomforts and risk reasonably to be expressed from the experiment.

4. Be given an explanation of any benefits to the subject reasonably to be expected from the experiment, if applicable.

5. Be given a disclosure of any appropriate alternative procedures, drugs, or devices that might be advantageous to the subject, and their relative risks and benefits.

6. Be informed of the avenues of medical treatment, if any, available to the subject after the experiment if complications should arise.

7. Be given an opportunity to ask any questions concerning the experiment or the procedures involved.

8. Be instructed that consent to participate in the medical experiment may be withdrawn at any time. The subject may discontinue participation in the medical experiment without prejudice.

9. Be given a copy of a signed and dated written consent form when one is required.

10. Be given the opportunity to decide to consent or not to consent to a medical experiment without the intervention of any element of force, fraud, deceit, duress, coercion, or undue influence on the subject's decision.

THE REASON FOR INSTITUTIONAL REVIEW BOARDS AND INFORMED CONSENT

What is a consent form?
The Informed Consent document contains the required information as found in and required by the United States regulations regarding the protection of human subjects (Code of Federal Regulations, Title 21, Part 50-Protection of Human Subjects). As required by this regulation, the informed consent must be reviewed and approved by an Institutional Review Board (IRB).

What is an Institutional Review Board (IRB)?
An Institutional Review Board (IRB) is any board, committee or other group, which reviews, approves, and does continuing review of biomedical research involving human subjects. The primary purpose of such review is to guarantee the protection of the rights and welfare of the human subjects.

IRBs were established as the result of unfair treatment of human subjects. Prior to this, other

**APPROVED BY
INTEGREVIEW ETHICAL REVIEW BOARD
MARCH 28, 2005**

committees existed as a requirement of the United States Public Health Service (USPHS) policy established in 1965. IRBs are regulated by the Food and Drug Administration and the Office for Human Research Protections (OHRP). The FDA and OHRP regulations require IRB review and approval of the study design (Protocol), Informed Consent form, and any recruiting materials prior to the enrollment of study subjects.

What does an IRB mean to me?

The purpose of the IRB is to inform and protect human subjects through the information provided in the informed consent document. Therefore, the IRB is acting as a supporter for the research subject. This means that the IRB, during its review of the informed consent document, has the right and responsibility to ensure that the research subject is fully informed of the procedures involved in the study as well as the risks and other treatments that are available if participation in the study is refused.

How can I tell that an IRB has reviewed and approved this study?

The date that IntegReview approved the study design as well as the information in this Informed Consent document is printed on the top of each page of this Informed Consent form.

IntegReview, the IRB for this study

IntegReview is an independent IRB whose board members are individuals who work in the Austin community. IntegReview provides services nation-wide to research professionals.

FDA regulations require that the committee have at least five members with varying backgrounds to provide complete and adequate review of research activities.

To fulfill these requirements the IntegReview Board currently includes physicians, pharmacists, Ph.Ds., a toxicologist (someone who studies the harmful effects of chemicals), a psychologist, an oral surgeon, and lay members (non-scientific).

The telephone number of the Chair is available in every informed consent document in the contacts section. You may contact the Chair with concerns regarding your rights as a subject.

APPROVED BY
INTEGREVIEW ETHICAL REVIEW BOARD
MARCH 28, 2005

AGREEMENT TO BE IN THE STUDY

This consent form contains important information to help you decide if you want to be in the study. If you have any questions that are not answered in this consent form, ask one of the study staff. Please write out "yes" or "no" in response to the following questions:

A. Do you understand the information in this consent form? _____

B. Have you been able to ask questions and talk about the study? _____

C. Have all of your questions been answered to your satisfaction? _____

D. Do you think you received enough information about the study? _____

E. Do you understand that you can leave the study at any time without giving a reason and without affecting your medical care? _____

F. Do you understand that your medical records from this study may be reviewed by the testing company and by government authorities? _____

If you answered NO to any of these six questions, you should not sign this consent form.

When you sign this consent form you agree that:

- You have had a chance to ask questions
- You understand English
- You want to be in the study

You will not lose any of your legal rights by signing this consent form.

_____
Printed Name of Study Subject

_____
Signature of Study Subject Date
DO NOT SIGN AFTER MARCH 28, 2006

_____
Printed Name of Person Explaining Informed Consent

_____
Signature of Person Explaining Informed Consent Date

You will be given a copy of this informed consent to keep.

THIS IS AN IMPORTANT DOCUMENT - KEEP FOR FUTURE REFERENCE

VERSION CONTROL

prg/3-28-05
g:\current ic's\senetek plc\2005.091\3-28-05.doc

PHOTOGRAPHIC INFORMED CONSENT FORM

You are being asked to allow photographs to be taken of your face. The photographs will be used for marketing purposes, training and scientific evaluation. Only the face will be photographed.

I, the undersigned, voluntarily consent to the taking and use of my picture by the sponsoring company, its affiliates, successors and assignees. All personal information and records will be kept confidential. The said photographs may be used for marketing (business), education, research, or informational purposes. It is understood that the sponsoring company shall make a decision as to how the said photographs are used or whether or not they are used at all. It is possible that the sponsoring company will use my photograph in company literature or other types of media to demonstrate the benefits of the products I am evaluating.

I hereby release the sponsoring company from any claim, demand, and cause of action or proceeding of whatever nature arising out of distribution of the said photographs in accordance with the terms of this release. This release also includes the officers, directors, employees, and agents of the sponsoring company.

_____ _____

Panelist's Signature Date

_____

Panelist's Name (Print)

_____ _____

Witness Date

APPENDIX 2 SUBJECT DATA LISTINGS

Expert Assessment of Fine Wrinkles

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Fine Wrinkles				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	2	2	2	1	1
5	LMP	45	Female	3	2	2	2	1
6	PJW	43	Female	1				
10	JCL	41	Female	2	2	2	2	1
11	TLM	50	Female	3	3	3	2	1
13	DKS	38	Female	2	2	1	1	1
14	LKB	56	Female	4	4	4	4	3
15	NHK	56	Female	2	2			
16	VLH	57	Female	2	2	2	1	1
22	JKP	48	Female					
23	RMS	51	Female	3	2	2	2	2
25	TJJ	40	Female	3	2	2	2	2
29	DSE	59	Female	3	3	3	2	3
30	MMC	64	Female	3	3	3	3	3
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	2	2	2	2	2
36	MAE	51	Female	2	2	1	1	1
37	GLJ	54	Female	2	2	1	1	1
38	KAS	42	Female					
41	E-N	61	Female	3	3	3	3	3
42	KAM	52	Female	3	3	2	2	2
43	CGC	48	Female	2	2	2	1	1
45	TDC	48	Female	2	2	1	1	1
48	JLL	47	Female	3	2	2	1	1
50	DKH	49	Female	2	2	1	1	1
52	CJL	53	Female	3	3	2	1	1
53	DSB	54	Female	3	3	2	2	2
55	SKR	57	Female	2	2	2	2	1
56	DAH	45	Female					
58	CZR	49	Female	2	2	2	1	1
62	KME	45	Female	3	3	2	2	2
63	MRG	51	Female	3				
68	SAM	53	Female	3	3	3	3	3
69	GHD	55	Female	3	3	3	3	3
70	CAC	62	Female	4	4	4	4	4
71	JAR	40	Female	2	2	2	2	1
72	NRC	56	Female	3	2	2	2	2
73	NLW	47	Female	1	1			
	Discontinued		Mean	2.61	2.45	2.17	1.90	1.73
			SD	0.62	0.62	0.79	0.88	0.91
			Median	3.00	2.00	2.00	2.00	1.00
			N	31	31	30	30	30

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Fine Wrinkles Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	0	0	-1	-1
5	LMP	45	Female	-1	-1	-1	-2
6	PJW	43	Female				
10	JCL	41	Female	0	0	0	-1
11	TLM	50	Female	0	0	-1	-2
13	DKS	38	Female	0	-1	-1	-1
14	LKB	56	Female	0	0	0	-1
15	NHK	56	Female	0			
16	VLH	57	Female	0	0	-1	-1
22	JKP	48	Female				
23	RMS	51	Female	-1	-1	-1	-1
25	TJJ	40	Female	-1	-1	-1	-1
29	DSE	59	Female	0	0	-1	0
30	MMC	64	Female	0	0	0	0
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	0	0	0	0
36	MAE	51	Female	0	-1	-1	-1
37	GLJ	54	Female	0	-1	-1	-1
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	0	-1	-1	-1
43	CGC	48	Female	0	0	-1	-1
45	TDC	48	Female	0	-1	-1	-1
48	JLL	47	Female	-1	-1	-2	-2
50	DKH	49	Female	0	-1	-1	-1
52	CJL	53	Female	0	-1	-2	-2
53	DSB	54	Female	0	-1	-1	-1
55	SKR	57	Female	0	0	0	-1
56	DAH	45	Female				
58	CZR	49	Female	0	0	-1	-1
62	KME	45	Female	0	-1	-1	-1
63	MRG	51	Female	-3			
68	SAM	53	Female	0	0	0	0
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	0	0	0	-1
72	NRC	56	Female	-1	-1	-1	-1
73	NLW	47	Female	0			
			Mean	-0.16	-0.47	-0.73	-0.90
			SD	0.37	0.51	0.58	0.61
			Median	0.00	0.00	-1.00	-1.00
			N	31	30	30	30

Expert Assessment of Coarse Wrinkles

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Coarse Wrinkles				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	2	2	2	2	2
5	LMP	45	Female	2	2	2	2	2
6	PJW	43	Female	0				
10	JCL	41	Female	1	1	1	1	0
11	TLM	50	Female	2	2	2	2	2
13	DKS	38	Female	1	1	1	1	1
14	LKB	56	Female	3	3	3	3	3
15	NHK	56	Female	1	1			
16	VLH	57	Female	1	1	1	1	1
22	JKP	48	Female					
23	RMS	51	Female	1	1	1	1	1
25	TJJ	40	Female	1	1	1	1	1
29	DSE	59	Female	3	3	3	2	2
30	MMC	64	Female	4	4	4	4	4
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	3	3	3	3	3
36	MAE	51	Female	1	1	1	0	0
37	GLJ	54	Female	3	3	3	3	3
38	KAS	42	Female					
41	E-N	61	Female	3	3	3	3	3
42	KAM	52	Female	4	3	3	2	2
43	CGC	48	Female	3	3	3	2	2
45	TDC	48	Female	0	1	0	0	0
48	JLL	47	Female	1	1	1	1	1
50	DKH	49	Female	1	1	1	1	1
52	CJL	53	Female	1	1	1	2	2
53	DSB	54	Female	2	2	2	2	2
55	SKR	57	Female	1	1	1	1	1
56	DAH	45	Female					
58	CZR	49	Female	1	1	1	1	0
62	KME	45	Female	1	1	1	1	1
63	MRG	51	Female	1				
68	SAM	53	Female	2	2	2	2	2
69	GHD	55	Female	4	4	4	4	4
70	CAC	62	Female	4	4	4	4	4
71	JAR	40	Female	1	1	1	0	0
72	NRC	56	Female	3	3	3	3	3
73	NLW	47	Female	0	0			
	Discontinued		Mean	1.97	1.97	1.97	1.83	1.77
			SD	1.17	1.08	1.13	1.15	1.22
			Median	2.00	2.00	2.00	2.00	2.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Coarse Wrinkles Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	0	0	0	0
5	LMP	45	Female	0	0	0	0
6	PJW	43	Female				
10	JCL	41	Female	0	0	0	-1
11	TLM	50	Female	0	0	0	0
13	DKS	38	Female	0	0	0	0
14	LKB	56	Female	0	0	0	0
15	NHK	56	Female	0			
16	VLH	57	Female	0	0	0	0
22	JKP	48	Female				
23	RMS	51	Female	0	0	0	0
25	TJJ	40	Female	0	0	0	0
29	DSE	59	Female	0	0	-1	-1
30	MMC	64	Female	0	0	0	0
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	0	0	0	0
36	MAE	51	Female	0	0	-1	-1
37	GLJ	54	Female	0	0	0	0
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	-1	-1	-2	-2
43	CGC	48	Female	0	0	-1	-1
45	TDC	48	Female	1	0	0	0
48	JLL	47	Female	0	0	0	0
50	DKH	49	Female	0	0	0	0
52	CJL	53	Female	0	0	1	1
53	DSB	54	Female	0	0	0	0
55	SKR	57	Female	0	0	0	0
56	DAH	45	Female				
58	CZR	49	Female	0	0	0	-1
62	KME	45	Female	0	0	0	0
63	MRG	51	Female	-1			
68	SAM	53	Female	0	0	0	0
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	0	0	-1	-1
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	0			
			Mean	0.00	-0.03	-0.17	-0.23
			SD	0.26	0.18	0.53	0.57
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

Expert Assessment of Roughness

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Roughnness				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	3	3	2	1	0
5	LMP	45	Female	3	2	2	0	0
6	PJW	43	Female	3				
10	JCL	41	Female	3	2	2	1	1
11	TLM	50	Female	2	2	0	0	0
13	DKS	38	Female	3	2	2	1	0
14	LKB	56	Female	2	3	1	1	1
15	NHK	56	Female	3	3			
16	VLH	57	Female	3	2	2	0	0
22	JKP	48	Female					
23	RMS	51	Female	2	1	0	0	0
25	TJJ	40	Female	3	3	2	1	1
29	DSE	59	Female	2	1	0	0	0
30	MMC	64	Female	3	2	1	1	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	3	1	1	0	0
36	MAE	51	Female	3	2	2	1	0
37	GLJ	54	Female	2	1	1	1	0
38	KAS	42	Female					
41	E-N	61	Female	2	0	0	0	0
42	KAM	52	Female	3	1	1	1	1
43	CGC	48	Female	3	2	1	0	0
45	TDC	48	Female	3	3	2	1	1
48	JLL	47	Female	3	3	2	2	1
50	DKH	49	Female	3	3	3	3	1
52	CJL	53	Female	2	1	1	1	1
53	DSB	54	Female	3	1	2	1	0
55	SKR	57	Female	3	0	0	0	0
56	DAH	45	Female					
58	CZR	49	Female	3	3	2	2	1
62	KME	45	Female	3	2	2	2	1
63	MRG	51	Female	2				
68	SAM	53	Female	2	0	0	0	0
69	GHD	55	Female	2	1	1	0	0
70	CAC	62	Female	2	1	1	1	0
71	JAR	40	Female	3	2	1	0	0
72	NRC	56	Female	3	2	1	1	1
73	NLW	47	Female	2	2			
	Discontinued		Mean	2.68	1.77	1.27	0.77	0.37
			SD	0.48	0.96	0.83	0.77	0.49
			Median	3.00	2.00	1.00	1.00	0.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Roughness Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	0	-1	-2	-3
5	LMP	45	Female	-1	-1	-3	-3
6	PJW	43	Female				
10	JCL	41	Female	-1	-1	-2	-2
11	TLM	50	Female	0	-2	-2	-2
13	DKS	38	Female	-1	-1	-2	-3
14	LKB	56	Female	1	-1	-1	-1
15	NHK	56	Female	0			
16	VLH	57	Female	-1	-1	-3	-3
22	JKP	48	Female				
23	RMS	51	Female	-1	-2	-2	-2
25	TJJ	40	Female	0	-1	-2	-2
29	DSE	59	Female	-1	-2	-2	-2
30	MMC	64	Female	-1	-2	-2	-3
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	-2	-2	-3	-3
36	MAE	51	Female	-1	-1	-2	-3
37	GLJ	54	Female	-1	-1	-1	-2
38	KAS	42	Female				
41	E-N	61	Female	-2	-2	-2	-2
42	KAM	52	Female	-2	-2	-2	-2
43	CGC	48	Female	-1	-2	-3	-3
45	TDC	48	Female	0	-1	-2	-2
48	JLL	47	Female	0	-1	-1	-2
50	DKH	49	Female	0	0	0	-2
52	CJL	53	Female	-1	-1	-1	-1
53	DSB	54	Female	-2	-1	-2	-3
55	SKR	57	Female	-3	-3	-3	-3
56	DAH	45	Female				
58	CZR	49	Female	0	-1	-1	-2
62	KME	45	Female	-1	-1	-1	-2
63	MRG	51	Female	-2			
68	SAM	53	Female	-2	-2	-2	-2
69	GHD	55	Female	-1	-1	-2	-2
70	CAC	62	Female	-1	-1	-1	-2
71	JAR	40	Female	-1	-2	-3	-3
72	NRC	56	Female	-1	-2	-2	-2
73	NLW	47	Female	0			
			Mean	-0.90	-1.40	-1.90	-2.30
			SD	0.83	0.62	0.76	0.60
			Median	-1.00	-1.00	-2.00	-2.00
			N	31	30	30	30

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

Expert Assessment of Mottled Hyperpigmentation

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Mottled Hyperpigmentation				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	2	2	2	2	2
5	LMP	45	Female	2	2	2	2	2
6	PJW	43	Female	1				
10	JCL	41	Female	1	1	1	1	1
11	TLM	50	Female	3	3	2	2	2
13	DKS	38	Female	1	1	0	0	0
14	LKB	56	Female	3	3	3	3	3
15	NHK	56	Female	3	3			
16	VLH	57	Female	2	2	1	1	1
22	JKP	48	Female					
23	RMS	51	Female	1	1	1	1	1
25	TJJ	40	Female	1	1	1	1	1
29	DSE	59	Female	2	1	1	1	1
30	MMC	64	Female	2	2	2	1	1
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	3	3	3	3	2
36	MAE	51	Female	2	2	2	2	2
37	GLJ	54	Female	3	3	2	2	2
38	KAS	42	Female					
41	E-N	61	Female	1	1	1	2	1
42	KAM	52	Female	3	3	3	3	3
43	CGC	48	Female	1	1	1	1	0
45	TDC	48	Female	2	1	1	1	1
48	JLL	47	Female	1	0	0	1	0
50	DKH	49	Female	0	0	0	0	0
52	CJL	53	Female	2	2	1	1	1
53	DSB	54	Female	3	3	3	3	3
55	SKR	57	Female	1	1	1	1	1
56	DAH	45	Female					
58	CZR	49	Female	2	2	2	2	2
62	KME	45	Female	2	2	2	2	2
63	MRG	51	Female	2				
68	SAM	53	Female	3	3	1	2	2
69	GHD	55	Female	3	2	2	2	1
70	CAC	62	Female	3	3	3	3	3
71	JAR	40	Female	2	2	2	2	2
72	NRC	56	Female	1	1	1	1	1
73	NLW	47	Female	2	2			
	Discontinued		Mean	1.97	1.84	1.57	1.63	1.47
			SD	0.87	0.93	0.90	0.85	0.90
			Median	2.00	2.00	1.50	2.00	1.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Mottled Hyperpigmentation Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	0	0	0	0
5	LMP	45	Female	0	0	0	0
6	PJW	43	Female				
10	JCL	41	Female	0	0	0	0
11	TLM	50	Female	0	-1	-1	-1
13	DKS	38	Female	0	-1	-1	-1
14	LKB	56	Female	0	0	0	0
15	NHK	56	Female	0			
16	VLH	57	Female	0	-1	-1	-1
22	JKP	48	Female				
23	RMS	51	Female	0	0	0	0
25	TJJ	40	Female	0	0	0	0
29	DSE	59	Female	-1	-1	-1	-1
30	MMC	64	Female	0	0	-1	-1
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	0	0	0	-1
36	MAE	51	Female	0	0	0	0
37	GLJ	54	Female	0	-1	-1	-1
38	KAS	42	Female				
41	E-N	61	Female	0	0	1	0
42	KAM	52	Female	0	0	0	0
43	CGC	48	Female	0	0	0	-1
45	TDC	48	Female	-1	-1	-1	-1
48	JLL	47	Female	-1	-1	0	-1
50	DKH	49	Female	0	0	0	0
52	CJL	53	Female	0	-1	-1	-1
53	DSB	54	Female	0	0	0	0
55	SKR	57	Female	0	0	0	0
56	DAH	45	Female				
58	CZR	49	Female	0	0	0	0
62	KME	45	Female	0	0	0	0
63	MRG	51	Female	-2			
68	SAM	53	Female	0	-2	-1	-1
69	GHD	55	Female	-1	-1	-1	-2
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	0	0	0	0
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	0			
			Mean	-0.13	-0.37	-0.30	-0.47
			SD	0.34	0.56	0.53	0.57
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

Expert Assessment of Overall Severity of Skin Aging

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Overall Severity (Skin Aging)				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	4	4	3	2	2
5	LMP	45	Female	4	3	3	2	2
6	PJW	43	Female	2				
10	JCL	41	Female	4	3	3	2	2
11	TLM	50	Female	5	4	3	3	3
13	DKS	38	Female	2	2	1	1	1
14	LKB	56	Female	6	6	5	5	5
15	NHK	56	Female	4	4			
16	VLH	57	Female	4	3	3	2	2
22	JKP	48	Female					
23	RMS	51	Female	3	2	2	3	2
25	TJJ	40	Female	3	2	2	2	1
29	DSE	59	Female	4	3	3	2	3
30	MMC	64	Female	6	6	5	5	5
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	5	5	5	5	5
36	MAE	51	Female	3	3	3	2	1
37	GLJ	54	Female	4	4	4	4	4
38	KAS	42	Female					
41	E-N	61	Female	4	4	4	5	5
42	KAM	52	Female	5	5	5	4	4
43	CGC	48	Female	3	3	2	2	2
45	TDC	48	Female	3	3	2	1	1
48	JLL	47	Female	3	2	2	1	1
50	DKH	49	Female	2	2	2	2	2
52	CJL	53	Female	3	3	2	2	2
53	DSB	54	Female	5	4	3	3	3
55	SKR	57	Female	2	1	1	1	1
56	DAH	45	Female					
58	CZR	49	Female	4	4	3	3	2
62	KME	45	Female	4	4	2	3	3
63	MRG	51	Female	4				
68	SAM	53	Female	5	4	4	4	4
69	GHD	55	Female	6	5	5	5	5
70	CAC	62	Female	6	6	6	6	5
71	JAR	40	Female	3	3	2	2	1
72	NRC	56	Female	4	3	2	3	2
73	NLW	47	Female	2	1			
	Discontinued		Mean	3.97	3.55	3.07	2.90	2.70
			SD	1.17	1.26	1.31	1.42	1.47
			Median	4.00	3.00	3.00	2.50	2.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Overall Severity (Skin Aging) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	0	-1	-2	-2
5	LMP	45	Female	-1	-1	-2	-2
6	PJW	43	Female				
10	JCL	41	Female	-1	-1	-2	-2
11	TLM	50	Female	-1	-2	-2	-2
13	DKS	38	Female	0	-1	-1	-1
14	LKB	56	Female	0	-1	-1	-1
15	NHK	56	Female	0			
16	VLH	57	Female	-1	-1	-2	-2
22	JKP	48	Female				
23	RMS	51	Female	-1	-1	0	-1
25	TJJ	40	Female	-1	-1	-1	-2
29	DSE	59	Female	-1	-1	-2	-1
30	MMC	64	Female	0	-1	-1	-1
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	0	0	0	0
36	MAE	51	Female	0	0	-1	-2
37	GLJ	54	Female	0	0	0	0
38	KAS	42	Female				
41	E-N	61	Female	0	0	1	1
42	KAM	52	Female	0	0	-1	-1
43	CGC	48	Female	0	-1	-1	-1
45	TDC	48	Female	0	-1	-2	-2
48	JLL	47	Female	-1	-1	-2	-2
50	DKH	49	Female	0	0	0	0
52	CJL	53	Female	0	-1	-1	-1
53	DSB	54	Female	-1	-2	-2	-2
55	SKR	57	Female	-1	-1	-1	-1
56	DAH	45	Female				
58	CZR	49	Female	0	-1	-1	-2
62	KME	45	Female	0	-2	-1	-1
63	MRG	51	Female				
68	SAM	53	Female	-1	-1	-1	-1
69	GHD	55	Female	-1	-1	-1	-1
70	CAC	62	Female	0	0	0	-1
71	JAR	40	Female	0	-1	-1	-2
72	NRC	56	Female	-1	-2	-1	-2
73	NLW	47	Female				
			Mean	-0.42	-0.90	-1.07	-1.27
			SD	0.50	0.61	0.78	0.78
			Median	0.00	-1.00	-1.00	-1.00
			N	31	30	30	30

0 = None
1-3 = Mild
4-6 = Moderate
7-9 = Severe

Expert Assessment of Improvement of Skin Aging

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Improvement (Skin Aging)				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	N/A	5	4	4	4
5	LMP	45	Female	N/A	4	4	4	4
6	PJW	43	Female	N/A				
10	JCL	41	Female	N/A	5	4	4	4
11	TLM	50	Female	N/A	5	4	4	4
13	DKS	38	Female	N/A	5	4	4	4
14	LKB	56	Female	N/A	5	5	5	5
15	NHK	56	Female	N/A	5			
16	VLH	57	Female	N/A	5	4	4	4
22	JKP	48	Female	N/A				
23	RMS	51	Female	N/A	4	4	4	4
25	TJJ	40	Female	N/A	4	4	4	4
29	DSE	59	Female	N/A	4	4	4	5
30	MMC	64	Female	N/A	5	5	5	5
33	J-G	47	Female	N/A				
34	LLL	31	Female	N/A				
35	DLM	52	Female	N/A	5	5	5	5
36	MAE	51	Female	N/A	5	4	4	4
37	GLJ	54	Female	N/A	5	4	4	4
38	KAS	42	Female	N/A				
41	E-N	61	Female	N/A	5	5	5	5
42	KAM	52	Female	N/A	4	4	4	4
43	CGC	48	Female	N/A	5	4	4	4
45	TDC	48	Female	N/A	4	4	4	4
48	JLL	47	Female	N/A	4	4	4	4
50	DKH	49	Female	N/A	5	4	4	4
52	CJL	53	Female	N/A	5	4	4	4
53	DSB	54	Female	N/A	5	5	5	5
55	SKR	57	Female	N/A	5	4	4	4
56	DAH	45	Female	N/A				
58	CZR	49	Female	N/A	5	4	4	4
62	KME	45	Female	N/A	5	4	4	4
63	MRG	51	Female	N/A				
68	SAM	53	Female	N/A	5	4	4	4
69	GHD	55	Female	N/A	5	5	5	5
70	CAC	62	Female	N/A	5	5	5	4
71	JAR	40	Female	N/A	5	4	4	4
72	NRC	56	Female	N/A	4	4	4	4
73	NLW	47	Female	N/A	5			
	Discontinued		Mean		4.74	4.23	4.23	4.23
			SD		0.44	0.43	0.43	0.43
			Median		5.00	4.00	4.00	4.00
			N		31	30	30	30

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Improvement (Skin Aging) Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
4	SKH	46	Female	-1	-1	-1
5	LMP	45	Female	0	0	0
6	PJW	43	Female			
10	JCL	41	Female	-1	-1	-1
11	TLM	50	Female	-1	-1	-1
13	DKS	38	Female	-1	-1	-1
14	LKB	56	Female	0	0	0
15	NHK	56	Female			
16	VLH	57	Female	-1	-1	-1
22	JKP	48	Female			
23	RMS	51	Female	0	0	0
25	TJJ	40	Female	0	0	0
29	DSE	59	Female	0	0	1
30	MMC	64	Female	0	0	0
33	J-G	47	Female			
34	LLL	31	Female			
35	DLM	52	Female	0	0	0
36	MAE	51	Female	-1	-1	-1
37	GLJ	54	Female	-1	-1	-1
38	KAS	42	Female			
41	E-N	61	Female	0	0	0
42	KAM	52	Female	0	0	0
43	CGC	48	Female	-1	-1	-1
45	TDC	48	Female	0	0	0
48	JLL	47	Female	0	0	0
50	DKH	49	Female	-1	-1	-1
52	CJL	53	Female	-1	-1	-1
53	DSB	54	Female	0	0	0
55	SKR	57	Female	-1	-1	-1
56	DAH	45	Female			
58	CZR	49	Female	-1	-1	-1
62	KME	45	Female	-1	-1	-1
63	MRG	51	Female			
68	SAM	53	Female	-1	-1	-1
69	GHD	55	Female	0	0	0
70	CAC	62	Female	0	0	-1
71	JAR	40	Female	-1	-1	-1
72	NRC	56	Female	0	0	0
73	NLW	47	Female			
			Mean	-0.50	-0.50	-0.50
			SD	0.51	0.51	0.57
			Median	-0.50	-0.50	-1.00
			N	30	30	30

1 = Excellent Improvement (~100%)
2 = Marked Improvement (~75%)
3 = Moderate Improvement (~50%)
4 = Slight Improvement (~25%)
5 = No Improvement (0%)
6 = Worse

Expert Assessment of Skin Irritation

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Skin Irritation				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	1	2	1	0	1
5	LMP	45	Female	1	1	1	0	1
6	PJW	43	Female	2				
10	JCL	41	Female	1	1	0	0	0
11	TLM	50	Female	1	1	1	0	0
13	DKS	38	Female	2	2	1	1	1
14	LKB	56	Female	1	1	1	1	1
15	NHK	56	Female	1	1			
16	VLH	57	Female	1	1	0	1	0
22	JKP	48	Female					
23	RMS	51	Female	1	1	1	1	1
25	TJJ	40	Female	2	2	2	1	1
29	DSE	59	Female	1	0	0	0	0
30	MMC	64	Female	1	1	1	0	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	1	1	0	0	0
36	MAE	51	Female	1	0	0	0	0
37	GLJ	54	Female	1	1	0	0	0
38	KAS	42	Female					
41	E-N	61	Female	2	1	1	0	1
42	KAM	52	Female	1	0	0	0	0
43	CGC	48	Female	1	0	0	0	0
45	TDC	48	Female	1	1	2	1	1
48	JLL	47	Female	1	1	1	1	0
50	DKH	49	Female	1	2	2	1	1
52	CJL	53	Female	1	0	1	0	1
53	DSB	54	Female	1	1	1	0	0
55	SKR	57	Female	1	0	0	0	0
56	DAH	45	Female					
58	CZR	49	Female	1	1	0	0	0
62	KME	45	Female	0	0	0	0	0
63	MRG	51	Female	1				
68	SAM	53	Female	1	1	1	1	1
69	GHD	55	Female	1	1	0	0	0
70	CAC	62	Female	1	1	0	0	1
71	JAR	40	Female	1	1	1	1	1
72	NRC	56	Female	2	2	1	0	0
73	NLW	47	Female	2	3			
	Discontinued		Mean	1.10	0.94	0.67	0.33	0.43
			SD	0.40	0.63	0.66	0.48	0.50
			Median	1.00	1.00	1.00	0.00	0.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Skin Irritation Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	1	0	-1	0
5	LMP	45	Female	0	0	-1	0
6	PJW	43	Female				
10	JCL	41	Female	0	-1	-1	-1
11	TLM	50	Female	0	0	-1	-1
13	DKS	38	Female	0	-1	-1	-1
14	LKB	56	Female	0	0	0	0
15	NHK	56	Female	0			
16	VLH	57	Female	0	-1	0	-1
22	JKP	48	Female				
23	RMS	51	Female	0	0	0	0
25	TJJ	40	Female	0	0	-1	-1
29	DSE	59	Female	-1	-1	-1	-1
30	MMC	64	Female	0	0	-1	-1
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	0	-1	-1	-1
36	MAE	51	Female	-1	-1	-1	-1
37	GLJ	54	Female	0	-1	-1	-1
38	KAS	42	Female				
41	E-N	61	Female	-1	-1	-2	-1
42	KAM	52	Female	-1	-1	-1	-1
43	CGC	48	Female	-1	-1	-1	-1
45	TDC	48	Female	0	1	0	0
48	JLL	47	Female	0	0	0	-1
50	DKH	49	Female	1	1	0	0
52	CJL	53	Female	-1	0	-1	0
53	DSB	54	Female	0	0	-1	-1
55	SKR	57	Female	-1	-1	-1	-1
56	DAH	45	Female				
58	CZR	49	Female	0	-1	-1	-1
62	KME	45	Female	0	0	0	0
63	MRG	51	Female				
68	SAM	53	Female	0	0	0	0
69	GHD	55	Female	0	-1	-1	-1
70	CAC	62	Female	0	-1	-1	0
71	JAR	40	Female	0	0	0	0
72	NRC	56	Female	0	-1	-2	-2
73	NLW	47	Female	1			
			Mean	-0.16	-0.43	-0.77	-0.67
			SD	0.52	0.63	0.57	0.55
			Median	0.00	-0.50	-1.00	-1.00
			N	31	30	30	30

0 = None
1 = Mild
2 = Moderate
3 = Severe

Expert Assessment of Overall Severity of Acne

				Expert Assessment of Overall Severity (Acne)				
Subject No.	Subject Initials	Age	Sex	Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	1	1	1	1	1
5	LMP	45	Female	1	1	1	1	1
6	PJW	43	Female	1				
10	JCL	41	Female	1	1	1	0	1
11	TLM	50	Female	1	1	1	1	1
13	DKS	38	Female	1	1	1	1	1
14	LKB	56	Female	1	1	1	0	1
15	NHK	56	Female	1	1			
16	VLH	57	Female	1	1	1	0	1
22	JKP	48	Female					
23	RMS	51	Female	0	1	0	0	0
25	TJJ	40	Female	0	1	1	0	1
29	DSE	59	Female	1	1	1	0	1
30	MMC	64	Female	1	0	1	1	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	2	1	1	1	1
36	MAE	51	Female	1	1	0	1	0
37	GLJ	54	Female	1	1	1	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	1	0	1	0	1
43	CGC	48	Female	1	1	1	1	1
45	TDC	48	Female	1	1	1	0	1
48	JLL	47	Female	1	1	1	1	1
50	DKH	49	Female	1	1	1	1	2
52	CJL	53	Female	1	1	1	1	1
53	DSB	54	Female	1	1	1	0	1
55	SKR	57	Female	1	1	1	1	0
56	DAH	45	Female					
58	CZR	49	Female	1	1	1	0	1
62	KME	45	Female	1	1	2	1	1
63	MRG	51	Female	1				
68	SAM	53	Female	0	1	1	1	1
69	GHD	55	Female	0	1	1	0	0
70	CAC	62	Female	0	0	1	0	0
71	JAR	40	Female	1	1	1	1	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	2	0			
	Discontinued		Mean	0.81	0.84	0.90	0.50	0.70
			SD	0.48	0.37	0.40	0.51	0.53
			Median	1.00	1.00	1.00	0.50	1.00
			N	31	31	30	30	30

				Expert Assessment of Overall Severity (Acne) Intra-Subject Change			
Subject No.	Subject Initials	Age	Sex	Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	0	0	0	0
5	LMP	45	Female	0	0	0	0
6	PJW	43	Female				
10	JCL	41	Female	0	0	-1	0
11	TLM	50	Female	0	0	0	0
13	DKS	38	Female	0	0	0	0
14	LKB	56	Female	0	0	-1	0
15	NHK	56	Female	0			
16	VLH	57	Female	0	0	-1	0
22	JKP	48	Female				
23	RMS	51	Female	1	0	0	0
25	TJJ	40	Female	1	1	0	1
29	DSE	59	Female	0	0	-1	0
30	MMC	64	Female	-1	0	0	-1
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	-1	-1	-1	-1
36	MAE	51	Female	0	-1	0	-1
37	GLJ	54	Female	0	0	-1	-1
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	-1	0	-1	0
43	CGC	48	Female	0	0	0	0
45	TDC	48	Female	0	0	-1	0
48	JLL	47	Female	0	0	0	0
50	DKH	49	Female	0	0	0	1
52	CJL	53	Female	0	0	0	0
53	DSB	54	Female	0	0	-1	0
55	SKR	57	Female	0	0	0	-1
56	DAH	45	Female				
58	CZR	49	Female	0	0	-1	0
62	KME	45	Female	0	1	0	0
63	MRG	51	Female				
68	SAM	53	Female	1	1	1	1
69	GHD	55	Female	1	1	0	0
70	CAC	62	Female	0	1	0	0
71	JAR	40	Female	0	0	0	-1
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-2			
			Mean	0.03	0.10	-0.30	-0.10
			SD	0.48	0.48	0.53	0.55
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

0 = None
1 = Mild
2 = Moderate
3 = Severe

Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Forehead) Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	0	0	0	0	1
5	LMP	45	Female	0	1	0	0	1
6	PJW	43	Female	0				
10	JCL	41	Female	0	1	2	0	1
11	TLM	50	Female	0	1	2	0	0
13	DKS	38	Female	0	0	0	0	0
14	LKB	56	Female	0	0	1	0	0
15	NHK	56	Female	0	1			
16	VLH	57	Female	0	4	2	0	2
22	JKP	48	Female					
23	RMS	51	Female	0	1	0	0	0
25	TJJ	40	Female	0	3	2	0	1
29	DSE	59	Female	0	0	0	0	1
30	MMC	64	Female	0	0	0	0	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	0	1	0	0	0
36	MAE	51	Female	0	0	0	1	0
37	GLJ	54	Female	3	0	0	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	1	0	1	0	0
43	CGC	48	Female	0	1	0	2	2
45	TDC	48	Female	0	0	0	0	0
48	JLL	47	Female	0	1	0	0	0
50	DKH	49	Female	0	1	4	0	3
52	CJL	53	Female	0	0	0	0	0
53	DSB	54	Female	3	2	4	0	0
55	SKR	57	Female	0	1	0	0	0
56	DAH	45	Female					
58	CZR	49	Female	0	0	4	0	1
62	KME	45	Female	1	0	0	2	1
63	MRG	51	Female	1				
68	SAM	53	Female	0	2	1	4	0
69	GHD	55	Female	0	0	0	0	0
70	CAC	62	Female	0	0	1	0	0
71	JAR	40	Female	0	0	1	0	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	4	0			
			Mean	0.26	0.68	0.83	0.30	0.47
			SD	0.77	0.98	1.29	0.88	0.78
			Median	0.00	0.00	0.00	0.00	0.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Forehead) Intra-Subject Change Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	0	0	0	1
5	LMP	45	Female	1	0	0	1
6	PJW	43	Female				
10	JCL	41	Female	1	2	0	1
11	TLM	50	Female	1	2	0	0
13	DKS	38	Female	0	0	0	0
14	LKB	56	Female	0	1	0	0
15	NHK	56	Female	1			
16	VLH	57	Female	4	2	0	2
22	JKP	48	Female				
23	RMS	51	Female	1	0	0	0
25	TJJ	40	Female	3	2	0	1
29	DSE	59	Female	0	0	0	1
30	MMC	64	Female	0	0	0	0
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	1	0	0	0
36	MAE	51	Female	0	0	1	0
37	GLJ	54	Female	-3	-3	-3	-3
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	-1	0	-1	-1
43	CGC	48	Female	1	0	2	2
45	TDC	48	Female	0	0	0	0
48	JLL	47	Female	1	0	0	0
50	DKH	49	Female	1	4	0	3
52	CJL	53	Female	0	0	0	0
53	DSB	54	Female	-1	1	-3	-3
55	SKR	57	Female	1	0	0	0
56	DAH	45	Female				
58	CZR	49	Female	0	4	0	1
62	KME	45	Female	-1	-1	1	0
63	MRG	51	Female				
68	SAM	53	Female	2	1	4	0
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	1	0	0
71	JAR	40	Female	0	1	0	0
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-4			
			Mean	0.42	0.57	0.03	0.20
			SD	1.23	1.36	1.19	1.19
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

Discontinued

Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Left Cheek)				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	5	0	2	0	1
5	LMP	45	Female	0	0	0	0	0
6	PJW	43	Female	2				
10	JCL	41	Female	0	0	1	0	0
11	TLM	50	Female	1	1	0	0	0
13	DKS	38	Female	0	0	0	0	1
14	LKB	56	Female	1	0	0	0	0
15	NHK	56	Female	0	4			
16	VLH	57	Female	6	0	0	0	0
22	JKP	48	Female					
23	RMS	51	Female	0	0	0	0	0
25	TJJ	40	Female	0	0	0	0	0
29	DSE	59	Female	0	1	1	0	0
30	MMC	64	Female	0	0	0	0	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	2	0	0	2	0
36	MAE	51	Female	0	0	0	0	0
37	GLJ	54	Female	3	0	1	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	0	0	2	0	0
43	CGC	48	Female	1	1	1	1	3
45	TDC	48	Female	0	0	0	0	0
48	JLL	47	Female	1	1	1	0	0
50	DKH	49	Female	0	2	0	2	4
52	CJL	53	Female	0	2	0	0	0
53	DSB	54	Female	0	0	0	0	0
55	SKR	57	Female	0	0	0	2	0
56	DAH	45	Female					
58	CZR	49	Female	0	1	3	0	0
62	KME	45	Female	1	0	0	0	0
63	MRG	51	Female	0				
68	SAM	53	Female	0	0	0	0	0
69	GHD	55	Female	0	1	1	0	0
70	CAC	62	Female	0	0	0	0	0
71	JAR	40	Female	0	0	0	0	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	1	0			
			Mean	0.68	0.45	0.43	0.23	0.30
			SD	1.47	0.89	0.77	0.63	0.92
			Median	0.00	0.00	0.00	0.00	0.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Left Cheek) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-5	-3	-5	-4
5	LMP	45	Female	0	0	0	0
6	PJW	43	Female				
10	JCL	41	Female	0	1	0	0
11	TLM	50	Female	0	-1	-1	-1
13	DKS	38	Female	0	0	0	1
14	LKB	56	Female	-1	-1	-1	-1
15	NHK	56	Female	4			
16	VLH	57	Female	-6	-6	-6	-6
22	JKP	48	Female				
23	RMS	51	Female	0	0	0	0
25	TJJ	40	Female	0	0	0	0
29	DSE	59	Female	1	1	0	0
30	MMC	64	Female	0	0	0	0
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	-2	-2	0	-2
36	MAE	51	Female	0	0	0	0
37	GLJ	54	Female	-3	-2	-3	-3
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	0	2	0	0
43	CGC	48	Female	0	0	0	2
45	TDC	48	Female	0	0	0	0
48	JLL	47	Female	0	0	-1	-1
50	DKH	49	Female	2	0	2	4
52	CJL	53	Female	2	0	0	0
53	DSB	54	Female	0	0	0	0
55	SKR	57	Female	0	0	2	0
56	DAH	45	Female				
58	CZR	49	Female	1	3	0	0
62	KME	45	Female	-1	-1	-1	-1
63	MRG	51	Female				
68	SAM	53	Female	0	0	0	0
69	GHD	55	Female	1	1	0	0
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	0	0	0	0
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-1			
			Mean	-0.23	-0.27	-0.47	-0.40
			SD	1.84	1.55	1.61	1.71
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

Discontinued

Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Right Cheek)				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	4	3	0	4	3
5	LMP	45	Female	0	0	1	0	2
6	PJW	43	Female	1				
10	JCL	41	Female	0	1	0	0	1
11	TLM	50	Female	0	0	0	1	0
13	DKS	38	Female	0	0	0	0	2
14	LKB	56	Female	0	0	0	0	0
15	NHK	56	Female	0	1			
16	VLH	57	Female	3	0	3	0	3
22	JKP	48	Female					
23	RMS	51	Female	0	1	0	0	0
25	TJJ	40	Female	0	0	2	0	0
29	DSE	59	Female	0	0	0	0	0
30	MMC	64	Female	0	0	0	0	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	0	2	0	0	0
36	MAE	51	Female	0	0	0	0	0
37	GLJ	54	Female	1	0	1	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	0	0	0	0	0
43	CGC	48	Female	0	2	0	2	1
45	TDC	48	Female	0	0	0	0	1
48	JLL	47	Female	1	0	2	1	0
50	DKH	49	Female	1	4	1	3	1
52	CJL	53	Female	1	0	0	0	1
53	DSB	54	Female	0	0	1	0	0
55	SKR	57	Female	0	0	0	0	0
56	DAH	45	Female					
58	CZR	49	Female	0	0	3	0	0
62	KME	45	Female	0	0	3	1	0
63	MRG	51	Female	0				
68	SAM	53	Female	0	2	1	1	0
69	GHD	55	Female	0	0	0	0	0
70	CAC	62	Female	0	0	0	0	0
71	JAR	40	Female	0	0	3	0	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	2	0			
			Mean	0.35	0.52	0.70	0.43	0.50
			SD	0.91	1.03	1.09	0.97	0.90
			Median	0.00	0.00	0.00	0.00	0.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Right Cheek) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-1	-4	0	-1
5	LMP	45	Female	0	1	0	2
6	PJW	43	Female				
10	JCL	41	Female	1	0	0	1
11	TLM	50	Female	0	0	1	0
13	DKS	38	Female	0	0	0	2
14	LKB	56	Female	0	0	0	0
15	NHK	56	Female	1			
16	VLH	57	Female	-3	0	-3	0
22	JKP	48	Female				
23	RMS	51	Female	1	0	0	0
25	TJJ	40	Female	0	2	0	0
29	DSE	59	Female	0	0	0	0
30	MMC	64	Female	0	0	0	0
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	2	0	0	0
36	MAE	51	Female	0	0	0	0
37	GLJ	54	Female	-1	0	-1	-1
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	0	0	0	0
43	CGC	48	Female	2	0	2	1
45	TDC	48	Female	0	0	0	1
48	JLL	47	Female	-1	1	0	-1
50	DKH	49	Female	3	0	2	0
52	CJL	53	Female	-1	-1	-1	0
53	DSB	54	Female	0	1	0	0
55	SKR	57	Female	0	0	0	0
56	DAH	45	Female				
58	CZR	49	Female	0	3	0	0
62	KME	45	Female	0	3	1	0
63	MRG	51	Female				
68	SAM	53	Female	2	1	1	0
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	0	3	0	0
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-2			
			Mean	0.16	0.33	0.07	0.13
			SD	1.10	1.30	0.87	0.68
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

Discontinued

Inflammatory Lesion Count

				Inflammatory Lesion Count (Chin)				
Subject No.	Subject Initials	Age	Sex	Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	1	0	1	2	1
5	LMP	45	Female	0	0	1	3	1
6	PJW	43	Female	2				
10	JCL	41	Female	1	1	0	0	2
11	TLM	50	Female	0	0	1	1	1
13	DKS	38	Female	1	1	0	0	2
14	LKB	56	Female	0	0	0	0	0
15	NHK	56	Female	0	0			
16	VLH	57	Female	0	0	0	0	0
22	JKP	48	Female					
23	RMS	51	Female	0	0	0	0	0
25	TJJ	40	Female	0	0	1	0	2
29	DSE	59	Female	2	0	0	0	0
30	MMC	64	Female	0	0	0	0	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	0	0	0	0	2
36	MAE	51	Female	0	0	0	0	0
37	GLJ	54	Female	0	0	0	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	0	0	0	0	0
43	CGC	48	Female	0	0	0	1	2
45	TDC	48	Female	0	0	0	0	0
48	JLL	47	Female	0	3	0	3	0
50	DKH	49	Female	1	2	4	1	2
52	CJL	53	Female	1	0	0	0	0
53	DSB	54	Female	0	1	1	0	0
55	SKR	57	Female	0	0	0	0	0
56	DAH	45	Female					
58	CZR	49	Female	0	0	0	0	0
62	KME	45	Female	1	0	4	4	2
63	MRG	51	Female	1				
68	SAM	53	Female	0	0	0	0	0
69	GHD	55	Female	0	0	0	0	0
70	CAC	62	Female	0	0	1	0	0
71	JAR	40	Female	3	1	1	0	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	1	0			
	Discontinued		Mean	0.35	0.29	0.50	0.50	0.57
			SD	0.71	0.69	1.04	1.07	0.86
			Median	0.00	0.00	0.00	0.00	0.00
			N	31	31	30	30	30

				Inflammatory Lesion Count (Chin) Intra-Subject Change			
Subject No.	Subject Initials	Age	Sex	Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-1	0	1	0
5	LMP	45	Female	0	1	3	1
6	PJW	43	Female				
10	JCL	41	Female	0	-1	-1	1
11	TLM	50	Female	0	1	1	1
13	DKS	38	Female	0	-1	-1	1
14	LKB	56	Female	0	0	0	0
15	NHK	56	Female	0			
16	VLH	57	Female	0	0	0	0
22	JKP	48	Female				
23	RMS	51	Female	0	0	0	0
25	TJJ	40	Female	0	1	0	2
29	DSE	59	Female	-2	-2	-2	-2
30	MMC	64	Female	0	0	0	0
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	0	0	0	2
36	MAE	51	Female	0	0	0	0
37	GLJ	54	Female	0	0	0	0
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	0	0	0	0
43	CGC	48	Female	0	0	1	2
45	TDC	48	Female	0	0	0	0
48	JLL	47	Female	3	0	3	0
50	DKH	49	Female	1	3	0	1
52	CJL	53	Female	-1	-1	-1	-1
53	DSB	54	Female	1	1	0	0
55	SKR	57	Female	0	0	0	0
56	DAH	45	Female				
58	CZR	49	Female	0	0	0	0
62	KME	45	Female	-1	3	3	1
63	MRG	51	Female				
68	SAM	53	Female	0	0	0	0
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	1	0	0
71	JAR	40	Female	-2	-2	-3	-3
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-1			
			Mean	-0.06	0.13	0.13	0.20
			SD	0.85	1.07	1.25	1.03
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

Non-Inflammatory Lesion Count

				Non-Inflammatory Lesion Count (Forehead)				
Subject No.	Subject Initials	Age	Sex	Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	11	3	2	1	7
5	LMP	45	Female	1	2	0	0	0
6	PJW	43	Female	1				
10	JCL	41	Female	0	0	0	0	1
11	TLM	50	Female	4	2	0	1	0
13	DKS	38	Female	0	0	1	2	0
14	LKB	56	Female	0	0	0	0	1
15	NHK	56	Female	0	1			
16	VLH	57	Female	0	3	0	0	3
22	JKP	48	Female					
23	RMS	51	Female	0	0	0	0	0
25	TJJ	40	Female	0	0	0	0	1
29	DSE	59	Female	4	0	2	0	0
30	MMC	64	Female	0	0	3	2	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	0	0	5	0	4
36	MAE	51	Female	5	1	0	2	0
37	GLJ	54	Female	0	0	0	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	3	0	1	0	4
43	CGC	48	Female	0	0	0	0	1
45	TDC	48	Female	0	0	0	0	0
48	JLL	47	Female	0	0	0	0	0
50	DKH	49	Female	0	0	2	0	6
52	CJL	53	Female	1	4	3	3	1
53	DSB	54	Female	0	0	2	0	2
55	SKR	57	Female	2	0	1	0	0
56	DAH	45	Female					
58	CZR	49	Female	0	2	3	0	0
62	KME	45	Female	4	3	8	1	0
63	MRG	51	Female	0				
68	SAM	53	Female	0	2	0	0	0
69	GHD	55	Female	0	0	0	0	0
70	CAC	62	Female	0	0	0	0	0
71	JAR	40	Female	1	2	0	6	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	16	0			
			Mean	1.16	0.81	1.10	0.60	1.03
			SD	2.37	1.22	1.84	1.30	1.88
			Median	0.00	0.00	0.00	0.00	0.00
			N	31	31	30	30	30

				Non-Inflammatory Lesion Count (Forehead) Intra-Subject Change			
Subject No.	Subject Initials	Age	Sex	Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-8	-9	-10	-4
5	LMP	45	Female	1	-1	-1	-1
6	PJW	43	Female				
10	JCL	41	Female	0	0	0	1
11	TLM	50	Female	-2	-4	-3	-4
13	DKS	38	Female	0	1	2	0
14	LKB	56	Female	0	0	0	1
15	NHK	56	Female	1			
16	VLH	57	Female	3	0	0	3
22	JKP	48	Female				
23	RMS	51	Female	0	0	0	0
25	TJJ	40	Female	0	0	0	1
29	DSE	59	Female	-4	-2	-4	-4
30	MMC	64	Female	0	3	2	0
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	0	5	0	4
36	MAE	51	Female	-4	-5	-3	-5
37	GLJ	54	Female	0	0	0	0
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	-3	-2	-3	1
43	CGC	48	Female	0	0	0	1
45	TDC	48	Female	0	0	0	0
48	JLL	47	Female	0	0	0	0
50	DKH	49	Female	0	2	0	6
52	CJL	53	Female	3	2	2	0
53	DSB	54	Female	0	2	0	2
55	SKR	57	Female	-2	-1	-2	-2
56	DAH	45	Female				
58	CZR	49	Female	2	3	0	0
62	KME	45	Female	-1	4	-3	-4
63	MRG	51	Female				
68	SAM	53	Female	2	0	0	0
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	1	-1	5	-1
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-16			
			Mean	-0.35	-0.10	-0.60	-0.17
			SD	2.15	2.66	2.51	2.38
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

Discontinued

Non-Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Non-Inflammatory Lesion Count (Left Cheek)				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	12	3	9	8	9
5	LMP	45	Female	1	0	0	0	0
6	PJW	43	Female	1				
10	JCL	41	Female	0	0	0	0	0
11	TLM	50	Female	2	5	0	0	0
13	DKS	38	Female	1	0	3	0	0
14	LKB	56	Female	1	1	0	0	2
15	NHK	56	Female	6	0			
16	VLH	57	Female	0	0	2	0	2
22	JKP	48	Female					
23	RMS	51	Female	0	1	0	0	0
25	TJJ	40	Female	0	0	0	0	0
29	DSE	59	Female	2	1	0	0	1
30	MMC	64	Female	2	0	0	0	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	18	0	11	0	6
36	MAE	51	Female	3	1	0	0	0
37	GLJ	54	Female	0	0	0	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	0	0	0	0	5
43	CGC	48	Female	1	0	0	0	1
45	TDC	48	Female	1	1	2	0	0
48	JLL	47	Female	0	0	0	0	0
50	DKH	49	Female	7	5	4	1	7
52	CJL	53	Female	17	4	5	4	7
53	DSB	54	Female	4	1	5	0	0
55	SKR	57	Female	0	0	1	0	0
56	DAH	45	Female					
58	CZR	49	Female	0	0	2	0	2
62	KME	45	Female	9	15	18	13	5
63	MRG	51	Female	1				
68	SAM	53	Female	0	0	1	0	2
69	GHD	55	Female	0	0	0	0	0
70	CAC	62	Female	0	0	0	0	0
71	JAR	40	Female	3	0	4	0	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	0	0			
			Mean	2.90	1.23	2.23	0.87	1.63
			SD	4.87	2.94	4.07	2.80	2.65
			Median	1.00	0.00	0.00	0.00	0.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Non-Inflammatory Lesion Count (Left Cheek) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-9	-3	-4	-3
5	LMP	45	Female	-1	-1	-1	-1
6	PJW	43	Female				
10	JCL	41	Female	0	0	0	0
11	TLM	50	Female	3	-2	-2	-2
13	DKS	38	Female	-1	2	-1	-1
14	LKB	56	Female	0	-1	-1	1
15	NHK	56	Female	-6			
16	VLH	57	Female	0	2	0	2
22	JKP	48	Female				
23	RMS	51	Female	1	0	0	0
25	TJJ	40	Female	0	0	0	0
29	DSE	59	Female	-1	-2	-2	-1
30	MMC	64	Female	-2	-2	-2	-2
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	-18	-7	-18	-12
36	MAE	51	Female	-2	-3	-3	-3
37	GLJ	54	Female	0	0	0	0
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	0	0	0	5
43	CGC	48	Female	-1	-1	-1	0
45	TDC	48	Female	0	1	-1	-1
48	JLL	47	Female	0	0	0	0
50	DKH	49	Female	-2	-3	-6	0
52	CJL	53	Female	-13	-12	-13	-10
53	DSB	54	Female	-3	1	-4	-4
55	SKR	57	Female	0	1	0	0
56	DAH	45	Female				
58	CZR	49	Female	0	2	0	2
62	KME	45	Female	6	9	4	-4
63	MRG	51	Female				
68	SAM	53	Female	0	1	0	2
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	-3	1	-3	-3
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	0			
			Mean	-1.68	-0.57	-1.93	-1.17
			SD	4.48	3.34	4.15	3.28
			Median	0.00	0.00	-0.50	0.00
			N	31	30	30	30

Discontinued

Non-Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Non-Inflammatory Lesion Count (Right Cheek)				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	9	2	5	4	5
5	LMP	45	Female	0	0	0	1	0
6	PJW	43	Female	5				
10	JCL	41	Female	1	2	1	0	1
11	TLM	50	Female	2	1	1	1	1
13	DKS	38	Female	2	3	3	0	0
14	LKB	56	Female	5	4	4	0	1
15	NHK	56	Female	5	0			
16	VLH	57	Female	2	1	0	0	1
22	JKP	48	Female					
23	RMS	51	Female	0	0	0	0	0
25	TJJ	40	Female	0	0	0	0	0
29	DSE	59	Female	3	0	0	0	0
30	MMC	64	Female	2	0	0	1	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	26	0	9	5	4
36	MAE	51	Female	3	0	0	0	0
37	GLJ	54	Female	1	6	3	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	5	0	3	0	6
43	CGC	48	Female	1	0	0	0	0
45	TDC	48	Female	2	0	0	0	0
48	JLL	47	Female	2	2	0	1	2
50	DKH	49	Female	3	2	8	2	10
52	CJL	53	Female	15	16	8	6	5
53	DSB	54	Female	1	2	3	0	1
55	SKR	57	Female	0	0	0	0	0
56	DAH	45	Female					
58	CZR	49	Female	0	0	4	0	0
62	KME	45	Female	10	3	6	6	4
63	MRG	51	Female	0				
68	SAM	53	Female	0	2	1	1	3
69	GHD	55	Female	0	0	0	0	0
70	CAC	62	Female	0	0	0	0	0
71	JAR	40	Female	0	0	1	0	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	8	0			
			Mean	3.23	1.48	2.00	0.93	1.47
			SD	5.44	3.08	2.77	1.82	2.43
			Median	2.00	0.00	0.50	0.00	0.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Non-Inflammatory Lesion Count (Right Cheek) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-7	-4	-5	-4
5	LMP	45	Female	0	0	1	0
6	PJW	43	Female				
10	JCL	41	Female	1	0	-1	0
11	TLM	50	Female	-1	-1	-1	-1
13	DKS	38	Female	1	1	-2	-2
14	LKB	56	Female	-1	-1	-5	-4
15	NHK	56	Female	-5			
16	VLH	57	Female	-1	-2	-2	-1
22	JKP	48	Female				
23	RMS	51	Female	0	0	0	0
25	TJJ	40	Female	0	0	0	0
29	DSE	59	Female	-3	-3	-3	-3
30	MMC	64	Female	-2	-2	-1	-2
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	-26	-17	-21	-22
36	MAE	51	Female	-3	-3	-3	-3
37	GLJ	54	Female	5	2	-1	-1
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	-5	-2	-5	1
43	CGC	48	Female	-1	-1	-1	-1
45	TDC	48	Female	-2	-2	-2	-2
48	JLL	47	Female	0	-2	-1	0
50	DKH	49	Female	-1	5	-1	7
52	CJL	53	Female	1	-7	-9	-10
53	DSB	54	Female	1	2	-1	0
55	SKR	57	Female	0	0	0	0
56	DAH	45	Female				
58	CZR	49	Female	0	4	0	0
62	KME	45	Female	-7	-4	-4	-6
63	MRG	51	Female				
68	SAM	53	Female	2	1	1	3
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	0	1	0	0
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-8			
			Mean	-1.74	-1.17	-2.23	-1.70
			SD	5.14	3.82	4.17	4.76
			Median	0.00	0.00	-1.00	0.00
			N	31	30	30	30

Discontinued

Non-Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Non-Inflammatory Lesion Count (Chin)				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	11	0	0	0	2
5	LMP	45	Female	2	0	0	0	0
6	PJW	43	Female	1				
10	JCL	41	Female	0	1	0	0	0
11	TLM	50	Female	2	1	0	1	0
13	DKS	38	Female	0	0	0	0	0
14	LKB	56	Female	0	0	0	0	0
15	NHK	56	Female	2	0			
16	VLH	57	Female	0	2	0	0	2
22	JKP	48	Female					
23	RMS	51	Female	0	1	0	0	0
25	TJJ	40	Female	0	0	0	0	0
29	DSE	59	Female	0	0	0	0	1
30	MMC	64	Female	0	0	0	0	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	0	0	1	1	3
36	MAE	51	Female	0	0	0	0	0
37	GLJ	54	Female	0	0	0	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	0	0	0	0	0
43	CGC	48	Female	0	0	0	0	0
45	TDC	48	Female	1	2	0	0	2
48	JLL	47	Female	0	0	4	0	0
50	DKH	49	Female	0	0	3	0	2
52	CJL	53	Female	0	0	0	0	0
53	DSB	54	Female	0	0	0	0	0
55	SKR	57	Female	0	0	0	0	0
56	DAH	45	Female					
58	CZR	49	Female	10	10	14	0	0
62	KME	45	Female	0	5	3	3	3
63	MRG	51	Female	0				
68	SAM	53	Female	0	0	0	2	1
69	GHD	55	Female	0	0	0	0	0
70	CAC	62	Female	0	0	0	0	0
71	JAR	40	Female	0	0	1	0	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	0	0			
	Discontinued		Mean	0.90	0.71	0.87	0.23	0.53
			SD	2.64	2.00	2.69	0.68	0.97
			Median	0.00	0.00	0.00	0.00	0.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Non-Inflammatory Lesion Count (Chin) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-11	-11	-11	-9
5	LMP	45	Female	-2	-2	-2	-2
6	PJW	43	Female				
10	JCL	41	Female	1	0	0	0
11	TLM	50	Female	-1	-2	-1	-2
13	DKS	38	Female	0	0	0	0
14	LKB	56	Female	0	0	0	0
15	NHK	56	Female	-2			
16	VLH	57	Female	2	0	0	2
22	JKP	48	Female				
23	RMS	51	Female	1	0	0	0
25	TJJ	40	Female	0	0	0	0
29	DSE	59	Female	0	0	0	1
30	MMC	64	Female	0	0	0	0
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	0	1	1	3
36	MAE	51	Female	0	0	0	0
37	GLJ	54	Female	0	0	0	0
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	0	0	0	0
43	CGC	48	Female	0	0	0	0
45	TDC	48	Female	1	-1	-1	1
48	JLL	47	Female	0	4	0	0
50	DKH	49	Female	0	3	0	2
52	CJL	53	Female	0	0	0	0
53	DSB	54	Female	0	0	0	0
55	SKR	57	Female	0	0	0	0
56	DAH	45	Female				
58	CZR	49	Female	0	4	-10	-10
62	KME	45	Female	5	3	3	3
63	MRG	51	Female				
68	SAM	53	Female	0	0	2	1
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	0	1	0	0
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	0			
			Mean	-0.19	0.00	-0.63	-0.33
			SD	2.32	2.51	2.81	2.72
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

Total Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Total Lesion Count (Inflammatory)				
				Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	10	3	3	6	6
5	LMP	45	Female	0	1	2	3	4
6	PJW	43	Female					
10	JCL	41	Female	1	3	3	0	4
11	TLM	50	Female	1	2	3	2	1
13	DKS	38	Female	1	1	0	0	5
14	LKB	56	Female	1	0	1	0	0
15	NHK	56	Female	0	6			
16	VLH	57	Female	9	4	5	0	5
22	JKP	48	Female					
23	RMS	51	Female	0	2	0	0	0
25	TJJ	40	Female	0	3	5	0	3
29	DSE	59	Female	2	1	1	0	1
30	MMC	64	Female	0	0	0	0	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	2	3	0	2	2
36	MAE	51	Female	0	0	0	1	0
37	GLJ	54	Female	7	0	2	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	1	0	3	0	0
43	CGC	48	Female	1	4	1	6	8
45	TDC	48	Female	0	0	0	0	1
48	JLL	47	Female	2	5	3	4	0
50	DKH	49	Female	2	9	9	6	10
52	CJL	53	Female	2	2	0	0	1
53	DSB	54	Female	3	3	6	0	0
55	SKR	57	Female	0	1	0	2	0
56	DAH	45	Female					
58	CZR	49	Female	0	1	10	0	1
62	KME	45	Female	3	0	7	7	3
63	MRG	51	Female	2				
68	SAM	53	Female	0	4	2	5	0
69	GHD	55	Female	0	1	1	0	0
70	CAC	62	Female	0	0	2	0	0
71	JAR	40	Female	3	1	5	0	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	8	0			
	Discontinued		Mean	1.65	1.94	2.47	1.47	1.83
			SD	2.58	2.14	2.78	2.32	2.68
			Median	1.00	1.00	2.00	0.00	0.50
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Total Lesion Count (Inflammatory) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-7	-7	-4	-4
5	LMP	45	Female	1	2	3	4
6	PJW	43	Female				
10	JCL	41	Female	2	2	-1	3
11	TLM	50	Female	1	2	1	0
13	DKS	38	Female	0	-1	-1	4
14	LKB	56	Female	-1	0	-1	-1
15	NHK	56	Female	6			
16	VLH	57	Female	-5	-4	-9	-4
22	JKP	48	Female				
23	RMS	51	Female	2	0	0	0
25	TJJ	40	Female	3	5	0	3
29	DSE	59	Female	-1	-1	-2	-1
30	MMC	64	Female	0	0	0	0
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	1	-2	0	0
36	MAE	51	Female	0	0	1	0
37	GLJ	54	Female	-7	-5	-7	-7
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	-1	2	-1	-1
43	CGC	48	Female	3	0	5	7
45	TDC	48	Female	0	0	0	1
48	JLL	47	Female	3	1	2	-2
50	DKH	49	Female	7	7	4	8
52	CJL	53	Female	0	-2	-2	-1
53	DSB	54	Female	0	3	-3	-3
55	SKR	57	Female	1	0	2	0
56	DAH	45	Female				
58	CZR	49	Female	1	10	0	1
62	KME	45	Female	-3	4	4	0
63	MRG	51	Female				
68	SAM	53	Female	4	2	5	0
69	GHD	55	Female	1	1	0	0
70	CAC	62	Female	0	2	0	0
71	JAR	40	Female	-2	2	-3	-3
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-8			
			Mean	0.29	0.77	-0.23	0.13
			SD	3.05	3.28	3.08	3.06
			Median	0.00	0.00	0.00	0.00
			N	31	30	30	30

Total Non-Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Total Lesion Count (Non-Inflammatory) Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	43	8	16	13	23
5	LMP	45	Female	4	2	0	1	0
6	PJW	43	Female					
10	JCL	41	Female	1	3	1	0	2
11	TLM	50	Female	10	9	1	3	1
13	DKS	38	Female	3	3	7	2	0
14	LKB	56	Female	6	5	4	0	4
15	NHK	56	Female	13	1			
16	VLH	57	Female	2	6	2	0	8
22	JKP	48	Female					
23	RMS	51	Female	0	2	0	0	0
25	TJJ	40	Female	0	0	0	0	1
29	DSE	59	Female	9	1	2	0	2
30	MMC	64	Female	4	0	3	3	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	44	0	26	6	17
36	MAE	51	Female	11	2	0	2	0
37	GLJ	54	Female	1	6	3	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	8	0	4	0	15
43	CGC	48	Female	2	0	0	0	2
45	TDC	48	Female	4	3	2	0	2
48	JLL	47	Female	2	2	4	1	2
50	DKH	49	Female	10	7	17	3	25
52	CJL	53	Female	33	24	16	13	13
53	DSB	54	Female	5	3	10	0	3
55	SKR	57	Female	2	0	2	0	0
56	DAH	45	Female					
58	CZR	49	Female	10	12	23	0	2
62	KME	45	Female	23	26	35	23	12
63	MRG	51	Female	1				
68	SAM	53	Female	0	4	2	3	6
69	GHD	55	Female	0	0	0	0	0
70	CAC	62	Female	0	0	0	0	0
71	JAR	40	Female	4	2	6	6	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	24	0			
	Discontinued		Mean	8.19	4.23	6.20	2.63	4.67
			SD	11.84	6.34	9.00	5.18	7.14
			Median	4.00	2.00	2.00	0.00	2.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Total Lesion Count (Non-Inflammatory) Intra-Subject Change Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-35	-27	-30	-20
5	LMP	45	Female	-2	-4	-3	-4
6	PJW	43	Female				
10	JCL	41	Female	2	0	-1	1
11	TLM	50	Female	-1	-9	-7	-9
13	DKS	38	Female	0	4	-1	-3
14	LKB	56	Female	-1	-2	-6	-2
15	NHK	56	Female	-12			
16	VLH	57	Female	4	0	-2	6
22	JKP	48	Female				
23	RMS	51	Female	2	0	0	0
25	TJJ	40	Female	0	0	0	1
29	DSE	59	Female	-8	-7	-9	-7
30	MMC	64	Female	-4	-1	-1	-4
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	-44	-18	-38	-27
36	MAE	51	Female	-9	-11	-9	-11
37	GLJ	54	Female	5	2	-1	-1
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	-8	-4	-8	7
43	CGC	48	Female	-2	-2	-2	0
45	TDC	48	Female	-1	-2	-4	-2
48	JLL	47	Female	0	2	-1	0
50	DKH	49	Female	-3	7	-7	15
52	CJL	53	Female	-9	-17	-20	-20
53	DSB	54	Female	-2	5	-5	-2
55	SKR	57	Female	-2	0	-2	-2
56	DAH	45	Female				
58	CZR	49	Female	2	13	-10	-8
62	KME	45	Female	3	12	0	-11
63	MRG	51	Female	-1			
68	SAM	53	Female	4	2	3	6
69	GHD	55	Female	0	0	0	0
70	CAC	62	Female	0	0	0	0
71	JAR	40	Female	-2	2	2	-4
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-24			
			Mean	-3.97	-1.83	-5.40	-3.37
			SD	10.38	8.21	9.11	8.40
			Median	-1.00	0.00	-2.00	-2.00
			N	31	30	30	30

Total Lesion Count (Inflammatory and Non-Inflammatory)

Subject No.	Subject Initials	Age	Sex	Total Lesion Count (Inflammatory & Non-Inflammatory) Baseline	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	53	11	19	19	29
5	LMP	45	Female	4	3	2	4	4
6	PJW	43	Female					
10	JCL	41	Female	2	6	4	0	6
11	TLM	50	Female	11	11	4	5	2
13	DKS	38	Female	4	4	7	2	5
14	LKB	56	Female	7	5	5	0	4
15	NHK	56	Female	13	7			
16	VLH	57	Female	11	10	7	0	13
22	JKP	48	Female					
23	RMS	51	Female	0	4	0	0	0
25	TJJ	40	Female	0	3	5	0	4
29	DSE	59	Female	11	2	3	0	3
30	MMC	64	Female	4	0	3	3	0
33	J-G	47	Female					
34	LLL	31	Female					
35	DLM	52	Female	46	3	26	8	19
36	MAE	51	Female	11	2	0	3	0
37	GLJ	54	Female	8	6	5	0	0
38	KAS	42	Female					
41	E-N	61	Female	0	0	0	0	0
42	KAM	52	Female	9	0	7	0	15
43	CGC	48	Female	3	4	1	6	10
45	TDC	48	Female	4	3	2	0	3
48	JLL	47	Female	4	7	7	5	2
50	DKH	49	Female	12	16	26	9	35
52	CJL	53	Female	35	26	16	13	14
53	DSB	54	Female	8	6	16	0	3
55	SKR	57	Female	2	1	2	2	0
56	DAH	45	Female					
58	CZR	49	Female	10	13	33	0	3
62	KME	45	Female	26	26	42	30	15
63	MRG	51	Female	3				
68	SAM	53	Female	0	8	4	8	6
69	GHD	55	Female	0	1	1	0	0
70	CAC	62	Female	0	0	2	0	0
71	JAR	40	Female	7	3	11	6	0
72	NRC	56	Female	0	0	0	0	0
73	NLW	47	Female	32	0			
	Discontinued		Mean	9.84	6.16	8.67	4.10	6.50
			SD	13.07	6.68	10.67	6.69	8.83
			Median	7.00	4.00	4.50	1.00	3.00
			N	31	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Total Lesion Count (Inflammatory & Non-Inflammatory) Intra-Subject Change: Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
4	SKH	46	Female	-42	-34	-34	-24
5	LMP	45	Female	-1	-2	0	0
6	PJW	43	Female				
10	JCL	41	Female	4	2	-2	4
11	TLM	50	Female	0	-7	-6	-9
13	DKS	38	Female	0	3	-2	1
14	LKB	56	Female	-2	-2	-7	-3
15	NHK	56	Female	-6			
16	VLH	57	Female	-1	-4	-11	2
22	JKP	48	Female				
23	RMS	51	Female	4	0	0	0
25	TJJ	40	Female	3	5	0	4
29	DSE	59	Female	-9	-8	-11	-8
30	MMC	64	Female	-4	-1	-1	-4
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	-43	-20	-38	-27
36	MAE	51	Female	-9	-11	-8	-11
37	GLJ	54	Female	-2	-3	-8	-8
38	KAS	42	Female				
41	E-N	61	Female	0	0	0	0
42	KAM	52	Female	-9	-2	-9	6
43	CGC	48	Female	1	-2	3	7
45	TDC	48	Female	-1	-2	-4	-1
48	JLL	47	Female	3	3	1	-2
50	DKH	49	Female	4	14	-3	23
52	CJL	53	Female	-9	-19	-22	-21
53	DSB	54	Female	-2	8	-8	-5
55	SKR	57	Female	-1	0	0	-2
56	DAH	45	Female				
58	CZR	49	Female	3	23	-10	-7
62	KME	45	Female	0	16	4	-11
63	MRG	51	Female				
68	SAM	53	Female	8	4	8	6
69	GHD	55	Female	1	1	0	0
70	CAC	62	Female	0	2	0	0
71	JAR	40	Female	-4	4	-1	-7
72	NRC	56	Female	0	0	0	0
73	NLW	47	Female	-32			
			Mean	-3.68	-1.07	-5.63	-3.23
			SD	11.17	10.65	10.10	9.70
			Median	-1.00	0.00	-2.00	-1.50
			N	31	30	30	30

Data Listing 1
Panel 1837
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Subject's Self Assessment of Skin Texture

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Texture			
				Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	2	2	3	2
5	LMP	45	Female	2	2	2	2
6	PJW	43	Female				
10	JCL	41	Female	3	3	2	2
11	TLM	50	Female	3	3	2	2
13	DKS	38	Female	3	3	1	1
14	LKB	56	Female	3	3	2	2
15	NHK	56	Female	4			
16	VLH	57	Female	3	2	2	1
22	JKP	48	Female				
23	RMS	51	Female	2	2	2	2
25	TJJ	40	Female	3	2	2	2
29	DSE	59	Female	2	2	1	2
30	MMC	64	Female	1	3	2	2
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	2	2	2	2
36	MAE	51	Female	2	1	1	1
37	GLJ	54	Female	2	2	2	1
38	KAS	42	Female				
41	E-N	61	Female	3	2	2	1
42	KAM	52	Female	2	2	2	2
43	CGC	48	Female	3	2	2	2
45	TDC	48	Female	2	2	2	2
48	JLL	47	Female	4	2	3	3
50	DKH	49	Female	2	2	2	2
52	CJL	53	Female	1	2	2	2
53	DSB	54	Female	2	4	2	1
55	SKR	57	Female	3	2	2	1
56	DAH	45	Female				
58	CZR	49	Female	2	3	2	2
62	KME	45	Female	3	2	2	2
63	MRG	51	Female				
68	SAM	53	Female	3	2	2	2
69	GHD	55	Female	3	3	2	3
70	CAC	62	Female	2	2	2	3
71	JAR	40	Female	2	2	2	1
72	NRC	56	Female	3	2	2	2
73	NLW	47	Female				
	Discontinued		Mean	2.48	2.27	1.97	1.83
			SD	0.72	0.58	0.41	0.59
			Median	2.00	2.00	2.00	2.00
			N	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Texture Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
4	SKH	46	Female	0	1	0
5	LMP	45	Female	0	0	0
6	PJW	43	Female			
10	JCL	41	Female	0	-1	-1
11	TLM	50	Female	0	-1	-1
13	DKS	38	Female	0	-2	-2
14	LKB	56	Female	0	-1	-1
15	NHK	56	Female			
16	VLH	57	Female	-1	-1	-2
22	JKP	48	Female			
23	RMS	51	Female	0	0	0
25	TJJ	40	Female	-1	-1	-1
29	DSE	59	Female	0	-1	0
30	MMC	64	Female	2	1	1
33	J-G	47	Female			
34	LLL	31	Female			
35	DLM	52	Female	0	0	0
36	MAE	51	Female	-1	-1	-1
37	GLJ	54	Female	0	0	-1
38	KAS	42	Female			
41	E-N	61	Female	-1	-1	-2
42	KAM	52	Female	0	0	0
43	CGC	48	Female	-1	-1	-1
45	TDC	48	Female	0	0	0
48	JLL	47	Female	-2	-1	-1
50	DKH	49	Female	0	0	0
52	CJL	53	Female	1	1	1
53	DSB	54	Female	2	0	-1
55	SKR	57	Female	-1	-1	-2
56	DAH	45	Female			
58	CZR	49	Female	1	0	0
62	KME	45	Female	-1	-1	-1
63	MRG	51	Female			
68	SAM	53	Female	-1	-1	-1
69	GHD	55	Female	0	-1	0
70	CAC	62	Female	0	0	1
71	JAR	40	Female	0	0	-1
72	NRC	56	Female	-1	-1	-1
73	NLW	47	Female			
			Mean	-0.17	-0.47	-0.60
			SD	0.87	0.73	0.86
			Median	0.00	-1.00	-1.00
			N	30	30	30

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Data Listing 1
Panel 1837
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Subject's Self Assessment of Skin Color

				Subject's Self Assessment of Skin Color			
Subject No.	Subject Initials	Age	Sex	Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	3	3	3	3
5	LMP	45	Female	2	3	2	2
6	PJW	43	Female				
10	JCL	41	Female	3	3	2	2
11	TLM	50	Female	3	3	3	3
13	DKS	38	Female	2	2	1	1
14	LKB	56	Female	3	3	3	2
15	NHK	56	Female	3			
16	VLH	57	Female	3	2	2	2
22	JKP	48	Female				
23	RMS	51	Female	3	2	3	2
25	TJJ	40	Female	4	3	3	3
29	DSE	59	Female	3	2	1	3
30	MMC	64	Female	2	3	3	3
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	3	3	3	3
36	MAE	51	Female	3	3	2	2
37	GLJ	54	Female	3	2	1	2
38	KAS	42	Female				
41	E-N	61	Female	3	2	2	2
42	KAM	52	Female	2	2	2	1
43	CGC	48	Female	3	3	3	2
45	TDC	48	Female	3	4	3	3
48	JLL	47	Female	3	2	4	3
50	DKH	49	Female	3	3	3	3
52	CJL	53	Female	3	3	2	2
53	DSB	54	Female	1	2	1	1
55	SKR	57	Female	3	3	2	1
56	DAH	45	Female				
58	CZR	49	Female	3	3	3	3
62	KME	45	Female	3	3	2	2
63	MRG	51	Female				
68	SAM	53	Female	2	2	2	3
69	GHD	55	Female	2	2	3	2
70	CAC	62	Female	3	3	3	3
71	JAR	40	Female	2	3	2	2
72	NRC	56	Female	3	3	2	2
73	NLW	47	Female				
	Discontinued		Mean	2.74	2.67	2.37	2.27
			SD	0.58	0.55	0.76	0.69
			Median	3.00	3.00	2.00	2.00
			N	31	30	30	30

				Subject's Self Assessment of Skin Texture Intra-Subject Change		
Subject No.	Subject Initials	Age	Sex	Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
4	SKH	46	Female	0	0	0
5	LMP	45	Female	1	0	0
6	PJW	43	Female			
10	JCL	41	Female	0	-1	-1
11	TLM	50	Female	0	0	0
13	DKS	38	Female	0	-1	-1
14	LKB	56	Female	0	0	-1
15	NHK	56	Female			
16	VLH	57	Female	-1	-1	-1
22	JKP	48	Female			
23	RMS	51	Female	-1	0	-1
25	TJJ	40	Female	-1	-1	-1
29	DSE	59	Female	-1	-2	0
30	MMC	64	Female	1	1	1
33	J-G	47	Female			
34	LLL	31	Female			
35	DLM	52	Female	0	0	0
36	MAE	51	Female	0	-1	-1
37	GLJ	54	Female	-1	-2	-1
38	KAS	42	Female			
41	E-N	61	Female	-1	-1	-1
42	KAM	52	Female	0	0	-1
43	CGC	48	Female	0	0	-1
45	TDC	48	Female	1	0	0
48	JLL	47	Female	-1	1	0
50	DKH	49	Female	0	0	0
52	CJL	53	Female	0	-1	-1
53	DSB	54	Female	1	0	0
55	SKR	57	Female	0	-1	-2
56	DAH	45	Female			
58	CZR	49	Female	0	0	0
62	KME	45	Female	0	-1	-1
63	MRG	51	Female			
68	SAM	53	Female	0	0	1
69	GHD	55	Female	0	1	0
70	CAC	62	Female	0	0	0
71	JAR	40	Female	1	0	0
72	NRC	56	Female	0	-1	-1
73	NLW	47	Female			
			Mean	-0.07	-0.37	-0.47
			SD	0.64	0.76	0.68
			Median	0.00	0.00	-0.50
			N	30	30	30

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Data Listing 1
Panel 1837
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Subject's Self Assessment of Skin Blotchiness - Brown Spots

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Blotchiness - Brown Spots			
				Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	3	2	3	3
5	LMP	45	Female	3	3	2	2
6	PJW	43	Female				
10	JCL	41	Female	3	3	3	3
11	TLM	50	Female	3	3	3	3
13	DKS	38	Female	3	2	1	1
14	LKB	56	Female	3	3	2	2
15	NHK	56	Female	4			
16	VLH	57	Female	3	2	2	2
22	JKP	48	Female				
23	RMS	51	Female	3	3	3	3
25	TJJ	40	Female	3	3	3	3
29	DSE	59	Female	3	3	2	2
30	MMC	64	Female	3	3	3	3
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	3	3	3	3
36	MAE	51	Female	3	2	2	2
37	GLJ	54	Female	4	4	2	2
38	KAS	42	Female				
41	E-N	61	Female	3	3	3	3
42	KAM	52	Female	3	3	2	2
43	CGC	48	Female	3	3	3	3
45	TDC	48	Female	3	4	2	4
48	JLL	47	Female	2	2	4	2
50	DKH	49	Female	3	3	3	3
52	CJL	53	Female	3	3	2	2
53	DSB	54	Female	2	3	2	2
55	SKR	57	Female	3	3	2	2
56	DAH	45	Female				
58	CZR	49	Female	3	3	3	3
62	KME	45	Female	3	3	3	3
63	MRG	51	Female				
68	SAM	53	Female	3	3	2	3
69	GHD	55	Female	3	3	3	3
70	CAC	62	Female	3	3	3	3
71	JAR	40	Female	3	3	3	3
72	NRC	56	Female	3	3	1	2
73	NLW	47	Female				
	Discontinued		Mean	3.00	2.90	2.50	2.57
			SD	0.37	0.48	0.68	0.63
			Median	3.00	3.00	3.00	3.00
			N	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Blotchiness - Brown Spots Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
4	SKH	46	Female	-1	0	0
5	LMP	45	Female	0	-1	-1
6	PJW	43	Female			
10	JCL	41	Female	0	0	0
11	TLM	50	Female	0	0	0
13	DKS	38	Female	-1	-2	-2
14	LKB	56	Female	0	-1	-1
15	NHK	56	Female			
16	VLH	57	Female	-1	-1	-1
22	JKP	48	Female			
23	RMS	51	Female	0	0	0
25	TJJ	40	Female	0	0	0
29	DSE	59	Female	0	-1	-1
30	MMC	64	Female	0	0	0
33	J-G	47	Female			
34	LLL	31	Female			
35	DLM	52	Female	0	0	0
36	MAE	51	Female	-1	-1	-1
37	GLJ	54	Female	0	-2	-2
38	KAS	42	Female			
41	E-N	61	Female	0	0	0
42	KAM	52	Female	0	-1	-1
43	CGC	48	Female	0	0	0
45	TDC	48	Female	1	-1	1
48	JLL	47	Female	0	2	0
50	DKH	49	Female	0	0	0
52	CJL	53	Female	0	-1	-1
53	DSB	54	Female	1	0	0
55	SKR	57	Female	0	-1	-1
56	DAH	45	Female			
58	CZR	49	Female	0	0	0
62	KME	45	Female	0	0	0
63	MRG	51	Female			
68	SAM	53	Female	0	-1	0
69	GHD	55	Female	0	0	0
70	CAC	62	Female	0	0	0
71	JAR	40	Female	0	0	0
72	NRC	56	Female	0	-2	-1
73	NLW	47	Female			
			Mean	-0.07	-0.47	-0.40
			SD	0.45	0.82	0.67
			Median	0.00	0.00	0.00
			N	30	30	30

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Data Listing 1
Panel 1837
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Subject's Self Assessment of Fine Wrinkles

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Fine Wrinkles			
				Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	2	2	2	3
5	LMP	45	Female	3	2	2	2
6	PJW	43	Female				
10	JCL	41	Female	3	3	3	2
11	TLM	50	Female	3	3	3	3
13	DKS	38	Female	4	2	2	1
14	LKB	56	Female	3	3	2	2
15	NHK	56	Female	2			
16	VLH	57	Female	3	2	2	2
22	JKP	48	Female				
23	RMS	51	Female	2	2	2	2
25	TJJ	40	Female	4	2	3	2
29	DSE	59	Female	2	2	1	2
30	MMC	64	Female	2	3	2	3
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	2	2	2	2
36	MAE	51	Female	2	2	1	1
37	GLJ	54	Female	3	2	2	2
38	KAS	42	Female				
41	E-N	61	Female	3	3	2	2
42	KAM	52	Female	2	2	2	2
43	CGC	48	Female	2	2	2	2
45	TDC	48	Female	3	3	2	3
48	JLL	47	Female	2	1	2	2
50	DKH	49	Female	2	2	2	3
52	CJL	53	Female	2	2	2	2
53	DSB	54	Female	1	3	2	1
55	SKR	57	Female	3	2	2	1
56	DAH	45	Female				
58	CZR	49	Female	2	3	2	2
62	KME	45	Female	3	3	3	3
63	MRG	51	Female				
68	SAM	53	Female	3	2	2	2
69	GHD	55	Female	3	2	2	2
70	CAC	62	Female	4	2	2	3
71	JAR	40	Female	3	2	2	2
72	NRC	56	Female	3	3	2	2
73	NLW	47	Female				
	Discontinued		Mean	2.61	2.30	2.07	2.10
			SD	0.72	0.53	0.45	0.61
			Median	3.00	2.00	2.00	2.00
			N	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Fine Wrinkles Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
4	SKH	46	Female	0	0	1
5	LMP	45	Female	-1	-1	-1
6	PJW	43	Female			
10	JCL	41	Female	0	0	-1
11	TLM	50	Female	0	0	0
13	DKS	38	Female	-2	-2	-3
14	LKB	56	Female	0	-1	-1
15	NHK	56	Female			
16	VLH	57	Female	-1	-1	-1
22	JKP	48	Female			
23	RMS	51	Female	0	0	0
25	TJJ	40	Female	-2	-1	-2
29	DSE	59	Female	0	-1	0
30	MMC	64	Female	1	0	1
33	J-G	47	Female			
34	LLL	31	Female			
35	DLM	52	Female	0	0	0
36	MAE	51	Female	0	-1	-1
37	GLJ	54	Female	-1	-1	-1
38	KAS	42	Female			
41	E-N	61	Female	0	-1	-1
42	KAM	52	Female	0	0	0
43	CGC	48	Female	0	0	0
45	TDC	48	Female	0	-1	0
48	JLL	47	Female	-1	0	0
50	DKH	49	Female	0	0	1
52	CJL	53	Female	0	0	0
53	DSB	54	Female	2	1	0
55	SKR	57	Female	-1	-1	-2
56	DAH	45	Female			
58	CZR	49	Female	1	0	0
62	KME	45	Female	0	0	0
63	MRG	51	Female			
68	SAM	53	Female	-1	-1	-1
69	GHD	55	Female	-1	-1	-1
70	CAC	62	Female	-2	-2	-1
71	JAR	40	Female	-1	-1	-1
72	NRC	56	Female	0	-1	-1
73	NLW	47	Female			
			Mean	-0.33	-0.57	-0.53
			SD	0.88	0.68	0.90
			Median	0.00	-1.00	-0.50
			N	30	30	30

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Data Listing 1
Panel 1837
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Subject's Self Assessment of Overall Improvement

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Overall Improvement			
				Week 2	Week 4	Week 8	Week 12
4	SKH	46	Female	2	2	2	2
5	LMP	45	Female	2	2	2	2
6	PJW	43	Female				
10	JCL	41	Female	3	3	2	2
11	TLM	50	Female	3	3	3	2
13	DKS	38	Female	3	2	1	1
14	LKB	56	Female	3	3	2	2
15	NHK	56	Female	4			
16	VLH	57	Female	3	2	2	1
22	JKP	48	Female				
23	RMS	51	Female	2	2	2	2
25	TJJ	40	Female	4	2	2	2
29	DSE	59	Female	2	2	1	2
30	MMC	64	Female	2	3	2	3
33	J-G	47	Female				
34	LLL	31	Female				
35	DLM	52	Female	2	2	2	2
36	MAE	51	Female	2	2	1	1
37	GLJ	54	Female	4	2	2	2
38	KAS	42	Female				
41	E-N	61	Female	3	2	2	2
42	KAM	52	Female	2	2	2	2
43	CGC	48	Female	3	2	2	2
45	TDC	48	Female	2	3	2	2
48	JLL	47	Female	2	2	3	2
50	DKH	49	Female	3	2	2	2
52	CJL	53	Female	2	2	2	2
53	DSB	54	Female	1	2	2	1
55	SKR	57	Female	3	2	2	1
56	DAH	45	Female				
58	CZR	49	Female	2	3	2	2
62	KME	45	Female	3	3	3	2
63	MRG	51	Female				
68	SAM	53	Female	3	2	2	2
69	GHD	55	Female	3	2	2	2
70	CAC	62	Female	2	2	2	3
71	JAR	40	Female	2	2	2	1
72	NRC	56	Female	3	2	2	2
73	NLW	47	Female				
	Discontinued		Mean	2.58	2.23	2.00	1.87
			SD	0.72	0.43	0.45	0.51
			Median	3.00	2.00	2.00	2.00
			N	31	30	30	30

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Overall Improvement Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
4	SKH	46	Female	0	0	0
5	LMP	45	Female	0	0	0
6	PJW	43	Female			
10	JCL	41	Female	0	-1	-1
11	TLM	50	Female	0	0	-1
13	DKS	38	Female	-1	-2	-2
14	LKB	56	Female	0	-1	-1
15	NHK	56	Female			
16	VLH	57	Female	-1	-1	-2
22	JKP	48	Female			
23	RMS	51	Female	0	0	0
25	TJJ	40	Female	-2	-2	-2
29	DSE	59	Female	0	-1	0
30	MMC	64	Female	1	0	1
33	J-G	47	Female			
34	LLL	31	Female			
35	DLM	52	Female	0	0	0
36	MAE	51	Female	0	-1	-1
37	GLJ	54	Female	-2	-2	-2
38	KAS	42	Female			
41	E-N	61	Female	-1	-1	-1
42	KAM	52	Female	0	0	0
43	CGC	48	Female	-1	-1	-1
45	TDC	48	Female	1	0	0
48	JLL	47	Female	0	1	0
50	DKH	49	Female	-1	-1	-1
52	CJL	53	Female	0	0	0
53	DSB	54	Female	1	1	0
55	SKR	57	Female	-1	-1	-2
56	DAH	45	Female			
58	CZR	49	Female	1	0	0
62	KME	45	Female	0	0	-1
63	MRG	51	Female			
68	SAM	53	Female	-1	-1	-1
69	GHD	55	Female	-1	-1	-1
70	CAC	62	Female	0	0	1
71	JAR	40	Female	0	0	-1
72	NRC	56	Female	-1	-1	-1
73	NLW	47	Female			
			Mean	-0.30	-0.53	-0.67
			SD	0.79	0.78	0.84
			Median	0.00	-0.50	-1.00
			N	30	30	30

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Expert Assessment of Fine Wrinkles

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Fine Wrinkles				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	2				
2	MLE	50	Female	3	2	1	1	1
3	SKH	47	Female	2	2	2	2	2
7	DBK	52	Female	4	4	4	3	3
8	JCF	54	Female	2	2	1	1	1
9	JRB	53	Female	2				
12	EFK	57	Female	3	3	3	2	2
17	BFH	59	Female	4	4	4	4	4
18	LJR	58	Female	3	3	3	3	3
19	D-M	58	Female	3	3	3	2	2
20	RLA	45	Female					
21	LGD	57	Female	2	2	2	2	2
24	VIP	52	Female	3	2	2	1	1
26	PKM	46	Female	1	1	1	1	
27	SMM	59	Female	3	3	3	3	3
28	EJD	56	Female	3				
31	JAC	56	Female	3	3	3	2	2
32	TML	38	Female	2	2	1	1	1
39	DKD	50	Female	2	1	1	1	1
40	CLM	43	Female	2	2	1	1	1
44	GSR	52	Female	3	3	3	2	1
46	LAA	55	Female	3	3	3	3	3
47	CMP	47	Female	2	2	2	1	1
49	L-R	58	Female	3	3	3	3	3
51	PCB	59	Female	3	3	3	3	3
54	TWS	55	Female	3	3			
57	MDS	52	Female	4	4	3	3	3
59	GFM	64	Female	3	3	3	3	3
60	JLF	32	Female	1	1	1	1	1
61	GEP	53	Female	3				
64	KKF	36	Female	3	3	2	2	2
65	EMM	39	Female	1	1	1	1	1
66	CYR	39	Female	2	2	2	2	1
67	AMM	37	Female	1	1	1	1	1
	Discontinued		Mean	2.55	2.45	2.21	1.96	1.93
			SD	0.87	0.91	0.99	0.92	0.96
			Median	3.00	3.00	2.00	2.00	2.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Fine Wrinkles Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	-1	-2	-2	-2
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	-1	-1
8	JCF	54	Female	0	-1	-1	-1
9	JRB	53	Female				
12	EFK	57	Female	0	0	-1	-1
17	BFH	59	Female	0	0	0	0
18	LJR	58	Female	0	0	0	0
19	D-M	58	Female	0	0	-1	-1
20	RLA	45	Female				
21	LGD	57	Female	0	0	0	0
24	VIP	52	Female	-1	-1	-2	-2
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	0	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	-1	-1
32	TML	38	Female	0	-1	-1	-1
39	DKD	50	Female	-1	-1	-1	-1
40	CLM	43	Female	0	-1	-1	-1
44	GSR	52	Female	0	0	-1	-2
46	LAA	55	Female	0	0	0	0
47	CMP	47	Female	0	0	-1	-1
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	0			
57	MDS	52	Female	0	-1	-1	-1
59	GFM	64	Female	0	0	0	0
60	JLF	32	Female	0	0	0	0
61	GEP	53	Female				
64	KKF	36	Female	0	-1	-1	-1
65	EMM	39	Female	0	0	0	0
66	CYR	39	Female	0	0	0	-1
67	AMM	37	Female	0	0	0	0
			Mean	-0.10	-0.32	-0.57	-0.67
			SD	0.31	0.55	0.63	0.68
			Median	0.00	0.00	-0.50	-1.00
			N	29	28	28	27

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

Expert Assessment of Coarse Wrinkles

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Coarse Wrinkles				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	1				
2	MLE	50	Female	1	1	1	1	1
3	SKH	47	Female	3	3	3	3	3
7	DBK	52	Female	3	3	3	3	3
8	JCF	54	Female	1	1	1	0	0
9	JRB	53	Female	1				
12	EFK	57	Female	3	3	3	3	3
17	BFH	59	Female	3	3	3	3	3
18	LJR	58	Female	4	4	4	4	4
19	D-M	58	Female	3	3	3	3	3
20	RLA	45	Female					
21	LGD	57	Female	1	1	1	1	1
24	VIP	52	Female	1	0	0	0	0
26	PKM	46	Female	0	0	0	0	
27	SMM	59	Female	4	4	4	4	4
28	EJD	56	Female	3				
31	JAC	56	Female	4	4	4	4	4
32	TML	38	Female	1	1	1	0	0
39	DKD	50	Female	1	1	0	1	1
40	CLM	43	Female	0	0	0	0	0
44	GSR	52	Female	2	2	2	2	2
46	LAA	55	Female	4	4	4	4	3
47	CMP	47	Female	1	1	1	1	1
49	L-R	58	Female	1	1	1	1	1
51	PCB	59	Female	2	2	2	2	2
54	TWS	55	Female	1	1			
57	MDS	52	Female	3	2	2	2	2
59	GFM	64	Female	4	4	4	4	4
60	JLF	32	Female	0	0	0	0	0
61	GEP	53	Female	1				
64	KKF	36	Female	1	1	0	0	0
65	EMM	39	Female	0	0	0	0	0
66	CYR	39	Female	1	1	1	1	1
67	AMM	37	Female	0	0	0	0	0
	Discontinued		Mean	1.83	1.76	1.71	1.68	1.70
			SD	1.42	1.43	1.51	1.54	1.49
			Median	1.00	1.00	1.00	1.00	1.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Coarse Wrinkles Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	0	0	0	0
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	0	0
8	JCF	54	Female	0	0	-1	-1
9	JRB	53	Female				
12	EFK	57	Female	0	0	0	0
17	BFH	59	Female	0	0	0	0
18	LJR	58	Female	0	0	0	0
19	D-M	58	Female	0	0	0	0
20	RLA	45	Female				
21	LGD	57	Female	0	0	0	0
24	VIP	52	Female	-1	-1	-1	-1
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	0	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	0	0
32	TML	38	Female	0	0	-1	-1
39	DKD	50	Female	0	-1	0	0
40	CLM	43	Female	0	0	0	0
44	GSR	52	Female	0	0	0	0
46	LAA	55	Female	0	0	0	-1
47	CMP	47	Female	0	0	0	0
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	0			
57	MDS	52	Female	-1	-1	-1	-1
59	GFM	64	Female	0	0	0	0
60	JLF	32	Female	0	0	0	0
61	GEP	53	Female				
64	KKF	36	Female	0	-1	-1	-1
65	EMM	39	Female	0	0	0	0
66	CYR	39	Female	0	0	0	0
67	AMM	37	Female	0	0	0	0
			Mean	-0.07	-0.14	-0.18	-0.22
			SD	0.26	0.36	0.39	0.42
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

Expert Assessment of Roughness

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Roughnness				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	2				
2	MLE	50	Female	3	3	2	1	1
3	SKH	47	Female	1	2	0	1	0
7	DBK	52	Female	3	3	2	2	1
8	JCF	54	Female	3	2	1	1	1
9	JRB	53	Female	3				
12	EFK	57	Female	2	3	1	0	0
17	BFH	59	Female	2	1	1	1	0
18	LJR	58	Female	1	1	0	0	0
19	D-M	58	Female	2	1	0	0	0
20	RLA	45	Female					
21	LGD	57	Female	3	3	2	2	1
24	VIP	52	Female	3	2	1	1	0
26	PKM	46	Female	3	2	2	1	
27	SMM	59	Female	3	2	2	1	2
28	EJD	56	Female	2				
31	JAC	56	Female	3	3	1	0	0
32	TML	38	Female	2	1	1	0	0
39	DKD	50	Female	3	0	1	1	1
40	CLM	43	Female	3	1	1	1	1
44	GSR	52	Female	2	1	0	0	0
46	LAA	55	Female	2	1	1	1	1
47	CMP	47	Female	3	2	1	0	0
49	L-R	58	Female	2	1	1	2	0
51	PCB	59	Female	2	2	1	0	0
54	TWS	55	Female	1	0			
57	MDS	52	Female	2	2	2	2	0
59	GFM	64	Female	2	1	1	1	0
60	JLF	32	Female	3	2	2	2	2
61	GEP	53	Female	3				
64	KKF	36	Female	3	1	1	0	0
65	EMM	39	Female	3	2	2	2	1
66	CYR	39	Female	2	1	0	0	0
67	AMM	37	Female	3	0	0	0	0
	Discontinued		Mean	2.41	1.59	1.07	0.82	0.44
			SD	0.68	0.91	0.72	0.77	0.64
			Median	3.00	2.00	1.00	1.00	0.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Roughness Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	0	-1	-2	-2
3	SKH	47	Female	1	-1	0	-1
7	DBK	52	Female	0	-1	-1	-2
8	JCF	54	Female	-1	-2	-2	-2
9	JRB	53	Female				
12	EFK	57	Female	1	-1	-2	-2
17	BFH	59	Female	-1	-1	-1	-2
18	LJR	58	Female	0	-1	-1	-1
19	D-M	58	Female	-1	-2	-2	-2
20	RLA	45	Female				
21	LGD	57	Female	0	-1	-1	-2
24	VIP	52	Female	-1	-2	-2	-3
26	PKM	46	Female	-1	-1	-2	
27	SMM	59	Female	-1	-1	-2	-1
28	EJD	56	Female				
31	JAC	56	Female	0	-2	-3	-3
32	TML	38	Female	-1	-1	-2	-2
39	DKD	50	Female	-3	-2	-2	-2
40	CLM	43	Female	-2	-2	-2	-2
44	GSR	52	Female	-1	-2	-2	-2
46	LAA	55	Female	-1	-1	-1	-1
47	CMP	47	Female	-1	-2	-3	-3
49	L-R	58	Female	-1	-1	0	-2
51	PCB	59	Female	0	-1	-2	-2
54	TWS	55	Female	-1			
57	MDS	52	Female	0	0	0	-2
59	GFM	64	Female	-1	-1	-1	-2
60	JLF	32	Female	-1	-1	-1	-1
61	GEP	53	Female				
64	KKF	36	Female	-2	-2	-3	-3
65	EMM	39	Female	-1	-1	-1	-2
66	CYR	39	Female	-1	-2	-2	-2
67	AMM	37	Female	-3	-3	-3	-3
			Mean	-0.83	-1.39	-1.64	-2.00
			SD	0.93	0.63	0.87	0.62
			Median	-1.00	-1.00	-2.00	-2.00
			N	29	28	28	27

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

Expert Assessment of Mottled Hyperpigmentation

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Mottled Hyperpigmentation				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	1				
2	MLE	50	Female	1	1	1	1	1
3	SKH	47	Female	3	3	2	3	3
7	DBK	52	Female	2	1	1	1	1
8	JCF	54	Female	2	3	2	2	2
9	JRB	53	Female	1				
12	EFK	57	Female	1	1	1	1	1
17	BFH	59	Female	2	2	1	1	1
18	LJR	58	Female	3	3	3	3	3
19	D-M	58	Female	3	3	2	1	1
20	RLA	45	Female					
21	LGD	57	Female	4	4	3	3	2
24	VIP	52	Female	0	0	0	0	0
26	PKM	46	Female	1	1	1	1	
27	SMM	59	Female	2	1	1	1	1
28	EJD	56	Female	2				
31	JAC	56	Female	2	1	1	1	1
32	TML	38	Female	1	1	1	1	1
39	DKD	50	Female	2	1	1	1	1
40	CLM	43	Female	2	2	2	2	2
44	GSR	52	Female	2	1	1	1	1
46	LAA	55	Female	1	1	1	1	1
47	CMP	47	Female	1	1	1	1	1
49	L-R	58	Female	3	3	2	2	1
51	PCB	59	Female	1	1	1	1	1
54	TWS	55	Female	3	3			
57	MDS	52	Female	0	0	0	0	1
59	GFM	64	Female	2	2	1	1	1
60	JLF	32	Female	2	1	1	1	1
61	GEP	53	Female	2				
64	KKF	36	Female	2	1	1	1	1
65	EMM	39	Female	2	2	1	0	0
66	CYR	39	Female	2	2	1	2	2
67	AMM	37	Female	2	1	1	2	2
	Discontinued		Mean	1.86	1.62	1.25	1.29	1.26
			SD	0.92	1.01	0.70	0.81	0.71
			Median	2.00	1.00	1.00	1.00	1.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Mottled Hyperpigmentation Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	0	0	0	0
3	SKH	47	Female	0	-1	0	0
7	DBK	52	Female	-1	-1	-1	-1
8	JCF	54	Female	1	0	0	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	0	0
17	BFH	59	Female	0	-1	-1	-1
18	LJR	58	Female	0	0	0	0
19	D-M	58	Female	0	-1	-2	-2
20	RLA	45	Female				
21	LGD	57	Female	0	-1	-1	-2
24	VIP	52	Female	0	0	0	0
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	-1	-1	-1	-1
28	EJD	56	Female				
31	JAC	56	Female	-1	-1	-1	-1
32	TML	38	Female	0	0	0	0
39	DKD	50	Female	-1	-1	-1	-1
40	CLM	43	Female	0	0	0	0
44	GSR	52	Female	-1	-1	-1	-1
46	LAA	55	Female	0	0	0	0
47	CMP	47	Female	0	0	0	0
49	L-R	58	Female	0	-1	-1	-2
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	0			
57	MDS	52	Female	0	0	0	1
59	GFM	64	Female	0	-1	-1	-1
60	JLF	32	Female	-1	-1	-1	-1
61	GEP	53	Female				
64	KKF	36	Female	-1	-1	-1	-1
65	EMM	39	Female	0	-1	-2	-2
66	CYR	39	Female	0	-1	0	0
67	AMM	37	Female	-1	-1	0	0
			Mean	-0.24	-0.57	-0.54	-0.59
			SD	0.51	0.50	0.64	0.80
			Median	0.00	-1.00	0.00	0.00
			N	29	28	28	27

0 = None
1 = Minimal
2 = Mild
3 = Moderate
4 = Severe

Expert Assessment of Overall Severity (Skin Aging)

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Overall Severity (Skin Aging)				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	4				
2	MLE	50	Female	3	2	2	1	1
3	SKH	47	Female	5	5	4	5	5
7	DBK	52	Female	5	5	4	4	4
8	JCF	54	Female	3	2	2	2	2
9	JRB	53	Female	2				
12	EFK	57	Female	5	5	3	3	3
17	BFH	59	Female	5	5	4	4	4
18	LJR	58	Female	6	6	5	5	5
19	D-M	58	Female	5	5	4	3	3
20	RLA	45	Female					
21	LGD	57	Female	4	4	4	4	3
24	VIP	52	Female	2	1	1	1	1
26	PKM	46	Female	1	1	1	1	
27	SMM	59	Female	6	5	5	5	5
28	EJD	56	Female	4				
31	JAC	56	Female	6	6	5	5	5
32	TML	38	Female	3	2	1	1	1
39	DKD	50	Female	4	2	2	1	1
40	CLM	43	Female	3	2	2	2	2
44	GSR	52	Female	4	4	4	3	2
46	LAA	55	Female	6	5	5	5	5
47	CMP	47	Female	3	2	2	1	2
49	L-R	58	Female	5	4	4	4	4
51	PCB	59	Female	3	3	2	3	3
54	TWS	55	Female	5	4			
57	MDS	52	Female	5	5	5	4	4
59	GFM	64	Female	6	6	5	5	5
60	JLF	32	Female	2	1	1	1	1
61	GEP	53	Female	4				
64	KKF	36	Female	4	3	2	1	1
65	EMM	39	Female	3	2	2	2	1
66	CYR	39	Female	3	2	2	3	2
67	AMM	37	Female	2	1	1	1	1
			Mean	4.03	3.45	3.00	2.86	2.81
			SD	1.43	1.70	1.49	1.58	1.57
			Median	4.00	4.00	2.50	3.00	3.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Overall Severity (Skin Aging) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	-1	-1	-2	-2
3	SKH	47	Female	0	-1	0	0
7	DBK	52	Female	0	-1	-1	-1
8	JCF	54	Female	-1	-1	-1	-1
9	JRB	53	Female				
12	EFK	57	Female	0	-2	-2	-2
17	BFH	59	Female	0	-1	-1	-1
18	LJR	58	Female	0	-1	-1	-1
19	D-M	58	Female	0	-1	-2	-2
20	RLA	45	Female				
21	LGD	57	Female	0	0	0	-1
24	VIP	52	Female	-1	-1	-1	-1
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	-1	-1	-1	-1
28	EJD	56	Female				
31	JAC	56	Female	0	-1	-1	-1
32	TML	38	Female	-1	-2	-2	-2
39	DKD	50	Female	-2	-2	-3	-3
40	CLM	43	Female	-1	-1	-1	-1
44	GSR	52	Female	0	0	-1	-2
46	LAA	55	Female	-1	-1	-1	-1
47	CMP	47	Female	-1	-1	-2	-1
49	L-R	58	Female	-1	-1	-1	-1
51	PCB	59	Female	0	-1	0	0
54	TWS	55	Female	-1			
57	MDS	52	Female	0	0	-1	-1
59	GFM	64	Female	0	-1	-1	-1
60	JLF	32	Female	-1	-1	-1	-1
61	GEP	53	Female				
64	KKF	36	Female	-1	-2	-3	-3
65	EMM	39	Female	-1	-1	-1	-2
66	CYR	39	Female	-1	-1	0	-1
67	AMM	37	Female	-1	-1	-1	-1
			Mean	-0.59	-1.00	-1.14	-1.30
			SD	0.57	0.54	0.80	0.72
			Median	-1.00	-1.00	-1.00	-1.00
			N	29	28	28	27

0 = None
1-3 = Mild
4-6 = Moderate
7-9 = Severe

Discontinued

Expert Assessment of Overall Severity (Skin Aging)

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Improvement (Skin Aging) Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	N/A				
2	MLE	50	Female	N/A	4	4	4	4
3	SKH	47	Female	N/A	5	5	5	5
7	DBK	52	Female	N/A	5	5	4	4
8	JCF	54	Female	N/A	5	4	4	4
9	JRB	53	Female	N/A				
12	EFK	57	Female	N/A	5	4	4	4
17	BFH	59	Female	N/A	5	5	5	5
18	LJR	58	Female	N/A	5	5	5	5
19	D-M	58	Female	N/A	5	4	4	4
20	RLA	45	Female	N/A				
21	LGD	57	Female	N/A	5	4	4	4
24	VIP	52	Female	N/A	4	4	4	4
26	PKM	46	Female	N/A	5	5	4	
27	SMM	59	Female	N/A	4	5	5	5
28	EJD	56	Female	N/A				
31	JAC	56	Female	N/A	5	5	5	5
32	TML	38	Female	N/A	4	4	4	4
39	DKD	50	Female	N/A	4	4	4	4
40	CLM	43	Female	N/A	5	4	4	4
44	GSR	52	Female	N/A	5	4	4	4
46	LAA	55	Female	N/A	4	5	5	5
47	CMP	47	Female	N/A	4	4	4	4
49	L-R	58	Female	N/A	5	5	5	4
51	PCB	59	Female	N/A	5	5	5	5
54	TWS	55	Female	N/A	5			
57	MDS	52	Female	N/A	5	4	4	4
59	GFM	64	Female	N/A	5	4	4	4
60	JLF	32	Female	N/A	4	4	4	4
61	GEP	53	Female	N/A				
64	KKF	36	Female	N/A	4	4	4	4
65	EMM	39	Female	N/A	5	5	5	4
66	CYR	39	Female	N/A	5	4	4	4
67	AMM	37	Female	N/A	4	4	4	4
	Discontinued			Mean	4.66	4.39	4.32	4.26
				SD	0.48	0.50	0.48	0.45
				Median	5.00	4.00	4.00	4.00
				N	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Improvement (Skin Aging) Intra-Subject Change: Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
1	SDC	40	Female			
2	MLE	50	Female	0	0	0
3	SKH	47	Female	0	0	0
7	DBK	52	Female	0	-1	-1
8	JCF	54	Female	-1	-1	-1
9	JRB	53	Female			
12	EFK	57	Female	-1	-1	-1
17	BFH	59	Female	0	0	0
18	LJR	58	Female	0	0	0
19	D-M	58	Female	-1	-1	-1
20	RLA	45	Female			
21	LGD	57	Female	-1	-1	-1
24	VIP	52	Female	0	0	0
26	PKM	46	Female	0	-1	
27	SMM	59	Female	1	1	1
28	EJD	56	Female			
31	JAC	56	Female	0	0	0
32	TML	38	Female	0	0	0
39	DKD	50	Female	0	0	0
40	CLM	43	Female	-1	-1	-1
44	GSR	52	Female	-1	-1	-1
46	LAA	55	Female	1	1	1
47	CMP	47	Female	0	0	0
49	L-R	58	Female	0	0	-1
51	PCB	59	Female	0	0	0
54*	TWS	55	Female			
57	MDS	52	Female	-1	-1	-1
59	GFM	64	Female	-1	-1	-1
60	JLF	32	Female	0	0	0
61	GEP	53	Female			
64	KKF	36	Female	0	0	0
65	EMM	39	Female	0	0	-1
66	CYR	39	Female	-1	-1	-1
67	AMM	37	Female	0	0	0
			Mean	-0.25	-0.32	-0.37
			SD	0.59	0.61	0.63
			Median	0.00	0.00	0.00
			N	28	28	27

1 = Excellent Improvement (~100%)
2 = Marked Improvement (~75%)
3 = Moderate Improvement (~50%)
4 = Slight Improvement (~25%)
5 = No Improvement (0%)
6 = Worse

Expert Assessment of Skin Irritation

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Skin Irritation				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	1				
2	MLE	50	Female	1	1	1	1	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	1	1	1	0	0
8	JCF	54	Female	1	0	0	0	0
9	JRB	53	Female	1				
12	EFK	57	Female	1	1	1	0	0
17	BFH	59	Female	1	1	1	1	0
18	LJR	58	Female	0	1	0	0	0
19	D-M	58	Female	1	0	0	0	0
20	RLA	45	Female					
21	LGD	57	Female	1	1	1	0	0
24	VIP	52	Female	1	1	0	0	0
26	PKM	46	Female	2	2	2	2	
27	SMM	59	Female	0	0	0	0	0
28	EJD	56	Female	1				
31	JAC	56	Female	1	0	0	0	0
32	TML	38	Female	1	0	0	0	0
39	DKD	50	Female	2	1	1	1	1
40	CLM	43	Female	1	1	1	1	1
44	GSR	52	Female	1	1	0	0	0
46	LAA	55	Female	1	1	0	0	0
47	CMP	47	Female	1	1	1	1	0
49	L-R	58	Female	1	1	0	0	0
51	PCB	59	Female	1	0	0	0	0
54	TWS	55	Female	1	1			
57	MDS	52	Female	1	1	1	0	0
59	GFM	64	Female	1	1	0	0	0
60	JLF	32	Female	1	0	0	0	1
61	GEP	53	Female	1				
64	KKF	36	Female	1	1	0	1	0
65	EMM	39	Female	1	0	0	0	0
66	CYR	39	Female	1	0	0	0	0
67	AMM	37	Female	1	1	1	1	1
	Discontinued		Mean	0.97	0.69	0.43	0.32	0.15
			SD	0.42	0.54	0.57	0.55	0.36
			Median	1.00	1.00	0.00	0.00	0.00
			N	29	29	28	28	27

0 = None
1 = Mild
2 = Moderate
3 = Severe

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Skin Irritation Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	0	0	0	-1
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	-1	-1
8	JCF	54	Female	-1	-1	-1	-1
9	JRB	53	Female				
12	EFK	57	Female	0	0	-1	-1
17	BFH	59	Female	0	0	0	-1
18	LJR	58	Female	1	0	0	0
19	D-M	58	Female	-1	-1	-1	-1
20	RLA	45	Female				
21	LGD	57	Female	0	0	-1	-1
24	VIP	52	Female	0	-1	-1	-1
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	0	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	-1	-1	-1	-1
32	TML	38	Female	-1	-1	-1	-1
39	DKD	50	Female	-1	-1	-1	-1
40	CLM	43	Female	0	0	0	0
44	GSR	52	Female	0	-1	-1	-1
46	LAA	55	Female	0	-1	-1	-1
47	CMP	47	Female	0	0	0	-1
49	L-R	58	Female	0	-1	-1	-1
51	PCB	59	Female	-1	-1	-1	-1
54	TWS	55	Female	0			
57	MDS	52	Female	0	0	-1	-1
59	GFM	64	Female	0	-1	-1	-1
60	JLF	32	Female	-1	-1	-1	0
61	GEP	53	Female				
64	KKF	36	Female	0	-1	0	-1
65	EMM	39	Female	-1	-1	-1	-1
66	CYR	39	Female	-1	-1	-1	-1
67	AMM	37	Female	0	0	0	0
			Mean	-0.28	-0.54	-0.64	-0.78
			SD	0.53	0.51	0.49	0.42
			Median	0.00	-1.00	-1.00	-1.00
			N	29	28	28	27

Expert Assessment of Overall Severity (Acne)

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Overall Severity (Acne)				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	1				
2	MLE	50	Female	1	1	0	1	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	1	0	0	1	0
8	JCF	54	Female	0	1	0	1	0
9	JRB	53	Female	1				
12	EFK	57	Female	0	0	0	1	1
17	BFH	59	Female	1	1	1	0	1
18	LJR	58	Female	1	1	0	0	0
19	D-M	58	Female	1	1	0	0	1
20	RLA	45	Female					
21	LGD	57	Female	1	1	1	1	1
24	VIP	52	Female	0	1	1	0	1
26	PKM	46	Female	1	0	1	0	
27	SMM	59	Female	0	1	0	0	0
28	EJD	56	Female	1				
31	JAC	56	Female	0	1	0	0	1
32	TML	38	Female	0	1	1	1	1
39	DKD	50	Female	1	0	1	1	1
40	CLM	43	Female	1	1	1	1	1
44	GSR	52	Female	1	1	1	1	1
46	LAA	55	Female	0	0	0	0	1
47	CMP	47	Female	1	0	1	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	1	0	0	0
54	TWS	55	Female	1	0			
57	MDS	52	Female	1	0	0	1	0
59	GFM	64	Female	1	1	1	1	0
60	JLF	32	Female	1	1	1	1	1
61	GEP	53	Female	1				
64	KKF	36	Female	1	1	2	1	1
65	EMM	39	Female	1	1	1	1	0
66	CYR	39	Female	1	1	1	1	1
67	AMM	37	Female	1	1	1	1	1
	Discontinued		Mean	0.66	0.66	0.57	0.57	0.56
			SD	0.48	0.48	0.57	0.50	0.51
			Median	1.00	1.00	1.00	1.00	1.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Expert Assessment of Overall Severity (Acne) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	0	-1	0	-1
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	-1	-1	0	-1
8	JCF	54	Female	1	0	1	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	1	1
17	BFH	59	Female	0	0	-1	0
18	LJR	58	Female	0	-1	-1	-1
19	D-M	58	Female	0	-1	-1	0
20	RLA	45	Female				
21	LGD	57	Female	0	0	0	0
24	VIP	52	Female	1	1	0	1
26	PKM	46	Female	-1	0	-1	
27	SMM	59	Female	1	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	1	0	0	1
32	TML	38	Female	1	1	1	1
39	DKD	50	Female	-1	0	0	0
40	CLM	43	Female	0	0	0	0
44	GSR	52	Female	0	0	0	0
46	LAA	55	Female	0	0	0	1
47	CMP	47	Female	-1	0	-1	-1
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	1	0	0	0
54	TWS	55	Female	-1			
57	MDS	52	Female	-1	-1	0	-1
59	GFM	64	Female	0	0	0	-1
60	JLF	32	Female	0	0	0	0
61	GEP	53	Female				
64	KKF	36	Female	0	1	0	0
65	EMM	39	Female	0	0	0	-1
66	CYR	39	Female	0	0	0	0
67	AMM	37	Female	0	0	0	0
			Mean	0.00	-0.07	-0.07	-0.07
			SD	0.65	0.54	0.54	0.68
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

0 = None
1 = Mild
2 = Moderate
3 = Severe

Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Forehead)				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	0				
2	MLE	50	Female	0	1	0	1	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	0	0	0	0	0
8	JCF	54	Female	0	1	0	1	0
9	JRB	53	Female	1				
12	EFK	57	Female	0	0	0	1	0
17	BFH	59	Female	0	0	0	0	0
18	LJR	58	Female	0	0	0	0	0
19	D-M	58	Female	0	0	0	0	1
20	RLA	45	Female					
21	LGD	57	Female	0	0	6	0	0
24	VIP	52	Female	0	0	0	0	0
26	PKM	46	Female	1	0	2	0	
27	SMM	59	Female	0	0	0	0	0
28	EJD	56	Female	0				
31	JAC	56	Female	0	2	0	0	0
32	TML	38	Female	0	2	0	1	0
39	DKD	50	Female	0	0	2	0	1
40	CLM	43	Female	0	2	1	1	0
44	GSR	52	Female	0	0	0	0	0
46	LAA	55	Female	0	0	0	0	0
47	CMP	47	Female	1	0	0	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	0	0	0	0
54	TWS	55	Female	2	0			
57	MDS	52	Female	1	0	0	0	0
59	GFM	64	Female	0	0	0	0	0
60	JLF	32	Female	0	0	2	4	0
61	GEP	53	Female	2				
64	KKF	36	Female	0	0	1	2	1
65	EMM	39	Female	4	1	1	0	0
66	CYR	39	Female	1	2	0	0	0
67	AMM	37	Female	0	0	0	0	0
	Discontinued		Mean	0.34	0.38	0.54	0.39	0.11
			SD	0.86	0.73	1.26	0.88	0.32
			Median	0.00	0.00	0.00	0.00	0.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Forehead) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	1	0	1	0
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	0	0
8	JCF	54	Female	1	0	1	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	1	0
17	BFH	59	Female	0	0	0	0
18	LJR	58	Female	0	0	0	0
19	D-M	58	Female	0	0	0	1
20	RLA	45	Female				
21	LGD	57	Female	0	6	0	0
24	VIP	52	Female	0	0	0	0
26	PKM	46	Female	-1	1	-1	
27	SMM	59	Female	0	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	2	0	0	0
32	TML	38	Female	2	0	1	0
39	DKD	50	Female	0	2	0	1
40	CLM	43	Female	2	1	1	0
44	GSR	52	Female	0	0	0	0
46	LAA	55	Female	0	0	0	0
47	CMP	47	Female	-1	-1	-1	-1
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	-2			
57	MDS	52	Female	-1	-1	-1	-1
59	GFM	64	Female	0	0	0	0
60	JLF	32	Female	0	2	4	0
61	GEP	53	Female				
64	KKF	36	Female	0	1	2	1
65	EMM	39	Female	-3	-3	-4	-4
66	CYR	39	Female	1	-1	-1	-1
67	AMM	37	Female	0	0	0	0
			Mean	0.03	0.25	0.11	-0.15
			SD	1.05	1.46	1.29	0.91
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Left Cheek)				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	0				
2	MLE	50	Female	2	1	0	0	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	0	0	0	0	0
8	JCF	54	Female	0	0	0	0	0
9	JRB	53	Female	0				
12	EFK	57	Female	0	0	0	0	1
17	BFH	59	Female	0	0	0	0	0
18	LJR	58	Female	0	2	0	0	0
19	D-M	58	Female	0	0	0	0	0
20	RLA	45	Female					
21	LGD	57	Female	1	0	1	1	0
24	VIP	52	Female	0	0	0	0	1
26	PKM	46	Female	0	0	0	0	
27	SMM	59	Female	0	0	0	0	0
28	EJD	56	Female	0				
31	JAC	56	Female	0	0	0	0	0
32	TML	38	Female	0	0	0	0	0
39	DKD	50	Female	0	0	0	0	1
40	CLM	43	Female	0	0	2	0	0
44	GSR	52	Female	0	0	1	0	0
46	LAA	55	Female	0	0	0	0	1
47	CMP	47	Female	1	0	0	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	0	0	0	0
54	TWS	55	Female	0	0			
57	MDS	52	Female	0	0	0	0	0
59	GFM	64	Female	0	0	0	0	0
60	JLF	32	Female	2	5	0	4	4
61	GEP	53	Female	0				
64	KKF	36	Female	0	0	2	0	0
65	EMM	39	Female	1	1	0	0	0
66	CYR	39	Female	1	0	0	0	1
67	AMM	37	Female	0	2	2	1	0
			Mean	0.28	0.38	0.29	0.21	0.33
			SD	0.59	1.05	0.66	0.79	0.83
			Median	0.00	0.00	0.00	0.00	0.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Left Cheek) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	-1	-2	-2	-2
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	0	0
8	JCF	54	Female	0	0	0	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	0	1
17	BFH	59	Female	0	0	0	0
18	LJR	58	Female	2	0	0	0
19	D-M	58	Female	0	0	0	0
20	RLA	45	Female				
21	LGD	57	Female	-1	0	0	-1
24	VIP	52	Female	0	0	0	1
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	0	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	0	0
32	TML	38	Female	0	0	0	0
39	DKD	50	Female	0	0	0	1
40	CLM	43	Female	0	2	0	0
44	GSR	52	Female	0	1	0	0
46	LAA	55	Female	0	0	0	1
47	CMP	47	Female	-1	-1	-1	-1
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	0			
57	MDS	52	Female	0	0	0	0
59	GFM	64	Female	0	0	0	0
60	JLF	32	Female	3	-2	2	2
61	GEP	53	Female				
64	KKF	36	Female	0	2	0	0
65	EMM	39	Female	0	-1	-1	-1
66	CYR	39	Female	-1	-1	-1	0
67	AMM	37	Female	2	2	1	0
			Mean	0.10	0.00	-0.07	0.04
			SD	0.86	0.94	0.66	0.76
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Discontinued

Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Right Cheek)				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	0				
2	MLE	50	Female	2	1	0	2	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	0	0	0	0	0
8	JCF	54	Female	0	2	0	0	0
9	JRB	53	Female	0				
12	EFK	57	Female	0	0	0	1	0
17	BFH	59	Female	0	0	1	0	0
18	LJR	58	Female	0	2	0	0	0
19	D-M	58	Female	0	0	0	0	0
20	RLA	45	Female					
21	LGD	57	Female	1	0	1	0	0
24	VIP	52	Female	0	1	1	0	2
26	PKM	46	Female	0	0	1	0	
27	SMM	59	Female	0	0	0	0	0
28	EJD	56	Female	0				
31	JAC	56	Female	0	0	0	0	1
32	TML	38	Female	0	0	0	1	0
39	DKD	50	Female	0	0	0	0	0
40	CLM	43	Female	0	0	3	0	0
44	GSR	52	Female	0	0	0	0	1
46	LAA	55	Female	0	0	0	0	0
47	CMP	47	Female	0	0	0	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	0	0	0	0
54	TWS	55	Female	1	0			
57	MDS	52	Female	0	0	0	0	0
59	GFM	64	Female	0	0	0	0	0
60	JLF	32	Female	1	3	2	8	6
61	GEP	53	Female	0				
64	KKF	36	Female	1	0	1	1	0
65	EMM	39	Female	0	0	0	0	0
66	CYR	39	Female	0	1	1	1	1
67	AMM	37	Female	0	1	1	0	1
			Mean	0.21	0.38	0.43	0.50	0.44
			SD	0.49	0.78	0.74	1.55	1.22
			Median	0.00	0.00	0.00	0.00	0.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Right Cheek) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	-1	-2	0	-2
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	0	0
8	JCF	54	Female	2	0	0	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	1	0
17	BFH	59	Female	0	1	0	0
18	LJR	58	Female	2	0	0	0
19	D-M	58	Female	0	0	0	0
20	RLA	45	Female				
21	LGD	57	Female	-1	0	-1	-1
24	VIP	52	Female	1	1	0	2
26	PKM	46	Female	0	1	0	
27	SMM	59	Female	0	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	0	1
32	TML	38	Female	0	0	1	0
39	DKD	50	Female	0	0	0	0
40	CLM	43	Female	0	3	0	0
44	GSR	52	Female	0	0	0	1
46	LAA	55	Female	0	0	0	0
47	CMP	47	Female	0	0	0	0
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	-1			
57	MDS	52	Female	0	0	0	0
59	GFM	64	Female	0	0	0	0
60	JLF	32	Female	2	1	7	5
61	GEP	53	Female				
64	KKF	36	Female	-1	0	0	-1
65	EMM	39	Female	0	0	0	0
66	CYR	39	Female	1	1	1	1
67	AMM	37	Female	1	1	0	1
			Mean	0.17	0.25	0.32	0.26
			SD	0.80	0.80	1.36	1.20
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Discontinued

Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Chin)				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	3				
2	MLE	50	Female	0	0	0	0	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	0	0	0	0	0
8	JCF	54	Female	0	0	0	0	0
9	JRB	53	Female	0				
12	EFK	57	Female	0	0	0	0	0
17	BFH	59	Female	1	1	0	0	0
18	LJR	58	Female	0	0	0	0	0
19	D-M	58	Female	2	0	0	0	0
20	RLA	45	Female					
21	LGD	57	Female	0	0	1	0	1
24	VIP	52	Female	0	0	1	0	0
26	PKM	46	Female	0	0	0	0	
27	SMM	59	Female	0	1	0	0	0
28	EJD	56	Female	2				
31	JAC	56	Female	0	0	0	0	1
32	TML	38	Female	0	2	0	0	2
39	DKD	50	Female	1	0	0	0	0
40	CLM	43	Female	0	2	2	1	0
44	GSR	52	Female	0	0	0	0	0
46	LAA	55	Female	0	0	0	0	0
47	CMP	47	Female	0	0	0	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	2	0	0	0
54	TWS	55	Female	1	0			
57	MDS	52	Female	0	0	0	0	0
59	GFM	64	Female	0	0	0	0	0
60	JLF	32	Female	1	4	2	3	5
61	GEP	53	Female	0				
64	KKF	36	Female	0	2	1	1	0
65	EMM	39	Female	0	0	0	0	0
66	CYR	39	Female	2	1	2	1	0
67	AMM	37	Female	3	0	0	1	1
			Mean	0.38	0.52	0.32	0.25	0.37
			SD	0.78	0.99	0.67	0.65	1.04
			Median	0.00	0.00	0.00	0.00	0.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Inflammatory Lesion Count (Chin) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	0	0	0	0
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	0	0
8	JCF	54	Female	0	0	0	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	0	0
17	BFH	59	Female	0	-1	-1	-1
18	LJR	58	Female	0	0	0	0
19	D-M	58	Female	-2	-2	-2	-2
20	RLA	45	Female				
21	LGD	57	Female	0	1	0	1
24	VIP	52	Female	0	1	0	0
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	1	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	0	1
32	TML	38	Female	2	0	0	2
39	DKD	50	Female	-1	-1	-1	-1
40	CLM	43	Female	2	2	1	0
44	GSR	52	Female	0	0	0	0
46	LAA	55	Female	0	0	0	0
47	CMP	47	Female	0	0	0	0
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	2	0	0	0
54	TWS	55	Female	-1			
57	MDS	52	Female	0	0	0	0
59	GFM	64	Female	0	0	0	0
60	JLF	32	Female	3	1	2	4
61	GEP	53	Female				
64	KKF	36	Female	2	1	1	0
65	EMM	39	Female	0	0	0	0
66	CYR	39	Female	-1	0	-1	-2
67	AMM	37	Female	-3	-3	-2	-2
			Mean	0.14	-0.04	-0.11	0.00
			SD	1.22	0.92	0.79	1.18
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Discontinued

Non-Inflammatory Lesion Count

				Non-Inflammatory Lesion Count (Forehead)				
Subject No.	Subject Initials	Age	Sex	Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	6				
2	MLE	50	Female	0	0	0	0	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	0	0	0	1	1
8	JCF	54	Female	0	1	0	0	0
9	JRB	53	Female	3				
12	EFK	57	Female	0	0	0	0	0
17	BFH	59	Female	0	0	0	0	2
18	LJR	58	Female	0	0	0	0	0
19	D-M	58	Female	0	0	0	0	0
20	RLA	45	Female					
21	LGD	57	Female	2	1	6	0	3
24	VIP	52	Female	0	3	2	0	0
26	PKM	46	Female	0	0	0	0	
27	SMM	59	Female	0	0	0	0	0
28	EJD	56	Female	4				
31	JAC	56	Female	0	0	0	0	0
32	TML	38	Female	0	0	3	0	2
39	DKD	50	Female	3	0	0	4	2
40	CLM	43	Female	7	0	1	5	3
44	GSR	52	Female	0	0	0	0	0
46	LAA	55	Female	0	0	0	0	0
47	CMP	47	Female	1	0	0	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	0	0	0	0
54	TWS	55	Female	0	0			
57	MDS	52	Female	0	0	0	0	0
59	GFM	64	Female	0	0	0	0	0
60	JLF	32	Female	3	0	0	0	0
61	GEP	53	Female	0				
64	KKF	36	Female	0	0	7	0	0
65	EMM	39	Female	7	0	2	0	0
66	CYR	39	Female	0	0	0	0	0
67	AMM	37	Female	2	0	0	0	0
	Discontinued		Mean	0.86	0.17	0.75	0.36	0.48
			SD	1.92	0.60	1.80	1.19	0.98
			Median	0.00	0.00	0.00	0.00	0.00
			N	29	29	28	28	27

				Non-Inflammatory Lesion Count (Forehead) Intra-Subject Change			
Subject No.	Subject Initials	Age	Sex	Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	0	0	0	0
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	1	1
8	JCF	54	Female	1	0	0	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	0	0
17	BFH	59	Female	0	0	0	2
18	LJR	58	Female	0	0	0	0
19	D-M	58	Female	0	0	0	0
20	RLA	45	Female				
21	LGD	57	Female	-1	4	-2	1
24	VIP	52	Female	3	2	0	0
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	0	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	0	0
32	TML	38	Female	0	3	0	2
39	DKD	50	Female	-3	-3	1	-1
40	CLM	43	Female	-7	-6	-2	-4
44	GSR	52	Female	0	0	0	0
46	LAA	55	Female	0	0	0	0
47	CMP	47	Female	-1	-1	-1	-1
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	0			
57	MDS	52	Female	0	0	0	0
59	GFM	64	Female	0	0	0	0
60	JLF	32	Female	-3	-3	-3	-3
61	GEP	53	Female				
64	KKF	36	Female	0	7	0	0
65	EMM	39	Female	-7	-5	-7	-7
66	CYR	39	Female	0	0	0	0
67	AMM	37	Female	-2	-2	-2	-2
			Mean	-0.69	-0.14	-0.54	-0.44
			SD	2.05	2.45	1.55	1.80
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Non-Inflammatory Lesion Count

				Non-Inflammatory Lesion Count (Left Cheek)				
Subject No.	Subject Initials	Age	Sex	Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	8				
2	MLE	50	Female	0	1	0	0	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	2	0	0	0	1
8	JCF	54	Female	0	0	0	0	0
9	JRB	53	Female	0				
12	EFK	57	Female	0	0	0	0	0
17	BFH	59	Female	0	0	0	0	1
18	LJR	58	Female	0	0	0	0	0
19	D-M	58	Female	1	1	0	0	2
20	RLA	45	Female					
21	LGD	57	Female	0	1	3	0	0
24	VIP	52	Female	0	0	0	0	0
26	PKM	46	Female	0	0	0	0	
27	SMM	59	Female	0	0	0	0	0
28	EJD	56	Female	2				
31	JAC	56	Female	0	0	0	0	0
32	TML	38	Female	0	0	0	0	0
39	DKD	50	Female	1	0	0	3	0
40	CLM	43	Female	0	2	0	0	0
44	GSR	52	Female	0	0	0	1	0
46	LAA	55	Female	0	0	0	0	0
47	CMP	47	Female	0	0	1	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	0	0	0	0
54	TWS	55	Female	0	0			
57	MDS	52	Female	0	0	0	2	2
59	GFM	64	Female	2	1	1	1	0
60	JLF	32	Female	3	0	1	0	0
61	GEP	53	Female	0				
64	KKF	36	Female	3	2	8	4	0
65	EMM	39	Female	6	0	1	3	0
66	CYR	39	Female	1	0	1	0	0
67	AMM	37	Female	2	4	4	0	3
			Mean	0.72	0.41	0.71	0.50	0.33
			SD	1.39	0.91	1.72	1.11	0.78
			Median	0.00	0.00	0.00	0.00	0.00
			N	29	29	28	28	27

				Non-Inflammatory Lesion Count (Left Cheek) Intra-Subject Change			
Subject No.	Subject Initials	Age	Sex	Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	1	0	0	0
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	-2	-2	-2	-1
8	JCF	54	Female	0	0	0	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	0	0
17	BFH	59	Female	0	0	0	1
18	LJR	58	Female	0	0	0	0
19	D-M	58	Female	0	-1	-1	1
20	RLA	45	Female				
21	LGD	57	Female	1	3	0	0
24	VIP	52	Female	0	0	0	0
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	0	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	0	0
32	TML	38	Female	0	0	0	0
39	DKD	50	Female	-1	-1	2	-1
40	CLM	43	Female	2	0	0	0
44	GSR	52	Female	0	0	1	0
46	LAA	55	Female	0	0	0	0
47	CMP	47	Female	0	1	0	0
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	0			
57	MDS	52	Female	0	0	2	2
59	GFM	64	Female	-1	-1	-1	-2
60	JLF	32	Female	-3	-2	-3	-3
61	GEP	53	Female				
64	KKF	36	Female	-1	5	1	-3
65	EMM	39	Female	-6	-5	-3	-6
66	CYR	39	Female	-1	0	-1	-1
67	AMM	37	Female	2	2	-2	1
			Mean	-0.31	-0.04	-0.25	-0.44
			SD	1.47	1.67	1.17	1.55
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Discontinued

Non-Inflammatory Lesion Count

				Non-Inflammatory Lesion Count (Right Cheek)				
Subject No.	Subject Initials	Age	Sex	Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	8				
2	MLE	50	Female	0	2	0	0	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	1	0	0	0	0
8	JCF	54	Female	0	0	0	0	0
9	JRB	53	Female	0				
12	EFK	57	Female	0	0	0	0	0
17	BFH	59	Female	0	2	0	0	0
18	LJR	58	Female	2	0	0	0	0
19	D-M	58	Female	2	4	0	0	0
20	RLA	45	Female					
21	LGD	57	Female	0	0	2	0	2
24	VIP	52	Female	0	0	1	0	1
26	PKM	46	Female	2	0	0	0	
27	SMM	59	Female	0	1	0	0	0
28	EJD	56	Female	3				
31	JAC	56	Female	0	0	0	0	0
32	TML	38	Female	0	0	0	0	0
39	DKD	50	Female	0	0	0	1	0
40	CLM	43	Female	0	1	2	3	2
44	GSR	52	Female	4	1	1	1	1
46	LAA	55	Female	0	0	0	0	2
47	CMP	47	Female	0	0	1	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	0	0	0	0
54	TWS	55	Female	1	0			
57	MDS	52	Female	1	0	0	2	1
59	GFM	64	Female	1	2	0	1	0
60	JLF	32	Female	7	0	1	2	0
61	GEP	53	Female	0				
64	KKF	36	Female	0	3	14	2	0
65	EMM	39	Female	9	4	2	8	0
66	CYR	39	Female	2	0	2	0	0
67	AMM	37	Female	0	0	0	0	4
			Mean	1.10	0.69	0.93	0.71	0.48
			SD	2.16	1.23	2.67	1.65	0.98
			Median	0.00	0.00	0.00	0.00	0.00
			N	29	29	28	28	27

				Non-Inflammatory Lesion Count (Right Cheek) Intra-Subject Change			
Subject No.	Subject Initials	Age	Sex	Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	2	0	0	0
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	-1	-1	-1	-1
8	JCF	54	Female	0	0	0	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	0	0
17	BFH	59	Female	2	0	0	0
18	LJR	58	Female	-2	-2	-2	-2
19	D-M	58	Female	2	-2	-2	-2
20	RLA	45	Female				
21	LGD	57	Female	0	2	0	2
24	VIP	52	Female	0	1	0	1
26	PKM	46	Female	-2	-2	-2	
27	SMM	59	Female	1	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	0	0
32	TML	38	Female	0	0	0	0
39	DKD	50	Female	0	0	1	0
40	CLM	43	Female	1	2	3	2
44	GSR	52	Female	-3	-3	-3	-3
46	LAA	55	Female	0	0	0	2
47	CMP	47	Female	0	1	0	0
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	-1			
57	MDS	52	Female	-1	-1	1	0
59	GFM	64	Female	1	-1	0	-1
60	JLF	32	Female	-7	-6	-5	-7
61	GEP	53	Female				
64	KKF	36	Female	3	14	2	0
65	EMM	39	Female	-5	-7	-1	-9
66	CYR	39	Female	-2	0	-2	-2
67	AMM	37	Female	0	0	0	4
			Mean	-0.41	-0.18	-0.39	-0.59
			SD	2.04	3.41	1.52	2.58
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Discontinued

Non-Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Non-Inflammatory Lesion Count (Chin) Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	2				
2	MLE	50	Female	0	0	0	1	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	0	0	0	0	0
8	JCF	54	Female	0	0	0	0	0
9	JRB	53	Female	0				
12	EFK	57	Female	0	0	0	0	0
17	BFH	59	Female	0	0	0	0	1
18	LJR	58	Female	0	0	0	0	0
19	D-M	58	Female	0	0	0	0	0
20	RLA	45	Female					
21	LGD	57	Female	1	0	3	1	0
24	VIP	52	Female	0	1	0	0	0
26	PKM	46	Female	0	0	0	0	
27	SMM	59	Female	0	0	0	0	0
28	EJD	56	Female	0				
31	JAC	56	Female	0	0	0	0	0
32	TML	38	Female	0	0	0	0	0
39	DKD	50	Female	0	0	0	0	0
40	CLM	43	Female	0	2	0	1	0
44	GSR	52	Female	1	3	1	2	1
46	LAA	55	Female	0	0	0	0	2
47	CMP	47	Female	0	0	0	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	0	0	0	0
54	TWS	55	Female	3	0			
57	MDS	52	Female	0	0	0	0	0
59	GFM	64	Female	1	0	0	0	0
60	JLF	32	Female	0	0	0	1	0
61	GEP	53	Female	0				
64	KKF	36	Female	0	2	4	5	2
65	EMM	39	Female	0	0	0	2	0
66	CYR	39	Female	1	0	0	1	0
67	AMM	37	Female	2	0	0	0	0
			Mean	0.31	0.28	0.29	0.50	0.22
			SD	0.71	0.75	0.94	1.07	0.58
			Median	0.00	0.00	0.00	0.00	0.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Non-Inflammatory Lesion Count (Chin) Intra-Subject Change Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	0	0	1	0
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	0	0
8	JCF	54	Female	0	0	0	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	0	0
17	BFH	59	Female	0	0	0	1
18	LJR	58	Female	0	0	0	0
19	D-M	58	Female	0	0	0	0
20	RLA	45	Female				
21	LGD	57	Female	-1	2	0	-1
24	VIP	52	Female	1	0	0	0
26	PKM	46	Female	0	0	0	
27	SMM	59	Female	0	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	0	0
32	TML	38	Female	0	0	0	0
39	DKD	50	Female	0	0	0	0
40	CLM	43	Female	2	0	1	0
44	GSR	52	Female	2	0	1	0
46	LAA	55	Female	0	0	0	2
47	CMP	47	Female	0	0	0	0
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	-3			
57	MDS	52	Female	0	0	0	0
59	GFM	64	Female	-1	-1	-1	-1
60	JLF	32	Female	0	0	1	0
61	GEP	53	Female				
64	KKF	36	Female	2	4	5	2
65	EMM	39	Female	0	0	2	0
66	CYR	39	Female	-1	-1	0	-1
67	AMM	37	Female	-2	-2	-2	-2
			Mean	-0.03	0.07	0.29	0.00
			SD	1.02	0.98	1.15	0.78
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Discontinued

Total Inflammatory Lesion Count

				Total Inflammatory Lesions				
Subject No.	Subject Initials	Age	Sex	Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	3				
2	MLE	50	Female	4	3	0	3	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	0	0	0	0	0
8	JCF	54	Female	0	3	0	1	0
9	JRB	53	Female	1				
12	EFK	57	Female	0	0	0	2	1
17	BFH	59	Female	1	1	1	0	0
18	LJR	58	Female	0	4	0	0	0
19	D-M	58	Female	2	0	0	0	1
20	RLA	45	Female					
21	LGD	57	Female	2	0	9	1	1
24	VIP	52	Female	0	1	2	0	3
26	PKM	46	Female	1	0	3	0	
27	SMM	59	Female	0	1	0	0	0
28	EJD	56	Female	2				
31	JAC	56	Female	0	2	0	0	2
32	TML	38	Female	0	4	0	2	2
39	DKD	50	Female	1	0	2	0	2
40	CLM	43	Female	0	4	8	2	0
44	GSR	52	Female	0	0	1	0	1
46	LAA	55	Female	0	0	0	0	1
47	CMP	47	Female	2	0	0	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	2	0	0	0
54	TWS	55	Female	4	0			
57	MDS	52	Female	1	0	0	0	0
59	GFM	64	Female	0	0	0	0	0
60	JLF	32	Female	4	12	6	19	15
61	GEP	53	Female	2				
64	KKF	36	Female	1	2	5	4	1
65	EMM	39	Female	5	2	1	0	0
66	CYR	39	Female	4	4	3	2	2
67	AMM	37	Female	3	3	3	2	2
	Discontinued		Mean	1.21	1.66	1.57	1.36	1.26
			SD	1.61	2.50	2.54	3.63	2.89
			Median	0.00	1.00	0.00	0.00	0.00
			N	29	29	28	28	27

				Total Inflammatory Lesions Intra-Subject Change			
Subject No.	Subject Initials	Age	Sex	Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	-1	-4	-1	-4
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	0	0	0	0
8	JCF	54	Female	3	0	1	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	2	1
17	BFH	59	Female	0	0	-1	-1
18	LJR	58	Female	4	0	0	0
19	D-M	58	Female	-2	-2	-2	-1
20	RLA	45	Female				
21	LGD	57	Female	-2	7	-1	-1
24	VIP	52	Female	1	2	0	3
26	PKM	46	Female	-1	2	-1	
27	SMM	59	Female	1	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	2	0	0	2
32	TML	38	Female	4	0	2	2
39	DKD	50	Female	-1	1	-1	1
40	CLM	43	Female	4	8	2	0
44	GSR	52	Female	0	1	0	1
46	LAA	55	Female	0	0	0	1
47	CMP	47	Female	-2	-2	-2	-2
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	2	0	0	0
54	TWS	55	Female	-4			
57	MDS	52	Female	-1	-1	-1	-1
59	GFM	64	Female	0	0	0	0
60	JLF	32	Female	8	2	15	11
61	GEP	53	Female				
64	KKF	36	Female	1	4	3	0
65	EMM	39	Female	-3	-4	-5	-5
66	CYR	39	Female	0	-1	-2	-2
67	AMM	37	Female	0	0	-1	-1
			Mean	0.45	0.46	0.25	0.15
			SD	2.44	2.57	3.27	2.74
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Total Non-Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Total Non-Inflammatory Lesion Count				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	24	0			
2	MLE	50	Female	0	3	0	1	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	3	0	0	1	2
8	JCF	54	Female	0	1	0	0	0
9	JRB	53	Female	3				
12	EFK	57	Female	0	0	0	0	0
17	BFH	59	Female	0	2	0	0	4
18	LJR	58	Female	2	0	0	0	0
19	D-M	58	Female	3	5	0	0	2
20	RLA	45	Female					
21	LGD	57	Female	3	2	14	1	5
24	VIP	52	Female	0	4	3	0	1
26	PKM	46	Female	2	0	0	0	
27	SMM	59	Female	0	1	0	0	0
28	EJD	56	Female	9	0			
31	JAC	56	Female	0	0	0	0	0
32	TML	38	Female	0	0	3	0	2
39	DKD	50	Female	4	0	0	8	2
40	CLM	43	Female	7	5	3	9	5
44	GSR	52	Female	5	4	2	4	2
46	LAA	55	Female	0	0	0	0	4
47	CMP	47	Female	1	0	2	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	0	0	0	0
54	TWS	55	Female	4	0			
57	MDS	52	Female	1	0	0	4	3
59	GFM	64	Female	4	3	1	2	0
60	JLF	32	Female	13	0	2	3	0
61	GEP	53	Female	0	0			
64	KKF	36	Female	3	7	33	11	2
65	EMM	39	Female	22	4	5	13	0
66	CYR	39	Female	4	0	3	1	0
67	AMM	37	Female	6	4	4	0	7
	Discontinued		Mean	3.00	1.55	2.68	2.07	1.52
			SD	4.68	2.08	6.59	3.67	1.99
			Median	2.00	0.00	0.00	0.00	0.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Total Non-Inflammatory Lesion Count Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	3	0	1	0
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	-3	-3	-2	-1
8	JCF	54	Female	1	0	0	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	0	0
17	BFH	59	Female	2	0	0	4
18	LJR	58	Female	-2	-2	-2	-2
19	D-M	58	Female	2	-3	-3	-1
20	RLA	45	Female				
21	LGD	57	Female	-1	11	-2	2
24	VIP	52	Female	4	3	0	1
26	PKM	46	Female	-2	-2	-2	
27	SMM	59	Female	1	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	0	0	0	0
32	TML	38	Female	0	3	0	2
39	DKD	50	Female	-4	-4	4	-2
40	CLM	43	Female	-2	-4	2	-2
44	GSR	52	Female	-1	-3	-1	-3
46	LAA	55	Female	0	0	0	4
47	CMP	47	Female	-1	1	-1	-1
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	0	0	0	0
54	TWS	55	Female	-4			
57	MDS	52	Female	-1	-1	3	2
59	GFM	64	Female	-1	-3	-2	-4
60	JLF	32	Female	-13	-11	-10	-13
61	GEP	53	Female				
64	KKF	36	Female	4	30	8	-1
65	EMM	39	Female	-18	-17	-9	-22
66	CYR	39	Female	-4	-1	-3	-4
67	AMM	37	Female	-2	-2	-6	1
			Mean	-1.45	-0.29	-0.89	-1.48
			SD	4.48	7.53	3.49	5.18
			Median	-1.00	0.00	0.00	0.00
			N	29	28	28	27

Total Inflammatory and Non-Inflammatory Lesion Count

Subject No.	Subject Initials	Age	Sex	Total Lesion Count (Inflammatory and Non-Inflammatory)				
				Baseline	Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female	27				
2	MLE	50	Female	4	6	0	4	0
3	SKH	47	Female	0	0	0	0	0
7	DBK	52	Female	3	0	0	1	2
8	JCF	54	Female	0	4	0	1	0
9	JRB	53	Female	4				
12	EFK	57	Female	0	0	0	2	1
17	BFH	59	Female	1	3	1	0	4
18	LJR	58	Female	2	4	0	0	0
19	D-M	58	Female	5	5	0	0	3
20	RLA	45	Female					
21	LGD	57	Female	5	2	23	2	6
24	VIP	52	Female	0	5	5	0	4
26	PKM	46	Female	3	0	3	0	
27	SMM	59	Female	0	2	0	0	0
28	EJD	56	Female	11				
31	JAC	56	Female	0	2	0	0	2
32	TML	38	Female	0	4	3	2	4
39	DKD	50	Female	5	0	2	8	4
40	CLM	43	Female	7	9	11	11	0
44	GSR	52	Female	5	4	3	4	3
46	LAA	55	Female	0	0	0	0	5
47	CMP	47	Female	3	0	2	0	0
49	L-R	58	Female	0	0	0	0	0
51	PCB	59	Female	0	2	0	0	0
54	TWS	55	Female	8	0			
57	MDS	52	Female	2	0	0	4	3
59	GFM	64	Female	4	3	1	2	0
60	JLF	32	Female	17	12	8	22	15
61	GEP	53	Female	2				
64	KKF	36	Female	4	9	38	15	3
65	EMM	39	Female	27	6	6	13	0
66	CYR	39	Female	8	4	6	3	2
67	AMM	37	Female	9	7	7	2	9
	Discontinued		Mean	4.21	3.21	4.25	3.43	2.59
			SD	5.81	3.23	8.24	5.49	3.39
			Median	3.00	3.00	1.00	1.50	2.00
			N	29	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Total Lesion Count (Inflammatory and Non-Inflammatory) Intra-Subject Change			
				Week 2 Minus Baseline	Week 4 Minus Baseline	Week 8 Minus Baseline	Week 12 Minus Baseline
1	SDC	40	Female				
2	MLE	50	Female	2	-4	0	-4
3	SKH	47	Female	0	0	0	0
7	DBK	52	Female	-3	-3	-2	-1
8	JCF	54	Female	4	0	1	0
9	JRB	53	Female				
12	EFK	57	Female	0	0	2	1
17	BFH	59	Female	2	0	-1	3
18	LJR	58	Female	2	-2	-2	-2
19	D-M	58	Female	0	-5	-5	-2
20	RLA	45	Female				
21	LGD	57	Female	-3	18	-3	1
24	VIP	52	Female	5	5	0	4
26	PKM	46	Female	-3	0	-3	
27	SMM	59	Female	2	0	0	0
28	EJD	56	Female				
31	JAC	56	Female	2	0	0	2
32	TML	38	Female	4	3	2	4
39	DKD	50	Female	-5	-3	3	-1
40	CLM	43	Female	2	4	4	-7
44	GSR	52	Female	-1	-2	-1	-2
46	LAA	55	Female	0	0	0	5
47	CMP	47	Female	-3	-1	-3	-3
49	L-R	58	Female	0	0	0	0
51	PCB	59	Female	2	0	0	0
54	TWS	55	Female	-8			
57	MDS	52	Female	-2	-2	2	1
59	GFM	64	Female	-1	-3	-2	-4
60	JLF	32	Female	-5	-9	5	-2
61	GEP	53	Female				
64	KKF	36	Female	5	34	11	-1
65	EMM	39	Female	-21	-21	-14	-27
66	CYR	39	Female	-4	-2	-5	-6
67	AMM	37	Female	-2	-2	-7	0
			Mean	-1.00	0.18	-0.64	-1.52
			SD	4.99	8.90	4.34	5.83
			Median	0.00	0.00	0.00	0.00
			N	29	28	28	27

Subject's Self Assessment of Skin Texture

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Texture			
				Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female				
2	MLE	50	Female	3	3	2	2
3	SKH	47	Female	2	3	2	3
7	DBK	52	Female	2	4	2	2
8	JCF	54	Female	2	2	2	1
9	JRB	53	Female				
12	EFK	57	Female	2	2	2	2
17	BFH	59	Female	1	2	2	1
18	LJR	58	Female	2	2	2	2
19	D-M	58	Female	2	2	1	1
20	RLA	45	Female				
21	LGD	57	Female	2	1	2	1
24	VIP	52	Female	3	2	2	2
26	PKM	46	Female	2	2	1	
27	SMM	59	Female	3	2	2	2
28	EJD	56	Female				
31	JAC	56	Female	3	2	2	2
32	TML	38	Female	2	1	1	1
39	DKD	50	Female	3	3	2	2
40	CLM	43	Female	2	3	2	2
44	GSR	52	Female	1	2	2	1
46	LAA	55	Female	2	2	2	2
47	CMP	47	Female	2	2	1	2
49	L-R	58	Female	3	2	2	2
51	PCB	59	Female	3	3	3	3
54	TWS	55	Female	3			
57	MDS	52	Female	3	3	2	3
59	GFM	64	Female	3	3	2	2
60	JLF	32	Female	2	2	2	2
61	GEP	53	Female				
64	KKF	36	Female	1	2	1	1
65	EMM	39	Female	2	2	1	1
66	CYR	39	Female	2	2	2	2
67	AMM	37	Female	2	2	1	1
	Discontinued		Mean	2.24	2.25	1.79	1.78
			SD	0.64	0.65	0.50	0.64
			Median	2.00	2.00	2.00	2.00
			N	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Texture Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
1	SDC	40	Female			
2	MLE	50	Female	0	-1	-1
3	SKH	47	Female	1	0	1
7	DBK	52	Female	2	0	0
8	JCF	54	Female	0	0	-1
9	JRB	53	Female			
12	EFK	57	Female	0	0	0
17	BFH	59	Female	1	1	0
18	LJR	58	Female	0	0	0
19	D-M	58	Female	0	-1	-1
20	RLA	45	Female			
21	LGD	57	Female	-1	0	-1
24	VIP	52	Female	-1	-1	-1
26	PKM	46	Female	0	-1	
27	SMM	59	Female	-1	-1	-1
28	EJD	56	Female			
31	JAC	56	Female	-1	-1	-1
32	TML	38	Female	-1	-1	-1
39	DKD	50	Female	0	-1	-1
40	CLM	43	Female	1	0	0
44	GSR	52	Female	1	1	0
46	LAA	55	Female	0	0	0
47	CMP	47	Female	0	-1	0
49	L-R	58	Female	-1	-1	-1
51	PCB	59	Female	0	0	0
54	TWS	55	Female			
57	MDS	52	Female	0	-1	0
59	GFM	64	Female	0	-1	-1
60	JLF	32	Female	0	0	0
61	GEP	53	Female			
64	KKF	36	Female	1	0	0
65	EMM	39	Female	0	-1	-1
66	CYR	39	Female	0	0	0
67	AMM	37	Female	0	-1	-1
			Mean	0.04	-0.43	-0.44
			SD	0.74	0.63	0.58
			Median	0.00	-0.50	0.00
			N	28	28	27

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Subject's Self Assessment of Skin Color

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Color			
				Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female				
2	MLE	50	Female	3	2	3	3
3	SKH	47	Female	3	3	2	3
7	DBK	52	Female	3	3	2	1
8	JCF	54	Female	2	2	2	2
9	JRB	53	Female				
12	EFK	57	Female	2	2	2	2
17	BFH	59	Female	2	3	2	1
18	LJR	58	Female	3	2	2	3
19	D-M	58	Female	2	2	1	1
20	RLA	45	Female				
21	LGD	57	Female	3	2	2	2
24	VIP	52	Female	3	3	2	3
26	PKM	46	Female	3	2	1	
27	SMM	59	Female	3	3	3	3
28	EJD	56	Female				
31	JAC	56	Female	3	3	3	3
32	TML	38	Female	3	3	2	2
39	DKD	50	Female	3	2	2	2
40	CLM	43	Female	3	3	2	2
44	GSR	52	Female	2	2	2	1
46	LAA	55	Female	2	2	2	2
47	CMP	47	Female	3	2	2	3
49	L-R	58	Female	3	3	2	3
51	PCB	59	Female	3	3	3	3
54	TWS	55	Female	3			
57	MDS	52	Female	4	3	2	3
59	GFM	64	Female	2	3	3	2
60	JLF	32	Female	3	2	2	2
61	GEP	53	Female				
64	KKF	36	Female	2	1	2	2
65	EMM	39	Female	3	2	1	1
66	CYR	39	Female	3	2	2	2
67	AMM	37	Female	2	2	2	2
	Discontinued		Mean	2.72	2.39	2.07	2.19
			SD	0.53	0.57	0.54	0.74
			Median	3.00	2.00	2.00	2.00
			N	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Color Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
1	SDC	40	Female			
2	MLE	50	Female	-1	0	0
3	SKH	47	Female	0	-1	0
7	DBK	52	Female	0	-1	-2
8	JCF	54	Female	0	0	0
9	JRB	53	Female			
12	EFK	57	Female	0	0	0
17	BFH	59	Female	1	0	-1
18	LJR	58	Female	-1	-1	0
19	D-M	58	Female	0	-1	-1
20	RLA	45	Female			
21	LGD	57	Female	-1	-1	-1
24	VIP	52	Female	0	-1	0
26	PKM	46	Female	-1	-2	
27	SMM	59	Female	0	0	0
28	EJD	56	Female			
31	JAC	56	Female	0	0	0
32	TML	38	Female	0	-1	-1
39	DKD	50	Female	-1	-1	-1
40	CLM	43	Female	0	-1	-1
44	GSR	52	Female	0	0	-1
46	LAA	55	Female	0	0	0
47	CMP	47	Female	-1	-1	0
49	L-R	58	Female	0	-1	0
51	PCB	59	Female	0	0	0
54	TWS	55	Female			
57	MDS	52	Female	-1	-2	-1
59	GFM	64	Female	1	1	0
60	JLF	32	Female	-1	-1	-1
61	GEP	53	Female			
64	KKF	36	Female	-1	0	0
65	EMM	39	Female	-1	-2	-2
66	CYR	39	Female	-1	-1	-1
67	AMM	37	Female	0	0	0
			Mean	-0.32	-0.64	-0.52
			SD	0.61	0.73	0.64
			Median	0.00	-1.00	0.00
			N	28	28	27

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Subject's Self Assessment of Skin Blotchiness

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Blotchiness - Brown Spots			
				Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female				
2	MLE	50	Female	2	3	3	3
3	SKH	47	Female	3	3	2	3
7	DBK	52	Female	3	4	3	2
8	JCF	54	Female	3	3	3	3
9	JRB	53	Female				
12	EFK	57	Female	3	2	2	2
17	BFH	59	Female	3	3	2	1
18	LJR	58	Female	3	3	2	2
19	D-M	58	Female	2	3	1	2
20	RLA	45	Female				
21	LGD	57	Female	3	2	1	1
24	VIP	52	Female	3	3	3	3
26	PKM	46	Female	3	3	1	
27	SMM	59	Female	3	3	3	3
28	EJD	56	Female				
31	JAC	56	Female	3	3	3	3
32	TML	38	Female	4	3	3	2
39	DKD	50	Female	3	3	3	3
40	CLM	43	Female	3	3	3	3
44	GSR	52	Female	2	2	2	1
46	LAA	55	Female	3	2	2	2
47	CMP	47	Female	3	3	3	3
49	L-R	58	Female	3	3	3	3
51	PCB	59	Female	3	3	3	3
54	TWS	55	Female	2			
57	MDS	52	Female	3	3	3	3
59	GFM	64	Female	3	2	3	2
60	JLF	32	Female	3	3	2	2
61	GEP	53	Female				
64	KKF	36	Female	2	2	2	2
65	EMM	39	Female	3	3	1	1
66	CYR	39	Female	3	2	2	2
67	AMM	37	Female	3	3	1	1
	Discontinued		Mean	2.86	2.79	2.32	2.26
			SD	0.44	0.50	0.77	0.76
			Median	3.00	3.00	2.50	2.00
			N	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Skin Blotchiness - Brown Spots Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
1	SDC	40	Female			
2	MLE	50	Female	1	1	1
3	SKH	47	Female	0	-1	0
7	DBK	52	Female	1	0	-1
8	JCF	54	Female	0	0	0
9	JRB	53	Female			
12	EFK	57	Female	-1	-1	-1
17	BFH	59	Female	0	-1	-2
18	LJR	58	Female	0	-1	-1
19	D-M	58	Female	1	-1	0
20	RLA	45	Female			
21	LGD	57	Female	-1	-2	-2
24	VIP	52	Female	0	0	0
26	PKM	46	Female	0	-2	
27	SMM	59	Female	0	0	0
28	EJD	56	Female			
31	JAC	56	Female	0	0	0
32	TML	38	Female	-1	-1	-2
39	DKD	50	Female	0	0	0
40	CLM	43	Female	0	0	0
44	GSR	52	Female	0	0	-1
46	LAA	55	Female	-1	-1	-1
47	CMP	47	Female	0	0	0
49	L-R	58	Female	0	0	0
51	PCB	59	Female	0	0	0
54	TWS	55	Female			
57	MDS	52	Female	0	0	0
59	GFM	64	Female	-1	0	-1
60	JLF	32	Female	0	-1	-1
61	GEP	53	Female			
64	KKF	36	Female	0	0	0
65	EMM	39	Female	0	-2	-2
66	CYR	39	Female	-1	-1	-1
67	AMM	37	Female	0	-2	-2
			Mean	-0.11	-0.57	-0.63
			SD	0.57	0.79	0.84
			Median	0.00	0.00	0.00
			N	28	28	27

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Subject's Self Assessment of Fine Wrinkles

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Fine Wrinkles			
				Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female				
2	MLE	50	Female	2	2	1	2
3	SKH	47	Female	2	2	2	3
7	DBK	52	Female	3	4	2	2
8	JCF	54	Female	3	3	3	2
9	JRB	53	Female				
12	EFK	57	Female	2	2	2	2
17	BFH	59	Female	2	3	2	1
18	LJR	58	Female	3	3	2	2
19	D-M	58	Female	3	2	2	2
20	RLA	45	Female				
21	LGD	57	Female	2	2	1	1
24	VIP	52	Female	2	2	2	1
26	PKM	46	Female	3	3	2	
27	SMM	59	Female	3	2	2	2
28	EJD	56	Female				
31	JAC	56	Female	2	2	2	2
32	TML	38	Female	3	2	2	1
39	DKD	50	Female	3	3	3	3
40	CLM	43	Female	2	2	3	2
44	GSR	52	Female	2	2	2	1
46	LAA	55	Female	2	2	2	2
47	CMP	47	Female	2	2	2	3
49	L-R	58	Female	2	2	2	2
51	PCB	59	Female	3	3	3	3
54	TWS	55	Female	2			
57	MDS	52	Female	3	3	2	4
59	GFM	64	Female	2	2	2	2
60	JLF	32	Female	2	2	2	1
61	GEP	53	Female				
64	KKF	36	Female	3	1	2	1
65	EMM	39	Female	2	2	2	1
66	CYR	39	Female	3	2	2	2
67	AMM	37	Female	2	2	2	2
	Discontinued		Mean	2.41	2.29	2.07	1.93
			SD	0.50	0.60	0.47	0.78
			Median	2.00	2.00	2.00	2.00
			N	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Fine Wrinkles Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
1	SDC	40	Female			
2	MLE	50	Female	0	-1	0
3	SKH	47	Female	0	0	1
7	DBK	52	Female	1	-1	-1
8	JCF	54	Female	0	0	-1
9	JRB	53	Female			
12	EFK	57	Female	0	0	0
17	BFH	59	Female	1	0	-1
18	LJR	58	Female	0	-1	-1
19	D-M	58	Female	-1	-1	-1
20	RLA	45	Female			
21	LGD	57	Female	0	-1	-1
24	VIP	52	Female	0	0	-1
26	PKM	46	Female	0	-1	
27	SMM	59	Female	-1	-1	-1
28	EJD	56	Female			
31	JAC	56	Female	0	0	0
32	TML	38	Female	-1	-1	-2
39	DKD	50	Female	0	0	0
40	CLM	43	Female	0	1	0
44	GSR	52	Female	0	0	-1
46	LAA	55	Female	0	0	0
47	CMP	47	Female	0	0	1
49	L-R	58	Female	0	0	0
51	PCB	59	Female	0	0	0
54	TWS	55	Female			
57	MDS	52	Female	0	-1	1
59	GFM	64	Female	0	0	0
60	JLF	32	Female	0	0	-1
61	GEP	53	Female			
64	KKF	36	Female	-2	-1	-2
65	EMM	39	Female	0	0	-1
66	CYR	39	Female	-1	-1	-1
67	AMM	37	Female	0	0	0
			Mean	-0.14	-0.36	-0.48
			SD	0.59	0.56	0.80
			Median	0.00	0.00	-1.00
			N	28	28	27

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

Subject's Self Assessment of Overall Improvement

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Overall Improvement			
				Week 2	Week 4	Week 8	Week 12
1	SDC	40	Female				
2	MLE	50	Female	2	2	2	2
3	SKH	47	Female	2	3	2	3
7	DBK	52	Female	2	3	3	2
8	JCF	54	Female	2	2	2	2
9	JRB	53	Female				
12	EFK	57	Female	2	2	2	2
17	BFH	59	Female	2	2	2	1
18	LJR	58	Female	3	2	2	2
19	D-M	58	Female	2	2	1	2
20	RLA	45	Female				
21	LGD	57	Female	2	2	2	1
24	VIP	52	Female	2	2	2	1
26	PKM	46	Female	3	2	1	
27	SMM	59	Female	3	2	2	2
28	EJD	56	Female				
31	JAC	56	Female	2	2	2	2
32	TML	38	Female	3	2	2	2
39	DKD	50	Female	3	2	2	2
40	CLM	43	Female	3	3	3	2
44	GSR	52	Female	2	1	2	1
46	LAA	55	Female	2	2	2	2
47	CMP	47	Female	2	2	2	2
49	L-R	58	Female	3	2	2	2
51	PCB	59	Female	3	3	3	3
54	TWS	55	Female	2			
57	MDS	52	Female	3	4	2	3
59	GFM	64	Female	2	2	2	2
60	JLF	32	Female	2	2	2	2
61	GEP	53	Female				
64	KKF	36	Female	2	2	2	2
65	EMM	39	Female	3	2	2	1
66	CYR	39	Female	2	2	2	2
67	AMM	37	Female	2	2	1	1
	Discontinued		Mean	2.34	2.18	2.00	1.89
			SD	0.48	0.55	0.47	0.58
			Median	2.00	2.00	2.00	2.00
			N	29	28	28	27

Subject No.	Subject Initials	Age	Sex	Subject's Self Assessment of Overall Improvement Intra-Subject Change		
				Week 4 Minus Week 2	Week 8 Minus Week 2	Week 12 Minus Week 2
1	SDC	40	Female			
2	MLE	50	Female	0	0	0
3	SKH	47	Female	1	0	1
7	DBK	52	Female	1	1	0
8	JCF	54	Female	0	0	0
9	JRB	53	Female			
12	EFK	57	Female	0	0	0
17	BFH	59	Female	0	0	-1
18	LJR	58	Female	-1	-1	-1
19	D-M	58	Female	0	-1	0
20	RLA	45	Female			
21	LGD	57	Female	0	0	-1
24	VIP	52	Female	0	0	-1
26	PKM	46	Female	-1	-2	
27	SMM	59	Female	-1	-1	-1
28	EJD	56	Female			
31	JAC	56	Female	0	0	0
32	TML	38	Female	-1	-1	-1
39	DKD	50	Female	-1	-1	-1
40	CLM	43	Female	0	0	-1
44	GSR	52	Female	-1	0	-1
46	LAA	55	Female	0	0	0
47	CMP	47	Female	0	0	0
49	L-R	58	Female	-1	-1	-1
51	PCB	59	Female	0	0	0
54	TWS	55	Female			
57	MDS	52	Female	1	-1	0
59	GFM	64	Female	0	0	0
60	JLF	32	Female	0	0	0
61	GEP	53	Female			
64	KKF	36	Female	0	0	0
65	EMM	39	Female	-1	-1	-2
66	CYR	39	Female	0	0	0
67	AMM	37	Female	0	-1	-1
			Mean	-0.18	-0.36	-0.44
			SD	0.61	0.62	0.64
			Median	0.00	0.00	0.00
			N	28	28	27

1 = Much Improved
2 = Somewhat Improved
3 = No Change
4 = Somewhat Worse
5 = Much Worse

TEWL Values (g/m2/hr) of Both Cheeks (Average of Right and Left)

				Baseline				Week 2				Week 4				Week 8				Week 12			
Subject Number	Subject's Initials	Subject's Age	Gender	Measurement 1	Measurement 2	Mean	SD	Measurement 1	Measurement 2	Mean	SD	Measurement 1	Measurement 2	Mean	SD	Measurement 1	Measurement 2	Mean	SD	Measurement 1	Measurement 2	Mean	SD
4	SKH	46	Female	11.5	11.5	11.48	0.04	20.9	22.3	21.60	0.99	13.5	15.6	14.53	1.45	13.9	14.0	13.93	0.04	9.7	10.5	10.05	0.57
5	LMP	45	Female	17.0	17.6	17.28	0.46	10.7	12.2	11.40	1.06	15.1	16.2	15.60	0.78	11.5	11.8	11.63	0.18	15.1	15.8	15.45	0.49
6	PJW	43	Female																				
10	JCL	41	Female	17.0	16.4	16.70	0.42	9.2	10.1	9.65	0.64	13.3	14.6	13.90	0.92	12.0	13.4	12.68	1.03	10.9	10.9	10.90	0.00
11	TLM	50	Female	10.2	10.3	10.23	0.11	14.9	14.2	14.53	0.46	13.1	15.1	14.05	1.41	15.2	15.3	15.25	0.07	15.7	15.8	15.70	0.07
13	DKS	38	Female	9.7	9.8	9.73	0.11	13.6	13.7	13.65	0.07	11.9	12.4	12.10	0.35	9.8	10.1	9.93	0.18	14.8	14.6	14.68	0.18
14	LKB	56	Female	8.6	8.8	8.68	0.18	8.2	8.8	8.48	0.39	9.1	10.5	9.78	1.03	9.7	10.7	10.15	0.71	11.7	12.1	11.88	0.25
15	NHK	56	Female	7.6	7.7	7.60	0.07	17.1	16.5	16.78	0.46												
16	VLH	57	Female	11.0	11.1	11.03	0.11	10.6	10.5	10.55	0.07	9.6	9.8	9.70	0.14	9.2	8.3	8.70	0.64	8.8	8.6	8.70	0.14
22	JKP	48	Female																				
23	RMS	51	Female	8.0	9.2	8.58	0.81	5.4	6.4	5.88	0.67	8.0	9.1	8.50	0.78	9.4	9.2	9.25	0.14	9.4	9.9	9.65	0.35
25	TJJ	40	Female	17.5	18.7	18.10	0.85	16.9	18.7	17.80	1.27	15.0	15.8	15.40	0.57	14.4	15.2	14.75	0.57	15.4	16.4	15.88	0.74
29	DSE	59	Female	6.3	6.6	6.43	0.18	6.6	7.0	6.75	0.28	8.1	8.4	8.23	0.25	12.4	11.9	12.10	0.35	6.9	7.6	7.25	0.49
30	MMC	64	Female	6.5	7.0	6.70	0.35	10.2	10.9	10.53	0.46	9.8	11.3	10.50	1.06	9.7	9.1	9.40	0.42	11.2	11.7	11.40	0.35
33	J-G	47	Female																				
34	LLL	31	Female																				
35	DLM	52	Female	7.6	8.6	8.08	0.74	9.5	10.7	10.10	0.85	10.2	10.8	10.48	0.39	10.9	10.6	10.75	0.21	13.6	12.9	13.25	0.49
36	MAE	51	Female	7.5	8.4	7.93	0.67	11.9	12.7	12.30	0.57	12.6	13.8	13.20	0.85	9.6	10.1	9.80	0.35	10.0	10.8	10.40	0.57
37	GLJ	54	Female	11.2	10.8	10.98	0.32	13.1	14.4	13.70	0.92	10.4	10.6	10.45	0.14	11.1	10.0	10.53	0.74	10.4	9.7	10.03	0.46
38	KAS	42	Female																				
41	E-N	61	Female	8.7	8.5	8.55	0.14	10.4	10.6	10.50	0.14	7.8	8.0	7.88	0.18	8.9	9.3	9.08	0.25	9.6	8.8	9.18	0.53
42	KAM	52	Female	7.9	9.3	8.58	0.95	9.9	10.8	10.30	0.64	8.3	9.1	8.70	0.57	8.4	8.7	8.50	0.21	8.4	9.3	8.83	0.60
43	CGC	48	Female	9.8	10.7	10.23	0.67	11.1	11.4	11.20	0.21	8.9	8.9	8.88	0.04	11.4	11.8	11.55	0.28	13.7	13.8	13.73	0.11
45	TDC	48	Female	6.1	6.1	6.08	0.04	9.0	9.9	9.45	0.64	9.2	10.0	9.58	0.53	12.4	13.2	12.80	0.57	10.0	10.6	10.28	0.39
48	JLL	47	Female	6.5	6.3	6.38	0.11	8.2	8.3	8.23	0.11	10.2	11.0	10.58	0.53	13.4	12.9	13.10	0.35	9.8	10.1	9.95	0.21
50	DKH	49	Female	10.7	10.7	10.70	0.00	20.0	21.8	20.88	1.31	9.7	10.9	10.30	0.85	10.1	9.8	9.95	0.21	13.0	11.4	12.18	1.17
52	CJL	53	Female	7.7	8.4	8.05	0.49	8.1	10.0	9.03	1.31	8.2	8.9	8.55	0.49	8.7	7.3	7.98	0.95	10.4	10.0	10.18	0.25
53	DSB	54	Female	7.0	7.7	7.35	0.49	8.4	9.1	8.75	0.49	7.2	7.3	7.23	0.04	9.5	9.8	9.65	0.21	8.2	8.8	8.50	0.42
55	SKR	57	Female	5.2	4.8	5.00	0.28	4.2	4.1	4.13	0.11	6.1	5.8	5.93	0.18	6.0	5.9	5.93	0.04	7.8	7.0	7.38	0.53
56	DAH	45	Female																				
58	CZR	49	Female	18.9	20.5	19.68	1.17	21.9	22.8	22.33	0.60	22.3	23.8	23.03	1.10	16.4	16.5	16.45	0.07	18.4	18.3	18.30	0.07
62	KME	45	Female	14.6	15.3	14.90	0.49	14.8	16.4	15.58	1.10	11.6	12.4	11.98	0.53	7.1	7.2	7.10	0.07	11.8	11.3	11.55	0.35
63	MRG	51	Female	10.5	11.0	10.70	0.35																
68	SAM	53	Female	8.0	7.9	7.93	0.04	10.7	11.4	11.00	0.49	6.7	7.1	6.88	0.25	7.0	7.0	6.98	0.04	9.5	9.7	9.55	0.14
69	GHD	55	Female	13.1	13.6	13.35	0.35	12.6	13.7	13.15	0.78	12.6	14.1	13.33	1.10	11.0	11.5	11.25	0.35	12.4	12.9	12.60	0.35
70	CAC	62	Female	6.6	7.4	6.98	0.53	13.3	14.8	14.03	1.10	11.4	12.0	11.65	0.42	10.9	10.1	10.50	0.57	8.1	7.8	7.90	0.21
71	JAR	40	Female	11.4	12.0	11.68	0.39	14.2	14.7	14.40	0.35	13.6	14.4	13.95	0.57	12.4	12.1	12.23	0.18	11.1	11.2	11.10	0.07
72	NRC	56	Female	25.7	28.5	27.05	1.98	27.4	27.2	27.30	0.14	22.6	24.1	23.35	1.06	26.7	27.9	27.28	0.81	28.7	28.9	28.78	0.11
73	NLW	47	Female	19.5	20.0	19.73	0.32	44.5	49.8	47.13	3.71												
	Discontinued				Mean	10.71			Mean	12.71			Mean	11.61			Mean	11.30			Mean	11.84	
					SD	4.82			SD	5.13			SD	4.08			SD	3.90			SD	4.19	
					Median	8.68			Median	11.20			Median	10.49			Median	10.51			Median	10.65	
					N	31			N	31			N	30			N	30			N	30	

Intra-Subject Change in TEWL Values (g/m2/hr) of Both Cheeks (Average of Right and Left)

Subject Number	Subject's Initials	Subject's Age	Gender	Week 2 vs. Baseline		Mean	SD	Week 4 vs. Baseline		Mean	SD	Week 8 vs. Baseline		Mean	SD	Week 12 vs. Baseline		Mean	SD
				Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2		
4	SKH	46	Female	9.5	10.8	10.13	0.95	2.1	4.1	3.05	1.41	2.5	2.5	2.45	0.00	-1.8	-1.1	-1.43	0.53
5	LMP	45	Female	-6.3	-5.5	-5.88	0.60	-1.9	-1.5	-1.68	0.32	-5.5	-5.9	-5.65	0.28	-1.9	-1.8	-1.83	0.04
6	PJW	43	Female																
10	JCL	41	Female	-7.8	-6.3	-7.05	1.06	-3.8	-1.9	-2.80	1.34	-5.1	-3.0	-4.03	1.45	-6.1	-5.5	-5.80	0.42
11	TLM	50	Female	4.7	3.9	4.30	0.57	2.9	4.8	3.83	1.31	5.1	5.0	5.03	0.04	5.5	5.5	5.48	0.04
13	DKS	38	Female	4.0	3.9	3.93	0.04	2.2	2.6	2.38	0.25	0.2	0.3	0.20	0.07	5.2	4.8	4.95	0.28
14	LKB	56	Female	-0.4	-0.1	-0.20	0.21	0.5	1.7	1.10	0.85	1.1	1.9	1.48	0.53	3.2	3.3	3.20	0.07
15	NHK	56	Female	9.6	8.8	9.18	0.53												
16	VLH	57	Female	-0.4	-0.6	-0.48	0.18	-1.4	-1.3	-1.33	0.04	-1.8	-2.9	-2.33	0.74	-2.2	-2.5	-2.33	0.25
22	JKP	48	Female																
23	RMS	51	Female	-2.6	-2.8	-2.70	0.14	0.0	-0.1	-0.07	0.04	1.4	0.0	0.68	0.95	1.4	0.7	1.08	0.46
25	TJJ	40	Female	-0.6	0.0	-0.30	0.42	-2.5	-2.9	-2.70	0.28	-3.2	-3.6	-3.35	0.28	-2.2	-2.3	-2.23	0.11
29	DSE	59	Female	0.3	0.4	0.33	0.11	1.8	1.9	1.80	0.07	6.1	5.3	5.68	0.53	0.6	1.1	0.83	0.32
30	MMC	64	Female	3.8	3.9	3.83	0.11	3.3	4.3	3.80	0.71	3.3	2.2	2.70	0.78	4.7	4.7	4.70	0.00
33	J-G	47	Female																
34	LLL	31	Female																
35	DLM	52	Female	2.0	2.1	2.03	0.11	2.7	2.2	2.40	0.35	3.4	2.0	2.68	0.95	6.1	4.3	5.18	1.24
36	MAE	51	Female	4.5	4.3	4.38	0.11	5.2	5.4	5.28	0.18	2.1	1.7	1.88	0.32	2.6	2.4	2.48	0.11
37	GLJ	54	Female	1.9	3.6	2.73	1.24	-0.9	-0.2	-0.52	0.46	-0.1	-0.8	-0.45	0.42	-0.9	-1.1	-0.95	0.14
38	KAS	42	Female																
41	E-N	61	Female	1.8	2.2	1.95	0.28	-0.9	-0.4	-0.67	0.32	0.3	0.8	0.53	0.39	0.9	0.4	0.63	0.39
42	KAM	52	Female	2.0	1.5	1.73	0.32	0.4	-0.2	0.13	0.39	0.5	-0.6	-0.07	0.74	0.5	0.0	0.25	0.35
43	CGC	48	Female	1.3	0.7	0.98	0.46	-0.9	-1.9	-1.35	0.71	1.6	1.1	1.33	0.39	3.9	3.1	3.50	0.57
45	TDC	48	Female	2.9	3.9	3.38	0.67	3.1	3.9	3.50	0.57	6.3	7.2	6.73	0.60	3.9	4.5	4.20	0.42
48	JLL	47	Female	1.7	2.0	1.85	0.21	3.8	4.7	4.20	0.64	6.9	6.6	6.73	0.25	3.4	3.8	3.58	0.32
50	DKH	49	Female	9.3	11.1	10.18	1.31	-1.0	0.2	-0.40	0.85	-0.6	-0.9	-0.75	0.21	2.3	0.7	1.48	1.17
52	CJL	53	Female	0.4	1.6	0.98	0.81	0.5	0.5	0.50	0.00	0.9	-1.1	-0.07	1.45	2.7	1.6	2.13	0.74
53	DSB	54	Female	1.4	1.4	1.40	0.00	0.2	-0.4	-0.13	0.46	2.5	2.1	2.30	0.28	1.2	1.1	1.15	0.07
55	SKR	57	Female	-1.0	-0.8	-0.88	0.18	0.9	1.0	0.93	0.11	0.8	1.1	0.93	0.25	2.6	2.2	2.38	0.25
56	DAH	45	Female																
58	CZR	49	Female	3.1	2.3	2.65	0.57	3.4	3.3	3.35	0.07	-2.5	-4.0	-3.23	1.10	-0.5	-2.3	-1.38	1.24
62	KME	45	Female	0.3	1.1	0.68	0.60	-3.0	-2.9	-2.93	0.04	-7.5	-8.1	-7.80	0.42	-2.8	-4.0	-3.35	0.85
63	MRG	51	Female																
68	SAM	53	Female	2.7	3.5	3.08	0.53	-1.3	-0.9	-1.05	0.28	-1.0	-1.0	-0.95	0.00	1.5	1.8	1.63	0.18
69	GHD	55	Female	-0.5	0.1	-0.20	0.42	-0.6	0.5	-0.03	0.74	-2.1	-2.1	-2.10	0.00	-0.8	-0.7	-0.75	0.00
70	CAC	62	Female	6.7	7.5	7.05	0.57	4.8	4.6	4.68	0.11	4.3	2.8	3.53	1.10	1.5	0.4	0.93	0.74
71	JAR	40	Female	2.8	2.7	2.73	0.04	2.2	2.4	2.28	0.18	0.9	0.2	0.55	0.57	-0.4	-0.8	-0.57	0.32
72	NRC	56	Female	1.8	-1.3	0.25	2.12	-3.1	-4.4	-3.70	0.92	1.1	-0.6	0.23	1.17	3.1	0.4	1.73	1.87
73	NLW	47	Female	25.0	29.8	27.40	3.39												
	Discontinued				Mean	2.00			Mean	0.79			Mean	0.49			Mean	1.03	
					SD	3.82			SD	2.48			SD	3.37			SD	2.74	
					Median	1.85			Median	0.31			Median	0.54			Median	1.11	
					N	31			N	30			N	30			N	30	

TEWL Values (g/m^2/hr) of the Right Cheek

Subject Number	Subject's Initials	Subject's Age	Gender	Baseline		Mean	SD	Week 2		Mean	SD	Week 4		Mean	SD	Week 8		Mean	SD	Week 12		Mean	SD
				Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2		
4	SKH	46	Female	12.3	12.4	12.35	0.07	20.8	21.3	21.05	0.35	12.5	14.5	13.50	1.41	15.2	15.1	15.15	0.07	9.8	10.8	10.30	0.71
5	LMP	45	Female	18.2	19.7	18.95	1.06	11.6	14.0	12.80	1.70	17.5	18.3	17.90	0.57	12.3	12.2	12.25	0.07	14.1	14.6	14.35	0.35
6	PJW	43	Female																				
10	JCL	41	Female	17.6	16.7	17.15	0.64	8.8	9.7	9.25	0.64	14.0	16.5	15.25	1.77	11.7	11.9	11.80	0.14	11.9	10.5	11.20	0.99
11	TLM	50	Female	10.9	11.3	11.10	0.28	12.9	12.6	12.75	0.21	13.0	15.8	14.40	1.98	14.3	14.2	14.25	0.07	14.5	15.2	14.85	0.49
13	DKS	38	Female	9.4	9.1	9.25	0.21	13.3	13.5	13.40	0.14	13.4	14.1	13.75	0.49	10.1	9.7	9.90	0.28	13.3	14.6	13.95	0.92
14	LKB	56	Female	9.8	10.1	9.95	0.21	8.5	9.0	8.75	0.35	9.5	11.1	10.30	1.13	10.9	11.7	11.30	0.57	12.3	12.5	12.40	0.14
15	NHK	56	Female	7.8	7.2	7.50	0.42	18.1	17.8	17.95	0.21												
16	VLH	57	Female	9.3	8.9	9.10	0.28	10.5	10.0	10.25	0.35	9.0	9.3	9.15	0.21	7.6	6.6	7.10	0.71	8.3	8.3	8.30	0.00
22	JKP	48	Female																				
23	RMS	51	Female	9.2	10.0	9.60	0.57	5.0	6.6	5.80	1.13	7.9	9.1	8.50	0.85	8.8	9.7	9.25	0.64	8.7	9.7	9.20	0.71
25	TJJ	40	Female	16.8	17.0	16.90	0.14	19.5	21.4	20.45	1.34	15.0	15.6	15.30	0.42	14.5	14.6	14.55	0.07	14.0	15.6	14.80	1.13
29	DSE	59	Female	5.7	6.1	5.90	0.28	6.2	7.5	6.85	0.92	7.6	7.3	7.45	0.21	13.6	13.6	13.60	0.00	5.5	7.1	6.30	1.13
30	MMC	64	Female	6.0	6.1	6.05	0.07	10.4	11.0	10.70	0.42	9.0	11.3	10.15	1.63	10.8	10.2	10.50	0.42	10.6	12.8	11.70	1.56
33	J-G	47	Female																				
34	LLL	31	Female																				
35	DLM	52	Female	6.5	7.4	6.95	0.64	10.2	11.8	11.00	1.13	10.5	10.9	10.70	0.28	10.4	10.5	10.45	0.07	13.3	12.7	13.00	0.42
36	MAE	51	Female	8.2	9.2	8.70	0.71	12.3	12.8	12.55	0.35	14.2	15.3	14.75	0.78	9.2	9.6	9.40	0.28	9.4	9.7	9.55	0.21
37	GLJ	54	Female	11.9	10.3	11.10	1.13	12.8	13.6	13.20	0.57	10.6	10.9	10.75	0.21	10.0	10.2	10.10	0.14	9.0	8.7	8.85	0.21
38	KAS	42	Female																				
41	E-N	61	Female	8.7	8.8	8.75	0.07	10.6	10.1	10.35	0.35	8.1	8.7	8.40	0.42	7.6	8.8	8.20	0.85	8.5	8.0	8.25	0.35
42	KAM	52	Female	7.5	9.5	8.50	1.41	9.6	10.8	10.20	0.85	8.6	9.0	8.80	0.28	7.9	8.4	8.15	0.35	6.8	8.0	7.40	0.85
43	CGC	48	Female	6.7	8.3	7.50	1.13	10.1	10.7	10.40	0.42	8.5	9.0	8.75	0.35	12.3	12.9	12.60	0.42	12.7	12.3	12.50	0.28
45	TDC	48	Female	6.1	6.3	6.20	0.14	9.5	10.0	9.75	0.35	9.3	9.6	9.45	0.21	9.9	10.0	9.95	0.07	10.6	11.5	11.05	0.64
48	JLL	47	Female	6.9	6.5	6.70	0.28	8.3	8.7	8.50	0.28	10.2	11.1	10.65	0.64	13.5	11.6	12.55	1.34	9.8	10.2	10.00	0.28
50	DKH	49	Female	10.8	10.6	10.70	0.14	21.9	23.1	22.50	0.85	9.1	11.2	10.15	1.48	9.4	9.3	9.35	0.07	12.8	11.7	12.25	0.78
52	CJL	53	Female	7.4	8.2	7.80	0.57	6.1	7.9	7.00	1.27	7.8	8.5	8.15	0.49	9.1	7.2	8.15	1.34	9.7	9.3	9.50	0.28
53	DSB	54	Female	4.3	5.2	4.75	0.64	7.8	8.1	7.95	0.21	6.6	6.5	6.55	0.07	8.0	8.3	8.15	0.21	6.2	5.9	6.05	0.21
55	SKR	57	Female	4.6	4.6	4.60	0.00	4.3	4.3	4.30	0.00	5.5	5.1	5.30	0.28	5.9	6.2	6.05	0.21	5.7	5.5	5.60	0.14
56	DAH	45	Female																				
58	CZR	49	Female	18.3	20.6	19.45	1.63	20.2	21.1	20.65	0.64	25.0	27.0	26.00	1.41	19.0	17.7	18.35	0.92	18.1	17.8	17.95	0.21
62	KME	45	Female	14.0	15.3	14.65	0.92	16.1	19.3	17.70	2.26	12.1	13.0	12.55	0.64	6.4	6.4	6.40	0.00	9.7	9.4	9.55	0.21
63	MRG	51	Female	10.0	10.6	10.30	0.42																
68	SAM	53	Female	6.1	7.1	6.60	0.71	12.0	12.6	12.30	0.42	7.1	8.0	7.55	0.64	7.4	8.7	8.05	0.92	9.5	9.5	9.50	0.00
69	GHD	55	Female	12.9	12.6	12.75	0.21	12.5	13.7	13.10	0.85	13.5	13.7	13.60	0.14	10.7	11.9	11.30	0.85	12.7	12.9	12.80	0.14
70	CAC	62	Female	6.6	7.9	7.25	0.92	15.2	17.3	16.25	1.48	11.2	11.5	11.35	0.21	10.4	10.9	10.65	0.35	7.4	6.9	7.15	0.35
71	JAR	40	Female	11.8	12.0	11.90	0.14	14.8	15.1	14.95	0.21	15.8	16.6	16.20	0.57	14.0	14.0	14.00	0.00	11.2	10.8	11.00	0.28
72	NRC	56	Female	24.2	24.7	24.45	0.35	30.3	27.3	28.80	2.12	24.4	26.7	25.55	1.63	25.4	26.4	25.90	0.71	30.2	30.3	30.25	0.07
73	NLW	47	Female	17.4	15.9	16.65	1.06	35.5	38.0	36.75	1.77												
	Discontinued				Mean	10.42			Mean	12.95			Mean	12.03			Mean	11.25			Mean	11.32	
					SD	4.76			SD	5.50			SD	4.85			SD	3.95			SD	4.61	
					Median	9.10			Median	12.30			Median	10.68			Median	10.48			Median	10.65	
					N	31			N	31			N	30			N	30			N	30	

Intra-Subject Change in TEWL Values ($g/m^2/hr$) of the Right Cheek

Subject Number	Subject's Initials	Subject's Age	Gender	Week 2 vs. Baseline		Mean	SD	Week 4 vs. Baseline		Mean	SD	Week 8 vs. Baseline		Mean	SD	Week 12 vs. Baseline		Mean	SD
				Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2		
4	SKH	46	Female	8.5	8.9	8.70	0.28	0.2	2.1	1.15	1.34	2.9	2.7	2.80	0.14	-2.5	-1.6	-2.05	0.64
5	LMP	45	Female	-6.6	-5.7	-6.15	0.64	-0.7	-1.4	-1.05	0.49	-5.9	-7.5	-6.70	1.13	-4.1	-5.1	-4.60	0.71
6	PJW	43	Female																
10	JCL	41	Female	-8.8	-7.0	-7.90	1.27	-3.6	-0.2	-1.90	2.40	-5.9	-4.8	-5.35	0.78	-5.7	-6.2	-5.95	0.35
11	TLM	50	Female	2.0	1.3	1.65	0.49	2.1	4.5	3.30	1.70	3.4	2.9	3.15	0.35	3.6	3.9	3.75	0.21
13	DKS	38	Female	3.9	4.4	4.15	0.35	4.0	5.0	4.50	0.71	0.7	0.6	0.65	0.07	3.9	5.5	4.70	1.13
14	LKB	56	Female	-1.3	-1.1	-1.20	0.14	-0.3	1.0	0.35	0.92	1.1	1.6	1.35	0.35	2.5	2.4	2.45	0.07
15	NHK	56	Female	10.3	10.6	10.45	0.21												
16	VLH	57	Female	1.2	1.1	1.15	0.07	-0.3	0.4	0.05	0.49	-1.7	-2.3	-2.00	0.42	-1.0	-0.6	-0.80	0.28
22	JKP	48	Female																
23	RMS	51	Female	-4.2	-3.4	-3.80	0.57	-1.3	-0.9	-1.10	0.28	-0.4	-0.3	-0.35	0.07	-0.5	-0.3	-0.40	0.14
25	TJJ	40	Female	2.7	4.4	3.55	1.20	-1.8	-1.4	-1.60	0.28	-2.3	-2.4	-2.35	0.07	-2.8	-1.4	-2.10	0.99
29	DSE	59	Female	0.5	1.4	0.95	0.64	1.9	1.2	1.55	0.49	7.9	7.5	7.70	0.28	-0.2	1.0	0.40	0.85
30	MMC	64	Female	4.4	4.9	4.65	0.35	3.0	5.2	4.10	1.56	4.8	4.1	4.45	0.49	4.6	6.7	5.65	1.48
33	J-G	47	Female																
34	LLL	31	Female																
35	DLM	52	Female	3.7	4.4	4.05	0.49	4.0	3.5	3.75	0.35	3.9	3.1	3.50	0.57	6.8	5.3	6.05	1.06
36	MAE	51	Female	4.1	3.6	3.85	0.35	6.0	6.1	6.05	0.07	1.0	0.4	0.70	0.42	1.2	0.5	0.85	0.49
37	GLJ	54	Female	0.9	3.3	2.10	1.70	-1.3	0.6	-0.35	1.34	-1.9	-0.1	-1.00	1.27	-2.9	-1.6	-2.25	0.92
38	KAS	42	Female																
41	E-N	61	Female	1.9	1.3	1.60	0.42	-0.6	-0.1	-0.35	0.35	-1.1	0.0	-0.55	0.78	-0.2	-0.8	-0.50	0.42
42	KAM	52	Female	2.1	1.3	1.70	0.57	1.1	-0.5	0.30	1.13	0.4	-1.1	-0.35	1.06	-0.7	-1.5	-1.10	0.57
43	CGC	48	Female	3.4	2.4	2.90	0.71	1.8	0.7	1.25	0.78	5.6	4.6	5.10	0.71	6.0	4.0	5.00	1.41
45	TDC	48	Female	3.4	3.7	3.55	0.21	3.2	3.3	3.25	0.07	3.8	3.7	3.75	0.07	4.5	5.2	4.85	0.49
48	JLL	47	Female	1.4	2.2	1.80	0.57	3.3	4.6	3.95	0.92	6.6	5.1	5.85	1.06	2.9	3.7	3.30	0.57
50	DKH	49	Female	11.1	12.5	11.80	0.99	-1.7	0.6	-0.55	1.63	-1.4	-1.3	-1.35	0.07	2.0	1.1	1.55	0.64
52	CJL	53	Female	-1.3	-0.3	-0.80	0.71	0.4	0.3	0.35	0.07	1.7	-1.0	0.35	1.91	2.3	1.1	1.70	0.85
53	DSB	54	Female	3.5	2.9	3.20	0.42	2.3	1.3	1.80	0.71	3.7	3.1	3.40	0.42	1.9	0.7	1.30	0.85
55	SKR	57	Female	-0.3	-0.3	-0.30	0.00	0.9	0.5	0.70	0.28	1.3	1.6	1.45	0.21	1.1	0.9	1.00	0.14
56	DAH	45	Female																
58	CZR	49	Female	1.9	0.5	1.20	0.99	6.7	6.4	6.55	0.21	0.7	-2.9	-1.10	2.55	-0.2	-2.8	-1.50	1.84
62	KME	45	Female	2.1	4.0	3.05	1.34	-1.9	-2.3	-2.10	0.28	-7.6	-8.9	-8.25	0.92	-4.3	-5.9	-5.10	1.13
63	MRG	51	Female																
68	SAM	53	Female	5.9	5.5	5.70	0.28	1.0	0.9	0.95	0.07	1.3	1.6	1.45	0.21	3.4	2.4	2.90	0.71
69	GHD	55	Female	-0.4	1.1	0.35	1.06	0.6	1.1	0.85	0.35	-2.2	-0.7	-1.45	1.06	-0.2	0.3	0.05	0.35
70	CAC	62	Female	8.6	9.4	9.00	0.57	4.6	3.6	4.10	0.71	3.8	3.0	3.40	0.57	0.8	-1.0	-0.10	1.27
71	JAR	40	Female	3.0	3.1	3.05	0.07	4.0	4.6	4.30	0.42	2.2	2.0	2.10	0.14	-0.6	-1.2	-0.90	0.42
72	NRC	56	Female	6.1	2.6	4.35	2.47	0.2	2.0	1.10	1.27	1.2	1.7	1.45	0.35	6.0	5.6	5.80	0.28
73	NLW	47	Female	18.1	22.1	20.10	2.83												
	Discontinued				Mean	2.53			Mean	1.51			Mean	0.73			Mean	0.80	
					SD	4.19			SD	2.35			SD	3.53			SD	3.23	
					Median	2.90			Median	1.03			Median	1.03			Median	0.63	
					N	31			N	30			N	30			N	30	

Data Listing 3
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

TEWL Values (g/m^2/hr) of the Left Cheek

Subject Number	Subject's Initials	Subject's Age	Gender	Baseline		Mean	SD	Week 2		Mean	SD	Week 4		Mean	SD	Week 8		Mean	SD	Week 12		Mean	SD
				Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2		
4	SKH	46	Female	10.6	10.6	10.60	0.00	21.0	23.3	22.15	1.63	14.5	16.6	15.55	1.48	12.6	12.8	12.70	0.14	9.5	10.1	9.80	0.42
5	LMP	45	Female	15.7	15.5	15.60	0.14	9.7	10.3	10.00	0.42	12.6	14.0	13.30	0.99	10.7	11.3	11.00	0.42	16.1	17.0	16.55	0.64
6	PJW	43	Female																				
10	JCL	41	Female	16.4	16.1	16.25	0.21	9.6	10.5	10.05	0.64	12.5	12.6	12.55	0.07	12.2	14.9	13.55	1.91	9.9	11.3	10.60	0.99
11	TLM	50	Female	9.4	9.3	9.35	0.07	16.8	15.8	16.30	0.71	13.1	14.3	13.70	0.85	16.1	16.4	16.25	0.21	16.8	16.3	16.55	0.35
13	DKS	38	Female	9.9	10.5	10.20	0.42	13.9	13.9	13.90	0.00	10.3	10.6	10.45	0.21	9.5	10.4	9.95	0.64	16.3	14.5	15.40	1.27
14	LKB	56	Female	7.3	7.5	7.40	0.14	7.9	8.5	8.20	0.42	8.6	9.9	9.25	0.92	8.4	9.6	9.00	0.85	11.1	11.6	11.35	0.35
15	NHK	56	Female	7.3	8.1	7.70	0.57	16.1	15.1	15.60	0.71												
16	VLH	57	Female	12.6	13.3	12.95	0.49	10.7	11.0	10.85	0.21	10.2	10.3	10.25	0.07	10.7	9.9	10.30	0.57	9.3	8.9	9.10	0.28
22	JKP	48	Female																				
23	RMS	51	Female	6.8	8.3	7.55	1.06	5.8	6.1	5.95	0.21	8.0	9.0	8.50	0.71	9.9	8.6	9.25	0.92	10.1	10.1	10.10	0.00
25	TJJ	40	Female	18.2	20.4	19.30	1.56	14.3	16.0	15.15	1.20	15.0	16.0	15.50	0.71	14.2	15.7	14.95	1.06	16.7	17.2	16.95	0.35
29	DSE	59	Female	6.9	7.0	6.95	0.07	6.9	6.4	6.65	0.35	8.5	9.5	9.00	0.71	11.1	10.1	10.60	0.71	8.3	8.1	8.20	0.14
30	MMC	64	Female	6.9	7.8	7.35	0.64	10.0	10.7	10.35	0.49	10.5	11.2	10.85	0.49	8.6	8.0	8.30	0.42	11.7	10.5	11.10	0.85
33	J-G	47	Female																				
34	LLL	31	Female																				
35	DLM	52	Female	8.6	9.8	9.20	0.85	8.8	9.6	9.20	0.57	9.9	10.6	10.25	0.49	11.4	10.7	11.05	0.49	13.9	13.1	13.50	0.57
36	MAE	51	Female	6.7	7.6	7.15	0.64	11.5	12.6	12.05	0.78	11.0	12.3	11.65	0.92	9.9	10.5	10.20	0.42	10.6	11.9	11.25	0.92
37	GLJ	54	Female	10.5	11.2	10.85	0.49	13.3	15.1	14.20	1.27	10.1	10.2	10.15	0.07	12.1	9.8	10.95	1.63	11.7	10.7	11.20	0.71
38	KAS	42	Female																				
41	E-N	61	Female	8.6	8.1	8.35	0.35	10.2	11.1	10.65	0.64	7.4	7.3	7.35	0.07	10.2	9.7	9.95	0.35	10.6	9.6	10.10	0.71
42	KAM	52	Female	8.3	9.0	8.65	0.49	10.1	10.7	10.40	0.42	8.0	9.2	8.60	0.85	8.8	8.9	8.85	0.07	10.0	10.5	10.25	0.35
43	CGC	48	Female	12.8	13.1	12.95	0.21	12.0	12.0	12.00	0.00	9.3	8.7	9.00	0.42	10.4	10.6	10.50	0.14	14.6	15.3	14.95	0.49
45	TDC	48	Female	6.1	5.8	5.95	0.21	8.5	9.8	9.15	0.92	9.1	10.3	9.70	0.85	14.9	16.4	15.66	1.07	9.4	9.6	9.50	0.14
48	JLL	47	Female	6.0	6.1	6.05	0.07	8.0	7.9	7.95	0.07	10.2	10.8	10.50	0.42	13.2	14.1	13.65	0.64	9.8	10.0	9.90	0.14
50	DKH	49	Female	10.6	10.8	10.70	0.14	18.0	20.5	19.25	1.77	10.3	10.6	10.45	0.21	10.8	10.3	10.55	0.35	13.2	11.0	12.10	1.56
52	CJL	53	Female	8.0	8.6	8.30	0.42	10.1	12.0	11.05	1.34	8.6	9.3	8.95	0.49	8.2	7.4	7.80	0.57	11.0	10.7	10.85	0.21
53	DSB	54	Female	9.7	10.2	9.95	0.35	9.0	10.1	9.55	0.78	7.8	8.0	7.90	0.14	11.0	11.3	11.15	0.21	10.2	11.7	10.95	1.06
55	SKR	57	Female	5.8	5.0	5.40	0.57	4.1	3.8	3.95	0.21	6.6	6.5	6.55	0.07	6.0	5.6	5.80	0.28	9.8	8.5	9.15	0.92
56	DAH	45	Female																				
58	CZR	49	Female	19.4	20.4	19.90	0.71	23.6	24.4	24.00	0.57	19.5	20.6	20.05	0.78	13.8	15.3	14.55	1.06	18.6	18.7	18.65	0.07
62	KME	45	Female	15.1	15.2	15.15	0.07	13.5	13.4	13.45	0.07	11.1	11.7	11.40	0.42	7.7	7.9	7.80	0.14	13.9	13.2	13.55	0.49
63	MRG	51	Female	10.9	11.3	11.10	0.28																
68	SAM	53	Female	9.8	8.7	9.25	0.78	9.3	10.1	9.70	0.57	6.3	6.1	6.20	0.14	6.6	5.2	5.90	0.99	9.4	9.8	9.60	0.28
69	GHD	55	Female	13.3	14.6	13.95	0.92	12.7	13.7	13.20	0.71	11.6	14.5	13.05	2.05	11.3	11.1	11.20	0.14	12.0	12.8	12.40	0.57
70	CAC	62	Female	6.6	6.8	6.70	0.14	11.3	12.3	11.80	0.71	11.5	12.4	11.95	0.64	11.4	9.3	10.35	1.48	8.7	8.6	8.65	0.07
71	JAR	40	Female	11.0	11.9	11.45	0.64	13.5	14.2	13.85	0.49	11.3	12.1	11.70	0.57	10.7	10.2	10.45	0.35	10.9	11.5	11.20	0.42
72	NRC	56	Female	27.1	32.2	29.65	3.61	24.5	27.1	25.80	1.84	20.8	21.5	21.15	0.49	28.0	29.3	28.65	0.92	27.2	27.4	27.30	0.14
73	NLW	47	Female	21.6	24.0	22.80	1.70	53.5	61.5	57.50	5.66												
	Discontinued				Mean	10.99			Mean	12.46			Mean	11.18			Mean	11.36			Mean	12.36	
					SD	5.13			SD	4.98			SD	3.44			SD	4.15			SD	3.92	
					Median	9.35			Median	11.05			Median	10.45			Median	10.53			Median	11.15	
					N	31			N	31			N	30			N	30			N	30	

Data Listing 3
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Intra-Subject Change in TEWL Values (g/m ^{2}/hr) of the Left Cheek

Subject Number	Subject's Initials	Subject's Age	Gender	Week 2 vs. Baseline		Mean	SD	Week 4 vs. Baseline		Mean	SD	Week 8 vs. Baseline		Mean	SD	Week 12 vs. Baseline		Mean	SD
				Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2		
4	SKH	46	Female	10.4	12.7	11.55	1.63	3.9	6.0	4.95	1.48	2.0	2.2	2.10	0.14	-1.1	-0.5	-0.80	0.42
5	LMP	45	Female	-6.0	-5.2	-5.60	0.57	-3.1	-1.5	-2.30	1.13	-5.0	-4.2	-4.60	0.57	0.4	1.5	0.95	0.78
6	PJW	43	Female																
10	JCL	41	Female	-6.8	-5.6	-6.20	0.85	-3.9	-3.5	-3.70	0.28	-4.2	-1.2	-2.70	2.12	-6.5	-4.8	-5.65	1.20
11	TLM	50	Female	7.4	6.5	6.95	0.64	3.7	5.0	4.35	0.92	6.7	7.1	6.90	0.28	7.4	7.0	7.20	0.28
13	DKS	38	Female	4.0	3.4	3.70	0.42	0.4	0.1	0.25	0.21	-0.4	-0.1	-0.25	0.21	6.4	4.0	5.20	1.70
14	LKB	56	Female	0.6	1.0	0.80	0.28	1.3	2.4	1.85	0.78	1.1	2.1	1.60	0.71	3.8	4.1	3.95	0.21
15	NHK	56	Female	8.8	7.0	7.90	1.27												
16	VLH	57	Female	-1.9	-2.3	-2.10	0.28	-2.4	-3.0	-2.70	0.42	-1.9	-3.4	-2.65	1.06	-3.3	-4.4	-3.85	0.78
22	JKP	48	Female																
23	RMS	51	Female	-1.0	-2.2	-1.60	0.85	1.2	0.7	0.95	0.35	3.1	0.3	1.70	1.98	3.3	1.8	2.55	1.06
25	TJJ	40	Female	-3.9	-4.4	-4.15	0.35	-3.2	-4.4	-3.80	0.85	-4.0	-4.7	-4.35	0.49	-1.5	-3.2	-2.35	1.20
29	DSE	59	Female	0.0	-0.6	-0.30	0.42	1.6	2.5	2.05	0.64	4.2	3.1	3.65	0.78	1.4	1.1	1.25	0.21
30	MMC	64	Female	3.1	2.9	3.00	0.14	3.6	3.4	3.50	0.14	1.7	0.2	0.95	1.06	4.8	2.7	3.75	1.48
33	J-G	47	Female																
34	LLL	31	Female																
35	DLM	52	Female	0.2	-0.2	0.00	0.28	1.3	0.8	1.05	0.35	2.8	0.9	1.85	1.34	5.3	3.3	4.30	1.41
36	MAE	51	Female	4.8	5.0	4.90	0.14	4.3	4.7	4.50	0.28	3.2	2.9	3.05	0.21	3.9	4.3	4.10	0.28
37	GLJ	54	Female	2.8	3.9	3.35	0.78	-0.4	-1.0	-0.70	0.42	1.6	-1.4	0.10	2.12	1.2	-0.5	0.35	1.20
38	KAS	42	Female																
41	E-N	61	Female	1.6	3.0	2.30	0.99	-1.2	-0.8	-1.00	0.28	1.6	1.6	1.60	0.00	2.0	1.5	1.75	0.35
42	KAM	52	Female	1.8	1.7	1.75	0.07	-0.3	0.2	-0.05	0.35	0.5	-0.1	0.20	0.42	1.7	1.5	1.60	0.14
43	CGC	48	Female	-0.8	-1.1	-0.95	0.21	-3.5	-4.4	-3.95	0.64	-2.4	-2.5	-2.45	0.07	1.8	2.2	2.00	0.28
45	TDC	48	Female	2.4	4.0	3.20	1.13	3.0	4.5	3.75	1.06	8.8	10.6	9.71	1.28	3.3	3.8	3.55	0.35
48	JLL	47	Female	2.0	1.8	1.90	0.14	4.2	4.7	4.45	0.35	7.2	8.0	7.60	0.57	3.8	3.9	3.85	0.07
50	DKH	49	Female	7.4	9.7	8.55	1.63	-0.3	-0.2	-0.25	0.07	0.2	-0.5	-0.15	0.49	2.6	0.2	1.40	1.70
52	CJL	53	Female	2.1	3.4	2.75	0.92	0.6	0.7	0.65	0.07	0.2	-1.2	-0.50	0.99	3.0	2.1	2.55	0.64
53	DSB	54	Female	-0.7	-0.1	-0.40	0.42	-1.9	-2.2	-2.05	0.21	1.3	1.1	1.20	0.14	0.5	1.5	1.00	0.71
55	SKR	57	Female	-1.7	-1.2	-1.45	0.35	0.8	1.5	1.15	0.49	0.2	0.6	0.40	0.28	4.0	3.5	3.75	0.35
56	DAH	45	Female																
58	CZR	49	Female	4.2	4.0	4.10	0.14	0.1	0.2	0.15	0.07	-5.6	-5.1	-5.35	0.35	-0.8	-1.7	-1.25	0.64
62	KME	45	Female	-1.6	-1.8	-1.70	0.14	-4.0	-3.5	-3.75	0.35	-7.4	-7.3	-7.35	0.07	-1.2	-2.0	-1.60	0.57
63	MRG	51	Female																
68	SAM	53	Female	-0.5	1.4	0.45	1.34	-3.5	-2.6	-3.05	0.64	-3.2	-3.5	-3.35	0.21	-0.4	1.1	0.35	1.06
69	GHD	55	Female	-0.6	-0.9	-0.75	0.21	-1.7	-0.1	-0.90	1.13	-2.0	-3.5	-2.75	1.06	-1.3	-1.8	-1.55	0.35
70	CAC	62	Female	4.7	5.5	5.10	0.57	4.9	5.6	5.25	0.49	4.8	2.5	3.65	1.63	2.1	1.8	1.95	0.21
71	JAR	40	Female	2.5	2.3	2.40	0.14	0.3	0.2	0.25	0.07	-0.3	-1.7	-1.00	0.99	-0.1	-0.4	-0.25	0.21
72	NRC	56	Female	-2.6	-5.1	-3.85	1.77	-6.3	-10.7	-8.50	3.11	0.9	-2.9	-1.00	2.69	0.1	-4.8	-2.35	3.46
73	NLW	47	Female	31.9	37.5	34.70	3.96												
	Discontinued				Mean	1.47			Mean	0.08			Mean	0.26			Mean	1.26	
					SD	4.09			SD	3.25			SD	3.79			SD	2.85	
					Median	1.75			Median	0.20			Median	0.15			Median	1.50	
					N	31			N	30			N	30			N	30	

				Baseline					Week 2					Week 4					Week 8					Week 12				
Subject No.	Subject Initials	Age	Gender	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
4	SKH	46	Female	130	137	132	133.00	3.61	130	134	135	133.00	2.65	124	126	136	129.33	7.57	138	148	145	143.67	5.13	94	95	96	95.00	1.00
5	LMP	45	Female	115	113	110	112.67	2.52	103	100	100	101.00	1.73	100	106	112	106.00	6.00	148	148	155	150.33	4.04	120	120	124	121.33	2.31
6	PJW	43	Female	0	0	0			0	0	0																	
10	JCL	41	Female	93	92	94	93.00	1.00	104	104	107	105.00	1.73	110	106	112	109.33	3.06	92	92	92	92.00	0.00	100	97	96	97.67	2.08
11	TLM	50	Female	121	130	126	125.67	4.51	103	108	111	107.33	4.04	107	113	115	111.67	4.16	97	100	99	97.67	2.08	109	106	111	108.67	2.52
13	DKS	38	Female	155	152	159	155.33	3.51	109	106	110	108.33	2.08	129	136	132	132.33	3.51	133	132	136	133.67	2.08	127	133	134	131.33	3.79
14	LKB	56	Female	124	128	127	126.33	2.08	101	97	96	98.00	2.65	113	105	103	107.00	5.29	124	118	110	117.33	7.02	118	120	119	119.00	1.00
15	NHK	56	Female	106	113	112	110.33	3.79	102	96	105	101.00	4.58															
16	VLH	57	Female	103	104	107	104.67	2.08	123	126	129	126.00	3.00	131	135	136	134.00	2.65	185	192	181	186.00	5.57	195	194	189	192.67	3.21
22	JKR	48	Female	0	0	0			0	0	0																	
23	RMS	51	Female	150	152	159	153.67	4.73	138	138	141	139.00	1.73	133	138	138	136.33	2.89	185	189	195	189.67	5.03	122	116	125	121.00	4.58
25	TJJ	40	Female	101	100	100	100.33	0.58	112	112	110	111.33	1.15	106	114	106	108.67	4.62	106	111	107	108.00	2.65	121	119	110	116.67	5.86
29	DSE	59	Female	142	142	144	142.67	1.15	115	118	111	114.67	3.51	143	140	151	144.67	5.69	146	152	148	148.67	3.06	116	121	118	118.33	2.52
30	MMC	64	Female	102	103	104	103.00	1.00	119	122	121	120.67	1.53	109	109	112	110.00	1.73	144	148	148	146.67	2.31	118	111	114	114.33	3.51
33	JLG	47	Female	0	0	0			0	0	0																	
34	LLL	31	Female	0	0	0			0	0	0																	
35	DLM	52	Female	110	100	109	106.33	5.51	149	140	147	145.33	4.73	163	165	165	164.33	1.15	158	148	150	152.00	5.29	126	122	122	123.33	2.31
36	MAE	51	Female	122	117	117	118.67	2.89	136	140	133	136.33	3.51	103	105	104	104.00	1.00	128	133	130	130.33	2.52	140	140	144	141.33	2.31
37	GLJ	54	Female	113	122	116	117.00	4.58	132	138	140	136.67	4.16	154	152	151	152.33	1.53	114	129	128	123.67	8.39	106	108	106	106.67	1.15
38	KAS	42	Female	0	0	0			0	0	0																	
41	E-N	61	Female	136	141	138	138.33	2.52	136	134	142	137.33	4.16	133	129	127	129.67	3.06	158	163	160	160.33	2.52	136	136	134	135.33	1.15
42	KAM	52	Female	105	100	95	100.00	5.00	104	96	100	100.00	4.00	92	95	102	96.33	5.13	96	94	94	94.67	1.15	105	106	104	105.00	1.00
43	COC	48	Female	110	110	108	109.33	1.15	102	109	109	106.67	4.04	118	125	125	122.67	4.04	148	150	149	149.00	1.00	114	116	113	114.33	1.53
45	TDC	48	Female	90	92	94	92.00	2.00	96	96	94	95.33	1.15	96	98	102	98.67	3.06	96	94	96	95.33	1.15	100	99	104	101.00	2.65
48	JLL	47	Female	96	98	94	96.00	2.00	96	96	106	99.33	5.77	99	100	104	101.00	2.65	103	106	104	104.33	1.53	108	109	113	110.00	2.65
50	DKH	49	Female	142	140	141	141.00	1.00	168	170	171	169.67	1.53	129	132	129	130.00	1.73	182	184	176	180.67	4.16	136	148	144	142.67	6.11
52	CJL	53	Female	148	150	150	149.33	1.15	205	203	208	205.33	2.52	231	230	227	229.33	2.08	208	208	219	211.67	6.35	165	170	170	168.33	2.89
53	DSB	54	Female	200	198	199	199.00	1.00	98	100	97	98.33	1.53	139	134	129	134.00	5.00	140	145	144	143.00	2.65	130	127	130	129.00	1.73
55	SKR	57	Female	125	128	129	127.33	2.08	139	140	145	141.33	3.21	109	112	112	111.00	1.73	132	130	138	133.33	4.16	132	137	140	136.33	4.04
56	DAH	45	Female	0	0	0			0	0	0																	
58	CZR	49	Female	97	96	100	97.67	2.08	93	97	94	94.67	2.08	90	94	95	93.00	2.65	110	104	110	108.00	3.46	99	98	100	99.00	1.00
62	KME	45	Female	136	142	140	139.33	3.06	168	172	164	168.00	4.00	130	138	136	134.67	4.16	262	264	258	261.33	3.06	130	135	137	134.00	3.61
63	MRG	51	Female	112	115	123	116.67	5.69	0	0	0																	
68	SAM	53	Female	104	101	104	103.00	1.73	123	127	124	124.67	2.08	107	115	110	110.67	4.04	120	122	126	122.67	3.06	96	96	99	97.00	1.73
69	GHD	55	Female	131	140	138	136.33	4.73	138	142	139	139.67	2.08	125	130	129	128.00	2.65	146	142	152	146.67	5.03	146	143	144	144.33	1.53
70	CAC	62	Female	112	113	115	113.33	1.53	106	98	102	102.00	4.00	98	96	108	100.67	6.43	94	98	99	97.00	2.65	112	110	116	112.67	3.06
71	JAR	40	Female	116	111	109	111.67	3.06	94	97	96	95.67	1.53	100	97	102	99.67	2.52	104	109	102	105.00	3.61	120	118	116	118.00	2.00
72	NRC	56	Female	110	127	129	122.00	10.44	101	108	96	101.67	6.03	95	92	91	92.67	2.08	96	92	92	93.33	2.31	105	104	106	105.00	1.00
73	NLW	47	Female	173	180	188	180.33	7.51	123	131	129	127.67	4.16															
	Discontinued					Mean	121.88				Mean	121.40				Mean	122.07				Mean	137.53			Mean	121.98	
						SD	23.36				SD	26.28				SD	27.33				SD	39.31			SD	21.52	
						Median	117.00				Median	111.33				Median	111.33				Median	133.50			Median	118.17	
						N	31				N	31				N	30				N	30			N	30	

Intra-Subject Change in DPM Values of Both Cheeks (Average of Right and Left)

Subject No.	Subject Initials	Age	Gender	Week 2 vs. Baseline					Week 4 vs. Baseline					Week 8 vs. Baseline					Week 12 vs. Baseline				
				Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
4	SKH	46	Female	0	-3	3	0.00	3.00	-6	-11	6	-3.67	8.74	8	11	13	10.67	2.52	-36	-42	-36	-38.00	3.46
5	LMP	45	Female	-12	-13	-10	-11.67	1.53	-15	-7	2	-6.67	8.50	33	35	45	37.67	6.43	5	7	14	8.67	4.73
6	PJW	43	Female																0	0	0		
10	JCL	41	Female	11	12	13	12.00	1.00	17	14	18	16.33	2.08	-1	0	-2	-1.00	1.00	7	5	2	4.67	2.52
11	TLM	50	Female	-18	-22	-15	-18.33	3.51	-14	-17	-11	-14.00	3.00	-24	-30	-30	-28.00	3.46	-12	-24	-15	-17.00	6.24
13	DKS	38	Female	-46	-46	-49	-47.00	1.73	-26	-16	-27	-23.00	6.08	-22	-20	-23	-21.67	1.53	-26	-19	-25	-24.00	4.58
14	LKB	56	Female	-23	-31	-31	-28.33	4.62	-11	-23	-24	-19.33	7.23	0	-10	-17	-9.00	8.54	-6	-8	-8	-7.33	1.15
15	NHK	56	Female	-4	-17	-7	-9.33	6.81															
16	VLH	57	Female	20	22	22	21.33	1.15	28	31	29	29.33	1.53	82	88	74	81.33	7.02	92	90	82	88.00	5.29
22	JKP	48	Female																				
23	RMS	51	Female	-12	-14	-18	-14.67	3.06	-17	-14	-21	-17.33	3.51	35	37	36	36.00	1.00	-28	-36	-34	-32.67	4.16
25	TJJ	40	Female	11	12	10	11.00	1.00	5	14	6	8.33	4.93	5	11	7	7.67	3.06	20	19	10	16.33	5.51
29	DSE	59	Female	-27	-24	-33	-28.00	4.58	1	-2	7	2.00	4.58	4	10	4	6.00	3.46	-26	-21	-26	-24.33	2.89
30	MMC	64	Female	17	19	17	17.67	1.15	7	6	8	7.00	1.00	42	45	44	43.67	1.53	16	8	10	11.33	4.16
33	J-G	47	Female																				
34	LLL	31	Female																				
35	DLM	52	Female	39	40	38	39.00	1.00	53	65	56	58.00	6.24	48	48	41	45.67	4.04	16	22	13	17.00	4.58
36	MAE	51	Female	14	23	16	17.67	4.73	-19	-12	-13	-14.67	3.79	6	16	13	11.67	5.13	18	23	27	22.67	4.51
37	GLJ	54	Female	19	16	24	19.67	4.04	41	30	35	35.33	5.51	1	7	12	6.67	5.51	-7	-14	-10	-10.33	3.51
38	KAS	42	Female																				
41	E-N	61	Female	0	-7	4	-1.00	5.57	-3	-12	-11	-8.67	4.93	22	22	22	22.00	0.00	0	-5	-4	-3.00	2.65
42	KAM	52	Female	-1	-4	5	0.00	4.58	-13	-5	7	-3.67	10.07	-9	-6	-1	-5.33	4.04	0	6	9	5.00	4.58
43	CGC	48	Female	-5	-1	1	-2.67	4.73	8	15	17	13.33	4.73	38	40	41	39.67	1.53	4	6	5	5.00	1.00
45	TDC	48	Female	6	4	0	3.33	3.06	6	6	8	6.67	1.15	6	2	2	3.33	2.31	10	7	10	9.00	1.73
48	JLL	47	Female	0	-2	12	3.33	7.57	3	2	10	5.00	4.36	7	8	10	8.33	1.53	12	11	19	14.00	4.36
50	DKH	49	Female	26	30	30	28.67	2.31	-13	-8	-12	-11.00	2.65	40	44	35	39.67	4.51	-6	8	3	1.67	7.09
52	CJL	53	Female	57	53	58	56.00	2.65	83	80	77	80.00	3.00	60	58	69	62.33	5.86	17	20	20	19.00	1.73
53	DSB	54	Female	-102	-98	-102	-100.67	2.31	-61	-64	-70	-65.00	4.58	-60	-53	-55	-56.00	3.61	-70	-71	-69	-70.00	1.00
55	SKR	57	Female	14	12	16	14.00	2.00	-16	-16	-17	-16.33	0.58	7	2	9	6.00	3.61	7	9	11	9.00	2.00
56	DAH	45	Female																				
58	CZR	49	Female	-4	1	-6	-3.00	3.61	-7	-2	-5	-4.67	2.52	13	8	10	10.33	2.52	2	2	0	1.33	1.15
62	KME	45	Female	32	30	24	28.67	4.16	-6	-4	-4	-4.67	1.15	126	122	118	122.00	4.00	-6	-7	-3	-5.33	2.08
63	MRG	51	Female																				
68	SAM	53	Female	19	26	20	21.67	3.79	3	14	6	7.67	5.69	16	21	22	19.67	3.21	-8	-5	-5	-6.00	1.73
69	GHD	55	Female	7	2	1	3.33	3.21	-6	-10	-9	-8.33	2.08	15	2	14	10.33	7.23	15	3	6	8.00	6.24
70	CAC	62	Female	-6	-15	-13	-11.33	4.73	-14	-17	-7	-12.67	5.13	-18	-15	-16	-16.33	1.53	0	-3	1	-0.67	2.08
71	JAR	40	Female	-21	-14	-13	-16.00	4.36	-15	-14	-7	-12.00	4.36	-11	-2	-7	-6.67	4.51	5	7	7	6.33	1.15
72	NRC	56	Female	-9	-19	-33	-20.33	12.06	-15	-35	-38	-29.33	12.50	-14	-35	-37	-28.67	12.74	-5	-23	-23	-17.00	10.39
73	NLW	47	Female																				
Discontinued						Mean	-0.48				Mean	-0.20				Mean	15.27				Mean	-0.29	
						SD	28.43				SD	26.40				SD	34.97				SD	25.80	
						Median	0.00				Median	-4.67				Median	9.33				Median	3.17	
						N	31				N	30				N	30				N	30	

Data Listing 3
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

DPM Values of the Right Cheek

				Baseline					Week 2					Week 4					Week 8					Week 12				
Subject No.	Subject Initials	Age	Gender	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
4	SKH	46	Female	122	136	134	130.67	7.57	140	144	140	141.33	2.31	142	146	158	148.67	8.33	140	148	152	146.67	6.11	96	94	96	95.33	1.15
5	LMP	45	Female	96	92	96	94.67	2.31	92	100	96	96.00	4.00	94	102	110	102.00	8.00	160	152	166	159.33	7.02	120	112	116	116.00	4.00
6	PJW	43	Female																									
10	JCL	41	Female	96	92	96	94.67	2.31	108	100	98	102.00	5.29	110	106	110	108.67	2.31	92	92	92	92.00	0.00	100	102	100	100.67	1.15
11	TLM	50	Female	124	136	126	128.67	6.43	100	104	106	103.33	3.06	104	106	108	106.00	2.00	90	98	98	95.33	4.62	106	104	108	106.00	2.00
13	DKS	38	Female	164	158	146	162.67	6.11	122	108	112	114.00	7.21	126	132	126	128.00	3.46	156	156	164	159.33	4.16	126	134	132	130.67	4.16
14	LKB	56	Female	114	114	110	112.67	2.31	94	96	92	94.00	2.00	108	96	98	100.67	6.43	134	124	124	127.33	5.77	116	116	118	116.67	1.15
15	NHK	56	Female	112	110	108	110.00	2.00	104	96	96	98.67	4.62															
16	VLH	57	Female	112	110	114	112.00	2.00	124	124	132	126.67	4.62	130	138	134	134.00	4.00	196	196	184	192.00	6.93	198	198	196	197.33	1.15
22	JKP	48	Female																									
23	RMS	51	Female	134	136	142	137.33	4.16	134	130	130	131.33	2.31	132	134	142	136.00	5.29	174	162	180	172.00	9.17	122	108	118	116.00	7.21
25	TJJ	40	Female	110	100	100	103.33	5.77	98	102	98	99.33	2.31	108	110	102	106.00	4.00	108	122	114	114.67	7.02	120	114	110	114.67	5.03
29	DSE	59	Female	134	134	142	136.67	4.62	126	132	130	129.33	3.06	152	150	162	154.67	6.43	148	152	140	146.67	6.11	118	120	118	118.67	1.15
30	MMC	64	Female	94	98	98	96.67	2.31	130	132	130	130.67	1.15	108	110	112	110.00	2.00	120	124	124	122.67	2.31	118	100	106	108.00	9.17
33	JG	47	Female																									
34	LLL	31	Female																									
35	DLM	52	Female	110	108	108	108.67	1.15	150	144	154	149.33	5.03	168	172	168	169.33	2.31	148	142	136	142.00	6.00	132	126	122	126.67	5.03
36	MAE	51	Female	120	116	118	118.00	2.00	148	152	140	146.67	6.11	104	108	102	104.67	3.06	132	132	136	133.33	2.31	150	154	154	152.67	2.31
37	GLJ	54	Female	118	126	116	120.67	4.62	140	152	152	148.00	6.93	158	162	160	160.00	2.00	112	126	124	120.67	7.57	106	102	110	106.00	4.00
38	KAB	42	Female																									
41	E-N	61	Female	130	136	140	135.33	5.03	120	128	128	125.33	4.62	134	134	130	132.67	2.31	158	168	154	159.33	6.11	146	142	146	144.67	2.31
42	KAM	52	Female	106	96	98	100.00	5.29	108	98	100	102.00	5.29	90	98	102	96.67	6.11	96	96	96	96.00	0.00	98	98	100	98.67	1.15
43	CSC	48	Female	112	106	104	107.33	4.16	96	106	96	99.33	5.77	118	122	126	122.00	4.00	144	140	140	141.33	2.31	118	114	112	114.67	3.06
45	TDC	48	Female	90	94	94	92.67	2.31	100	96	96	97.33	2.31	98	98	110	102.00	6.93	100	92	92	94.67	4.62	100	104	106	103.33	3.06
48	JLL	47	Female	100	100	92	97.33	4.62	100	100	116	105.33	9.24	98	100	102	100.00	2.00	108	118	108	111.33	5.77	108	112	114	111.33	3.06
50	DKH	49	Female	136	134	128	132.67	4.16	164	176	174	171.33	6.43	130	130	122	127.33	4.62	176	186	180	181.33	4.16	138	148	138	141.33	5.77
52	CJL	53	Female	152	154	162	156.00	5.29	216	208	210	211.33	4.16	234	230	220	228.00	7.21	242	244	254	246.67	6.43	174	180	180	178.00	3.46
53	DSB	54	Female	170	180	172	174.00	5.29	96	96	92	94.67	2.31	134	128	124	128.67	5.03	128	134	124	128.67	5.03	126	128	122	125.33	3.06
55	SKR	57	Female	128	136	136	133.33	4.62	142	140	142	141.33	1.15	108	116	110	111.33	4.16	128	128	132	129.33	2.31	134	132	138	134.67	3.06
56	DAH	45	Female																									
58	CZR	49	Female	92	92	92	92.00	0.00	94	98	96	96.00	2.00	90	84	92	92.00	2.00	104	104	112	106.67	4.62	100	102	104	102.00	2.00
62	KME	45	Female	146	150	146	147.33	2.31	174	182	170	175.33	6.11	126	134	138	132.67	6.11	262	258	240	253.33	11.72	126	130	132	129.33	3.06
63	MRG	51	Female	116	108	118	114.00	5.29																				
68	SAM	53	Female	100	110	108	106.00	5.29	122	126	122	123.33	2.31	114	126	118	119.33	6.11	124	124	128	125.33	2.31	98	98	102	99.33	2.31
69	GHD	55	Female	130	134	138	134.00	4.00	144	148	144	145.33	2.31	132	144	136	137.33	6.11	136	140	144	140.00	4.00	154	144	152	150.00	5.29
70	CAC	62	Female	124	130	134	129.33	5.03	108	104	106	106.00	2.00	102	100	114	105.33	7.57	96	100	104	100.00	4.00	118	110	122	116.67	6.11
71	JAR	40	Female	130	122	126	126.00	4.00	92	90	96	92.67	3.06	94	98	102	98.00	4.00	100	104	100	101.33	2.31	134	130	128	130.67	3.06
72	NRC	56	Female	128	148	154	143.33	13.61	100	104	92	98.67	6.11	100	90	92	94.00	5.29	100	92	92	94.67	4.62	114	114	118	115.33	2.31
73	NLW	47	Female	152	164	160	158.67	6.11	148	162	158	156.00	7.21															
	Discontinued					Mean	121.42				Mean	122.45				Mean	123.20				Mean	137.80				Mean	123.36	
						SD	21.15				SD	28.89				SD	28.61				SD	40.72				SD	23.38	
						Median	120.67				Median	114.00				Median	115.33				Median	129.00				Median	116.33	
						N	31				N	31				N	30				N	30				N	30	

Intra-Subject Change in DPM Values of the Right Cheek

				Week 2 vs. Baseline					Week 4 vs. Baseline					Week 8 vs. Baseline					Week 12 vs. Baseline				
Subject No.	Subject Initials	Age	Gender	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
4	SKH	46	Female	18	8	6	10.67	6.43	20	10	24	18.00	7.21	18	12	18	16.00	3.46	-26	-42	-38	-35.33	8.33
5	LMP	45	Female	-4	8	0	1.33	6.11	-2	10	14	7.33	8.33	64	60	70	64.67	5.03	24	20	20	21.33	2.31
6	PJW	43	Female																				
10	JCL	41	Female	12	8	2	7.33	5.03	14	14	14	14.00	0.00	-4	0	-4	-2.67	2.31	4	10	4	6.00	3.46
11	TLM	50	Female	-24	-32	-20	-25.33	6.11	-20	-30	-18	-22.67	6.43	-34	-38	-28	-33.33	5.03	-18	-32	-18	-22.67	8.08
13	DKS	38	Female	-32	-50	-34	-38.67	9.87	-28	-26	-20	-24.67	4.16	4	-2	18	6.67	10.26	-28	-24	-14	-22.00	7.21
14	LKB	56	Female	-20	-18	-18	-18.67	1.15	-6	-18	-12	-12.00	6.00	20	10	14	14.67	5.03	2	2	8	4.00	3.46
15	NHK	56	Female	-8	-14	-12	-11.33	3.06															
16	VLH	57	Female	12	14	18	14.67	3.06	18	28	20	22.00	5.29	84	86	70	80.00	8.72	86	88	82	85.33	3.06
22	JKP	48	Female																				
23	RMS	51	Female	0	-6	-12	-6.00	6.00	-2	-2	0	-1.33	1.15	40	26	38	34.67	7.57	-12	-28	-24	-21.33	8.33
25	TJJ	40	Female	-12	2	-2	-4.00	7.21	-4	10	2	2.67	7.02	-2	22	14	11.33	12.22	10	14	10	11.33	2.31
29	DSE	59	Female	-8	-2	-12	-7.33	5.03	18	16	20	18.00	2.00	14	18	-2	10.00	10.58	-16	-14	-24	-18.00	5.29
30	MMC	64	Female	36	34	32	34.00	2.00	14	12	14	13.33	1.15	26	26	26	26.00	0.00	24	2	8	11.33	11.37
33	J-G	47	Female																				
34	LLL	31	Female																				
35	DLM	52	Female	40	36	46	40.67	5.03	58	64	60	60.67	3.06	38	34	28	33.33	5.03	22	18	14	18.00	4.00
36	MAE	51	Female	28	36	22	28.67	7.02	-16	-8	-16	-13.33	4.62	12	16	18	15.33	3.06	30	38	36	34.67	4.16
37	GLJ	54	Female	22	26	34	27.33	6.11	40	36	42	39.33	3.06	-6	0	6	0.00	6.00	-12	-24	-8	-14.67	8.33
38	KAS	42	Female																				
41	E-N	61	Female	-10	-8	-12	-10.00	2.00	4	-2	-10	-2.67	7.02	28	30	14	24.00	8.72	16	6	6	9.33	5.77
42	KAM	52	Female	2	2	2	2.00	0.00	-16	2	4	-3.33	11.02	-10	0	-2	-4.00	5.29	-8	2	2	-1.33	5.77
43	CGC	48	Female	-16	0	-8	-8.00	8.00	6	16	22	14.67	8.08	32	34	36	34.00	2.00	6	8	8	7.33	1.15
45	TDC	48	Female	10	2	2	4.67	4.62	8	4	16	9.33	6.11	10	-2	-2	2.00	6.93	10	10	12	10.67	1.15
48	JLL	47	Female	0	0	24	8.00	13.86	-2	0	10	2.67	6.43	8	18	16	14.00	5.29	8	12	22	14.00	7.21
50	DKH	49	Female	28	42	46	38.67	9.45	-6	-4	-6	-5.33	1.15	42	52	52	48.67	5.77	2	14	10	8.67	6.11
52	CJL	53	Female	64	54	48	55.33	8.08	82	76	58	72.00	12.49	90	90	92	90.67	1.15	22	26	18	22.00	4.00
53	DSB	54	Female	-74	-84	-80	-79.33	5.03	-36	-52	-48	-45.33	8.33	-42	-46	-48	-45.33	3.06	-44	-52	-50	-48.67	4.16
55	SKR	57	Female	14	4	6	8.00	5.29	-20	-20	-26	-22.00	3.46	0	-8	-4	-4.00	4.00	6	-4	2	1.33	5.03
56	DAH	45	Female																				
58	CZR	49	Female	2	6	4	4.00	2.00	-2	2	0	0.00	2.00	12	12	20	14.67	4.62	8	10	12	10.00	2.00
62	KME	45	Female	28	32	24	28.00	4.00	-20	-16	-8	-14.67	6.11	116	108	94	106.00	11.14	-20	-20	-14	-18.00	3.46
63	MRG	51	Female																				
68	SAM	53	Female	22	16	14	17.33	4.16	14	16	10	13.33	3.06	24	14	20	19.33	5.03	-2	-12	-6	-6.67	5.03
69	GHD	55	Female	14	14	6	11.33	4.62	2	10	-2	3.33	6.11	6	6	6	6.00	0.00	24	10	14	16.00	7.21
70	CAC	62	Female	-16	-26	-28	-23.33	6.43	-22	-30	-20	-24.00	5.29	-28	-30	-30	-29.33	1.15	-6	-20	-12	-12.67	7.02
71	JAR	40	Female	-38	-32	-30	-33.33	4.16	-36	-24	-24	-28.00	6.93	-30	-18	-26	-24.67	6.11	4	8	2	4.67	3.06
72	NRC	56	Female	-28	-44	-62	-44.67	17.01	-28	-58	-62	-49.33	18.58	-28	-56	-62	-48.67	18.15	-14	-34	-36	-28.00	12.17
73	NLW	47	Female																				
	Discontinued					Mean	1.03				Mean	1.40				Mean	16.00				Mean	1.56	
						SD	27.99				SD	26.56				SD	36.34				SD	24.78	
						Median	4.00				Median	1.33				Median	14.33				Median	5.33	
						N	31				N	30				N	30				N	30	

				Baseline					Week 2					Week 4					Week 8					Week 12				
Subject No.	Subject Initials	Age	Gender	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
4	SKH	46	Female	138	138	130	135.33	4.62	120	124	130	124.67	5.03	106	106	118	110.00	6.93	136	148	138	140.67	6.43	92	96	96	94.67	2.31
5	LMP	45	Female	134	134	124	130.67	5.77	114	100	104	106.00	7.21	106	110	114	110.00	4.00	136	144	144	141.33	4.62	130	128	132	126.67	6.11
6	PJW	43	Female																									
10	JCL	41	Female	90	92	92	91.33	1.15	100	108	116	108.00	8.00	110	106	114	110.00	4.00	92	92	92	92.00	0.00	100	92	92	94.67	4.62
11	TLM	50	Female	118	124	126	122.67	4.16	106	112	116	111.33	5.03	110	120	122	117.33	6.43	104	102	94	100.00	5.29	112	108	114	111.33	3.06
13	DKS	38	Female	156	146	172	158.00	13.11	96	104	108	102.67	6.11	132	140	138	136.67	4.16	106	108	108	108.00	0.00	128	132	136	132.00	4.00
14	LKB	56	Female	134	142	144	140.00	5.29	108	98	100	102.00	5.29	118	114	108	113.33	5.03	114	112	96	107.33	9.87	120	124	120	121.33	2.31
15	NHK	56	Female	100	116	116	110.67	9.24	100	96	114	103.33	9.45															
16	VLH	57	Female	94	98	100	97.33	3.06	122	128	126	125.33	3.06	132	132	138	134.00	3.46	174	188	178	180.00	7.21	192	190	182	188.00	5.29
22	JKP	48	Female																									
23	RMS	51	Female	166	168	176	170.00	5.29	142	146	152	146.67	5.03	134	142	134	136.67	4.62	196	216	210	207.33	10.26	122	124	132	126.00	5.29
25	TJJ	40	Female	92	100	100	97.33	4.62	126	122	122	123.33	2.31	106	118	110	111.33	6.11	104	100	100	101.33	2.31	122	124	110	118.67	7.57
29	DSE	58	Female	150	150	146	148.67	2.31	104	104	92	100.00	6.93	134	130	140	134.67	5.03	144	152	156	150.67	6.11	114	122	118	118.00	4.00
30	MMC	64	Female	110	108	110	109.33	1.15	108	112	112	110.67	2.31	110	108	112	110.00	2.00	168	172	172	170.67	2.31	118	122	122	120.67	2.31
33	JG	47	Female																									
34	LLL	31	Female																									
35	DLM	52	Female	110	92	110	104.00	10.39	148	136	140	141.33	6.11	158	158	162	159.33	2.31	168	154	164	162.00	7.21	120	118	122	120.00	2.00
36	MAE	51	Female	124	118	116	119.33	4.16	124	128	126	126.00	2.00	102	102	106	103.33	2.31	124	134	124	127.33	5.77	130	126	134	130.00	4.00
37	GLJ	54	Female	108	118	114	113.33	5.03	124	124	128	125.33	2.31	150	142	142	144.67	4.62	116	132	132	126.67	9.24	106	114	102	107.33	6.11
38	KAS	42	Female																									
41	E-N	61	Female	142	148	136	141.33	6.03	152	140	156	149.33	8.33	132	124	124	126.67	4.62	158	160	166	161.33	4.16	126	130	122	126.00	4.00
42	KAM	52	Female	104	104	92	100.00	6.93	100	94	100	98.00	3.46	94	92	102	96.00	5.29	96	92	92	93.33	2.31	112	114	108	111.33	3.06
43	CGC	48	Female	108	114	112	111.33	3.06	108	112	122	114.00	7.21	118	128	124	123.33	5.03	152	160	158	156.67	4.16	110	118	114	114.00	4.00
45	TDC	48	Female	90	90	94	91.33	2.31	92	96	92	93.33	2.31	94	98	94	95.33	2.31	92	96	100	96.00	4.00	100	94	102	98.67	4.16
48	JLL	47	Female	92	96	96	94.67	2.31	92	92	96	93.33	2.31	100	100	106	102.00	3.46	98	94	100	97.33	3.06	108	106	112	108.67	3.06
50	DKH	48	Female	148	146	154	149.33	4.16	172	164	168	168.00	4.00	128	134	136	132.67	4.16	186	182	172	180.00	7.21	134	148	150	144.00	8.72
52	CJL	53	Female	144	146	138	142.67	4.16	194	198	206	199.33	6.11	228	230	234	230.67	3.06	174	172	184	176.67	6.43	156	160	160	158.67	2.31
53	DSB	54	Female	230	216	226	224.00	7.21	100	104	102	102.00	2.00	144	140	134	139.33	5.03	152	156	164	157.33	6.11	134	126	138	132.67	6.11
55	SKR	57	Female	122	120	122	121.33	1.15	136	140	146	141.33	6.11	110	108	114	110.67	3.06	136	132	144	137.33	6.11	130	142	142	138.00	6.93
56	DAH	45	Female																									
58	CZR	49	Female	102	100	108	103.33	4.16	92	96	92	93.33	2.31	90	94	98	94.00	4.00	116	104	108	109.33	6.11	98	94	96	96.00	2.00
62	KME	45	Female	126	134	134	131.33	4.62	162	162	158	160.67	2.31	134	142	134	136.67	4.62	262	270	276	269.33	7.02	134	140	142	138.67	4.16
63	MRG	51	Female	108	122	128	119.33	10.26																				
68	SAM	53	Female	108	92	100	100.00	8.00	124	128	126	126.00	2.00	100	104	102	102.00	2.00	116	120	124	120.00	4.00	94	94	96	94.67	1.15
69	GHD	55	Female	132	146	138	138.67	7.02	132	136	134	134.00	2.00	118	116	122	118.67	3.06	156	144	160	153.33	8.33	138	142	136	138.67	3.06
70	CAC	62	Female	100	96	96	97.33	2.31	104	92	98	98.00	6.00	94	92	102	96.00	5.29	92	96	94	94.00	2.00	106	110	110	108.67	2.31
71	JAR	40	Female	100	100	92	97.33	4.62	96	104	96	98.67	4.62	106	96	102	101.33	5.03	108	114	104	108.67	5.03	106	106	104	105.33	1.15
72	NRC	56	Female	92	106	104	100.67	7.57	102	112	100	104.67	5.43	90	94	90	91.33	2.31	92	92	92	92.00	0.00	96	94	94	94.67	1.15
73	NLW	47	Female	194	196	216	202.00	12.17	96	100	100	99.33	1.15															
	Discontinued					Mean	122.34				Mean	120.34				Mean	120.93				Mean	137.27				Mean	120.60	
						SD	28.78				SD	25.19				SD	27.14				SD	41.04				SD	20.89	
						Median	113.33				Median	111.33				Median	112.33				Median	132.33				Median	119.33	
						N	31				N	31				N	30				N	30				N	30	

Data Listing 3
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Intra-Subject Change in DPM Values of the Left Cheek

				Week 2 vs. Baseline					Week 4 vs. Baseline					Week 8 vs. Baseline					Week 12 vs. Baseline				
Subject No.	Subject Initials	Age	Gender	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
4	SKH	46	Female	-18	-14	0	-10.67	9.45	-32	-32	-12	-25.33	11.55	-2	10	8	5.33	6.43	-46	-42	-34	-40.67	6.11
5	LMP	45	Female	-20	-34	-20	-24.67	8.08	-28	-24	-10	-20.67	9.45	2	10	20	10.67	9.02	-14	-6	6	-4.00	11.14
6	PJW	43	Female																				
10	JCL	41	Female	10	16	24	16.67	7.02	20	14	22	18.67	4.16	2	0	0	0.67	1.15	10	0	0	3.33	5.77
11	TLM	50	Female	-12	-12	-10	-11.33	1.15	-8	-4	-4	-5.33	2.31	-14	-22	-32	-22.67	9.02	-6	-16	-12	-11.33	5.03
13	DKS	38	Female	-60	-42	-64	-55.33	11.72	-24	-6	-34	-21.33	14.19	-48	-38	-64	-50.00	13.11	-28	-14	-36	-26.00	11.14
14	LKB	56	Female	-26	-44	-44	-38.00	10.39	-16	-28	-36	-26.67	10.07	-20	-30	-48	-32.67	14.19	-14	-18	-24	-18.67	5.03
15	NHK	56	Female	0	-20	-2	-7.33	11.02															
16	VLH	57	Female	28	30	26	28.00	2.00	38	34	38	36.67	2.31	80	90	78	82.67	6.43	98	92	82	90.67	8.08
22	JKP	48	Female																				
23	RMS	51	Female	-24	-22	-24	-23.33	1.15	-32	-26	-42	-33.33	8.08	30	48	34	37.33	9.45	-44	-44	-44	-44.00	0.00
25	TJJ	40	Female	34	22	22	26.00	6.93	14	18	10	14.00	4.00	12	0	0	4.00	6.93	30	24	10	21.33	10.26
29	DSE	59	Female	-46	-46	-54	-48.67	4.62	-16	-20	-6	-14.00	7.21	-6	2	10	2.00	8.00	-36	-28	-28	-30.67	4.62
30	MMC	64	Female	-2	4	2	1.33	3.06	0	0	2	0.67	1.15	58	64	62	61.33	3.06	8	14	12	11.33	3.06
33	J-G	47	Female																				
34	LLL	31	Female																				
35	DLM	52	Female	38	44	30	37.33	7.02	48	66	52	55.33	9.45	58	62	54	58.00	4.00	10	26	12	16.00	8.72
36	MAE	51	Female	0	10	10	6.67	5.77	-22	-16	-10	-16.00	6.00	0	16	8	8.00	8.00	6	8	18	10.67	6.43
37	GLJ	54	Female	16	6	14	12.00	5.29	42	24	28	31.33	9.45	8	14	18	13.33	5.03	-2	-4	-12	-6.00	5.29
38	KAS	42	Female																				
41	E-N	61	Female	10	-6	20	8.00	13.11	-10	-22	-12	-14.67	6.43	16	14	30	20.00	8.72	-16	-16	-14	-15.33	1.15
42	KAM	52	Female	-4	-10	8	-2.00	9.17	-10	-12	10	-4.00	12.17	-8	-12	0	-6.67	6.11	8	10	16	11.33	4.16
43	CGC	48	Female	0	-2	10	2.67	6.43	10	14	12	12.00	2.00	44	46	46	45.33	1.15	2	4	2	2.67	1.15
45	TDC	48	Female	2	6	-2	2.00	4.00	4	8	0	4.00	4.00	2	6	6	4.67	2.31	10	4	8	7.33	3.06
48	JLL	47	Female	0	-4	0	-1.33	2.31	8	4	10	7.33	3.06	6	-2	4	2.67	4.16	16	10	16	14.00	3.46
50	DKH	49	Female	24	18	14	18.67	5.03	-20	-12	-18	-16.67	4.16	38	36	18	30.67	11.02	-14	2	-4	-5.33	8.08
52	CJL	53	Female	60	52	68	56.67	9.87	84	84	96	88.00	6.93	30	26	46	34.00	10.58	12	14	22	16.00	5.29
53	DSB	54	Female	-130	-112	-124	-122.00	9.17	-86	-76	-92	-84.67	8.08	-78	-60	-62	-66.67	9.87	-96	-90	-88	-91.33	4.16
55	SKR	57	Female	14	20	26	20.00	6.00	-12	-12	-8	-10.67	2.31	14	12	22	16.00	5.29	8	22	20	16.67	7.57
56	DAH	45	Female																				
58	CZR	49	Female	-10	-4	-16	-10.00	6.00	-12	-6	-10	-9.33	3.06	14	4	0	6.00	7.21	-4	-6	-12	-7.33	4.16
62	KME	45	Female	36	28	24	29.33	6.11	8	6	0	5.33	4.62	136	136	142	138.00	3.46	8	6	8	7.33	1.15
63	MRG	51	Female																				
68	SAM	53	Female	16	36	26	26.00	10.00	-8	12	2	2.00	10.00	8	28	24	20.00	10.58	-14	2	-4	-5.33	8.08
69	GHD	55	Female	0	-10	-4	-4.67	5.03	-14	-30	-16	-20.00	8.72	24	-2	22	14.67	14.47	6	-4	-2	0.00	5.29
70	CAC	62	Female	4	-4	2	0.67	4.16	-6	-4	6	-1.33	6.43	-8	0	-2	-3.33	4.16	6	14	14	11.33	4.62
71	JAR	40	Female	-4	4	4	1.33	4.62	6	-4	10	4.00	7.21	8	14	12	11.33	3.06	6	6	12	8.00	3.46
72	NRC	56	Female	10	6	-4	4.00	7.21	-2	-12	-14	-9.33	6.43	0	-14	-12	-8.67	7.57	4	-12	-10	-6.00	8.72
73	NLW	47	Female	-96	-96	-116	-102.67	11.55															
	Discontinued					Mean	-2.00				Mean	-1.80				Mean	14.53				Mean	-2.13	
						SD	32.72				SD	29.96				SD	38.39				SD	29.17	
						Median	1.33				Median	-4.67				Median	9.33				Median	1.33	
						N	31				N	30				N	30				N	30	

TEWL Values (g/m ^{2}/hr) of Both Cheeks (Average of Right and Left)

				Baseline				Week 2				Week 4				Week 8				Week 12			
Subject Number	Subject's Initials	Subject's Age	Gender	Measurement 1	Measurement 2	Mean	SD	Measurement 1	Measurement 2	Mean	SD	Measurement 1	Measurement 2	Mean	SD	Measurement 1	Measurement 2	Mean	SD	Measurement 1	Measurement 2	Mean	SD
1	SDC	40	Female	9.8	10.0	9.85	0.14																
2	MLE	50	Female	13.6	14.4	13.98	0.60	13.4	13.9	13.63	0.39	11.7	11.2	11.40	0.35	11.3	10.0	10.60	0.92	15.6	14.5	15.00	0.78
3	SKH	47	Female	11.1	11.2	11.13	0.11	10.7	10.7	10.68	0.04	12.0	13.0	12.48	0.67	12.8	13.6	13.20	0.57	12.7	13.2	12.93	0.39
7	DBK	52	Female	4.3	4.5	4.35	0.14	4.5	4.7	4.55	0.14	5.0	4.5	4.73	0.32	4.1	3.9	3.98	0.18	6.0	5.8	5.90	0.14
8	JCF	54	Female	6.0	6.8	6.38	0.60	8.0	7.9	7.93	0.04	6.6	6.9	6.75	0.21	8.6	8.6	8.58	0.04	8.8	9.1	8.93	0.18
9	JRB	53	Female	10.7	10.1	10.38	0.39																
12	EFK	57	Female	9.7	10.0	9.83	0.18	12.8	13.1	12.95	0.21	11.9	13.7	12.78	1.24	11.1	10.4	10.75	0.49	10.4	11.2	10.75	0.57
17	BFH	59	Female	13.1	14.1	13.55	0.71	14.4	15.3	14.85	0.64	13.8	14.5	14.15	0.49	11.5	11.3	11.38	0.18	8.1	8.4	8.23	0.18
18	LJR	58	Female	10.4	10.5	10.43	0.11	14.1	14.3	14.15	0.14	12.0	13.3	12.63	0.95	14.1	14.0	14.05	0.07	10.3	10.0	10.13	0.25
19	D-M	58	Female	9.4	10.2	9.78	0.53	10.1	10.3	10.15	0.14	11.7	12.1	11.88	0.25	8.8	9.0	8.88	0.18	14.5	15.2	14.83	0.46
20	RLA	45	Female																				
21	LGD	57	Female	6.4	7.1	6.73	0.53	6.2	6.0	6.10	0.14	7.2	7.0	7.08	0.11	6.3	6.2	6.20	0.07	6.4	5.6	5.98	0.53
24	VIP	52	Female	10.5	11.0	10.75	0.35	8.4	9.1	8.70	0.49	8.5	8.7	8.58	0.18	8.5	9.0	8.73	0.39	11.6	12.1	11.80	0.35
26	PKM	46	Female	12.1	12.6	12.35	0.35	11.9	12.1	12.00	0.14	9.4	9.6	9.45	0.14	7.4	8.5	7.95	0.78				
27	SMM	59	Female	10.5	11.7	11.10	0.85	10.2	10.9	10.53	0.46	12.0	12.5	12.25	0.35	11.1	11.7	11.35	0.42	11.0	10.8	10.88	0.18
28	EJD	56	Female																				
31	JAC	56	Female	16.5	16.9	16.68	0.25	20.2	21.2	20.70	0.71	17.5	17.1	17.28	0.32	15.8	16.3	16.03	0.32	13.6	13.4	13.48	0.11
32	TML	38	Female	18.0	17.8	17.85	0.14	10.1	11.7	10.90	1.13	11.1	13.2	12.10	1.48	14.1	14.4	14.25	0.21	19.4	22.6	20.99	2.22
39	DKD	50	Female	10.3	10.8	10.55	0.35	8.3	8.5	8.35	0.14	8.2	8.4	8.28	0.11	8.2	8.4	8.25	0.14	8.7	9.2	8.90	0.35
40	CLM	43	Female	10.2	11.9	11.03	1.17	12.8	13.6	13.20	0.57	11.0	11.7	11.35	0.49	11.5	11.5	11.48	0.04	12.7	12.8	12.75	0.07
44	GSR	52	Female	16.9	17.6	17.25	0.49	23.9	26.5	25.18	1.87	17.9	19.8	18.83	1.31	14.8	15.9	15.33	0.74	13.4	14.4	13.90	0.71
46	LAA	55	Female	18.5	19.4	18.93	0.67	14.7	15.6	15.15	0.64	10.8	11.1	10.90	0.21	15.1	15.6	15.33	0.32	16.1	16.0	16.05	0.07
47	CMP	47	Female	11.8	12.4	12.08	0.39	10.9	12.1	11.45	0.85	13.3	14.4	13.80	0.78	11.7	11.8	11.75	0.07	12.1	11.9	12.00	0.14
49	L-R	58	Female	6.7	7.0	6.83	0.25	5.3	5.6	5.40	0.21	7.1	7.8	7.40	0.49	8.2	8.4	8.25	0.14	11.3	10.2	10.75	0.78
51	PCB	59	Female	8.5	9.5	8.98	0.74	11.6	12.8	12.18	0.81	13.8	15.0	14.38	0.88	13.4	14.2	13.75	0.57	13.6	14.1	13.83	0.32
54	TWS	55	Female	3.9	4.2	4.05	0.21	8.7	8.9	8.80	0.14												
57	MDS	52	Female	10.7	12.0	11.33	0.88	23.9	25.4	24.63	1.03	12.7	14.2	13.40	1.06	7.7	8.8	8.23	0.81	11.4	10.9	11.13	0.39
59	GFM	64	Female	5.6	5.6	5.58	0.04	6.8	6.8	6.80	0.00	6.6	7.0	6.80	0.28	4.7	5.7	5.15	0.71	8.2	6.9	7.50	0.92
60	JLF	32	Female	11.4	13.1	12.20	1.20	18.6	18.1	18.30	0.35	11.3	11.4	11.30	0.07	10.7	9.1	9.88	1.10	21.2	19.8	20.48	1.03
61	GEP	53	Female	9.3	10.2	9.70	0.64																
64	KKF	36	Female	12.2	12.6	12.35	0.28	11.8	13.0	12.40	0.85	11.5	12.2	11.83	0.46	10.8	11.4	11.05	0.42	14.0	13.2	13.55	0.57
65	EMM	39	Female	18.7	21.1	19.88	1.73	18.4	18.2	18.28	0.18	14.7	16.9	15.78	1.59	11.3	11.5	11.35	0.14	15.5	15.0	15.25	0.35
66	CYR	39	Female	13.6	13.8	13.68	0.18	21.5	21.4	21.43	0.11	13.5	14.5	13.98	0.67	11.4	12.3	11.85	0.64	15.8	14.4	15.05	0.99
67	AMM	37	Female	8.1	8.3	8.18	0.18	11.2	11.2	11.18	0.04	10.1	10.8	10.45	0.49	7.9	7.9	7.88	0.04	9.1	9.6	9.35	0.35
	Discontinued				Mean	11.30			Mean	12.78			Mean	11.50			Mean	10.55			Mean	12.23	
					SD	4.14			SD	5.37			SD	3.29			SD	3.08			SD	3.72	
					Median	11.10			Median	12.00			Median	11.85			Median	10.90			Median	12.00	
					N	29			N	29			N	28			N	28			N	27	

Intra-Subject Change in TEWL Values (g/m ^{2}/hr) of Both Cheeks (Average of Right and Left)

Subject Number	Subject's Initials	Subject's Age	Gender	Week 2 vs. Baseline Measurement 1	Week 2 vs. Baseline Measurement 2	Mean	SD	Week 4 vs. Baseline Measurement 1	Week 4 vs. Baseline Measurement 2	Mean	SD	Week 8 vs. Baseline Measurement 1	Week 8 vs. Baseline Measurement 2	Mean	SD	Week 12 vs. Baseline Measurement 1	Week 12 vs. Baseline Measurement 2	Mean	SD
1	SDC	40	Female																
2	MLE	50	Female	-0.2	-0.5	-0.35	0.21	-1.9	-3.3	-2.58	0.95	-2.3	-4.5	-3.38	1.52	2.0	0.0	1.03	1.38
3	SKH	47	Female	-0.4	-0.5	-0.45	0.07	0.9	1.8	1.35	0.57	1.8	2.4	2.08	0.46	1.6	2.0	1.80	0.28
7	DBK	52	Female	0.2	0.2	0.20	0.00	0.7	0.0	0.38	0.46	-0.2	-0.6	-0.38	0.32	1.8	1.4	1.55	0.28
8	JCF	54	Female	2.0	1.1	1.55	0.64	0.6	0.1	0.38	0.39	2.6	1.8	2.20	0.57	2.9	2.3	2.55	0.42
9	JRB	53	Female																
12	EFK	57	Female	3.1	3.2	3.13	0.04	2.2	3.7	2.95	1.06	1.4	0.5	0.93	0.67	0.7	1.2	0.93	0.39
17	BFH	59	Female	1.4	1.3	1.30	0.07	0.8	0.4	0.60	0.21	-1.6	-2.8	-2.18	0.88	-5.0	-5.7	-5.33	0.53
18	LJR	58	Female	3.7	3.8	3.73	0.04	1.6	2.8	2.20	0.85	3.8	3.5	3.63	0.18	-0.1	-0.6	-0.30	0.35
19	D-M	58	Female	0.7	0.1	0.38	0.39	2.3	1.9	2.10	0.28	-0.7	-1.2	-0.90	0.35	5.1	5.0	5.05	0.07
20	RLA	45	Female																
21	LGD	57	Female	-0.2	-1.1	-0.63	0.67	0.8	-0.1	0.35	0.64	-0.1	-0.9	-0.52	0.60	0.0	-1.5	-0.75	1.06
24	VIP	52	Female	-2.2	-2.0	-2.05	0.14	-2.1	-2.3	-2.18	0.18	-2.1	-2.0	-2.03	0.04	1.1	1.1	1.05	0.00
26	PKM	46	Female	-0.2	-0.5	-0.35	0.21	-2.8	-3.1	-2.90	0.21	-4.7	-4.1	-4.40	0.42				
27	SMM	59	Female	-0.3	-0.8	-0.57	0.39	1.5	0.8	1.15	0.49	0.6	0.0	0.25	0.42	0.5	-0.9	-0.23	1.03
28	EJD	56	Female																
31	JAC	56	Female	3.7	4.4	4.03	0.46	1.0	0.2	0.60	0.57	-0.7	-0.6	-0.65	0.07	-3.0	-3.5	-3.20	0.35
32	TML	38	Female	-7.9	-6.1	-6.95	1.27	-6.9	-4.6	-5.75	1.63	-3.9	-3.4	-3.60	0.35	1.5	4.8	3.14	2.37
39	DKD	50	Female	-2.1	-2.4	-2.20	0.21	-2.1	-2.5	-2.28	0.25	-2.2	-2.5	-2.30	0.21	-1.7	-1.7	-1.65	0.00
40	CLM	43	Female	2.6	1.8	2.18	0.60	0.8	-0.2	0.33	0.67	1.3	-0.4	0.45	1.20	2.5	1.0	1.73	1.10
44	GSR	52	Female	7.0	8.9	7.93	1.38	1.0	2.2	1.58	0.81	-2.1	-1.8	-1.93	0.25	-3.5	-3.2	-3.35	0.21
46	LAA	55	Female	-3.8	-3.8	-3.78	0.04	-7.7	-8.4	-8.03	0.46	-3.4	-3.9	-3.60	0.35	-2.4	-3.4	-2.88	0.74
47	CMP	47	Female	-1.0	-0.3	-0.63	0.46	1.5	2.0	1.73	0.39	-0.1	-0.5	-0.33	0.32	0.3	-0.4	-0.08	0.53
49	L-R	58	Female	-1.4	-1.5	-1.43	0.04	0.4	0.8	0.58	0.25	1.5	1.4	1.43	0.11	4.7	3.2	3.93	1.03
51	PCB	59	Female	3.2	3.3	3.20	0.07	5.3	5.5	5.40	0.14	4.9	4.7	4.78	0.18	5.2	4.6	4.85	0.42
54	TWS	55	Female	4.8	4.7	4.75	0.07												
57	MDS	52	Female	13.2	13.4	13.30	0.14	2.0	2.2	2.08	0.18	-3.1	-3.2	-3.10	0.07	0.7	-1.1	-0.20	1.27
59	GFM	64	Female	1.2	1.3	1.23	0.04	1.0	1.5	1.23	0.32	-0.9	0.1	-0.42	0.74	2.6	1.3	1.93	0.88
60	JLF	32	Female	7.2	5.0	6.10	1.56	-0.1	-1.7	-0.90	1.13	-0.7	-4.0	-2.33	2.30	9.9	6.7	8.28	2.23
61	GEP	53	Female																
64	KKF	36	Female	-0.4	0.4	0.05	0.57	-0.7	-0.4	-0.53	0.18	-1.4	-1.2	-1.30	0.14	1.8	0.6	1.20	0.85
65	EMM	39	Female	-0.3	-3.0	-1.60	1.91	-4.0	-4.2	-4.10	0.14	-7.4	-9.7	-8.53	1.59	-3.2	-6.1	-4.63	2.09
66	CYR	39	Female	8.0	7.6	7.75	0.28	-0.1	0.6	0.30	0.49	-2.2	-1.5	-1.83	0.46	2.2	0.5	1.38	1.17
67	AMM	37	Female	3.2	2.9	3.00	0.21	2.1	2.5	2.28	0.32	-0.2	-0.4	-0.30	0.14	1.1	1.3	1.18	0.18
	Discontinued				Mean	1.48			Mean	-0.06			Mean	-1.01			Mean	0.70	
					SD	3.98			SD	2.78			SD	2.65			SD	3.03	
					Median	0.38			Median	0.48			Median	-0.78			Median	1.05	
					N	29			N	28			N	28			N	27	

Data Listing 4
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

TEWL Values (g/m^2/hr) of the Right Cheek

Subject Number	Subject's Initials	Subject's Age	Gender	Baseline		Mean	SD	Week 2		Mean	SD	Week 4		Mean	SD	Week 8		Mean	SD	Week 12		Mean	SD
				Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2		
1	BDC	40	Female	9.4	9.9	9.65	0.35																
2	MLE	50	Female	13.8	15.3	14.55	1.06	14.6	15.3	14.95	0.49	12.2	11.0	11.60	0.85	10.1	9.3	9.70	0.57	15.4	15.2	15.30	0.14
3	SKH	47	Female	11.0	11.0	11.00	0.00	12.8	10.8	11.80	1.41	12.5	13.7	13.10	0.85	12.1	14.0	13.05	1.34	13.2	13.4	13.30	0.14
7	DBK	52	Female	4.5	5.0	4.75	0.35	4.0	4.0	4.00	0.00	3.8	3.8	3.80	0.00	4.0	4.7	4.35	0.49	5.9	5.3	5.60	0.42
8	JCF	54	Female	6.0	7.5	6.75	1.06	6.3	6.4	6.35	0.07	6.1	6.3	6.20	0.14	8.9	8.9	8.90	0.00	8.5	8.4	8.45	0.07
9	JRB	53	Female	10.1	10.2	10.15	0.07																
12	EFK	57	Female	10.3	11.0	10.65	0.49	12.5	14.2	13.35	1.20	12.2	15.2	13.70	2.12	10.1	11.9	11.00	1.27	10.5	12.5	11.50	1.41
17	BFH	59	Female	13.1	12.6	12.85	0.35	16.5	18.1	17.30	1.13	15.6	16.5	16.05	0.64	12.7	12.9	12.80	0.14	8.9	9.8	9.35	0.64
18	LJR	58	Female	11.8	12.0	11.90	0.14	13.8	15.3	14.55	1.06	12.0	13.5	12.75	1.06	12.6	13.0	12.80	0.28	10.6	9.8	10.20	0.57
19	D-M	58	Female	6.8	7.7	7.25	0.64	8.8	8.2	8.50	0.42	9.8	10.3	10.05	0.35	7.4	8.0	7.70	0.42	14.3	15.3	14.80	0.71
20	RLA	45	Female																				
21	LGD	57	Female	5.6	6.5	6.05	0.64	7.3	6.6	6.95	0.49	5.6	6.2	5.90	0.42	4.9	4.9	4.90	0.00	5.2	4.3	4.75	0.64
24	VIP	52	Female	9.5	10.5	10.00	0.71	8.7	9.0	8.85	0.21	9.0	8.9	8.95	0.07	8.2	8.5	8.35	0.21	9.8	10.3	10.05	0.35
26	PKM	46	Female	10.6	10.2	10.40	0.28	12.8	13.0	12.90	0.14	9.4	9.6	9.50	0.14	6.5	8.8	7.65	1.63				
27	SMM	59	Female	10.0	11.1	10.55	0.78	10.0	10.4	10.20	0.28	12.0	12.9	12.45	0.64	9.1	10.3	9.70	0.85	8.7	9.3	9.00	0.42
28	EJD	56	Female																				
31	JAC	56	Female	12.9	13.4	13.15	0.35	21.3	22.8	22.05	1.06	20.5	19.9	20.20	0.42	13.1	14.2	13.65	0.78	11.8	12.3	12.05	0.35
32	TML	38	Female	22.1	20.2	21.15	1.34	10.4	12.8	11.60	1.70	11.8	14.9	13.35	2.19	14.5	16.2	15.35	1.20	16.4	18.1	17.24	1.16
39	DKD	50	Female	9.8	10.4	10.10	0.42	8.0	8.7	8.35	0.49	6.6	6.3	6.45	0.21	7.0	7.7	7.35	0.49	8.6	9.3	8.95	0.49
40	CLM	43	Female	10.7	12.1	11.40	0.99	12.8	13.5	13.15	0.49	11.8	12.6	12.20	0.57	9.8	10.6	10.20	0.57	13.3	13.1	13.20	0.14
44	GSR	52	Female	17.0	17.7	17.35	0.49	25.6	28.6	27.10	2.12	21.3	24.1	22.70	1.98	14.5	16.1	15.30	1.13	12.0	13.2	12.60	0.85
46	LAA	55	Female	19.5	20.6	20.05	0.78	14.6	14.6	14.60	0.00	9.3	9.7	9.50	0.28	13.1	13.7	13.40	0.42	15.8	15.5	15.65	0.21
47	CMP	47	Female	12.2	13.5	12.85	0.92	10.0	10.5	10.25	0.35	12.4	13.1	12.75	0.49	11.4	11.3	11.35	0.07	12.6	12.3	12.45	0.21
49	L-R	58	Female	7.0	7.5	7.25	0.35	5.7	5.8	5.75	0.07	7.8	8.5	8.15	0.49	8.7	8.7	8.70	0.00	12.1	10.1	11.10	1.41
51	PCB	59	Female	8.4	8.5	8.45	0.07	11.9	13.0	12.45	0.78	13.6	15.0	14.30	0.99	13.5	14.6	14.05	0.78	11.1	12.5	11.80	0.99
54	TWS	55	Female	3.4	3.5	3.45	0.07	8.5	7.8	8.15	0.49												
57	MDS	52	Female	9.9	11.5	10.70	1.13	21.5	22.3	21.90	0.57	11.6	13.5	12.55	1.34	6.6	8.7	7.65	1.48	11.5	10.5	11.00	0.71
59	GFM	64	Female	5.9	5.6	5.75	0.21	6.3	7.0	6.65	0.49	7.1	8.3	7.70	0.85	4.6	5.1	4.85	0.35	7.0	5.5	6.25	1.06
60	JLF	32	Female	11.5	13.1	12.30	1.13	15.5	15.9	15.70	0.28	11.3	11.1	11.20	0.14	12.3	9.3	10.80	2.12	18.9	18.5	18.70	0.28
61	GEP	53	Female	8.5	8.1	8.30	0.28																
64	KKF	36	Female	12.5	12.8	12.65	0.21	12.0	14.0	13.00	1.41	11.7	12.3	12.00	0.42	9.6	10.3	9.95	0.49	12.3	11.7	12.00	0.42
65	EMM	39	Female	20.0	22.6	21.30	1.84	16.7	16.8	16.75	0.07	15.0	17.8	16.40	1.98	9.7	11.0	10.35	0.92	16.3	15.6	15.95	0.49
66	CYR	39	Female	11.8	11.8	11.80	0.00	21.8	20.7	21.25	0.78	14.0	15.0	14.50	0.71	10.3	12.3	11.30	1.41	15.2	16.0	15.60	0.57
67	AMM	37	Female	7.6	9.0	8.30	0.99	11.8	12.0	11.90	0.14	9.1	10.8	9.95	1.20	7.8	7.7	7.75	0.07	8.0	8.2	8.10	0.14
	Discontinued				Mean	11.20			Mean	12.77			Mean	11.71			Mean	10.10			Mean	11.66	
					SD	4.52			SD	5.45			SD	4.16			SD	3.02			SD	3.52	
					Median	10.70			Median	12.45			Median	12.10			Median	10.08			Median	11.80	
					N	29			N	29			N	28			N	28			N	27	

Intra-Subject Change in TEWL Values (g/m^2/hr) of the Right Cheek

Subject Number	Subject's Initials	Subject's Age	Gender	Week 2 vs. Baseline		Mean	SD	Week 4 vs. Baseline		Mean	SD	Week 8 vs. Baseline		Mean	SD	Week 12 vs. Baseline		Mean	SD
				Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2		
1	SDC	40	Female																
2	MLE	50	Female	0.8	0.0	0.40	0.57	-1.6	-4.3	-2.95	1.91	-3.7	-6.0	-4.85	1.63	1.6	-0.1	0.75	1.20
3	SKH	47	Female	1.8	-0.2	0.80	1.41	1.5	2.7	2.10	0.85	1.1	3.0	2.05	1.34	2.2	2.4	2.30	0.14
7	DBK	52	Female	-0.5	-1.0	-0.75	0.35	-0.7	-1.2	-0.95	0.35	-0.5	-0.3	-0.40	0.14	1.4	0.3	0.85	0.78
8	JCF	54	Female	0.3	-1.1	-0.40	0.99	0.1	-1.2	-0.55	0.92	2.9	1.4	2.15	1.06	2.5	0.9	1.70	1.13
9	JRB	53	Female																
12	EFK	57	Female	2.2	3.2	2.70	0.71	1.9	4.2	3.05	1.63	-0.2	0.9	0.35	0.78	0.2	1.5	0.85	0.92
17	BFH	59	Female	3.4	5.5	4.45	1.48	2.5	3.9	3.20	0.99	-0.4	0.3	-0.05	0.49	-4.2	-2.8	-3.50	0.99
18	LJR	58	Female	2.0	3.3	2.65	0.92	0.2	1.5	0.85	0.92	0.8	1.0	0.90	0.14	-1.2	-2.2	-1.70	0.71
19	D-M	58	Female	2.0	0.5	1.25	1.06	3.0	2.6	2.80	0.28	0.6	0.3	0.45	0.21	7.5	7.6	7.55	0.07
20	RLA	45	Female																
21	LGD	57	Female	1.7	0.1	0.90	1.13	0.0	-0.3	-0.15	0.21	-0.7	-1.6	-1.15	0.64	-0.4	-2.2	-1.30	1.27
24	VIP	52	Female	-0.8	-1.5	-1.15	0.49	-0.5	-1.6	-1.05	0.78	-1.3	-2.0	-1.65	0.49	0.3	-0.2	0.05	0.35
26	PKM	46	Female	2.2	2.8	2.50	0.42	-1.2	-0.6	-0.90	0.42	-4.1	-1.4	-2.75	1.91				
27	SMM	59	Female	0.0	-0.7	-0.35	0.49	2.0	1.8	1.90	0.14	-0.9	-0.8	-0.85	0.07	-1.3	-1.8	-1.55	0.35
28	EJD	56	Female																
31	JAC	56	Female	8.4	9.4	8.90	0.71	7.6	6.5	7.05	0.78	0.2	0.8	0.50	0.42	-1.1	-1.1	-1.10	0.00
32	TML	38	Female	-11.7	-7.4	-9.55	3.04	-10.3	-5.3	-7.80	3.54	-7.6	-4.0	-5.80	2.55	-5.7	-2.1	-3.91	2.50
39	DKD	50	Female	-1.8	-1.7	-1.75	0.07	-3.2	-4.1	-3.65	0.64	-2.8	-2.7	-2.75	0.07	-1.2	-1.1	-1.15	0.07
40	CLM	43	Female	2.1	1.4	1.75	0.49	1.1	0.5	0.80	0.42	-0.9	-1.5	-1.20	0.42	2.6	1.0	1.80	1.13
44	GSR	52	Female	8.6	10.9	9.75	1.63	4.3	6.4	5.35	1.48	-2.5	-1.6	-2.05	0.64	-5.0	-4.5	-4.75	0.35
46	LAA	55	Female	-4.9	-6.0	-5.45	0.78	-10.2	-10.9	-10.55	0.49	-6.4	-6.9	-6.65	0.35	-3.7	-5.1	-4.40	0.99
47	CMP	47	Female	-2.2	-3.0	-2.60	0.57	0.2	-0.4	-0.10	0.42	-0.8	-2.2	-1.50	0.99	0.4	-1.2	-0.40	1.13
49	L-R	58	Female	-1.3	-1.7	-1.50	0.28	0.8	1.0	0.90	0.14	1.7	1.2	1.45	0.35	5.1	2.6	3.85	1.77
51	PCB	59	Female	3.5	4.5	4.00	0.71	5.2	6.5	5.85	0.92	5.1	6.1	5.60	0.71	2.7	4.0	3.35	0.92
54	TWS	55	Female	5.1	4.3	4.70	0.57												
57	MDS	52	Female	11.6	10.8	11.20	0.57	1.7	2.0	1.85	0.21	-3.3	-2.8	-3.05	0.35	1.6	-1.0	0.30	1.84
59	GFM	64	Female	0.4	1.4	0.90	0.71	1.2	2.7	1.95	1.06	-1.3	-0.5	-0.90	0.57	1.1	-0.1	0.50	0.85
60	JLF	32	Female	4.0	2.8	3.40	0.85	-0.2	-2.0	-1.10	1.27	0.8	-3.8	-1.50	3.25	7.4	5.4	6.40	1.41
61	GEP	53	Female																
64	KKF	36	Female	-0.5	1.2	0.35	1.20	-0.8	-0.5	-0.65	0.21	-2.9	-2.5	-2.70	0.28	-0.2	-1.1	-0.65	0.64
65	EMM	39	Female	-3.3	-5.8	-4.55	1.77	-5.0	-4.8	-4.90	0.14	-10.3	-11.6	-10.95	0.92	-3.7	-7.0	-5.35	2.33
66	CYR	39	Female	10.0	8.9	9.45	0.78	2.2	3.2	2.70	0.71	-1.5	0.5	-0.50	1.41	3.4	4.2	3.80	0.57
67	AMM	37	Female	4.2	3.0	3.60	0.85	1.5	1.8	1.65	0.21	0.2	-1.3	-0.55	1.06	0.4	-0.8	-0.20	0.85
	Discontinued				Mean	1.57			Mean	0.24			Mean	-1.37			Mean	0.15	
					SD	4.56			SD	3.79			SD	3.11			SD	3.16	
					Median	0.90			Median	0.83			Median	-1.03			Median	0.05	
					N	29			N	28			N	28			N	27	

TEWL Values (g/m^2/hr) of the Left Cheek

Subject Number	Subject's Initials	Subject's Age	Gender	Baseline		Mean	SD	Week 2		Mean	SD	Week 4		Mean	SD	Week 8		Mean	SD	Week 12		Mean	SD
				Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2		
1	SDC	40	Female	10.1	10.0	10.05	0.07																
2	MLE	50	Female	13.3	13.5	13.40	0.14	12.1	12.5	12.30	0.28	11.1	11.3	11.20	0.14	12.4	10.6	11.50	1.27	15.7	13.7	14.70	1.41
3	SKH	47	Female	11.1	11.4	11.25	0.21	8.5	10.6	9.55	1.48	11.5	12.2	11.85	0.49	13.5	13.2	13.35	0.21	12.1	13.0	12.55	0.64
7	DBK	52	Female	4.0	3.9	3.95	0.07	4.9	5.3	5.10	0.28	6.1	5.2	5.65	0.64	4.2	3.0	3.60	0.85	6.1	6.3	6.20	0.14
8	JCF	54	Female	5.9	6.1	6.00	0.14	9.6	9.4	9.50	0.14	7.1	7.5	7.30	0.28	8.2	8.3	8.25	0.07	9.1	9.7	9.40	0.42
9	JRB	53	Female	11.2	10.0	10.60	0.85																
12	EFK	57	Female	9.1	8.9	9.00	0.14	13.1	12.0	12.55	0.78	11.6	12.1	11.85	0.35	12.1	8.9	10.50	2.26	10.2	9.8	10.00	0.28
17	BFH	59	Female	13.0	15.5	14.25	1.77	12.3	12.5	12.40	0.14	12.0	12.5	12.25	0.35	10.3	9.6	9.95	0.49	7.3	6.9	7.10	0.28
18	LJR	58	Female	8.9	9.0	8.95	0.07	14.3	13.2	13.75	0.78	11.9	13.1	12.50	0.85	15.6	15.0	15.30	0.42	10.0	10.1	10.05	0.07
19	D-M	58	Female	12.0	12.6	12.30	0.42	11.3	12.3	11.80	0.71	13.6	13.8	13.70	0.14	10.1	10.0	10.05	0.07	14.7	15.0	14.85	0.21
20	RLA	45	Female																				
21	LGD	57	Female	7.1	7.7	7.40	0.42	5.1	5.4	5.25	0.21	8.7	7.8	8.25	0.64	7.6	7.4	7.50	0.14	7.5	6.9	7.20	0.42
24	VIP	52	Female	11.5	11.5	11.50	0.00	8.0	9.1	8.55	0.78	7.9	8.5	8.20	0.42	8.7	9.5	9.10	0.57	13.3	13.8	13.55	0.35
26	PKM	46	Female	13.6	15.0	14.30	0.99	11.0	11.2	11.10	0.14	9.3	9.5	9.40	0.14	8.3	8.2	8.25	0.07				
27	SMM	59	Female	11.0	12.3	11.65	0.92	10.4	11.3	10.85	0.64	12.0	12.1	12.05	0.07	13.0	13.0	13.00	0.00	13.3	12.2	12.75	0.78
28	EJD	56	Female																				
31	JAC	56	Female	20.1	20.3	20.20	0.14	19.1	19.6	19.35	0.35	14.5	14.2	14.35	0.21	18.5	18.3	18.40	0.14	15.3	14.5	14.90	0.57
32	TML	38	Female	13.8	15.3	14.55	1.06	9.8	10.6	10.20	0.57	10.3	11.4	10.85	0.78	13.7	12.6	13.15	0.78	22.4	27.1	24.75	3.29
39	DKD	50	Female	10.8	11.2	11.00	0.28	8.5	8.2	8.35	0.21	9.8	10.4	10.10	0.42	9.3	9.0	9.15	0.21	8.7	9.0	8.85	0.21
40	CLM	43	Female	9.7	11.6	10.65	1.34	12.8	13.7	13.25	0.64	10.2	10.8	10.50	0.42	13.2	12.3	12.75	0.64	12.1	12.5	12.30	0.28
44	GSR	52	Female	16.8	17.5	17.15	0.49	22.1	24.4	23.25	1.63	14.5	15.4	14.95	0.64	15.1	15.6	15.35	0.35	14.8	15.6	15.20	0.57
46	LAA	55	Female	17.4	18.2	17.80	0.57	14.8	16.6	15.70	1.27	12.2	12.4	12.30	0.14	17.1	17.4	17.25	0.21	16.4	16.5	16.45	0.07
47	CMP	47	Female	11.4	11.2	11.30	0.14	11.7	13.6	12.65	1.34	14.1	15.6	14.85	1.06	12.0	12.3	12.15	0.21	11.6	11.5	11.55	0.07
49	L-R	58	Female	6.3	6.5	6.40	0.14	4.8	5.3	5.05	0.35	6.3	7.0	6.65	0.49	7.6	8.0	7.80	0.28	10.5	10.3	10.40	0.14
51	PCB	59	Female	8.5	10.5	9.50	1.41	11.3	12.5	11.90	0.85	13.9	15.0	14.45	0.78	13.2	13.7	13.45	0.35	16.1	15.6	15.85	0.35
54	TWS	55	Female	4.4	4.9	4.65	0.35	8.9	10.0	9.45	0.78												
57	MDS	52	Female	11.5	12.4	11.95	0.64	26.3	28.4	27.35	1.48	13.7	14.8	14.25	0.78	8.7	8.9	8.80	0.14	11.3	11.2	11.25	0.07
59	GFM	64	Female	5.3	5.5	5.40	0.14	7.3	6.6	6.95	0.49	6.1	5.7	5.90	0.28	4.7	6.2	5.45	1.06	9.3	8.2	8.75	0.78
60	JLF	32	Female	11.2	13.0	12.10	1.27	21.6	20.2	20.90	0.99	11.2	11.6	11.40	0.28	9.0	8.9	8.95	0.07	23.5	21.0	22.25	1.77
61	GEP	53	Female	10.0	12.2	11.10	1.56																
64	KKF	36	Female	11.8	12.3	12.05	0.35	11.6	12.0	11.80	0.28	11.3	12.0	11.65	0.49	11.9	12.4	12.15	0.35	15.6	14.6	15.10	0.71
65	EMM	39	Female	17.3	19.6	18.45	1.63	20.1	19.5	19.80	0.42	14.3	16.0	15.15	1.20	12.8	11.9	12.35	0.64	14.7	14.4	14.55	0.21
66	CYR	39	Female	15.3	15.8	15.55	0.35	21.2	22.0	21.60	0.57	13.0	13.9	13.45	0.64	12.5	12.3	12.40	0.14	16.3	12.7	14.50	2.55
67	AMM	37	Female	8.5	7.6	8.05	0.64	10.6	10.3	10.45	0.21	11.1	10.8	10.95	0.21	7.9	8.1	8.00	0.14	10.2	11.0	10.60	0.57
Discontinued					Mean	11.40			Mean	12.78			Mean	11.28			Mean	11.00			Mean	12.80	
					SD	4.16			SD	5.57			SD	2.77			SD	3.40			SD	4.23	
					Median	11.50			Median	11.80			Median	11.75			Median	11.00			Median	12.55	
					N	29			N	29			N	28			N	28			N	27	

Data Listing 4
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Intra-Subject Change in TEWL Values (g/m^2/hr) of the Left Cheek

Subject Number	Subject's Initials	Subject's Age	Gender	Week 2 vs. Baseline		Mean	SD	Week 4 vs. Baseline		Mean	SD	Week 8 vs. Baseline		Mean	SD	Week 12 vs. Baseline		Mean	SD
				Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2			Measurement 1	Measurement 2		
1	SDC	40	Female																
2	MLE	50	Female	-1.2	-1.0	-1.10	0.14	-2.2	-2.2	-2.20	0.00	-0.9	-2.9	-1.90	1.41	2.4	0.2	1.30	1.56
3	SKH	47	Female	-2.6	-0.8	-1.70	1.27	0.4	0.8	0.60	0.28	2.4	1.8	2.10	0.42	1.0	1.6	1.30	0.42
7	DBK	52	Female	0.9	1.4	1.15	0.35	2.1	1.3	1.70	0.57	0.2	-0.9	-0.35	0.78	2.1	2.4	2.25	0.21
8	JCF	54	Female	3.7	3.3	3.50	0.28	1.2	1.4	1.30	0.14	2.3	2.2	2.25	0.07	3.2	3.6	3.40	0.28
9	JRB	53	Female																
12	EFK	57	Female	4.0	3.1	3.55	0.64	2.5	3.2	2.85	0.49	3.0	0.0	1.50	2.12	1.1	0.9	1.00	0.14
17	BFH	59	Female	-0.7	-3.0	-1.85	1.63	-1.0	-3.0	-2.00	1.41	-2.7	-5.9	-4.30	2.26	-5.7	-8.6	-7.15	2.05
18	LJR	58	Female	5.4	4.2	4.80	0.85	3.0	4.1	3.55	0.78	6.7	6.0	6.35	0.49	1.1	1.1	1.10	0.00
19	D-M	58	Female	-0.7	-0.3	-0.50	0.28	1.6	1.2	1.40	0.28	-1.9	-2.6	-2.25	0.49	2.7	2.4	2.55	0.21
20	RLA	45	Female																
21	LGD	57	Female	-2.0	-2.3	-2.15	0.21	1.6	0.1	0.85	1.06	0.5	-0.3	0.10	0.57	0.4	-0.8	-0.20	0.85
24	VIP	52	Female	-3.5	-2.4	-2.95	0.78	-3.6	-3.0	-3.30	0.42	-2.8	-2.0	-2.40	0.57	1.8	2.3	2.05	0.35
26	PKM	46	Female	-2.6	-3.8	-3.20	0.85	-4.3	-5.5	-4.90	0.85	-5.3	-6.8	-6.05	1.06				
27	SMM	59	Female	-0.6	-1.0	-0.80	0.28	1.0	-0.2	0.40	0.85	2.0	0.7	1.35	0.92	2.3	-0.1	1.10	1.70
28	EJD	56	Female																
31	JAC	56	Female	-1.0	-0.7	-0.85	0.21	-5.6	-6.1	-5.85	0.35	-1.6	-2.0	-1.80	0.28	-4.8	-5.8	-5.30	0.71
32	TML	38	Female	-4.0	-4.7	-4.35	0.49	-3.5	-3.9	-3.70	0.28	-0.1	-2.7	-1.40	1.84	8.6	11.8	10.20	2.23
39	DKD	50	Female	-2.3	-3.0	-2.65	0.49	-1.0	-0.8	-0.90	0.14	-1.5	-2.2	-1.85	0.49	-2.1	-2.2	-2.15	0.07
40	CLM	43	Female	3.1	2.1	2.60	0.71	0.5	-0.8	-0.15	0.92	3.5	0.7	2.10	1.98	2.4	0.9	1.65	1.06
44	GSR	52	Female	5.3	6.9	6.10	1.13	-2.3	-2.1	-2.20	0.14	-1.7	-1.9	-1.80	0.14	-2.0	-1.9	-1.95	0.07
46	LAA	55	Female	-2.6	-1.6	-2.10	0.71	-5.2	-5.8	-5.50	0.42	-0.3	-0.8	-0.55	0.35	-1.0	-1.7	-1.35	0.49
47	CMP	47	Female	0.3	2.4	1.35	1.48	2.7	4.4	3.55	1.20	0.6	1.1	0.85	0.35	0.2	0.3	0.25	0.07
49	L-R	58	Female	-1.5	-1.2	-1.35	0.21	0.0	0.5	0.25	0.35	1.3	1.5	1.40	0.14	4.2	3.8	4.00	0.28
51	PCB	59	Female	2.8	2.0	2.40	0.57	5.4	4.5	4.95	0.64	4.7	3.2	3.95	1.06	7.6	5.1	6.35	1.77
54	TWS	55	Female	4.5	5.1	4.80	0.42												
57	MDS	52	Female	14.8	16.0	15.40	0.85	2.2	2.4	2.30	0.14	-2.8	-3.5	-3.15	0.49	-0.2	-1.2	-0.70	0.71
59	GFM	64	Female	2.0	1.1	1.55	0.64	0.8	0.2	0.50	0.42	-0.6	0.7	0.05	0.92	4.0	2.7	3.35	0.92
60	JLF	32	Female	10.4	7.2	8.80	2.26	0.0	-1.4	-0.70	0.99	-2.2	-4.1	-3.15	1.34	12.3	8.0	10.15	3.04
61	GEP	53	Female																
64	KKF	36	Female	-0.2	-0.3	-0.25	0.07	-0.5	-0.3	-0.40	0.14	0.1	0.1	0.10	0.00	3.8	2.3	3.05	1.06
65	EMM	39	Female	2.8	-0.1	1.35	2.05	-3.0	-3.6	-3.30	0.42	-4.5	-7.7	-6.10	2.26	-2.6	-5.2	-3.90	1.84
66	CYR	39	Female	5.9	6.2	6.05	0.21	-2.3	-1.9	-2.10	0.28	-2.8	-3.5	-3.15	0.49	1.0	-3.1	-1.05	2.90
67	AMM	37	Female	2.1	2.7	2.40	0.42	2.6	3.2	2.90	0.42	-0.6	0.5	-0.05	0.78	1.7	3.4	2.55	1.20
	Discontinued				Mean	1.38			Mean	-0.36			Mean	-0.65			Mean	1.25	
					SD	4.20			SD	2.85			SD	2.81			SD	3.88	
					Median	1.15			Median	0.05			Median	-0.45			Median	1.30	
					N	29			N	28			N	28			N	27	

Data Listing 4
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

DPM Values of Both Cheeks (Average of Right and Left)

				Baseline					Week 2					Week 4					Week 8					Week 12				
Subject No	Subject Initials	Age	Gender	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
1	EDC	40	Female	94	101	98	97.67	3.51																				
2	MLE	50	Female	102	96	100	99.33	3.06	110	101	114	108.33	6.66	104	111	94	103.00	8.54	92	95	95	94.00	1.73	152	141	147	146.67	5.51
3	SKH	47	Female	108	98	112	106.00	7.21	102	96	102	100.00	3.46	107	115	115	112.33	4.62	116	118	120	118.00	2.00	156	158	160	158.00	2.00
7	DBK	52	Female	94	92	92	92.67	1.15	100	98	98	98.67	1.15	101	96	96	97.67	2.89	94	94	92	93.33	1.15	96	96	94	95.33	1.15
8	JCF	54	Female	104	104	108	105.33	2.31	115	123	122	120.00	4.36	113	114	110	112.33	2.08	100	102	102	101.33	1.15	142	142	142	142.00	0.00
9	JRB	53	Female	114	113	105	110.67	4.93																				
12	EFK	57	Female	99	104	106	103.00	3.61	96	100	105	100.33	4.51	106	108	109	107.67	1.53	92	90	94	92.00	2.00	95	96	94	95.00	1.00
17	BFH	59	Female	104	102	101	102.33	1.53	106	109	113	109.33	3.51	118	120	124	120.67	3.06	116	116	122	118.00	3.46	124	122	124	123.33	1.15
18	LJR	58	Female	93	94	95	94.00	1.00	102	107	112	107.00	5.00	105	108	108	107.00	1.73	118	126	121	121.67	4.04	107	111	113	110.33	3.06
19	DJM	58	Female	106	106	112	108.00	3.46	128	128	130	128.67	1.15	118	114	123	118.33	4.51	152	142	154	149.33	6.43	148	146	148	147.33	1.15
20	RLA	45	Female	0	0	0																						
21	LGD	57	Female	139	144	144	142.33	2.89	129	124	128	127.00	2.65	126	135	138	133.00	6.24	170	168	172	170.00	2.00	110	105	110	108.33	2.89
24	VIP	52	Female	94	99	100	97.67	3.21	117	115	120	117.33	2.52	127	123	120	123.33	3.51	130	118	126	124.67	6.11	106	103	108	105.67	2.52
26	PKM	46	Female	94	100	100	98.00	3.46	100	104	108	104.00	4.00	108	108	100	105.33	4.62	160	160	158	156.33	5.51					
27	SMM	59	Female	98	100	99	99.00	1.00	114	108	117	113.00	4.58	127	127	126	126.67	0.58	120	122	121	121.00	1.00	130	134	132	132.00	2.00
28	EJD	58	Female	0	0	0			0	0	0																	
31	JAC	56	Female	108	113	111	110.67	2.52	96	99	95	96.67	2.08	145	147	152	148.00	3.61	116	121	124	120.33	4.04	131	137	138	135.33	3.79
32	TML	38	Female	103	101	104	102.67	1.53	115	118	115	116.00	1.73	96	95	101	97.33	3.21	158	162	153	157.67	4.51	92	96	98	95.33	3.06
38	DKD	50	Female	101	103	98	100.67	2.52	100	104	105	103.00	2.65	98	107	104	103.00	4.58	110	121	114	115.00	5.57	132	132	134	132.67	1.15
40	CLM	43	Female	100	98	104	100.67	3.06	94	105	100	99.67	5.51	104	108	111	107.67	3.51	122	118	122	120.67	2.31	101	106	110	105.67	4.51
44	GSR	52	Female	104	106	101	103.67	2.52	104	99	101	101.33	2.52	96	99	100	98.33	2.08	94	94	96	94.67	1.15	106	106	105	105.67	0.58
46	LAA	55	Female	101	103	101	101.67	1.15	98	101	106	101.67	4.04	122	124	121	122.33	1.53	116	114	114	114.67	1.15	112	113	121	115.33	4.93
47	CMP	47	Female	98	98	100	98.67	1.15	102	104	102	102.67	1.15	111	114	117	114.00	3.00	128	134	142	134.67	7.02	110	108	106	108.00	2.00
49	LR	58	Female	158	164	163	161.67	3.21	175	174	178	175.67	2.08	140	138	140	139.33	1.15	162	168	160	163.33	4.16	143	138	143	141.33	2.89
51	PCB	59	Female	104	106	104	104.67	1.15	94	92	96	94.00	2.00	108	103	112	107.67	4.51	93	94	100	95.67	3.79	102	103	103	102.67	0.58
54	TWS	55	Female	172	171	169	170.67	1.53	204	223	210	212.33	9.71															
57	MDS	52	Female	99	103	106	102.67	3.51	100	92	94	95.33	4.16	95	100	98	97.67	2.52	98	104	102	101.33	3.06	109	114	113	112.00	2.65
59	GFM	64	Female	106	106	109	107.00	1.73	99	106	106	103.67	4.04	110	111	111	110.67	0.58	138	144	132	138.00	6.00	112	111	111	111.33	0.58
60	JLF	32	Female	124	127	125	125.33	1.53	109	115	118	114.00	4.58	112	101	104	105.67	5.69	143	138	140	140.33	2.52	114	123	122	119.67	4.93
61	GEP	53	Female	160	160	164	161.33	2.31																				
64	KKF	36	Female	105	97	104	102.00	4.36	132	136	138	135.33	3.06	102	106	102	103.33	2.31	116	120	125	120.33	4.51	98	104	109	103.67	5.51
65	EMM	39	Female	110	125	128	121.00	9.64	104	105	104	104.33	0.58	106	109	116	110.33	5.13	92	92	101	95.00	5.20	146	154	149	149.67	4.04
66	CYR	39	Female	102	97	99	99.33	2.52	105	104	110	106.33	3.21	115	114	118	115.67	2.08	105	106	102	104.33	2.08	114	111	113	112.67	1.53
67	AMM	37	Female	169	151	182	167.33	15.57	106	112	116	111.33	5.03	121	118	120	119.67	1.53	106	107	107	106.67	0.58	108	108	109	108.33	0.58
	Discontinued					Mean	111.31				Mean	114.03				Mean	113.14				Mean	120.80				Mean	119.38	
						SD	21.52				SD	24.83				SD	12.63				SD	22.89				SD	18.62	
						Median	102.67				Median	106.33				Median	110.50				Median	119.17				Median	112.00	
						N	29				N	29				N	28				N	28				N	27	

Intra-Subject Change in DPM Values of Both Cheeks (Average of Right and Left)

Subject No.	Subject Initials	Age	Gender	Week 2 vs. Baseline					Week 4 vs. Baseline					Week 8 vs. Baseline					Week 12 vs. Baseline				
				Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
1	SDC	40	Female																				
2	MLE	50	Female	8	5	14	9.00	4.58	2	15	-6	3.67	10.60	-10	-1	-5	-5.33	4.51	50	45	47	47.33	2.52
3	SKH	47	Female	-6	-2	-10	-6.00	4.00	-1	17	3	6.33	9.45	8	20	8	12.00	6.93	48	60	48	52.00	6.93
7	DBK	52	Female	6	6	6	6.00	0.00	7	4	4	5.00	1.73	0	2	0	0.67	1.15	2	4	2	2.67	1.15
8	JCF	54	Female	11	19	14	14.67	4.04	9	10	2	7.00	4.36	-4	-2	-6	-4.00	2.00	38	38	34	36.67	2.31
9	JRB	53	Female																				
12	EFK	57	Female	-3	-4	-1	-2.67	1.53	7	4	3	4.67	2.08	-7	-14	-12	-11.00	3.61	-4	-8	-12	-8.00	4.00
17	BFH	59	Female	2	7	12	7.00	5.00	14	18	23	18.33	4.51	12	14	21	15.67	4.73	20	20	23	21.00	1.73
18	LJR	58	Female	9	13	17	13.00	4.00	12	14	13	13.00	1.00	25	32	26	27.67	3.79	14	17	18	16.33	2.08
19	D-M	58	Female	22	22	18	20.67	2.31	12	8	11	10.33	2.08	46	36	42	41.33	5.03	42	40	36	39.33	3.06
20	RLA	45	Female																				
21	LGD	57	Female	-10	-20	-16	-15.33	5.03	-13	-9	-6	-9.33	3.51	31	24	28	27.67	3.51	-29	-39	-34	-34.00	5.00
24	VIP	52	Female	23	16	20	19.67	3.51	33	24	20	25.67	6.66	36	19	26	27.00	8.54	12	4	8	8.00	4.00
26	PKM	46	Female	6	4	8	6.00	2.00	14	8	0	7.33	7.02	56	60	59	58.33	2.08					
27	SMM	59	Female	16	8	18	14.00	5.29	29	27	27	27.67	1.15	22	22	22	22.00	0.00	32	34	33	33.00	1.00
28	EJD	56	Female																				
31	JAC	56	Female	-12	-14	-16	-14.00	2.00	37	34	41	37.33	3.51	8	8	13	9.67	2.89	23	24	27	24.67	2.08
32	TML	38	Female	12	17	11	13.33	3.21	-7	-6	-3	-5.33	2.08	55	61	49	55.00	6.00	-11	-5	-6	-7.33	3.21
39	DKD	50	Female	-1	1	7	2.33	4.16	-3	4	6	2.33	4.73	9	18	16	14.33	4.73	31	29	36	32.00	3.61
40	CLM	43	Female	-6	7	-4	-1.00	7.00	4	10	7	7.00	3.00	22	20	18	20.00	2.00	1	8	6	5.00	3.61
44	GSR	52	Female	0	-7	0	-2.33	4.04	-8	-7	-1	-5.33	3.79	-10	-12	-5	-9.00	3.61	2	0	4	2.00	2.00
46	LAA	55	Female	-3	-2	5	0.00	4.36	21	21	20	20.67	0.58	15	11	13	13.00	2.00	11	10	20	13.67	5.51
47	CMP	47	Female	4	6	2	4.00	2.00	13	16	17	15.33	2.08	30	36	42	36.00	6.00	12	10	6	9.33	3.06
49	L-R	58	Female	17	10	15	14.00	3.61	-18	-26	-23	-22.33	4.04	4	4	-3	1.67	4.04	-15	-26	-20	-20.33	5.51
51	PCB	59	Female	-10	-14	-8	-10.67	3.06	4	-3	8	3.00	5.57	-11	-12	-4	-9.00	4.36	-2	-3	-1	-2.00	1.00
54	TWS	55	Female	32	52	41	41.67	10.02															
57	MDS	52	Female	1	-11	-12	-7.33	7.23	-4	-3	-8	-5.00	2.65	-1	1	-4	-1.33	2.52	10	11	7	9.33	2.08
59	GFM	64	Female	-7	0	-3	-3.33	3.51	4	5	2	3.67	1.53	32	38	23	31.00	7.55	6	5	2	4.33	2.08
60	JLF	32	Female	-15	-12	-7	-11.33	4.04	-12	-26	-21	-19.67	7.09	19	11	15	15.00	4.00	-10	-4	-3	-5.67	3.79
61	GEF	53	Female																				
64	KKF	36	Female	27	39	34	33.33	6.03	-3	9	-2	1.33	6.66	11	23	21	18.33	6.43	-7	7	5	1.67	7.57
65	EMM	39	Female	-6	-20	-24	-16.67	9.45	-4	-16	-12	-10.67	6.11	-18	-33	-27	-26.00	7.55	36	29	21	28.67	7.51
66	CYR	39	Female	3	7	11	7.00	4.00	13	17	19	16.33	3.06	3	9	3	5.00	3.46	12	14	14	13.33	1.15
67	AMM	37	Female	-63	-39	-66	-56.00	14.80	-48	-33	-62	-47.67	14.50	-63	-44	-75	-60.67	15.63	-61	-43	-73	-59.00	15.10
	Discontinued					Mean	2.72				Mean	3.95				Mean	11.61				Mean	9.78	
						SD	17.80				SD	16.83				SD	24.26				SD	24.31	
						Median	4.00				Median	4.83				Median	13.67				Median	9.33	
						N	29				N	28				N	28				N	27	

				Baseline					Week 2					Week 4					Week 8					Week 12				
Subject No.	Subject Initials	Age	Gender	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
1	SDC	40	Female	98	102	98	98.00	3.46																				
2	MLE	50	Female	106	98	104	102.67	4.16	108	102	110	106.67	4.16	110	110	94	104.67	9.24	92	96	96	94.67	2.31	148	132	140	140.00	8.00
3	SKH	47	Female	104	100	106	104.00	4.00	106	98	106	103.33	4.62	106	114	120	113.33	7.02	112	112	112	112.00	0.00	148	152	160	153.33	6.11
7	DBK	52	Female	98	94	94	95.33	2.31	102	98	98	99.33	2.31	108	96	94	99.33	7.57	92	92	92	92.00	0.00	96	96	94	95.33	1.15
8	JCF	54	Female	102	102	102	102.00	0.00	104	112	106	107.33	4.16	100	108	104	104.00	4.00	92	100	96	96.00	4.00	140	148	144	144.00	4.00
9	JRB	53	Female	114	116	104	111.33	6.43																				
12	EFK	57	Female	106	108	108	107.33	1.15	96	104	104	101.33	4.62	94	98	100	97.33	3.06	94	90	98	94.00	4.00	96	98	94	96.00	2.00
17	BRH	59	Female	108	100	102	103.33	4.16	108	108	114	110.00	3.46	116	118	126	120.00	5.29	120	120	128	122.67	4.62	126	122	122	123.33	2.31
18	LJR	58	Female	94	92	92	92.67	1.15	108	114	118	113.33	5.03	114	118	118	116.67	2.31	108	116	110	111.33	4.16	114	118	118	116.67	2.31
19	D-M	58	Female	116	112	116	114.67	2.31	134	134	134	134.00	0.00	110	110	116	112.00	3.46	148	140	156	148.00	8.00	154	158	154	155.33	2.31
20	RLA	45	Female																									
21	LGO	57	Female	150	150	154	151.33	2.31	120	116	108	114.67	6.11	122	128	130	126.67	4.16	176	168	172	172.00	4.00	110	110	110	110.00	0.00
24	VIP	52	Female	96	100	104	100.00	4.00	126	118	122	122.00	4.00	118	118	110	115.33	4.62	124	112	120	118.67	6.11	106	96	106	102.67	5.77
26	PKM	46	Female	92	92	92	92.00	0.00	100	100	104	101.33	2.31	98	98	102	99.33	2.31	152	164	160	158.67	6.11					
27	SMM	59	Female	100	104	104	102.67	2.31	116	112	122	116.67	5.03	122	124	126	124.00	2.00	120	120	114	118.00	3.46	128	132	134	131.33	3.06
28	EJO	56	Female																									
31	JAC	56	Female	100	108	96	101.33	6.11	100	88	96	98.00	2.00	140	144	156	146.67	8.33	114	118	126	119.33	6.11	128	134	138	133.33	5.03
32	TML	38	Female	92	102	94	96.00	5.29	104	106	96	102.00	5.29	94	94	98	95.33	2.31	156	156	140	150.67	9.24	94	98	98	96.67	2.31
39	DKD	50	Female	98	98	100	98.67	1.15	104	108	112	108.00	4.00	98	104	106	102.67	4.16	110	118	114	114.00	4.00	126	130	126	127.33	2.31
40	CLM	43	Female	100	104	100	101.33	2.31	92	104	100	98.67	6.11	114	114	120	116.00	3.46	120	120	124	121.33	2.31	100	106	106	104.00	3.46
44	GSR	52	Female	92	112	96	100.00	10.58	96	98	92	95.33	3.06	92	94	102	96.00	5.29	92	92	92	92.00	0.00	98	100	102	100.00	2.00
46	LAA	55	Female	92	102	96	96.67	5.03	100	96	106	100.67	5.03	122	126	128	125.33	3.06	108	100	108	105.33	4.62	106	108	116	110.00	5.29
47	CMP	47	Female	100	104	108	104.00	4.00	100	92	104	98.67	6.11	122	118	126	122.00	4.00	124	128	136	129.33	6.11	114	112	108	111.33	3.06
49	L-R	58	Female	162	166	172	166.67	5.03	178	170	170	172.67	4.62	146	136	138	140.00	5.29	168	168	164	166.67	2.31	142	142	136	140.00	3.46
51	PCB	59	Female	92	96	96	94.67	2.31	96	92	92	93.33	2.31	108	106	114	109.33	4.16	92	92	92	92.00	0.00	94	106	96	99.33	6.11
54	TWS	55	Female	162	164	158	161.33	3.06	222	236	230	229.33	7.02															
57	MDS	52	Female	104	110	110	108.00	3.46	108	92	92	97.33	9.24	90	94	94	92.67	2.31	92	96	96	94.67	2.31	106	108	108	107.33	1.15
59	GFM	64	Female	116	108	110	111.33	4.16	106	112	108	108.67	3.06	98	104	102	101.33	3.06	116	120	120	118.67	2.31	118	114	118	116.67	2.31
60	JLF	32	Female	126	118	124	122.67	4.16	106	112	116	112.00	6.00	114	104	102	106.67	6.43	136	128	124	129.33	6.11	118	128	122	122.67	5.03
61	GEP	53	Female	180	174	174	176.33	3.06																				
64	KKF	36	Female	96	94	100	96.67	3.06	144	146	150	146.67	3.06	94	102	96	97.33	4.16	112	124	128	121.33	8.33	94	98	98	96.67	2.31
65	EMM	39	Female	116	114	130	118.00	10.58	106	108	108	107.33	1.15	102	106	114	107.33	6.11	92	92	108	97.33	9.24	150	158	152	153.33	4.16
66	CYR	39	Female	102	102	98	100.67	2.31	106	106	112	108.00	3.46	112	114	118	114.67	3.06	110	108	100	106.00	5.29	122	116	116	118.00	3.46
67	AMM	37	Female	164	142	156	154.00	11.14	108	116	114	112.67	4.16	118	116	118	118.00	0.00	112	114	110	112.00	2.00	110	110	106	108.67	2.31
	Discontinued					Mean	110.34				Mean	114.46				Mean	111.57				Mean	118.14				Mean	119.01	
						SD	20.90				SD	27.58				SD	13.35				SD	22.97				SD	19.06	
						Median	102.67				Median	107.33				Median	110.67				Median	116.00				Median	116.67	
						N	29				N	29				N	28				N	28				N	27	

Sponsor's Test Article Code:
GROUP B

Data Listing 4
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Intra-Subject Change in DPM Values of the Right Cheek

Subject No.	Subject Initials	Age	Gender	Week 2 vs. Baseline					Week 4 vs. Baseline					Week 8 vs. Baseline					Week 12 vs. Baseline				
				Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
1	SDC	40	Female																				
2	MLE	50	Female	2	4	6	4.00	2.00	4	12	-10	2.00	11.14	-14	-2	-8	-8.00	6.00	42	34	36	37.33	4.16
3	SKH	47	Female	2	-2	-2	-0.67	2.31	2	14	12	9.33	6.43	8	12	4	8.00	4.00	44	52	52	49.33	4.62
7	DBK	52	Female	4	4	4	4.00	0.00	10	2	0	4.00	5.29	-6	-2	-2	-3.33	2.31	-2	2	0	0.00	2.00
8	JCF	54	Female	2	10	4	5.33	4.16	-2	6	2	2.00	4.00	-10	-2	-6	-6.00	4.00	38	46	42	42.00	4.00
9	JRB	53	Female																				
12	EFK	57	Female	-10	-4	-4	-6.00	3.46	-12	-10	-8	-10.00	2.00	-12	-18	-10	-13.33	4.16	-10	-10	-14	-11.33	2.31
17	BFH	59	Female	0	8	12	6.67	6.11	8	18	24	16.67	8.08	12	20	26	19.33	7.02	18	22	20	20.00	2.00
18	LJR	58	Female	14	22	26	20.67	6.11	20	26	26	24.00	3.46	14	24	18	18.67	5.03	20	26	26	24.00	3.46
19	D-M	58	Female	18	22	18	19.33	2.31	-6	-2	0	-2.67	3.06	32	28	40	33.33	6.11	38	46	38	40.67	4.62
20	RLA	45	Female	0	0	0																	
21	LGD	57	Female	-30	-34	-46	-36.67	8.33	-28	-22	-24	-24.67	3.06	26	18	18	20.67	4.62	-40	-40	-44	-41.33	2.31
24	VIP	52	Female	30	18	18	22.00	6.93	22	18	6	15.33	8.33	28	12	16	18.67	8.33	10	-4	2	2.67	7.02
26	PKM	46	Female	8	8	12	9.33	2.31	6	6	10	7.33	2.31	60	72	68	66.67	6.11	-92	-92	-92	-92.00	0.00
27	SMM	59	Female	16	8	18	14.00	5.29	22	20	22	21.33	1.15	20	16	10	15.33	5.03	28	28	30	28.67	1.15
28	EJD	56	Female																				
31	JAC	56	Female	0	-10	0	-3.33	5.77	40	36	60	45.33	12.86	14	10	30	18.00	10.58	28	26	42	32.00	8.72
32	TML	38	Female	12	4	2	6.00	5.29	2	-8	4	-0.67	6.43	64	54	46	54.67	9.02	2	-4	4	0.67	4.16
39	DKD	50	Female	6	10	12	9.33	3.06	0	6	6	4.00	3.46	12	20	14	15.33	4.16	28	32	26	28.67	3.06
40	CLM	43	Female	-8	0	0	-2.67	4.62	14	10	20	14.67	5.03	20	16	24	20.00	4.00	0	2	6	2.67	3.06
44	GSR	52	Female	4	-14	-4	-4.67	9.02	0	-18	6	-4.00	12.49	0	-20	-4	-8.00	10.58	6	-12	6	0.00	10.39
46	LAA	55	Female	8	-6	10	4.00	8.72	30	24	32	28.67	4.16	16	-2	12	8.67	9.45	14	6	20	13.33	7.02
47	CMP	47	Female	0	-12	-4	-5.33	6.11	22	14	18	18.00	4.00	24	24	28	25.33	2.31	14	8	0	7.33	7.02
49	L-R	58	Female	16	4	-2	6.00	9.17	-16	-30	-34	-26.67	9.45	6	2	-8	0.00	7.21	-20	-24	-36	-26.67	8.33
51	PCB	59	Female	4	-4	-4	-1.33	4.62	16	10	18	14.67	4.16	0	-4	-4	-2.67	2.31	2	10	2	4.67	4.62
54	TWS	55	Female	60	72	72	68.00	6.93															
57	MDS	52	Female	4	-18	-18	-10.67	12.70	-14	-16	-16	-15.33	1.15	-12	-14	-14	-13.33	1.15	2	-2	-2	-0.67	2.31
59	GFM	64	Female	-10	4	-2	-2.67	7.02	-18	-4	-8	-10.00	7.21	0	12	10	7.33	6.43	2	6	8	5.33	3.06
60	JLF	32	Female	-20	-6	-6	-10.67	8.08	-12	-14	-22	-16.00	5.29	10	10	0	6.67	5.77	-8	10	-2	0.00	9.17
61	GEP	53	Female																				
64	KKF	36	Female	48	52	50	50.00	2.00	-2	8	-4	0.67	6.43	16	30	28	24.67	7.57	-2	4	-2	0.00	3.46
65	EMM	39	Female	-4	-6	-22	-10.67	9.87	-8	-8	-16	-10.67	4.62	-18	-22	-22	-20.67	2.31	40	44	22	35.33	11.72
66	CYR	39	Female	4	4	14	7.33	5.77	10	12	20	14.00	5.29	8	6	2	5.33	3.06	20	14	18	17.33	3.06
67	AMM	37	Female	-56	-26	-42	-41.33	15.01	-46	-24	-38	-36.00	11.14	-52	-28	-46	-42.00	12.49	-54	-32	-50	-45.33	11.72
	Discontinued					Mean	4.11				Mean	3.05				Mean	9.62				Mean	9.88	
						SD	20.74				SD	17.99				SD	21.85				SD	23.78	
						Median	4.00				Median	3.00				Median	8.33				Median	5.33	
						N	29				N	28				N	28				N	27	

				Baseline					Week 2					Week 4					Week 8					Week 12				
Subject No.	Subject Initials	Age	Gender	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
1	SDC	40	Female	92	100	100	97.33	4.62																				
2	MLE	50	Female	98	94	96	96.00	2.00	112	100	118	110.00	9.17	98	112	94	101.33	9.45	92	94	94	93.33	1.15	156	150	154	153.33	3.06
3	SKH	47	Female	112	96	116	108.00	10.58	98	94	98	96.67	2.31	108	116	110	111.33	4.16	120	124	128	124.00	4.00	164	164	160	162.67	2.31
7	DBK	52	Female	90	90	90	90.00	0.00	98	98	98	98.00	0.00	94	96	98	96.00	2.00	96	96	92	94.67	2.31	96	96	94	95.33	1.15
8	JCF	54	Female	106	106	114	108.67	4.62	126	134	136	132.67	6.11	126	120	116	120.67	5.03	108	104	108	106.67	2.31	144	136	140	140.00	4.00
9	JRB	53	Female	114	110	106	110.00	4.00																				
12	EFK	57	Female	92	100	104	98.67	6.11	96	96	106	99.33	5.77	118	118	118	118.00	0.00	90	90	90	90.00	0.00	94	94	94	94.00	0.00
17	BFH	59	Female	100	104	100	101.33	2.31	104	110	112	108.67	4.16	120	122	122	121.33	1.15	112	112	116	113.33	2.31	122	122	126	123.33	2.31
18	LJR	58	Female	92	96	98	95.33	3.06	96	100	106	100.67	5.03	96	98	98	97.33	1.15	128	136	132	132.00	4.00	100	104	108	104.00	4.00
19	D-M	58	Female	96	100	108	101.33	6.11	122	122	126	123.33	2.31	126	118	130	124.67	6.11	156	144	152	150.67	6.11	142	134	142	139.33	4.62
20	RLA	45	Female																									
21	LGD	57	Female	128	138	134	133.33	5.03	138	132	148	139.33	8.08	130	142	146	139.33	8.33	164	168	172	168.00	4.00	110	100	110	106.67	5.77
24	VIP	52	Female	92	98	96	95.33	3.06	108	112	118	112.67	5.03	136	128	130	131.33	4.16	136	124	132	130.67	6.11	106	110	110	108.67	2.31
26	PKM	46	Female	96	108	108	104.00	6.93	100	108	112	106.67	6.11	118	118	98	111.33	11.55	148	156	156	154.00	5.29					
27	SMM	59	Female	96	96	94	95.33	1.15	112	104	112	109.33	4.62	132	130	126	129.33	3.06	120	124	128	124.00	4.00	132	136	130	132.67	3.06
28	EJD	56	Female																									
31	JAC	56	Female	116	118	126	120.00	5.29	92	100	94	95.33	4.16	150	150	148	149.33	1.15	118	124	122	121.33	3.06	134	140	138	137.33	3.06
32	TML	38	Female	114	100	114	109.33	8.08	126	130	134	130.00	4.00	98	96	104	99.33	4.16	160	168	166	164.67	4.16	90	94	88	94.00	4.00
39	DKD	50	Female	104	108	96	102.67	6.11	96	100	98	98.00	2.00	98	110	102	103.33	6.11	110	124	114	116.00	7.21	138	134	142	138.00	4.00
40	CLM	43	Female	100	92	108	100.00	8.00	96	106	100	100.67	5.03	94	102	102	99.33	4.62	124	116	120	120.00	4.00	102	106	114	107.33	5.11
44	GSR	52	Female	116	100	106	107.33	8.08	112	100	110	107.33	6.43	100	104	98	100.67	3.06	96	96	100	97.33	2.31	114	112	108	111.33	3.06
46	LAA	55	Female	110	104	106	106.67	3.06	96	106	106	102.67	5.77	122	122	114	119.33	4.62	124	128	120	124.00	4.00	118	118	126	120.67	4.62
47	CMP	47	Female	96	92	92	93.33	2.31	104	116	100	106.67	8.33	100	110	108	106.00	5.29	132	140	148	140.00	8.00	106	104	104	104.67	1.15
49	L-R	58	Female	154	162	154	156.67	4.62	172	178	186	178.67	7.02	134	140	142	138.67	4.16	156	168	156	160.00	6.93	144	134	150	142.67	8.08
51	PCB	59	Female	116	116	112	114.67	2.31	92	92	100	94.67	4.62	108	100	110	106.00	5.29	94	96	108	99.33	7.57	110	100	108	106.00	5.29
54	TWS	55	Female	182	178	180	180.00	2.00	186	210	190	195.33	12.86															
57	MDS	52	Female	94	96	102	97.33	4.16	92	92	96	93.33	2.31	100	106	102	102.67	3.06	104	112	108	108.00	4.00	112	120	118	116.67	4.16
59	GFM	64	Female	96	104	108	102.67	6.11	92	100	104	98.67	6.11	122	118	120	120.00	2.00	160	168	144	157.33	12.22	106	108	104	106.00	2.00
60	JLF	32	Female	122	136	126	128.00	7.21	112	118	118	116.00	3.46	110	98	106	104.67	6.11	150	148	156	151.33	4.16	110	118	122	116.67	6.11
61	OEP	53	Female	160	146	154	153.33	7.02																				
64	KKF	36	Female	114	100	108	107.33	7.02	120	126	126	124.00	3.46	110	110	108	109.33	1.15	120	116	122	119.33	3.06	102	110	120	110.67	9.02
65	EMM	39	Female	110	136	126	124.00	13.11	102	102	100	101.33	1.15	110	112	118	113.33	4.16	92	92	94	92.67	1.15	142	150	146	146.00	4.00
66	CYR	39	Female	102	92	100	98.00	5.29	104	102	108	104.67	3.06	118	114	118	116.67	2.31	100	104	104	102.67	2.31	106	106	110	107.33	2.31
67	AMM	37	Female	174	160	208	180.67	24.68	104	108	118	110.00	7.21	124	118	122	121.33	3.06	100	100	104	101.33	2.31	106	106	112	108.00	3.46
	Discontinued					Mean	112.28				Mean	113.61				Mean	114.71				Mean	123.45				Mean	119.75	
						SD	23.52				SD	23.61				SD	13.93				SD	24.13				SD	19.10	
						Median	104.00				Median	106.67				Median	112.33				Median	120.67				Median	111.33	
						N	29				N	29				N	28				N	28				N	27	

Data Listing 4
A CLINICAL STUDY OF TOPICAL ZEATIN FOR IMPROVING THE APPEARANCE OF PHOTODAMAGED SKIN

Intra-Subject Change in DPM Values of the Left Cheek

Subject No.	Subject Initials	Age	Gender	Week 2 vs. Baseline					Week 4 vs. Baseline					Week 8 vs. Baseline					Week 12 vs. Baseline				
				Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD	Measurement 1	Measurement 2	Measurement 3	Mean	SD
1	SDC	40	Female																				
2	MLE	50	Female	14	6	22	14.00	8.00	0	18	-2	5.33	11.02	-6	0	-2	-2.67	3.06	58	56	58	57.33	1.15
3	SKH	47	Female	-14	-2	-18	-11.33	8.33	-4	20	-6	3.33	14.47	8	28	12	16.00	10.58	52	68	44	54.67	12.22
7	DBK	52	Female	8	8	8	8.00	0.00	4	6	8	6.00	2.00	6	6	2	4.67	2.31	6	6	4	5.33	1.15
8	JCF	54	Female	20	28	24	24.00	4.00	20	14	2	12.00	9.17	2	-2	-6	-2.00	4.00	38	30	26	31.33	6.11
9	JRB	53	Female																				
12	EFK	57	Female	4	-4	2	0.67	4.16	26	18	14	19.33	6.11	-2	-10	-14	-8.67	6.11	2	-6	-10	-4.67	6.11
17	BFH	59	Female	4	6	12	7.33	4.16	20	18	22	20.00	2.00	12	8	16	12.00	4.00	22	18	26	22.00	4.00
18	LJR	58	Female	4	4	8	5.33	2.31	4	2	0	2.00	2.00	36	40	34	36.67	3.06	8	8	10	8.67	1.15
19	D-M	58	Female	26	22	18	22.00	4.00	30	18	22	23.33	6.11	60	44	44	49.33	9.24	46	34	34	38.00	6.93
20	RLA	45	Female																				
21	LGD	57	Female	10	-6	14	6.00	10.58	2	4	12	6.00	5.29	36	30	38	34.67	4.16	-18	-38	-24	-26.67	10.26
24	VIP	52	Female	16	14	22	17.33	4.16	44	30	34	36.00	7.21	44	26	36	35.33	9.02	14	12	14	13.33	1.15
26	PKM	46	Female	4	0	4	2.67	2.31	22	10	-10	7.33	16.17	52	48	50	50.00	2.00	-96	-108	-108	-104.00	6.93
27	SMM	59	Female	16	8	18	14.00	5.29	36	34	32	34.00	2.00	24	28	34	28.67	5.03	36	40	36	37.33	2.31
28	EJD	56	Female																				
31	JAC	56	Female	-24	-16	-32	-24.67	7.02	34	32	22	29.33	6.43	2	6	-4	1.33	5.03	18	22	12	17.33	5.03
32	TML	38	Female	12	30	20	20.67	9.02	-16	-4	-10	-10.00	6.00	46	68	52	55.33	11.37	-24	-6	-16	-15.33	9.02
39	DKD	50	Female	-8	-8	2	-4.67	5.77	-6	2	6	0.67	6.11	6	16	18	13.33	6.43	34	26	46	35.33	10.07
40	CLM	43	Female	-4	14	-8	0.67	11.72	-6	10	-6	-0.67	9.24	24	24	12	20.00	6.93	2	14	6	7.33	6.11
44	GSR	52	Female	-4	0	4	0.00	4.00	-16	4	-8	-6.67	10.07	-20	-4	-6	-10.00	8.72	-2	12	2	4.00	7.21
46	LAA	55	Female	-14	2	0	-4.00	8.72	12	18	8	12.67	5.03	14	24	14	17.33	5.77	8	14	20	14.00	6.00
47	CMP	47	Female	8	24	8	13.33	9.24	4	18	16	12.67	7.57	36	48	56	46.67	10.07	10	12	12	11.33	1.15
49	L-R	58	Female	18	16	32	22.00	8.72	-20	-22	-12	-18.00	5.29	2	6	2	3.33	2.31	-10	-28	-4	-14.00	12.49
51	PCB	59	Female	-24	-24	-12	-20.00	6.93	-8	-16	-2	-8.67	7.02	-22	-20	-4	-15.33	9.87	-6	-16	-4	-8.67	6.43
54	TWS	55	Female	4	32	10	15.33	14.74															
57	MDS	52	Female	-2	-4	-6	-4.00	2.00	6	10	0	5.33	5.03	10	16	6	10.67	5.03	18	24	16	19.33	4.16
59	GFM	64	Female	-4	-4	-4	-4.00	0.00	26	14	12	17.33	7.57	64	64	36	54.67	16.17	10	4	-4	3.33	7.02
60	JLF	32	Female	-10	-18	-8	-12.00	5.29	-12	-38	-20	-23.33	13.32	28	12	30	23.33	9.87	-12	-18	-4	-11.33	7.02
61	GEP	53	Female																				
64	KKF	38	Female	6	28	18	16.67	10.07	-4	10	0	2.00	7.21	6	16	14	12.00	5.29	-12	10	12	3.33	13.32
65	EMM	39	Female	-8	-34	-26	-22.67	13.32	0	-24	-8	-10.67	12.22	-18	-44	-32	-31.33	13.01	32	14	20	22.00	9.17
66	CYR	39	Female	2	10	8	6.67	4.16	16	22	18	18.67	3.06	-2	12	4	4.67	7.02	4	14	10	9.33	5.03
67	AMM	37	Female	-70	-52	-90	-70.67	19.01	-50	-42	-86	-59.33	23.44	-74	-60	-104	-79.33	22.48	-68	-54	-96	-72.67	21.39
	Discontinued					Mean	1.33				Mean	4.86				Mean	13.60				Mean	9.68	
						SD	19.27				SD	19.25				SD	28.83				SD	26.23	
						Median	5.33				Median	5.67				Median	12.67				Median	9.33	
						N	29				N	28				N	28				N	27	

Baseline to Week 2
Diary Comments

Subject No.	Initials	Age	Sex	Diary Comments (Baseline-Week Two Visit)
4	SKH	46	F	Disappears quickly. Skin feeling much smoother. Skin seems to be getting tighter.
10	JCL	41	F	Have noticed no difference.
11	TLM	50	F	Goes a long way. Helps make-up come off more easily.
15	NHK	56	F	Skin feeling sticky and tacky. Tacky in p.m. Dry in a.m. Blemishes present. Skin rough and dry.
16	VLH	57	F	Went on smooth.
25	TJJ	40	F	Make-up looks cakey after sunblock. Chin broke out.
29	DSE	59	F	Fast-absorbing; non-greasy; smooth.
36	MAE	51	F	Gentle and mild.
42	KAM	52	F	Skin felt tight.
43	CGC	48	F	Makes my face very dry.
45	TDC	48	F	Redness still there but no worse. Redness still on right cheek. Redness still there.
48	JLL	47	F	Notice blemishes.
50	DKH	49	F	Feels tight, but not uncomfortable. Feels more moist but firm. My face is feeling smoother.
52	CJL	53	F	Seems to clear skin up.
53	DSB	54	F	Improved wrinkles. Dryness, tight, tingling, redness-blotchy. Skin clearer. I can tell a marked difference in appearance.
55	SKR	57	F	Too dry. My skin doesn't feel moisturized after it dries.
58	CZR	49	F	Feels kind of greasy. Feels o.k. Feels good. Feels like face is tight. Feels O.K. Smooth.
70	CAC	62	F	Slight burning; face slightly red, felt soft. Slight swelling under right eye.
72	NRC	56	F	No irritation.
73	NLW	47	F	Jaw area began to breakout. Notice dry patches. Dryness continued. Skin very dry.

Week 2 to Week 4
Diary Comments

Subject No.	Initials	Age	Sex	Diary Comments (Baseline-Week Four Visit)
5	LMP	45	F	Starting to feel a little greasy.
10	JCL	41	F	Product absorbs well. Still haven't noticed improvement.
11	TLM	50	F	Burns your eyes when you wash it off.
29	DSE	59	F	No complications; continues to go on smoothly and absorb fast. Non-greasy; sunscreen is slightly greasy.
43	CGC	48	F	Makes my face very dry.
50	DKH	49	F	Face feels smoother after use.
53	DSB	53	F	Dryness. Put vaseline at eyes.
55	SKR	57	F	I noticed a little improvement.

Week 4 to Week 8
Diary Comments

Subject No.	Initials	Age	Sex	Diary Comments (Baseline-Week Two Visit)
5	LMP	45	F	Greasy feeling, but dry after a few minutes.
43	CGC	48	F	Moisturizes and sunblock is feeling better. Skin not as dry
45	TDC	48	F	Redness on right cheek.
50	DKH	49	F	Face feels firm and moist. Starting to get blemishes. Still feels smooth, but causing break-outs.
55	SKR	57	F	I can tell some difference for the better.

Week 8 to Week 12
Diary Comments

Subject No.	Initials	Age	Sex	Diary Comments (Baseline-Week Two Visit)
29	DSE	59	F	Makes my skin softer.
43	CGC	48	F	Skin dry.
50	DKH	49	F	Face feels smooth and moist. Face has dewy look.
55	SKR	57	F	Really like product!
69	GHD	55	F	The sunscreen clogs my pores.

Baseline to Week 2
Diary Comments

Subject No.	Initials	Age	Sex	Diary Comments (Baseline-Week Four Visit)
3	SKH	47	F	Soaks in skin quick. Started noticing some dryness around eye area. Quit putting so close to eye (outside). Like how it goes on skin-few minutes after, you can put make-up on. Like it.
7	DBK	52	F	Clear, cool, feels good. Don't like the sunblock. Sunblock burns my eyes.
8	JCF	54	F	Liked creaminess - no irritation. Dries fairly quickly.
17	BFH	59	F	I like the cream; it makes your face feel good, not greasy. I really like this product.
18	LJR	58	F	Skin feels tighter after application of product.
19	D-M	58	F	Feels soft, but not greasy. Feels and acts more like a hand lotion. I can tell my face is drying. Face is very dry. There are a couple of rough spots. Face feels like it's sloughing.
27	SMM	59	F	Soaks in quickly.
32	TML	38	F	Recurring blemishes.
39	DKD	50	F	Dries fast! Doesn't glide on slippery. Feels kind of stiff on skin. Easy to put make-up over, because it dries so fast.
49	L-R	58	F	Skin seems somewhat tightened.
59	GFM	64	F	Goes on smooth. No odor (great), no burn, and doesn't feel heavy.
60	JLF	32	F	I like how soft my face feels and the fact that the lotion does not smell bad.
65	EMM	39	F	Dryness.
66	CYR	39	F	The product feels soft.
67	AMM	37	F	Make-up went on smoother.

Week 2 to Week 4
Diary Comments

Subject No.	Initials	Age	Sex	Diary Comments (Baseline-Week Four Visit)
3	SKH	47	F	Like the tightness. Needs a little moisturizer in product.
17	BFH	59	F	Skin felt tight after study but it is now back to normal.
19	D-M	58	F	Face is peeled. Face is getting smoother. Face feels very smooth. Had a pimple-type bump. Face is drying again. Bump is gone.
40	CLM	43	F	It makes my face break out.
59	GFM	64	F	Goes on smooth. Slight redness. Feels o.k. Lines at eyes look less. Skin feels dry.

Week 4 to Week 8
Diary Comments

Subject No.	Initials	Age	Sex	Diary Comments (Baseline-Week Four Visit)
7	DBK	52	F	I see no change. I used both. Tanning one burns my eyes. The other is o.k. I don't like either cream. They don't feel the same as before. Sunscreen burns my eyes.
8	JCF	54	F	This face cream feels more creamy and not as drying as the other. I really like this cream - has no irritation.
17	BFH	59	F	Felt good to apply cream. Feels better than my cream. Absorbs quickly. Not at all greasy.
19	D-M	58	F	Seems like brown spots are disappearing. Face feels real smooth. My face looks really good - no more bumps or peeling.
27	SMM	59	F	Skin getting oily.
59	GFM	64	F	Face appears to look better.
67	AMM	37	F	Face clearing some. Face not completely clear, but looking better. 5.25.05 Face completely clear.

Week 8 to Week 12
Diary Comments

Subject No.	Initials	Age	Sex	Diary Comments (Baseline-Week Four Visit)
7	DBK	52	F	I used both. I still don't care for sunblock. I can see some difference but not as much as I thought I would have.
8	JCF	54	F	Soft and creamy.
17	BFH	59	F	I love this product. Don't like the sunscreen. It's helping my wrinkles. Sunscreen is pasty when used with the cream but I like it. I like the sunscreen a little better since I used the cream--it gets kind of pasty. I like the feel of this cream. I have grown to like the sunscreen and have used it more if out in the sun. I would love to know how to purchase this cream.
19	D-M	58	F	Face feels really smooth. People are making comments. -"I really look rested." etc.

Test Article Weight Tables

Distributed to Subject No:	Sample Number	Date Distributed	Weight (in grams) at Time of Distribution	Weight (in grams) at Time of Turning in the Sample:	Date Product Turned In for Weighing	Days Used	Amount Used (in grams)	Use up Rate (in grams)
4	4	4/11/2005	99.15	59.87	5/9/2005	28	39.28	1.40
	1	5/9/2005	97.29	82.02	6/6/2005	28	15.27	0.55
	57	6/6/2005	97.47	55.60	7/1/2005	25	41.87	1.67
5	5	4/11/2005	97.33	72.48	5/9/2005	28	24.85	0.89
	2	5/9/2005	97.45	43.59	6/6/2005	28	53.86	1.92
	56	6/6/2005	96.82	43.75	7/1/2005	25	53.07	2.12
6	6	4/11/2005	97.44	93.08	4/18/2005	7	4.36	0.62
10	10	4/12/2005	97.27	52.74	5/10/2005	28	44.53	1.59
	7	5/10/2005	96.84	61.10	6/7/2005	28	35.74	1.28
	59	6/7/2005	96.98	68.17	7/5/2005	28	28.81	1.03
11	11	4/12/2005	97.43	71.06	5/10/2005	28	26.37	0.94
	3	5/10/2005	97.47	62.65	6/7/2005	28	34.82	1.24
	60	6/7/2005	97.41	54.72	7/5/2005	28	42.69	1.52
13	13	4/12/2005	97.60	54.93	5/10/2005	28	42.67	1.52
	8	5/10/2005	98.09	55.16	6/7/2005	28	42.93	1.53
	66	6/7/2005	97.48	52.93	7/5/2005	28	44.55	1.59
14	14	4/12/2005	98.24	86.58	5/10/2005	28	11.66	0.42
	9	5/10/2005	97.26	91.28	6/7/2005	28	5.98	0.21
	67	6/7/2005	97.06	90.76	7/5/2005	28	6.30	0.23
15	15	4/12/2005	97.66	88.38	4/26/2005	14	9.28	0.66
16	16	4/12/2005	97.23	78.99	5/10/2005	28	18.24	0.65
	12	5/10/2005	97.23	83.05	6/7/2005	28	14.18	0.51
	61	6/7/2005	96.91	83.30	7/5/2005	28	13.61	0.49
23	23	4/14/2005	97.45	47.41	5/12/2005	28	50.04	1.79
	20	5/12/2005	97.21	70.56	6/9/2005	28	26.65	0.95
	80	6/9/2005	97.10	84.96	7/7/2005	28	12.14	0.43
25	25	4/14/2005	97.10	77.81	5/12/2005	28	19.29	0.69
	22	5/12/2005	98.29	82.46	6/9/2005	28	15.83	0.57
	75	6/9/2005	97.48	36.29	7/7/2005	28	61.19	2.19
29	29	4/15/2005	97.87	77.40	5/13/2005	28	20.47	0.73
	21	5/13/2005	99.71	79.26	6/10/2005	28	20.45	0.73
	82	6/10/2005	97.07	76.57	7/8/2005	28	20.50	0.73
30	30	4/15/2005	97.15	30.07	5/13/2005	28	67.08	2.40
	27	5/13/2005	96.90	24.84	6/10/2005	28	72.06	2.57
	76	6/10/2005	96.77	23.40	7/8/2005	28	73.37	2.62
35	35	4/18/2005	96.95	68.17	5/17/2005	29	28.78	0.99
	54	5/17/2005	97.63	73.17	6/13/2005	27	24.46	0.91
	83	6/13/2005	97.22	74.30	7/11/2005	28	22.92	0.82
36	36	4/18/2005	97.47	44.38	5/16/2005	28	53.09	1.90
	38	5/16/2005	97.53	41.98	6/14/2005	29	55.55	1.92
	88	6/14/2005	97.00	51.50	7/12/2005	28	45.50	1.63
37	37	4/18/2005	96.75	45.65	5/17/2005	29	51.10	1.76
	44	5/17/2005	97.26	63.86	6/13/2005	27	33.40	1.24
	84	6/13/2005	96.93	38.30	7/11/2005	28	58.63	2.09
41	41	4/19/2005	97.03	55.79	5/17/2005	28	41.24	1.47
	46	5/17/2005	97.21	35.51	6/14/2005	28	61.70	2.20
	86	6/14/2005	97.30	34.77	7/12/2005	28	62.53	2.23
42	42	4/19/2005	95.89	74.78	5/17/2005	28	21.11	0.75
	51	5/17/2005	97.21	76.52	6/14/2005	28	20.69	0.74
	89	6/14/2005	97.61	76.19	7/12/2005	28	21.42	0.77
43	43	4/13/2005	97.56	72.56	5/11/2005	28	25.00	0.89
	17	5/11/2005	97.09	70.58	6/8/2005	28	26.51	0.95
	64	6/8/2005	97.15	82.76	7/6/2005	28	14.39	0.51
45	45	4/13/2005	98.14	82.40	5/11/2005	28	15.74	0.56
	18	5/11/2005	97.17	82.25	6/8/2005	28	14.92	0.53
	65	6/8/2005	97.27	81.81	7/6/2005	28	15.46	0.55
48	48	4/13/2005	97.08	82.48	5/11/2005	28	14.60	0.52
	19	5/11/2005	97.43	82.15	6/8/2005	28	15.28	0.55
	79	6/8/2005	97.33	77.45	7/6/2005	28	19.88	0.71
50	50	4/14/2005	99.17	52.85	5/16/2005	32	46.32	1.45
	33	5/16/2005	97.14	46.76	6/10/2005	25	50.38	2.02
	87	6/10/2005	97.20	44.13	7/8/2005	28	53.07	1.90
52	52	4/15/2005	97.81	57.53	5/13/2005	28	40.28	1.44
	34	5/13/2005	97.17	56.01	6/10/2005	28	41.16	1.47
	77	6/10/2005	97.33	45.74	7/8/2005	28	51.59	1.84
53	53	4/15/2005	97.00	54.74	5/13/2005	28	42.26	1.51
	26	5/13/2005	97.42	40.54	6/10/2005	28	56.88	2.03
	78	6/10/2005	96.98	52.25	7/8/2005	28	44.73	1.60
55	55	4/15/2005	97.34	87.32	5/13/2005	28	10.02	0.36
	28	5/13/2005	96.68	87.06	6/10/2005	28	9.62	0.34
	81	6/10/2005	97.22	74.80	7/8/2005	28	22.42	0.80
58	58	4/18/2005	97.32	28.26	5/16/2005	28	69.06	2.47
	31	5/16/2005	97.49	57.35	6/14/2005	29	40.14	1.38
	90	6/14/2005	97.15	45.72	7/12/2005	28	51.43	1.84
62	62	4/18/2005	97.12	66.93	5/16/2005	28	30.19	1.08
	32	5/16/2005	97.28	66.23	6/13/2005	28	31.05	1.11
	94	6/13/2005	97.22	67.57	7/11/2005	28	29.65	1.06
63	63	4/18/2005	98.52	NR				
68	68	4/19/2005	97.11	63.09	5/17/2005	28	34.02	1.22
	39	5/17/2005	97.34	53.14	6/14/2005	28	44.20	1.58
	95	6/14/2005	97.31	52.46	7/12/2005	28	44.85	1.60
69	69	4/19/2005	97.45	74.15	5/17/2005	28	23.30	0.83
	40	5/17/2005	97.10	64.85	6/14/2005	28	32.25	1.15
	85	6/14/2005	97.51	53.87	7/12/2005	28	43.64	1.56

Test Article Weight Tables

Distributed to Subject No:	Sample Number	Date Distributed	Weight (in grams) at Time of Distribution	Weight (in grams) at Time of Turning in the Sample:	Date Product Turned In for Weighing	Days Used	Amount Used (in grams)	Use up Rate (in grams)
70	70	4/19/2005	97.19	29.73	5/13/2005	24	67.46	2.81
	24	5/13/2005	97.47	29.41	6/7/2005	25	68.06	2.72
	74	6/7/2005	97.38	53.46	6/23/2005	16	43.92	2.75
	96	6/23/2005	97.40	33.55	7/11/2005	18	63.85	3.55
71	71	4/19/2005	97.14	74.52	5/17/2005	28	22.62	0.81
	47	5/17/2005	97.36	63.98	6/14/2005	28	33.38	1.19
	92	6/14/2005	97.13	61.96	7/12/2005	28	35.17	1.26
72	72	4/19/2005	97.10	73.23	5/17/2005	28	23.87	0.85
	49	5/17/2005	97.11	78.50	6/14/2005	28	18.61	0.66
	93	6/14/2005	97.52	80.43	7/12/2005	28	17.09	0.61
73	73	4/19/2005	97.37	77.13	5/3/2005	14	20.24	1.45
	91*		97.50					
	97*		97.30					
	98*		97.06					
	99*		96.65					

Discontinued
*Product never distributed
NR-product was not returned

Mean	1.29
SD	0.70
Median	1.22
N	91

Test Article Weight Tables

Distributed to Subject No:	Sample Number	Date Distributed	Weight (in grams) at Time of Distribution	Weight (in grams) at Time of Turning in the Sample:	Date Product Turned In for Weighing	Days Used	Amount Used (in grams)	Use up Rate (in grams)
1	2	4/11/2005	96.78	NR				
2	1	4/11/2005	97.44	59.85	5/10/2005	29	37.59	1.30
	13	5/10/2005	97.57	69.17	6/6/2005	27	28.40	1.05
	68	6/6/2005	97.42	39.55	7/1/2005	25	57.87	2.31
3	3	4/11/2005	97.55	31.29	5/9/2005	28	66.26	2.37
	5	5/9/2005	97.53	40.96	6/6/2005	28	56.57	2.02
	52	6/6/2005	97.51	39.15	7/1/2005	25	58.36	2.33
7	7	4/11/2005	97.66	70.97	5/10/2005	29	26.69	0.92
	11	5/10/2005	97.64	59.50	6/6/2005	27	38.14	1.41
	53	6/6/2005	97.60	59.40	7/1/2005	25	38.20	1.53
8	8	4/11/2005	97.82	52.10	5/9/2005	28	45.72	1.63
	6	5/9/2005	98.35	71.62	6/6/2005	28	26.73	0.95
	55	6/6/2005	97.64	49.79	7/1/2005	25	47.85	1.91
9	9	4/11/2005	97.79	NR				
12	12	4/12/2005	98.12	63.66	5/10/2005	28	34.46	1.23
	14	5/10/2005	97.46	57.59	6/7/2005	28	39.87	1.42
	56	6/7/2005	97.89	50.50	7/5/2005	28	47.39	1.69
17	17	4/12/2005	97.71	70.26	5/10/2005	28	27.45	0.98
	15	5/10/2005	97.49	76.23	6/7/2005	28	21.26	0.76
	58	6/7/2005	97.66	71.24	7/5/2005	28	26.42	0.94
18	18	4/12/2005	97.85	39.19	5/10/2005	28	58.66	2.10
	16	5/10/2005	97.96	48.40	6/7/2005	28	49.56	1.77
	62	6/7/2005	97.45	51.66	7/5/2005	28	45.79	1.64
19	19	4/12/2005	97.32	50.87	5/10/2005	28	46.45	1.66
	10	5/10/2005	97.59	50.12	6/6/2005	27	47.47	1.76
	69	6/7/2005	97.59	40.20	7/5/2005	28	57.39	2.05
21	21	4/14/2005	97.56	78.38	5/12/2005	28	19.18	0.69
	23	5/12/2005	97.71	79.88	6/9/2005	28	17.83	0.64
	76	6/9/2005	96.88	67.57	7/7/2005	28	29.31	1.05
24	24	4/14/2005	96.84	69.99	5/12/2005	28	26.85	0.96
	28	5/12/2005	97.58	74.35	6/9/2005	28	23.23	0.83
	77	6/9/2005	97.60	66.06	7/7/2005	28	31.54	1.13
26	26	4/14/2005	97.56	69.31	5/13/2005	29	28.25	0.97
	33	5/13/2005	97.24	66.55	6/15/2005	33	30.69	0.93
	74	6/15/2005	97.77	NR				
27	27	4/14/2005	98.01	63.08	5/12/2005	28	34.93	1.25
	25	5/12/2005	97.77	58.26	6/9/2005	28	39.51	1.41
	71	6/9/2005	97.85	61.77	7/7/2005	28	36.08	1.29
31	31	4/18/2005	96.75	65.73	5/13/2005	25	31.02	1.24
	29	5/13/2005	98.07	60.16	6/10/2005	28	37.91	1.35
	72	6/10/2005	97.79	47.39	7/8/2005	28	50.40	1.80
32	32	4/15/2005	97.48	63.07	5/13/2005	28	34.41	1.23
	38	5/13/2005	97.80	59.34	6/10/2005	28	38.46	1.37
	79	6/10/2005	97.77	57.38	7/8/2005	28	40.39	1.44
39	39	4/19/2005	98.09	59.81	5/17/2005	28	38.28	1.37
	45	5/17/2005	97.80	52.79	6/14/2005	28	45.01	1.61
	92	6/14/2005	97.89	50.58	7/12/2005	28	47.31	1.69
40	40	4/18/2005	97.53	85.00	5/17/2005	29	12.53	0.43
	50	5/17/2005	97.86	92.63	6/13/2005	27	5.23	0.19
	86	6/13/2005	97.53	86.95	7/11/2005	28	10.58	0.38
44	44	4/19/2005	97.19	64.15	5/17/2005	28	33.04	1.18
	48	5/17/2005	97.40	62.38	6/14/2005	28	35.02	1.25
	81	6/14/2005	97.39	48.52	7/12/2005	28	48.87	1.75
46	46	4/13/2005	97.29	70.51	5/11/2005	28	26.78	0.96
	20	5/11/2005	99.99	81.86	6/8/2005	28	18.13	0.65
	63	6/8/2005	97.75	73.46	7/6/2005	28	24.29	0.87
47	47	4/13/2005	97.16	80.56	5/11/2005	28	16.60	0.59
	22	5/11/2005	97.60	49.38	6/8/2005	28	48.22	1.72
	70	6/8/2005	97.95	52.09	7/6/2005	28	45.86	1.64
49	49	4/14/2005	97.83	60.71	5/13/2005	29	37.12	1.28
	34	5/13/2005	97.63	33.75	6/13/2005	31	63.88	2.06
	90	6/13/2005	97.88	37.04	7/11/2005	28	60.84	2.17
51	51	4/15/2005	97.50	39.22	5/13/2005	28	58.28	2.08
	30	5/13/2005	97.47	40.43	6/10/2005	28	57.04	2.04
	73	6/10/2005	97.81	38.76	7/8/2005	28	59.05	2.11
54	54	4/15/2005	97.45	68.62	5/11/2005	26	28.83	1.11
57	57	4/18/2005	97.78	73.55	5/16/2005	28	24.23	0.87
	35	5/16/2005	97.61	70.38	6/13/2005	28	27.23	0.97
	97	6/13/2005	97.49	59.78	7/11/2005	28	37.71	1.35
59	59	4/18/2005	97.96	31.71	5/16/2005	28	66.25	2.37
	4	5/16/2005	97.54	53.97	6/13/2005	28	43.57	1.56
	83	6/13/2005	97.31	45.76	7/11/2005	28	51.55	1.84
60	60	4/18/2005	97.62	64.41	5/16/2005	28	33.21	1.19
	36	5/16/2005	101.65	75.28	6/13/2005	28	26.37	0.94
	82	6/13/2005	97.74	66.39	7/11/2005	28	31.35	1.12
61	61	4/18/2005	96.95	NR				
64	64	4/19/2005	97.78	83.38	5/16/2005	27	14.40	0.53
	37	5/16/2005	97.61	73.58	6/13/2005	28	24.03	0.86
	91	6/13/2005	97.30	80.55	7/11/2005	28	16.75	0.60
65	65	4/19/2005	97.77	51.51	5/17/2005	28	46.26	1.65
	41	5/17/2005	96.63	55.63	6/14/2005	28	41.00	1.46
	87	6/14/2005	97.57	56.88	7/12/2005	28	40.69	1.45
66	66	4/19/2005	97.93	49.31	5/17/2005	28	48.62	1.74
	42	5/17/2005	97.74	57.07	6/14/2005	28	40.67	1.45
	85	6/14/2005	97.52	55.80	7/12/2005	28	41.72	1.49

Test Article Weight Tables

Distributed to Subject No:	Sample Number	Date Distributed	Weight (in grams) at Time of Distribution	Weight (in grams) at Time of Turning in the Sample:	Date Product Turned In for Weighing	Days Used	Amount Used (in grams)	Use up Rate (in grams)
67	67	4/19/2005	98.41	50.77	5/17/2005	28	47.64	1.70
	43	5/17/2005	97.55	68.08	6/14/2005	28	29.47	1.05
	80	6/14/2005	97.79	62.27	7/12/2005	28	35.52	1.27
	75*		97.87					
	78*		98.02					
	84*		97.67					
	88*		97.86					
	89*		97.67					
	93*		98.02					
	94*		97.43					
	95*		97.71					
	96*		97.32					
	98*		97.47					
	99*		97.68					

Discontinued
*Product never distributed
NR-product was not returned

Mean	1.37
Median	1.37
SD	0.50
N	81

Test Article Weight Tables

Distributed to Subject No:	Sample Number	Date Distributed	Weight (in grams) at Time of Distribution	Weight (in grams) at Time of Turning in the Sample:	Date Product Turned In for Weighing	Days Used	Amount Used (in grams)	Use up Rate (in grams)
1	82	4/11/2005	152.62	NR				
2	2	4/11/2005	151.62	133.28	5/10/2005	29	18.34	0.63
	38	5/10/2005	155.89	140.63	6/6/2005	27	15.26	0.57
	129	6/6/2005	156.39	118.37	7/1/2005	25	38.02	1.52
3	123	4/11/2005	157.30	98.41	5/9/2005	28	58.89	2.10
	5	5/9/2005	154.48	102.98	6/6/2005	28	51.50	1.84
	125	6/6/2005	151.33	112.60	7/1/2005	25	38.73	1.55
4	119	4/11/2005	156.79	114.23	5/9/2005	28	42.56	1.52
	1	5/9/2005	152.70	118.86	6/6/2005	28	33.84	1.21
	128	6/6/2005	155.26	97.93	7/1/2005	25	57.33	2.29
5	92	4/11/2005	156.05	91.29	5/9/2005	28	64.76	2.31
	3	5/9/2005	151.09	118.28	6/6/2005	28	32.81	1.17
	126	6/6/2005	153.59	64.63	7/1/2005	25	88.96	3.56
6	6	4/11/2005	155.12	153.81	4/18/2005	7	1.31	0.19
7	7	4/11/2005	151.73	82.79	5/10/2005	29	68.94	2.38
	130	6/6/2005	153.30	123.83	7/1/2005	25	29.47	1.18
8	8	4/11/2005	155.07	127.97	5/9/2005	28	27.10	0.97
	4	5/9/2005	150.94	134.23	6/6/2005	28	16.71	0.60
	131	6/6/2005	155.89	142.52	7/1/2005	25	13.37	0.53
9	9	4/11/2005	151.93	NR				
10	10	4/12/2005	152.33	125.97	5/10/2005	28	26.36	0.94
	74	5/10/2005	153.00	143.53	6/7/2005	28	9.47	0.34
	140	6/7/2005	155.71	143.17	7/5/2005	28	12.54	0.45
11	11	4/12/2005	156.28	151.30	5/10/2005	28	4.98	0.18
	28	5/10/2005	155.14	110.64	6/7/2005	28	44.50	1.59
	133	6/7/2005	154.96	142.52	7/1/2005	24	12.44	0.52
12	12	4/12/2005	150.13	141.24	5/10/2005	28	8.89	0.32
	34	5/10/2005	155.68	139.47	6/7/2005	28	16.21	0.58
	141	6/7/2005	153.91	126.80	7/5/2005	28	27.11	0.97
13	13	4/12/2005	153.27	140.66	5/10/2005	28	12.61	0.45
	56	5/10/2005	151.87	136.92	6/7/2005	28	14.95	0.53
	160	6/7/2005	156.05	139.83	7/5/2005	28	16.22	0.58
14	14	4/12/2005	156.96	148.21	5/10/2005	28	8.75	0.31
	68	5/10/2005	150.21	144.29	6/7/2005	28	5.92	0.21
	146	6/7/2005	155.22	151.22	7/5/2005	28	4.00	0.14
15	15	4/12/2005	150.61	144.34	4/26/2005	14	6.27	0.45
16	16	4/12/2005	152.74	148.12	5/10/2005	28	4.62	0.17
	75	5/10/2005	153.34	148.65	6/7/2005	28	4.69	0.17
	145	6/7/2005	154.91	144.44	7/5/2005	28	10.47	0.37
17	17	4/12/2005	151.46	95.83	5/10/2005	28	55.63	1.99
	76	5/10/2005	154.60	110.35	6/7/2005	28	44.25	1.58
	147	6/7/2005	155.71	40.47	7/5/2005	28	115.24	4.12
18	18	4/12/2005	156.85	109.42	5/10/2005	28	47.43	1.69
	77	5/10/2005	155.14	106.27	6/7/2005	28	48.87	1.75
	132	6/7/2005	153.69	118.94	7/5/2005	28	34.75	1.24
19	19	4/12/2005	154.90	139.79	5/10/2005	28	15.11	0.54
	22	5/10/2005	154.12	139.95	6/7/2005	28	14.17	0.51
	127	6/7/2005	153.73	137.84	7/5/2005	28	15.89	0.57
21	21	4/14/2005	156.29	117.97	5/12/2005	28	38.32	1.37
	84	5/12/2005	149.49	116.67	6/9/2005	28	32.82	1.17
	156	6/9/2005	155.46	118.76	7/7/2005	28	36.70	1.31
23	23	4/14/2005	157.08	96.16	5/12/2005	28	60.92	2.18
	85	5/12/2005	154.52	128.68	6/9/2005	28	25.84	0.92
	142	6/9/2005	155.79	141.16	7/7/2005	28	14.63	0.52
24	24	4/14/2005	156.20	136.58	5/12/2005	28	19.62	0.70
	86	5/12/2005	160.65	150.32	6/9/2005	28	10.33	0.37
	143	6/9/2005	154.75	144.79	7/7/2005	28	9.96	0.36
25	25	4/14/2005	156.27	150.75	5/12/2005	28	5.52	0.20
	87	5/12/2005	155.62	153.78	6/9/2005	28	1.84	0.07
	161	6/9/2005	154.57	139.83	7/5/2005	26	14.74	0.57
26	26	4/14/2005	155.51	145.79	5/13/2005	29	9.72	0.34
	97	5/13/2005	155.88	144.32	6/15/2005	33	11.56	0.35
	177	6/15/2005	156.20	NR				
27	27	4/14/2005	154.81	138.01	5/12/2005	28	16.80	0.60
	88	5/12/2005	152.32	127.84	6/9/2005	28	24.48	0.87
	149	6/9/2005	154.49	132.94	7/7/2005	28	21.55	0.77
29	29	4/15/2005	155.11	148.99	5/13/2005	28	6.12	0.22
	89	5/13/2005	155.66	149.30	6/10/2005	28	6.36	0.23
	150	6/10/2005	156.43	151.57	7/8/2005	28	4.86	0.17
30	30	4/15/2005	150.62	131.60	5/13/2005	28	19.02	0.68
	90	5/13/2005	157.74	124.70	6/10/2005	28	33.04	1.18
	151	6/10/2005	155.07	122.77	7/8/2005	28	32.30	1.15
31	31	4/18/2005	157.84	145.50	5/13/2005	25	12.34	0.49
	91	5/13/2005	156.00	146.57	6/10/2005	28	9.43	0.34
	144	6/10/2005	153.96	145.80	7/8/2005	28	8.16	0.29
32	32	4/15/2005	149.47	134.72	4/29/2005	14	14.75	1.05
33	33	5/10/2005	154.39	80.37	6/6/2005	27	74.02	2.74
35	35	4/8/2005	155.85	131.21	5/17/2005	39	24.64	0.63
	124	5/17/2005	153.76	136.50	6/13/2005	27	17.26	0.64
	148	6/13/2005	156.99	133.41	7/11/2005	28	23.58	0.84
36	36	4/18/2005	155.26	146.62	5/16/2005	28	8.64	0.31
	103	5/16/2005	154.37	113.61	6/14/2005	29	40.76	1.41
	166	6/14/2005	156.81	107.55	7/12/2005	28	49.26	1.76
37	37	4/18/2005	153.87	119.53	5/17/2005	29	34.34	1.18
	111	5/17/2005	155.06	123.11	6/13/2005	27	31.95	1.18
	163	6/13/2005	155.61	71.02	7/11/2005	28	84.59	3.02

Test Article Weight Tables

Distributed to Subject No:	Sample Number	Date Distributed	Weight (in grams) at Time of Distribution	Weight (in grams) at Time of Turning in the Sample:	Date Product Turned In for Weighing	Days Used	Amount Used (in grams)	Use up Rate (in grams)
39	39	4/19/2005	153.10	114.49	5/17/2005	28	38.61	1.38
	114	5/17/2005	156.37	115.72	6/14/2005	28	40.65	1.45
	176	6/14/2005	154.77	95.88	7/12/2005	28	58.89	2.10
40	40	4/18/2005	151.23	133.72	5/17/2005	29	17.51	0.60
	117	5/17/2005	155.15	149.66	6/13/2005	27	5.49	0.20
	171	6/13/2005	153.60	128.60	7/11/2005	28	25.00	0.89
41	41	4/19/2005	154.43	148.22	5/17/2005	28	6.21	0.22
	118	5/17/2005	155.46	150.98	6/14/2005	28	4.48	0.16
	165	6/13/2005	156.10	119.85	7/12/2005	29	36.25	1.25
	154	6/14/2005	153.71	153.21	7/12/2005	28	0.50	0.02
42	42	4/19/2005	155.55	150.20	5/17/2005	28	5.35	0.19
	122	5/17/2005	159.38	153.39	6/14/2005	28	5.99	0.21
	168	6/14/2005	154.01	145.63	7/12/2005	28	8.38	0.30
43	43	4/13/2005	154.23	145.51	5/11/2005	28	8.72	0.31
	78	5/11/2005	149.38	NR				
	134	6/8/2005	155.87	149.83	7/6/2005	28	6.04	0.22
44	44	4/19/2005	151.98	119.69	5/17/2005	28	32.29	1.15
	116	5/17/2005	153.50	102.38	6/14/2005	28	51.12	1.83
	153	6/14/2005	156.05	139.72	7/12/2005	28	16.33	0.58
45	45	4/13/2005	156.52	150.34	5/11/2005	28	6.18	0.22
	79	5/11/2005	155.96	148.90	6/8/2005	28	7.06	0.25
	135	6/8/2005	155.75	141.05	7/6/2005	28	14.70	0.53
46	46	4/13/2005	155.27	136.00	5/11/2005	28	19.27	0.69
	80	5/11/2005	150.69	125.65	6/8/2005	28	25.04	0.89
	136	6/8/2005	155.12	121.99	7/6/2005	28	33.13	1.18
47	47	4/13/2005	154.15	148.68	5/11/2005	28	5.47	0.20
	83	5/11/2005	155.51	145.18	6/8/2005	28	10.33	0.37
	138	6/8/2005	156.58	148.24	7/6/2005	28	8.34	0.30
48	48	4/13/2005	153.60	150.29	5/11/2005	28	3.31	0.12
	81	5/11/2005	150.23	147.36	6/8/2005	28	2.87	0.10
	137	6/8/2005	157.45	154.57	7/6/2005	28	2.88	0.10
49	49	4/14/2005	153.92	137.61	5/13/2005	29	16.31	0.56
	99	5/13/2005	149.90	81.67	6/13/2005	31	68.23	2.20
	164	6/13/2005	155.83	72.07	7/11/2005	28	83.76	2.99
50	50	4/14/2005	152.25	136.51	5/16/2005	32	15.74	0.49
	107	5/16/2005	153.47	103.51	6/10/2005	25	49.96	2.00
	157	6/10/2005	155.50	83.49	7/7/2005	27	72.01	2.67
51	51	4/15/2005	149.80	138.71	5/13/2005	28	11.09	0.40
	93	5/13/2005	161.35	151.24	6/10/2005	28	10.11	0.36
	158	6/10/2005	155.73	144.05	7/8/2005	28	11.68	0.42
52	52	4/15/2005	150.69	95.42	5/13/2005	28	55.27	1.97
	94	5/13/2005	157.54	104.23	6/10/2005	28	53.31	1.90
	155	6/10/2005	155.19	70.61	7/8/2005	28	84.58	3.02
53	53	4/15/2005	155.84	145.14	5/13/2005	28	10.70	0.38
	96	5/13/2005	154.96	141.23	6/10/2005	28	13.73	0.49
	159	6/10/2005	154.12	NR				
	178	7/1/2005	156.66	154.94	7/8/2005	7	1.72	0.25
54	54	4/15/2005	151.33	143.42	5/11/2005	26	7.91	0.30
55	55	4/15/2005	154.94	146.67	5/13/2005	28	8.27	0.30
	98	5/13/2005	155.93	145.72	6/10/2005	28	10.21	0.36
	170	6/10/2005	155.72	136.11	7/8/2005	28	19.61	0.70
57	57	4/18/2005	157.07	147.57	5/16/2005	28	9.50	0.34
	101	5/16/2005	155.87	150.03	6/13/2005	28	5.84	0.21
	173	6/13/2005	155.52	148.91	7/11/2005	28	6.61	0.24
58	58	4/18/2005	152.17	92.62	5/16/2005	28	59.55	2.13
	102	5/16/2005	153.26	74.86	6/14/2005	29	78.40	2.70
59	59	4/18/2005	156.24	77.22	5/16/2005	28	79.02	2.82
	104	5/16/2005	154.61	90.07	6/13/2005	28	64.54	2.31
	152	6/13/2005	153.22	107.58	7/11/2005	28	45.64	1.63
60	60	4/18/2005	153.69	121.47	5/16/2005	28	32.22	1.15
	105	5/16/2005	154.75	139.63	6/13/2005	28	15.12	0.54
	172	6/13/2005	155.85	143.55	7/11/2005	28	12.30	0.44
61	61	4/18/2005	154.18	NR				
62	62	4/18/2005	156.84	120.09	5/16/2005	28	36.75	1.31
	106	5/16/2005	154.29	101.25	6/13/2005	28	53.04	1.89
	174	6/13/2005	154.75	126.68	7/11/2005	28	28.07	1.00
64	64	4/18/2005	152.30	145.68	5/16/2005	28	6.62	0.24
	108	5/16/2005	152.91	134.40	6/13/2005	28	18.51	0.66
	169	6/13/2005	156.40	149.76	7/11/2005	28	6.64	0.24
65	65	4/18/2005	153.13	148.69	5/17/2005	29	4.44	0.15
	109	5/17/2005	156.38	129.44	6/14/2005	28	26.94	0.96
66	66	4/18/2005	155.72	104.39	5/17/2005	29	51.33	1.77
	110	5/17/2005	155.59	118.94	6/14/2005	28	36.65	1.31
	182	6/14/2005	157.85	76.19	7/12/2005	28	81.66	2.92
67	67	4/19/2005	150.36	145.80	5/17/2005	28	4.56	0.16
	112	5/17/2005	151.93	149.94	6/14/2005	28	1.99	0.07
	183	6/14/2005	153.93	151.78	7/12/2005	28	2.15	0.08
68	63	4/18/2005	153.34	146.31	5/17/2005	29	7.03	0.24
	113	5/17/2005	153.18	125.02	6/14/2005	28	28.16	1.01
	184	6/14/2005	156.40	140.18	7/12/2005	28	16.22	0.58
69	69	4/19/2005	153.60	137.54	5/17/2005	28	16.06	0.57
	115	5/17/2005	155.10	138.40	6/14/2005	28	16.70	0.60
	139	6/14/2005	154.71	87.92	7/12/2005	28	66.79	2.39
70	70	4/19/2005	150.55	131.00	5/13/2005	24	19.55	0.81
	95	5/13/2005	155.89	140.30	6/13/2005	31	15.59	0.50
	162	6/13/2005	155.78	137.90	7/11/2005	28	17.88	0.64

Test Article Weight Tables

Distributed to Subject No:	Sample Number	Date Distributed	Weight (in grams) at Time of Distribution	Weight (in grams) at Time of Turning in the Sample:	Date Product Turned In for Weighing	Days Used	Amount Used (in grams)	Use up Rate (in grams)
71	71	4/19/2005	156.92	150.54	5/17/2005	28	6.38	0.23
	120	5/17/2005	156.36	133.12	6/14/2005	28	23.24	0.83
	167	6/14/2005	156.44	124.80	7/12/2005	28	31.64	1.13
72	72	4/19/2005	154.93	148.39	5/17/2005	28	6.54	0.23
	121	5/17/2005	156.91	92.52	6/14/2005	28	64.39	2.30
	175	6/14/2005	156.86	131.48	7/12/2005	28	25.38	0.91
73	73	4/19/2005	155.44	147.18	5/3/2005	14	8.26	0.59
90	185	6/14/2005	152.57	81.73	7/12/2005	28	70.84	2.53
R	100		155.33					
	20*		153.29					
	179*		153.48					
	180*		155.20					
	181*		154.10					

Discontinued
*Product never distributed
NR-product was not returned

Mean	0.96
Median	0.63
SD	0.82
N	167

Adverse Events

Subject Number	Subject's Initials	Age	Gender	Group	Description of Adverse Event	Severity	Date of Onset	Frequency	Outcome of Event	Action Taken	Comments
4	SKH	46	F	A	Tightness	Mild (aware or unaware of event, but easily tolerated)	4/20/2005	Event occurred one time	Resolved without treatment	None	Panelist described a tight sensation after 9 days of use. The sensation lasted about an hour before subsiding and has not occurred again.
5	LMP	45	F	A	Bump	Mild (aware or unaware of event, but easily tolerated)	5/8/2005	Event occurred intermittently	Resolved without treatment	None	Panelist currently has a small bump on her chin. It will appear for a few days then go away. RCTS was notified at her Week 8 visit. Follow up is needed. 7/1/05 - Week 12 visit - no bumps or breakouts have recurred since the last one cleared up on 6/10.
6	PJW	43	F	A	Dryness	Moderate (discomfort enough to cause interference with usual activity)	4/14/2005	Event occurred one time	Resolved with treatment (explain in comment section)	Dropped subject from study	The subject called her doctor on Friday morning and got a prescription. The subject normally uses the cream on her eczema (not on the facial area). She is going to call back with the name of the cream. The subject used Desonide0.05% lotion GLA to help with the redness and dryness. AED 4/19/05 Spoke with panelist and she said that all irritation went away as of 4/24/05 and she didn't have any more problems. MR 5/19/05
					Redness with Bumps	Moderate (discomfort enough to cause interference with usual activity)	4/14/2005	Event occurred one time	Resolved with treatment (explain in comment section)	Dropped subject from study	The subject called her doctor on Friday morning and got a prescription. The subject normally uses the cream on her eczema (not on the facial area). She is going to call back with the name of the cream. The subject used Desonide0.05% lotion GLA to help with the redness and dryness. AED 4/19/05 Redness subsided per the subject on 4/19/05.
7	DBK	52	F	B	Eyes Burning	Mild (aware or unaware of event, but easily tolerated)	4/12/2005	Event occurred with each installation for 80 days	Resolved without treatment	None	Subject states that her eyes burn with every application of the sunscreen since 4/12/05. This event lasted for 10-60 seconds. Subject continues to experience this problem. Follow up is needed. DS 4/27/05. Still ongoing 5/10/05. Subject has glaucoma and says that she doesn't use the product close to her eyes to avoid the burning sensation. If panelist does use product around eyes she still experiences burning. Panelist is not taking medication and hasn't consulted a doctor. MR 5/19/05 6/6 Week 8 visit - AE still ongoing. DS. Panelist reports that due to a pre-existing condition, her eyes have been burning intermittently since before she began the study. DS 7/1/05
11	TLM	50	F	A	Burns Eyes	Mild (aware or unaware of event, but easily tolerated)	4/28/2005	Event occurred with each installation for 2 days	Resolved without treatment	None	Panelist described a burning sensation to her eyes whenever she would shower at night and the product would rinse off into her eyes from the previous am application. She said it happened a couple of times before she began rinsing more carefully with her eyes closed. RCTS was notified at her Week 4 visit. Panelist reports that after the first two times she would close her eyes while in the shower and has not experienced the burning sensation since. FJ 07/5/05
15	NHK	56	F	A	Blemishes (breakout)	Mild (aware or unaware of event, but easily tolerated)	4/15/2005	Event occurred with each installation for {ongoing}	Panelist lost to follow-up, no further data available	None	Subject has had a few breakouts above her eyebrows, on her chin, left temple and left cheek bone. She is still breaking out. Follow up is needed. DS 4/26/05. Followed up with 5/19/05 and panelist said that the breakouts on her chin and left cheek bone are gone but the breakouts above her eyebrows and left temple are still there. Panelist has not used any creams but has gone back to using her regular cleansing soap on her face. Needs follow up. MR 5/19/05
17	BFH	59	F	B	Tightness	Mild (aware or unaware of event, but easily tolerated)	4/27/2005	Event occurred one time	Resolved without treatment	None	Panelist described a tight sensation on 4/27. The sensation lasted until she was able to apply the product. She says it feels tight because she was unable to apply the product because that was the day of her visit. RCTS was notified at her Week 4 visit.
18	LJR	58	F	B	Tightness	Mild (aware or unaware of event, but easily tolerated)	4/15/2005	Event occurred one time	Resolved without treatment	None	Panelist described a tight feeling upon application after the second use. She said it was not a negative sensation and it did not happen again. RCTS was notified at her Week 2 visit.
19	D-M	58	F	B	Peeling/Sloughing	Mild (aware or unaware of event, but easily tolerated)	4/24/2005	Event occurred intermittently	Resolved without treatment	None	Panelist noticed some sloughing on 4/24 and it tends to last for a couple days before her face becomes smooth again. Sloughing/peeling is occuring intermittently; follow up is needed. Panelist called and left a message on 5/24 stating that the peeling/sloughing has subsided.
					Breakout	Mild (aware or unaware of event, but easily tolerated)	5/6/2005	Event occurred one time	Resolved without treatment	None	Panelist got a pimple on 5/6 and it lasted until 5/8. She thinks it could be due to the sunscreen since it is a very greasy product. RCTS was notified at her week 4 visit.
25	TJJ	40	F	B	Breakout	Mild (aware or unaware of event, but easily tolerated)	4/21/2005	Event occurred with each installation for {ongoing}	Resolved without treatment	None	Panelist noticed some breakouts on her cheeks on 4/21/05. Since then her cheeks have cleared up but her chin is currently broken out. RCTS was notified at her Week 2 visit. Follow up is needed. DS 4/28. Week 4 visit - panelist states breakout is almost gone. DS 5/12. Follow up still needed. Followed up with panelist on 5/19/05 and she said that the breakout was gone as of 5/15/05. They did not seek medical attention or use any creams to help with breakout. Panelist said she thought it was because she was using too much sunscreen on her face. MR 5/19/05
26	PKM	47	F	B	Surgery on Hand	Moderate (discomfort enough to cause interference with usual activity)	6/28/2005	Event occurred one time	Panelist lost to follow-up, no further data available	Dropped subject from study	Panelist went to the hospital for day surgery on 6/28/05 where they took cartlidge from her rib and put it in her hand where she had the arthritis (arthroplasty). The medicines she is currently taking, or has taken, include: Hydroco/apap-10mg taken every 3-4 hours as needed for pain and Cephalexin- 500mg, taken every 6 hours for three days. The panelist called in on 7/8/05 to cancel her regular appointment. The surgery had nothing to do with the study because the panelist had been experiencing pain in her hand for many years. Follow up needed. MR 7/8/05
30	MMC	64	F	A	Headache	Severe (incapacitating; unable to work or do usual activity)	4/20/2005	Event occurred one time	Resolved with treatment (explain in comment section)	None	Panelist reported headache on 4/29/05. The headache occurred on 4/20/05 and lasted 30 minutes. Panelist was given BC Powder (1 pkg) as treatment of headache.

Discontinued due to adverse event

Subject Number	Subject's Initials	Age	Gender	Group	Description of Adverse Event	Severity	Date of Onset	Frequency	Outcome of Event	Action Taken	Comments
32	TML	38	F	B	Blemishes	Mild (aware or unaware of event, but easily tolerated)	4/17/2005	Event occurred intermittently	Resolved without treatment	Discontinued test article (sunscreen) permanently	Panelist is breaking out. She thinks it is due to the sunscreen because she has been known to breakout to sunscreens in the past. She quit using the suncreen for a few days and the blemishes seemed to clear up until she spoke with me and I instructed her to continue using it and this resulted in more blemishes. Sub-Investigator instructed panelist to discontinue use of the sunscreen permanently. Follow up is needed. Since panelist has discontinued use of the sunscreen, her blemishes cleared up around May 1st and have not reoccurred. AE complete.
40	CLM	43	F	B	Breakout	Mild (aware or unaware of event, but easily tolerated)	4/26/2005	Event occurred intermittently	Resolved without treatment	None	Panelist noticed her face breaking out after the first week of use. She thought it was just hormonal until the breakouts kept coming up. RCTS was notified at her week 4 visit. Follow up is needed. Breakouts still ongoing. Intensity is still the same AD 6/14/05. Panelist stated she has not had a breakout during the last 4 weeks. Her breakouts would take 4-5 days before clearing up. AE resolved without treatment. RCTS was notified at her Week 12 visit.
42	KAM	52	F	A	Tightness	Mild (aware or unaware of event, but easily tolerated)	4/20/2005	Event occurred one time	Resolved without treatment	None	Panelist described a tight sensation upon the 2nd day of use. Sensation lasted 10 seconds and resolved on its own. DS 5/3/05
43	CGC	48	F	A	Breakout	Mild (aware or unaware of event, but easily tolerated)	5/25/2005	Event occurred intermittently	Resolved without treatment	None	Panelist is experiencing intermittent breakouts that last for about a week and a half before clearing up. She says she hasn't broken out in 20 years. Follow up is needed. Panelist is still breaking out intermittently. Follow up is still needed. DS 7/6.
45	TDC	48	F	A	Redness	Mild (aware or unaware of event, but easily tolerated)	5/4/2005	Event occurred one time	Panelist lost to follow-up, no further data available	None	Panelist states that redness on her face has become more intense this last week. RCTS was notified at her Week 4 visit. Follow up is needed. Redness is still there and hasn't gotten any worse, and panelist hasn't used any creams or visited a doctor. MR 5/19/05 Wk 8 Visit - AE still ongoing. Follow up still needed. DS 6/8. Wk 12 visit--AE still ongoing. Follow up still needed. FJ 07/06/05
48	JLL	47	F	A	Blemishes	Mild (aware or unaware of event, but easily tolerated)	4/20/2005	Event occurred intermittently	Resolved without treatment	None	Panelist noticed blemishes on her chin and forehead on 4/20/05. RCTS was notified on her Week 2 visit. Spoke to panelist on her Week 4 visit and she stated the blemishes cleared up by 4/30/05.
49	L-R	58	F	B	Tightness	Mild (aware or unaware of event, but easily tolerated)	4/15/2005	Event occurred one time	Resolved without treatment	None	Panelist described a tight feeling upon application after the second use. She said it was not a negative sensation and it did not happen again. RCTS was notified at her Week 2 visit.
50	DKH	49	F	A	Breakouts	Mild (aware or unaware of event, but easily tolerated)	5/21/2005	Event occurred intermittently	Resolved without treatment	None	Panelist is getting breakouts starting on 5/21. She is not treating the breakouts. RCTS was notified on her Week 8 visit. Still ongoing at Week 12 Visit. Follow up needed. Panelist stated at Week 12 visit that she's not sure the product is the cause of her breakouts. She thinks they might be due to stress. She is currently broken out so follow up is needed. DS 7/6
53	DSB	54	F	A	Bronchitis	Moderate (discomfort enough to cause interference with usual activity)	4/19/2005	Event occurred one time	Resolved with treatment (explain in comment section)	Discontinued test article temporarily	Panelist came down with bronchitis on 4/19 and was treated with Avelox 400 mg (antibiotic 1 tablet), then amoxicillin 500mg BID for 10 days; claritin 1 tablet SID for 10 days and Duraphen Forte 1 tablet BID or as needed. Bronchitis was resolved by 4/28/05. On 4/19 pm and 4/20 am panelist was in bed and did not apply any test article
					Tightness	Mild (aware or unaware of event, but easily tolerated)	4/24/2005	Event occurred with each installation for 10 days	Resolved with treatment (explain in comment section)	None	Panelist experienced a tight sensation on 4/24 and 4/25. The sensation lasted about 10 minutes before subsiding. Panelist did treat tightness with her own moisturizers (Oil of Olay and another product) until instructed otherwise. The tightness has not reoccurred and she will no longer use any other moisturizers besides the test article
54	TWS	55	F	B	Rash (bumps)	Mild (aware or unaware of event, but easily tolerated)	5/9/2005	Event occurred one time	Resolved with treatment (explain in comment section)	Dropped subject from study	Panelist has broken out in a rash. Small red bumps (rash) and pimples are present on both sides of her face. RCTS was notified 1 day before her Week 4 visit (5/11). She will treat the rash with her normal moisturizer (Oil of Olay) and a steriod or antibiotic cream. Panelist is dropped from the study due to this AE per Sub-Investigator. Still two areas with a rash located under left eye. Panelist has used a cream and will call back with name of cream. Panelist said that the rash is going away and the rash under her right eye has gone away today, 5/19/05. Still needs follow up. MR 5/19/05 Panelist is using Psorcon Diforosone Diacetiat to treat.
58	CZR	49	F	A	Tightness	Mild (aware or unaware of event, but easily tolerated)	4/26/2005	Event occurred one time	Resolved without treatment	None	Panelist experienced a tight sensation one minute after applying the product on 4/26. This event lasted three minutes before subsiding. RCTS was notified at her week 2 visit.
59	GFM	64	F	B	Slight Redness	Mild (aware or unaware of event, but easily tolerated)	5/3/2005	Event occurred one time	Resolved without treatment	None	Panelist developed slight redness on both her cheeks. Sensation didn't last more than a day and was gone by the time of the next application. RCTS was notified at her week 4 visit.
67	AMM	37	F	B	Breakout	Mild (aware or unaware of event, but easily tolerated)	5/14/2005	Event occurred one time	Resolved without treatment	None	Panelist broke out over the weekend (~5/14). She has 2 blemishes on her chin. RCTS was notified at her week 4 visit. Still ongoing. Follow up needed. Face was completely clear of breakouts by 5/25/05 AD 6/14/05.
69	GHD	55	F	B	Sunscreen Clogs Pores	Mild (aware or unaware of event, but easily tolerated)	5/19/2005	Event occurred intermittently	Resolved without treatment	None	Panelist says the sunscreen is clogging her pores. RCTS was notified at her Week 12 visit. AE ongoing; follow up is needed. DS 7/12
70	CAC	62	F	A	Redness	Mild (aware or unaware of event, but easily tolerated)	4/20/2005	Event occurred one time	Resolved without treatment	None	Panelist experienced some redness upon the first application of the test article. This event resolved without treatment by the next day and has not occurred again. RCTS was notified at her week 2 visit.
					Swelling under Right Eye	Mild (aware or unaware of event, but easily tolerated)	4/21/2005	Event occurred one time	Resolved without treatment	None	Panelist described swelling under her right eye after the 2nd day of use. No action was taken to treat the swelling and it resolved on its own by the next day. RCTS was notified at her week 2 visit.
					Watery Eye	Moderate (discomfort enough to cause interference with usual activity)	4/22/2005	Event occurred intermittently	Resolved without treatment	None	Panelist stated that her right eye would become watery after applying the test article. Sensation would occur intermittently but at night the sensation would last longer. Watery eye has not occurred since 4/27/05. Panelist also stated that this same time last year, her eyes were burning and itching and her eye doctor said it was probably due to pollen in the air.
73	NLW	47	F	A	Breakout	Mild (aware or unaware of event, but easily tolerated)	4/22/2005	Event occurred one time	Resolved without treatment	None	Panelist noticed a breakout along her lower right jawline. After about a week the breakouts turned into dry patches. See adverse event for dryness. Panelist states that breakouts occur as a result of dry skin.
					Dryness	Moderate (discomfort enough to cause interference with usual activity)	4/23/2005	Event occurred with each installation for	Resolved with treatment (explain in comment section)	Dropped subject from study	Panelist noticed some dry patches beginning on 4/23 and the dryness has since then gotten much worse. RCTS was notified on her week 2 visit. Follow up is needed. Panelist called and left a message stating that by 5/10 80% of the dryness had cleared up and by 5/17 all of the dryness had subsided. She was using her normal moisturizer to treat

Discontinued due to adverse event

Subj. No.	Subj. Initials	Visit	Deviation
10	JCL	Baseline	The room temperature (73.6°F) and relative humidity (32%) at the time of entry were not according to protocol (70+3°F, RH - 45+10%). The room temperature and relative humidity at the time of TEWL (73.9°F, 32%) and NOVA (73.6°F, 32%) measurements were not according to protocol (70±3°F, RH - 45±10%).
11	TLM	Baseline	The relative humidity (34%) of the room at the time of entry was not according to protocol (RH - 45±10%).
13	DKS	Baseline	The relative humidity (34%) of the room at the time of entry was not according to protocol (RH - 45±10%). Per diary, panelist used the product twice on the day of her baseline visit (04/12/05). Per Sub-investigator, panelist was allowed to continue with study.
19	D-M	Baseline	The relative humidity (32%) of the room at the time of entry was not according to protocol (RH - 45±10%). The relative humidity (33%) of the room at the time of TEWL and NOVA measurements was not according to protocol (RH - 45±10%). Per diary, panelist used the product the morning of her baseline visit on 04/12/05. Per Sub-investigator, panelist was allowed to continue with the study.
3	SKH	Week 2	Panelist has not used the sunscreen since her baseline visit. She told technician she didn't use it because she never went outside. She was instructed to use the sunscreen in the morning regardless if she was inside or outside. Per Sub-investigator, panelist was allowed to continue with the study.
4	SKH	Week 2	Per diary, panelist did not use the product the evening of her baseline visit.(4/11/05). Also, she used the product on the morning before her week 2 visit on 04/25/05. Per Sub-Investigator, panelist was allowed to continue with the study.
12	EFK	Week 2	Panelist did not use the sunscreen once daily as per protocol. She told technician that she only used it when she was outside although she was told to use it every day regardless. Per Sub-Investigator, panelist was allowed to continue with the study.
18	LJR	Week 2	Per diary, panelist did not use the product in the evening before bedtime on 04/12/05. Her baseline visit was earlier that day, and she only needed to use the product once that evening. Per Sub-Investigator, panelist was allowed to continue with the study.
26	PKM	Week 2	Panelist came in one day after her scheduled week 2 visit, which was on 4/28/05. Per Sub-investigator, panelist was allowed to continue with the study.
29	DSE	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (04/15/05). Per Sub-Investigator, panelist was allowed to continue with the study.
30	MMC	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (04/15/05). Per Sub-Investigator, panelist was allowed to continue with the study.
31	JAC	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (04/18/05). Panelist came in for her week 2 visit on 04/29/05, 3 days earlier than her scheduled visit (on 05/02/05). Per Sub-Investigator, panelist was allowed to continue with the study.
32	TML	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (04/15/05). Panelist used the product at 12:30 A.M. (04/22/05 and 04/23/05) for her P.M. regime (04/21/05 and 04/22/05). Panelist discontinued use of sunscreen permanently due to breakouts that recurred after temporary disuse of product. Per Sub-Investigator, panelist was allowed to continue with the study.
37	GLJ	Week 2	Per diary, panelist did not use the product in the evening before bedtime on 04/18/05, and she used the product on the morning of her week 2 visit (05/02/05). Per Sub-Investigator, panelist was allowed to continue with the study.
40	CLM	Week 2	The room temperature at the time of entry (73.2°F), time of TEWL measurements (74.5°F) and time of NOVA measurements (74.8°F) was not according to protocol (70±3°F). Per diary, panelist did not begin using product until the day after her baseline visit (04/19/05). Panelist came in for her week 2 visit on 05/03/05, one day later than her scheduled visit (on 05/02/05). PerSub-investigator, panelist was allowed to continue with the study.
41	E-N	Week 2	Panelist did not use the product in the morning (AM) on 4/26/05 because she inadvertently thought that was her visit day. Per Sub-investigator, panelist was allowed to continue with the study.
43	CGC	Week 2	Per diary, panelist used the product the morning of her baseline visit on 04/13/05. Per Sub-investigator, panelist was allowed to continue with the study.
45	TDC	Week 2	Per diary, panelist did not use the product on the evening of her baseline visit (04/13/05) and the evening of 04/15/05. Per Sub-Investigator, panelist was allowed to continue with the study.

48	JLL	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (04/13/05). Per Sub-Investigator, panelist was allowed to continue with the study.
49	L-R	Week 2	Panelist came in one day after her scheduled week 2 visit, which was on 04/28/05. Per Sub-investigator, panelist was allowed to continue with the study.
51	PCB	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (04/15/05). Her baseline visit was earlier that day, and she only needed to use the product once that evening. Per Sub-Investigator, panelist was allowed to continue with the study.
52	CJL	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (04/15/05). Per Sub-Investigator, panelist was allowed to continue with the study.
53	DSB	Week 2	Per diary, panelist did not use product the evening of 04/19/05 and the morning of 04/20/05 due to bronchitis. Per Sub-investigator, panelist was allowed to continue with the study.
57	MDS	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (04/18/05). Her baseline visit was earlier that day, and she only needed to use the product once that evening. Per Sub-Investigator, panelist was allowed to continue with the study.
58	CZR	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (04/18/05). Per Sub-Investigator, panelist was allowed to continue. with the study
62	KME	Week 2	Per diary, panelist did not use the product in the evening before bedtime on 04/18/05. Per Sub-Investigator, panelist was allowed to continue with the study.
64	KKF	Week 2	Per diary, panelist did not use the product in the evening before bedtime on 04/18/05. Per Sub-Investigator, panelist was allowed to continue with the study.
65	EMM	Week 2	The relative humidity (34%) of the room at the time of entry was not according to protocol (RH - 45±10%). The room temperature (73.9°F) at the time of TEWL and NOVA measurements was not according to protocol (70±3°F).
66	CYR	Week 2	The relative humidity (34%) of the room at the time of entry was not according to protocol (RH - 45±10%). The room temperature at the time of TEWL (74.1°F) and NOVA (74.5°F) measurements was not according to protocol (70±3°F).
68	SAM	Week 2	Per diary, panelist used the product twice on the day of her baseline visit (4/19/05). Per Sub-Investigator, panelist was allowed to continue with the study.
70	CAC	Week 2	Panelist came in for her week 2 visit on 05/02/05, one (1) day prior to scheduled visit (05/03/05). Per Sub-investigator, panelist was allowed to continue with the study.
73	NLW	Week 2	Per diary, panelist did not use the product in the evening before bedtime on 04/19/05. Per Sub-Investigator, panelist was allowed to continue with the study.
2	MLE	Week 4	Panelist came in for her week 4 visit on 05/10/05, one day after her scheduled visit (on 05/09/05). Per Sub-investigator, panelist was allowed to continue with the study.
4	SKH	Week 4	Panelist did not use the product in pm for week 2 visit (02/25/05). Per Sub-investigator, panelist was allowed to continue with study.
7	DBK	Week 4	Per diary, panelist used the product the morning of her 4 week visit (05/10/05). Panelist came in for her week 4 visit on 05/10/05, one day after her scheduled visit (on 05/09/05). Per Sub-investigator, panelist was allowed to continue with the study.
13	DKS	Week 4	Per diary, panelist used the product in the afternoon for her morning regime on the following dates: 04/26/05 (2:30 P.M.), 05/01/05 (12:30 P.M.), and on 05/07/05 (12:40 P.M.). Per Sub-investigator, panelist was allowed to continue with the study.
27	SMM	Week 4	Per diary, panelist used the product at 12:30 A.M. (05/09/05) for her P.M. regime on 05/08/05. Per Sub-investigator, panelist was allowed to continue with the study.
32	TML	Week 4	Per diary, panelist used the product at 12:30 A.M. (05/03/05) for her P.M. regime on 05/02/05. Per Sub-investigator, panelist was allowed to continue with the study.
35	DLM	Week 4	Per diary, panelist did not use product for pm use on 5/15/05 and for am use on 5/16/05 due to personal problem. Per Sub-investigator, panelist was allowed to continue with study.

39	DKD	Week 4	Per diary, panelist used the product the morning of her 4 week visit (05/17/05). Panelist used the product at 1:00 A.M. (05/14/05) for her PM regime (05/13/05). Panelist did not use the product the evening of 05/16/05. Per Sub-investigator, panelist will be allowed to continue with study.
47	CMP	Week 4	Per diary, panelist used the product the morning of her 4 week visit (05/11/05). Per Sub-investigator, panelist was allowed to continue with the study.
48	JLL	Week 4	Per diary, panelist used the product in the afternoon (1:30 P.M.) for her morning regime on 04/27/05. She also used the product at 1:15 P.M. for her morning regime on 05/07/05. Per Sub-investigator, panelist was allowed to continue with the study.
49	L-R	Week 4	Per diary, panelist did not use the product in the evening before bedtime on 04/29/05. Per Sub-Investigator, panelist was allowed to continue with the study. Panelist came in for her week 8 visit on 6/13/05, three days after her scheduled visit (06/10/05).
50	DHK	Week 4	Panelist came in for her week 4 visit on 05/16/05, three (3) days later than the scheduled visit (05/13/05). Per Sub-investigator, panelist was allowed to continue with the study.
66	CYR	Week 4	Per diary, panelist did not use product in the evening of her week 4 visit (05/17/05). Per Sub-investigator, panelist was allowed to continue with study.
69	GHD	Week 4	Per diary, panelist used the product in the afternoon for her morning regime on the following dates: 05/03/05 (1:00 P.M.), 05/07/05 (1:00 P.M.), and on 05/14/05 (3:00 P.M.). Per Sub-investigator, panelist was allowed to continue with the study.
70	CAC	Week 4	Panelist came in for her week 4 visit on 05/02/05, one (1) day prior to scheduled visit (05/03/05). Per Sub-investigator, panelist was allowed to continue with the study.
13	DKS	Week 8	Per diary, panelist used the product in the afternoon for her morning regime on 05/10/05 (2:35 P.M.), 05/14/05(12:30 P.M.) 05/22/05 (3:30 P.M.) and on 06/04/05 (12:15 P.M.). Per Sub-investigator, panelist was allowed to continue with the study.
25	TJJ	Week 8	Per diary, panelist used product in the afternoon (5:45 P.M.) for her evening application on 05/12/05. Per Sub-investigator, panelist was allowed to continue with the study.
26	PKM	Week 8	Panelist came in for her week 8 visit on 6/15/05, five days after her scheduled visit (06/10/05). Per Sub-investigator, panelist was allowed to continue with the study.
27	SMM	Week 8	Per diary, panelist used the product at 1:30 A.M. (05/22/05) for her P.M. regime on 05/21/05. Panelist also used the product the morning of her week 8 visit (06/09/05). Per Sub-investigator, panelist was allowed to continue with the study.
32	TML	Week 8	Per diary, panelist used the product at 12:45 A.M. (05/22/05) for her P.M. regime on 05/21/05. Per Sub-investigator, panelist was allowed to continue with the study.
39	DKD	Week 8	Per diary, panelist used the product at 1:00 A.M. (06/18/05 and 07/02/05) for her P.M. regime on 06/18/05and 07/01/05. Per Sub-investigator, panelist was allowed to continue with study.
40	CLM	Week 8	Per diary, panelist the product in the afternoon for her morning regime on 05/17/05 (2:00 P.M.). Per Sub-investigator, panelist was allowed to continue with the study.
48	JLL	Week 8	Per diary, panelist used the product in the afternoon (1:30 P.M.) for her morning regime on 05/11/05. Per Sub-investigator, panelist was allowed to continue with the study.
49	L-R	Week 8	Panelist came in for her week 8 visit on 6/13/05, three (3) days after her scheduled visit (06/10/05). Panelist used the product on the morning of her week 8 visit .Per Sub-investigator, panelist was allowed to continue with the study.
50	DHK	Week 8	Panelist came in for her week 8 visit on 06/10/05, three (3) days prior to scheduled visit (06/13/05). Per Sub-investigator panelist was allowed to continue with the study.
53	DSB	Week 8	Per diary, panelist used the product in the afternoon for her morning regime at 12:45 P.M. on 05/28/05 and 1:00 P.M. on 06/08/05. Per Sub-investigator panelist was allowed to continue with the study.
68	SAM	Week 8	Per diary, panelist used the product in the after noon for her morning regime at 12:00 P.M. on 06/03/05 and at 12:15 P.M on 06/04/05. Per Sub-investigator panelist was allowed to continue with the study.
70	CAC	Week 8	Panelist came in for her week 8 visit on 06/13/05, three (3) days later than the scheduled visit (06/10/05). Per diary, panelist used the product 12:15 A.M. for the evening use for 06/10/05. Per Sub-investigator, panelist allowed to continue with the study.

2	MLE	Week 12	Panelist came in for her week 12 visit on 07/01/05, four (4) days prior to scheduled visit (07/04/05). Per Sub-investigator, panelist was allowed to continue with the study.
3	SKH	Week 12	Panelist came in for her week 12 visit on 07/01/05, four (4) days prior to scheduled visit (07/04/05). Per Sub-investigator, panelist was allowed to continue with the study.
4	SKH	Week 12	Panelist came in for her week 12 visit on 07/01/05, four (4) days prior to scheduled visit (07/04/05). Per Sub-investigator, panelist was allowed to continue with the study.
5	LMP	Week 12	Panelist came in for her week 12 visit on 07/01/05, three (3) days prior to scheduled visit (07/04/05) because of the holiday. Per Sub-investigator, panelist was allowed to continue with the study.
13	DKS	Week 12	Per diary, panelist used the product in the afternoon for her morning regime on 06/11/05 (12:10 P.M.), 06/13/05 (12:15 P.M.), and on 06/18/05 (12:10 P.M.). Per Sub-investigator, panelist was allowed to continue with the study.
17	BFH	Week 12	Per diary, panelist did not use the product the evening of 06/23/05. Per Sub-investigator, panelist was allowed to continue with the study.
25	TJJ	Week 12	Per diary, panelist used product in the early afternoon (4:30 P.M.) for her evening application on 06/09/05. Per Sub-investigator, panelist was allowed to continue with the study.
27	SMM	Week 12	Per diary, panelist used the product in the afternoon (1:30 P.M.) for her morning regime on 06/11/05. Also panelist used the product at 1:00 A.M. (07/03/05) for her P.M. regime (07/02/05). Per Sub-investigator, panelist was allowed to continue with study.
40	CLM	Week 12	Panelist came in for her week 12 visit on 07/11/05, one (1) day prior to scheduled visit (07/12/05). Per Sub-investigator, panelist was allowed to continue with the study.
42	KAM	Week 12	Per diary, panelist used the product the morning of her week 12 visit on 07/12/05 (6:00 A.M.). Per Sub-Investigator, panelist was allowed to continue with the study.
48	JLL	Week 12	Per diary, panelist used the product in the afternoon for her morning regime the day of her 4 week visit (06/08/05 at 2:00 P.M.). Per Sub-investigator, panelist was allowed to continue with the study.
49	L-R	Week 12	Panelist equilibrated for 12 minutes prior to TEWL and skin moisture measurements. Per Sub-investigator, panelist was allowed to continue with the study.
51	PCB	Week 12	Per diary, panelist did not use product for evening application on 07/01/05 until 3:00 A.M. (which is actually 07/02/05). Per Sub-investigator panelist was allowed to continue with the study.
53	DSB	Week 12	Per diary, panelist used the product in the afternoon for her morning regime on 06/22/05 (12:30 P.M.). Per Sub-investigator, panelist was allowed to continue with study.
68	SAM	Week 12	Per diary, panelist used the product in the morning for her evening regime on 06/14/05 (12:30 A.M.), 06/15/05 (12:15 A.M.), 06/16/05 (12:45 A.M.), 06.17.05 (1:00 A.M.), 06/20/05 (12:00 A.M.), 06/21/05 (12:15 A.M.), 06/24/05 (12:30 A.M.), and 06/27/05 (1:00 A.M.) Panelist also used the product in the afternoon for her morning regime on 06/23/05 (12:00 P.M.) Per Sub-investigator, panelist was allowed to continue with study.
69	GHD	Week 12	Per diary, panelist used the product in the early morning of 07/04/05 (1:00 A.M.) for her PM regime for 07/03/05. Per Sub-investigator, panelist was allowed to continue with study.
70	CAC	Week 12	Panelist was issued an extra product since she was running low during the Week 8 - Week 12 period.